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Abstract 
 
Motor vehicle accidents are the most common cause of injuries involving avulsion of 
spinal roots from the brachial or lumbosacral plexuses. This results in chronic 
intractable pain that is refractory to pharmacotherapy. This is largely due to lack of 
information on underlying mechanisms, and lack of an established animal model to test 
drug treatments. 
 
This thesis has: 1) compared the neuroanatomical effects of dorsal root rhizotomy 
(DRR) and avulsion (DRA) in the spinal cord. DRR is commonly used to model 
avulsion injury but unlike avulsion it does not damage the spinal cord, as often happens 
clinically. 2) Developed a behavioural model of spinal root avulsion injury (SRA). 3) 
Evaluated the behavioural effects of drugs prescribed to treat neuropathic pain or those 
used clinically to treat other conditions like motoneuron disease or spinal cord injury. 
 
DRA produced a greater and prolonged glial, inflammatory, vascular response and cell 
loss than DRR. SRA produced thermal and mechanical hypersensitivity in the affected 
hind-paw. Neurodegenerative and neuroinflammatory responses were observed in both 
the avulsed and adjacent spinal segments, but produced no changes in the neuronal 
phenotype adjacent dorsal root ganglion neurons, suggesting that the evoked behaviour 
is mediated by central mechanisms.  
 
Administration of amitriptyline or carbamazepine reduced behavioural hypersensitivity 
in SRA, confirming their limited clinical efficacy in treatment of avulsion injury. 
Minocycline and riluzole produced therapeutic efficacy. Both compounds prevented the 
establishment of behavioural hypersensitivity, which correlated histologically with 
microglial inhibition, although riluzole was transiently effective. Additionally, 
minocycline reversed the hypersensitivity, an effect that persisted beyond drug wash-
out, whereas riluzole had a limited effect that only lasted whilst the drug was 
administered.  
 
This thesis provides insight into the mechanisms of avulsion-induced neuropathic pain. 
The establishment of a behaviourally reproducible avulsion model provides a platform 
to test new pharmacological candidates for treatment, such as minocycline.  
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Chapter 1: General Introduction 
 
1.1: The peripheral nerves 
 
The mammalian nervous system comprises a central nervous system (CNS), consisting 
of the brain and spinal cord, and peripheral nervous system (PNS), consisting of nerves 
outside the CNS that make up the autonomic, and somatic nervous systems. The 
somatic nervous system is responsible for voluntary control of skeletal muscle through 
motor output via upper motor neurones, such as the corticospinal tract, which innervate 
lower motor neurones in the spinal ventral horn that innervate muscles. It also is 
responsible for sensory processing from the external and internal environment, through 
sensory receptors and afferent fibres in the periphery, with final projections to the spinal 
cord.  This somatic sensory system consists of neuronal endings of mainly 
exteroceptors, which provide information on the external body’s interaction within the 
environment, such as cutaneous, auditory, olfactory, vestibular, and vision modalities. 
Some neuronal endings are interoceptive, located in visceral tissue, providing 
information on internal homeostatic environments of organs, such as the mesentery and 
gut wall. Other sensory information includes proprioception that, unlike extero- and 
interoception, is an unconscious sensory feedback mechanism of muscles and joints 
enabling quick responses to body movement and position in the environment. (Brodal, 
2004) 
 
The transmission of sensory information from skin, muscle, joints, and viscera to the 
spinal cord involves a process of axon potential propagation via peripheral nerves. 
These fibres are referred to as afferents, as they convey information from the periphery 
to the CNS. They are coupled with non-neuronal cells called Schwann cells, which 
provide structural and nutrient support of peripheral nerves, influence conduction 
properties through their myelin sheath, and are essential for axon targeting and 
regeneration. The peripheral nerves of the cutaneous somatic nervous system consist of 
a transducing/receptive terminal in the dermis or epidermis, a nerve fibre that conducts 
action potentials centrally, a cell body in the dorsal root ganglion, and synaptic endings 
in the spinal cord. (Brodal, 2004) 
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Peripheral nerves supply specific areas of skin called dermatomes. A dermatome is 
supplied by the sensory fibres of a single nerve root. There are 31 spinal nerve roots (8 
cervical, 12 thoracic, 5 lumbar, 5 sacral, and 1 coccygeal) in the human (Gray et al., 
1980) and each has a separate sensory pattern of distribution, referred to in the spinal 
cord as segmental and in the periphery dermatomal. By this organization dermatome 
areas are generally isolated; however, adjacent dermatomes do overlap slightly (Brodal, 
2004).  
 
The mechanism by which sensory neurones are activated by a stimulus, lies within 
specific end organs/receptors with the dermis and epidermis of the skin. Primary 
afferent modality is defined as the type of stimulus that will induce a response in the 
neurone. This can be thermal (cooling/warming), mechanical (depression, stretch, 
pressure, hair movement), and chemical (capsaicin, PH) stimuli (Loeser and Bonica, 
2001). Afferents can exist in the periphery that respond to only one stimulus, or a 
mixture of many or all stimuli, referred to as ‘polymodal’ (Kumazawa, 1990). In some 
cases afferents have been shown to be totally inactive to natural stimuli, but these fibres 
become active under pathological conditions. These fibres are referred to as ‘silent’ 
nociceptors (Michaelis et al., 1996), and may be responsible for pain states. The 
intensity of the stimulus to which the end organ responds and therefore sets the primary 
afferent firing ‘threshold’ is also an important factor that defines sensory subsets. Low-
threshold mechanoreceptors (LTM) are activated by mechanical displacement of a low 
intensity, and high-threshold mechanoreceptors (HTM) are the opposite. This intensity 
‘graded’ sensory system is essential in defining noxious from innocuous stimuli.  
 
Primary afferents can be categorised by their anatomy and electrophysiological 
properties into A- and C- fibres (Djouhri and Lawson, 2004). Unmyelinated axons are 
classified as C-fibres, and are slowly conducting, in the order of <2m/s, and are thin 
with a diameter of 0.2-1.5µm. C-fibres typically innervate peripheral targets via 
unspecialised afferent endings called free nerve endings (FNE). Most FNEs are 
polymodal; therefore C-fibres can act as either thermoreceptors, mechanoreceptors, 
chemoreceptors and/or, polymodal nociceptors. Myelinated axons classified as A-fibres 
have a much greater rate of conduction, up to 120m/s, due to their capacity for 
‘saltatory’ conduction, first described by Tasaki (Tasaki, 1939). The action potential 
propagates through areas of ionic insulation (myelin), interrupted by areas of 
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unmyelinated spaces (nodes of Ranvier) containing large numbers of ion channels 
allowing for ionic efflux and influx. The node of Ranvier produces an ‘all-or-none’ 
action potential, maintaining the same conductivity on each propogation. These 
channels and ionic movement across the axon membrane provide quick refraction of the 
axon current and repolarisation at that location, in preparation for further action 
potential propagation (Tasaki, 1939). The consistent frequency of action potential 
propagation, and therefore the extent of myelination and axon diameter, is what encodes 
for the intensity of a stimulus: A-fibres can be subclassified into α, β, and δ, depending 
on this principle (Loeser and Bonica, 2001). Aα fibres are the largest diameter (13-
22um) primary afferent axons and have conduction velocities of 70-120m/s and have a 
substantial proprioceptive role (Brodal, 2004;Djouhri and Lawson, 2004). Aβ fibres 
have conduction velocities of 30-70m/s and range from 8-13µm in diameter, and make 
up the cutaneous mechanoreceptors and secondary muscle spindle proprioceptors, 
however they also have significant nociceptive properties (Djouhri and Lawson, 2004). 
Aδ fibres are thinly myelinated (1-5µm in diameter), with conduction velocity in the 
range of 3-30m/s, and comprise principally D-hair LTM units that respond to both 
stretch and cooling of the skin. They also have a substantial nociceptive role, conveying 
fast and sharp pain such as one would experience after a traumatic insult (Djouhri and 
Lawson, 2004).  
 
The peripheral nerves or afferents, when travelling toward the CNS, converge from the 
back of the body and limbs into dorsal rami, and from the front of the body and limbs 
into ventral rami. These rami contain both sensory fibres with afferent trajectory, but 
also motor axons with efferent trajectory toward muscle targets. Both somatic rami 
converge with the sympathetic axons of the autonomic nervous system arising from the 
sympathetic ganglion chain, via the white and grey ‘rami communicans’ (Gray et al., 
1980), and become a spinal nerve. The white rami, existing from T1-L2 spinal nerves, 
contain preganglionic axons from the intermediolateral cell column of the spinal cord, 
which innervate postganglionic sympathetic efferents. The grey rami, existing at all 
levels of the spinal cord, contain the postganglionic sympathetic efferent axons. At this 
point the spinal nerve enters the spinal column via the intervertebral foramina, somatic 
efferent and afferent projections separate into the ventral/anterior or dorsal/posterior 
root respectively. The dorsal root is where the cell bodies of the sensory neurones are 
located, bundled within ganglia. Dorsal root ganglion (DRG) cells are pseudo-unipolar 
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in anatomy. DRG cells are lined by a specific flattened Schwann cell called a satellite 
cell that supplies nutrients and structural support. DRG cell bodies can be sub-classified 
by their biochemical properties, which closely align with their electrophysiological 
properties (Priestley et al., 2002). Unmyelinated C-fibres can be divided into two 
classes: peptidergic and non-peptidergic neurones. Peptidergic neurones comprise 40% 
of the DRG population and express calcitonin gene-related peptide (CGRP) and 
substance P (Lawson et al., 1997), whereas non-peptidergic neurones, comprising 
another 40%, can be identified by the lectins they express, specifically Griffonia 
Simplicifolia Lectin-1 (IB4) (Streit et al., 1986), or by enzymes, such as fluoride 
resistant acid phosphatase (FRAP) (Carr et al., 1991;Carr et al., 1990) or LA4 antibody 
(Alvarez et al., 1991). However these two C-fibre populations are not mutually 
exclusive and overlap by approximately 8-30% depending on the markers used (Alvarez 
et al., 1991;Carr et al., 1990;Averill et al., 1995). Myelinated A-fibres, comprising the 
final 40% group can be identified by the heavy (200kDa) neurofilaments they contain, 
by several commercial antibodies (NF200, N52, and RT97) (Perry et al., 1991;Lawson 
et al., 1984). 
 
1.2: The spinal cord 
 
The DRG convey a central branch or root toward the central nervous system and 
provide the path for the sensory afferents to enter the spinal cord. The ventral root is 
where the motor efferents leave the spinal cord to join with the dorsal root at the spinal 
nerve level. One segment of the spinal cord is defined longitudinally by a pair of dorsal 
and ventral roots. Where the dorsal root crosses through the pia mater and enters the 
spinal cord, it no longer referred to as the PNS but rather now the CNS. The anatomical 
area for this is called the dorsal root entry zone (DREZ), and is situated between the 
external surface of the spinal cord and the apex of the dorsal horn grey matter. The 
DREZ is divided into a medial division of myelinated fibres involved in proprioception 
and mechanoreception, and a lateral division of mostly unmyelinated fibres involved in 
thermoreception, pressure reception, and nociception (Sindou et al., 1974;Light and 
Perl, 1977;Chung and Coggeshall, 1979;Chung et al., 1979). In this way somatic 
sensory modalities are beginning an anatomical separation before entering the CNS. The 
lateral division of the DREZ is usually referred to as Lissauer's Tract, and contains high 
threshold and nociceptive fibres (EARLE, 1952;Loeser and Bonica, 2001). Lissauer’s 
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tract does not contain cell bodies and for this reason is not defined as the one of the 
dorsal horn laminae, although it is located just dorsal to lamina I. The terminations of 
these sensory afferents, and some of those within the medial division, are distributed 
amongst the dorsal horn laminae. Small diameter axons (unmyelinated C and 
myelinated Aδ) branch after leaving Lissauer’s Tract where they enter the dorsal horn 
directly, or branch and travel longitudinally for one or two spinal segments before 
synapsing (Sindou et al., 1974;LaMotte, 1977;Light and Perl, 1977). Large (Aαβ) 
myelinated fibres enter the dorsal columns directly where they ascend the spinal cord as 
the dorsal column-medial lemniscal pathway (main non-noxious pathway), synapsing 
with the dorsal horn nuclei at the level of the medulla, in the cuneate and gracile nuclei. 
Aαβ-fibres also send collateral branches into the dorsal horn. This division creates two 
distinct sensory pathways from one fibre type (Light and Perl, 1977;LaMotte, 
1977;Traub and Mendell, 1988).  
 
The terminations of the different classes of sensory afferents show lamina specificity 
(Light and Perl, 1977). The structure of the dorsal horn was first defined in the cat 
(REXED, 1952;REXED, 1954), and can be divided into a series of six stacked laminae 
(I-VI) and the ventral horn divided into four (VII-X) containing second order dorsal 
horn neurones that respond to afferent and supraspinal input, as well as lower motor 
neurone cell bodies. Lamina I is referred to as the marginal layer, and lamina II as the 
substantia gelatinosa. Collectively, these two laminae are referred to as the superficial 
dorsal horn, and are essentially the most important laminae involved in nociceptive 
processing of all sensory modalities and peripheral origins (LaMotte, 1977;Light and 
Perl, 1979;Light et al., 1979;Sugiura et al., 1989;Ling et al., 2003;Light and Perl, 2003). 
These laminae contain a very complex neurochemical organisation of neurotransmitters, 
neuropeptides, and receptors (Coggeshall and Carlton, 1997). Lamina I receives input 
from Aδ fibres and peptidergic C-fibres (Light and Perl, 1979;Light et al., 1979). 
Lamina II, which can be subdivided into inner (IIi) and outer (IIo), receives input from 
Aδ and peptidergic-C fibres in IIo, and Aβ and non-peptidergic-C fibres terminate in IIi 
(Light and Perl, 1979;Light et al., 1979). The deeper laminae (III-VI) deal with low 
threshold tactile information, proprioception, and nociception (lamina V). The 
beginning of lamina III can be distinguished by the larger numbers of myelinated axons 
in the latter, and extensive dendritic arbors, and is responsive to low threshold Aαβ 
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afferents (Loeser and Bonica, 2001). Lamina IV, which is also innervated by Aαβ 
fibres, can be distinguished by the appearance of large cell bodies that send dendritic 
processes to the superficial laminae and axons up the dorsal columns and the 
contralateral lateral white matter (Brown et al., 1977;Bennett et al., 1983;Loeser and 
Bonica, 2001). Laminae V (as well as lamina IV) contain cells of a wide dynamic range 
of activation, that are activated by cutaneous and visceral nociceptive afferents, such as 
Aδ-fibres and visceral C-fibres (Light and Perl, 1979), and send axons via the 
spinothalamic and spinomesencephalic tracts, that contribute the perception of pain 
(Loeser and Bonica, 2001). Lamina VI, is the base of the dorsal horn, and its borders are 
difficult to distinguish within the cervical and thoracic segments (Molander et al., 
1989), and is usually only discernible in the lumbar enlargements (REXED, 
1952;Molander et al., 1984). It is thought to consist of both motor and sensory neurones 
(Loeser and Bonica, 2001) innervated by Aαβs. Laminae VII to X are ventrally located 
and contribute a small percentage of axons to nociceptive ascending tracts namely the 
spinoreticular tract (Kevetter et al., 1982), but are mostly associated with motor activity, 
from reflex arcs of primary afferent-interneuronal segmental loops, as well as 
descending voluntary input. Lamina VII contains neurones that send projections up the 
dorsal-columns (Bennett et al., 1983), contains the intermediolateral cell column 
(preganglionic sympathetic neurones T1-L2), and the sacral autonomic nucleus 
(preganglionic parasympathetic neurones S2-S4) depending on the segmental level 
(REXED, 1954;Molander et al., 1984;Molander et al., 1989) and are innervated by A-
αβ afferents. Medially to lamina VII is an area of neurones referred to as Clarke’s 
nucleus; a proprioceptive clustering of interneurones that project axons within the 
lateral funiculus, giving rise to the posterior spinocerebellar tract (Mann, 1973). 
Laminae VIII and IX contain α and γ motor neurones responsible for extrafusal (skeletal 
movement) and intrafusal (proprioceptive control) muscle innervation. Little is known 
about the function of lamina X (also called the dorsal commissural nucleus) that is 
located around the central canal. Some evidence suggests a visceral (C-fibre 
innervation) nociceptive function (Miller and Seybold, 1987) as well as an autonomic 
function (Nicholas et al., 1999), but most neurones have convergent stimuli suggesting 
this lamina has multiple functions (Loeser and Bonica, 2001). 
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The somatotopy of the dorsal horn is similar to sensory cortex in that it has an ordering 
of neurones that represents a dermatomal pattern. A precise ‘map’ has been established 
in the cat and rat, within laminae I-IV of the dorsal horn, using electrical stimulation 
(Takahashi et al., 1995) and neurochemical tracing of cutaneous peripheral nerves from 
the hindlimb (Brown and Culberson, 1981;Swett and Woolf, 1985;Molander and Grant, 
1985;Woolf and Fitzgerald, 1986;Molander and Grant, 1986;Shortland et al., 
1989;Takahashi et al., 2003). The central terminals of afferents originating from the 
periphery form a reliable somatotopic map of overlapping terminals in the dorsal horn. 
There is extensive spread of termination of roots within the spinal segments, typically 1 
or 2 segments rostrally and caudally from the corresponding segment (Brown and 
Culberson, 1981), but a distinct and separate somatotopy is found when labeling 
subdivisions of the sciatic nerve (Swett and Woolf, 1985;Molander and Grant, 1986). 
This distinct cutaneous-dorsal horn dermatomal somatotopy is conformed by 
intracutaneous wheat germ agglutinin-horseradish peroxidase (WGA-HRP) injections 
(Molander and Grant, 1985), with some degree of overlap due to overlapping peripheral 
fields. This overlap was confirmed by intra-axonal HRP injection of individual hair 
follicle afferents, with terminal collateral sprouting and arborisations noted in the 
laminae (Shortland et al., 1989). Further, different lamina distribution of A and C fibre 
projections was confirmed in the rat lumbar spinal cord (Woolf and Fitzgerald, 1986), 
suggesting not only location but also modality is distinguished by the organization of 
primary afferent termination. This dorsal horn somatotopy ensures sensory information 
is separated and ordered, before entering higher centres of the cortex. This provides the 
nervous system with a fast and efficient method to distinguish modality and location of 
stimulus.   
 
1.3: From nociception to pain. 
 
The second order dorsal horn neurones can be differentiated according to their 
responses to peripheral cutaneous stimuli, into classes numbered 1-4 (Cervero et al., 
1976;Menetrey et al., 1977;Cervero and Tattersall, 1986). Class 1 cells can be activated 
by innocuous stimuli, and can be subdivided into 1A- responsive to hair movement 
and/or touch, and 1B- hair movement and/or touch and pressure, or pressure only. These 
neurones were unresponsive to noxious stimuli suggesting this class integrates purely 
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LTM information from A-αβ afferents, and predominate in laminae III and IV 
(Menetrey et al., 1977). Class 2 are a group of neurones that are driven by both noxious 
and innocuous stimuli, and are similarly divided into A and B subcategories depending 
on stimulus modality (Menetrey et al., 1977). They are most often referred to as ‘wide 
dynamic range neurones’ or ‘multireceptive’, and are most abundant in the dorsal horn 
predominating in laminae I, II, V, and X, and respond to A- and C-fibre afferents. These 
neurones receive most of the descending input to the dorsal horn from higher centres, 
and are involved in response to a stimulus chain (Menetrey et al., 1977;Cervero and 
Tattersall, 1986). Class 3 cells code purely noxious mechanical stimuli, such as pin 
prick (Menetrey et al., 1977) and referred to as nociceptor specific, and are found 
predominantly in lamina I (Cervero et al., 1976;Cervero and Tattersall, 1986). Class 4 
neurones respond to joint and deep tissue pressure (Menetrey et al., 1977).  
 
The second order neurones within lamina I, III, V-VII, and X send projections to higher 
centre structures such as the thalamus, periaqueductal grey, parabrachial region, bulbar 
reticular formation, hypothalamus, amygdaloid nucleus, septal nucleus, and many 
others, in anatomically defined tracts. Most projection tracts are anterolaterally located 
in the spinal cord associated with the perception of pain, with the exception of the dorsal 
column pathway, required mainly for non-noxious sensing and detecting precise 
location of stimulus (Willis and Coggeshall, 1991;Willis and Westlund, 1997;Almeida 
et al., 2004). 
 
The Spinothalamic Tract (STT) is the major constituent of the anterolateral pathway, 
and is associated with directing information mainly of a noxious nature, but also crude 
touch. The tract has been mapped in monkeys, cats and rats, and originates from second 
order dorsal horn neurones mainly within laminae I and IV-VI, but some are also found 
in lamina X. The tract crosses the spinal cord through the anterior white commissure, 
and ascend contralaterally (located lateral to the ventral horn) eventually synapsing with 
the contralateral ventral posterolateral nucleus of the thalamus. This nucleus is 
subdivided for specific areas of the body, and each area projects to its own section of 
the primary sensory cortex. Two separate STT projections can be identified entering the 
thalamus and encode fast and slow pain: A bilateral medial-nuclear-group, called the 
paleospinothalamic tract, encodes slow pain and is involved in motivational-affective 
aspects of pain, and originates from the deep dorsal horn, ventral horn, and around the 
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central canal, and terminates within the intralaminar nuclear complex of the thalamus, 
namely the central lateral nucleus. The lateral-nuclear-group, called the 
neospinothalamic tract encodes fast pain and is involved in sensory-discriminative 
characterisation of pain, and originates from lamina I and V, and terminates within the 
ventrobasal complex, namely the posterior nuclei (Hodge, Jr. and Apkarian, 1990;Willis 
and Coggeshall, 1991;Ralston, III and Ralston, 1992;Willis and Westlund, 
1997;Almeida et al., 2004). 
 
The spinoreticular pathway from laminae V, VII and VIII, with smaller contribution 
from laminae I and X, ascends on both sides of the spinal cord, synapsing in the lateral 
reticular formation, involved in motor control, and the medial reticular formation 
involved in nociceptive mechanisms. Some fibres terminate bilaterally in the 
intralaminar nuclei of the thalamus. From there the next neuron in the chain takes the 
information to many areas of the brain, including the anterior part of the cingulate gyrus 
and amygdala (associated with memory and emotion), and hypothalamus (associated 
with autonomic responses). This complex pathway involves the integration of 
motivational-affective understanding of pain, and is also an essential modulator of 
descending inhibitory pathways (Willis and Westlund, 1997;Almeida et al., 2004).  
 
The spinomesencephalic tract originates from cells that closely aligned with the STT, 
namely within laminae I and IV-VI, with some in the ventral horn and lamina X, and so 
also encode nociceptive infomation. These projection neurones also travel 
contralaterally in the anterolateral pathway, and terminate in the periaqueductal grey, 
nucleus cuneiformis, intercolliculus nucleus, superior colliculus, pretectal nucleus and 
many more areas of the midbrain. The functions of the spinomesencephalic tract are 
likely a contribution to aversive behaviour; involving locomotion, cardiovascular, 
orientation, motivational, and possibly acute analgesia to prime the body for quick 
retreat from the noxious stimulus (Willis and Coggeshall, 1991;Willis and Westlund, 
1997;Almeida et al., 2004).  
 
The spinoparabrachial tract originates in lamina I, is an exclusively nociceptive 
pathway, and travels to the parabrachial nucleus in the pons, which in turn projects to 
the amygdala, hypothalamus, and other limbic system structures in the forebrain. These 
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areas most likely participate in the emotional-affective responses to noxious events, 
such as memory, fear, and autonomic functions such as stress (Almeida et al., 2004). 
 
The spinohypothalamic pathway originates from neurones of laminae I, V, X, the 
lateral spinal nucleus, and nucleus caudalis, carrying information of emotional 
significance from the skin, lips, sex organs, gastrointestinal tract, intracranial blood 
vessel tongue and cornea, directly to the medial and lateral hypothalamus, nucleus 
accumbens and the septal nucleus. The spinohypothalamic pathway is responsible for 
the integration of nociceptive input involved with autonomic, cardiovascular, and 
neuroendocrine responses to noxious stimuli, as well as some motivational aspects of 
pain (Willis and Westlund, 1997;Almeida et al., 2004). 
 
The post-synaptic dorsal column pathway (spinomedullary), and spinocervical tract, 
are not part of the anterolateral pathway and are essentially involved in transmitting 
tactile and non-noxious information to higher centres (Almeida et al., 2004). Neurones 
from laminae I, and a few originating in laminae V-VIII, project up the dorsal columns 
to the ventrolateral medulla (Andrew et al., 2003). Second order dorsal horn neurones 
from laminae III and IV send projections to the cervical nucleus (Brown, 1981;Willis 
and Coggeshall, 1991). These both have a major role in carrying information of a non-
noxious somatic modality (Giesler, Jr. and Cliffer, 1985), however many spinocervical 
tract cells have wide dynamic range and could respond to noxious cutaneous stimulation 
(Cervero et al., 1977).  
 
1.4: Nerve plexi and limb innervation 
 
External stimuli as well as motor coordination are processed initially within the spinal 
cord, in two anatomically distinct areas: the cervical and lumbar enlargements. These 
enlargements are responsible for the innervations of the upper and lower limbs 
respectively. Communication between these neuronal clusters and the periphery occur 
via intricate networks of roots and nerves, called the brachial and lumbosacral plexuses. 
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1.4.1: Anatomy of the brachial plexus in man  
 
The human brachial plexus is an arrangement of branching nerve fibres responsible for 
cutaneous and muscular innervations of the hand, arm, forearm, and shoulder (Fig 1.1), 
(Gray et al., 1980), and is anatomically similar to the rat (Rodrigues-Filho et al., 2003). 
 
Roots: 
The brachial plexus begins at the level of the spinal cord as a collection of nerve roots: 
C5, C6, C7, C8, and T1 (Fig 1.1). The roots emerge from the spinal vertebral foramina, 
immediately posterior to the vertebral artery, and merge forming three main trunk 
divisions: superior/upper (C5-C6), middle (C7), and inferior/lower (C8-T1) (Fig 1.1), 
that proceed through the neck, the axilla, and into the arm. The trunks of the brachial 
plexus pass between the anterior and middle scalene muscles and branch extensively. 
The trunks divide and cross, turning into anterior and posterior divisions, each 
consisting of upper, middle, and lower trunks (Fig 1.1), which innervate the ventral and 
dorsal halves of the arm. The six divisions then regroup to become three cords, which 
are named by their position with respect to the axillary artery. The posterior cord, 
behind the artery, is formed from the three posterior divisions of the trunk (consisting of 
all roots), the lateral cord comprises the anterior divisions from the upper and middle 
trunks (consisting of C5-C7 roots), and the medial cord is the continuation of the 
anterior division of the lower trunk (consisting of C8-T1 roots) (Fig 1.1) (Gray et al., 
1980). 
 
Peripheral nerve:  
The cord branches are the origins of the individual nerves that supply both innervation 
to the muscles controlling arm and hand movement, but also sensory cutaneous 
innervation to the arm and hand. A cutaneous nerve branch from the lateral cord, called 
the musculocutaneous (that later becomes the lateral cutaneous nerve of the forearm) 
(Fig 1.1), innervates portions of the forearm, wrist, and thumb. Cutaneous nerve 
branches from the posterior cord include, the axillary nerve (Fig 1.1) (that later becomes 
the superior lateral brachial cutaneous nerve) that innervates the skin above the deltoid 
and tricep brachii of the shoulder and top of the forearm, and the radial nerve (Fig 1.1) 
(that becomes the posterior brachial cutaneous nerve) that innervates most of the 
posterior surface of the arm. Cutaneous nerves branched from the medial cord include 
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the ulnar nerve (Fig 1.1) that innervates the skin of the medial side of the hand and 
fingers, the medial brachial and antebrachial cutaneous nerves (Fig 1.1) that innervate 
the front and medial skin of the forearm, arm, ending at the wrist, and lastly a limited 
innervation comes from the median nerve (Fig 1.1) that supplies regions of the hand not 
served by the ulna or radial nerve (Gray et al., 1980). 
 
 
 
 
 
 
 
1.4.2: Anatomy of the lumbo-sacral plexus in man  
 
The lumbo-sacral plexus is the network of nerves formed from the lumbar, sacral, and 
coccygeal roots, and provides motor and sensory innervations of the lower limbs, 
urogenital, and pelvic floor regions. It involves two main plexuses - the lumbar and 
sacral. The sacral plexus in turn contains two additional plexuses – the pudendal and the 
Figure 1.1: Brachial plexus and sensory system of the arm in human. Plexus constitutes C5-T1, with 
contributions from C4 and T2. These roots combine into 3 main cords: lateral, medial, and posterior. 
Sensory innervation comes from the nerves branched from these three cords (indicated in blue). These 
nerves also have motor function also, including other nerve branches (indicated in black) showed more 
proximally. Adapted from (Gray et al., 1980). 
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coccygeal (Fig 1.2, (Gray et al., 1980). In contrast to the brachial plexus, the 
lumbosacral plexus anatomy varies between species, the details of which are discussed 
below. It is important to consider these anatomical inconsistencies when attempting to 
interpret dissimilar behavioural responses to nerve injuries, within different species and 
strains, compared to human conditions. Indeed cats, dogs and rats are used as in vivo 
models for peripheral nerve injury, neuropathic pain, and inflammatory pain 
extensively. 
 
The Lumbar Plexus   
 
Roots: 
The spinal nerve roots of (T12), L1, L2, L3, and L4 form the beginning of the lumbar 
plexus in man. A division of L4 sends communicating branches to the sacral plexus via 
the L5 root (see later), and this region is referred to as the lumbosacral trunk (Fig 1.2). 
The rat in this context has an additional L6 root (Asato et al., 2000). The roots emerge 
from intervertebral foramina forming adjacent loops of communication, and are joined 
by gray rami communicans to the ganglia of the sympathetic trunk. The plexus passes 
obliquely in nerve branches outward behind the psoas major muscle of the vertebral 
column and down into the pelvic area, under the inguinal ligament and finally into and 
down the thigh (Gray et al., 1980).  
 
Peripheral nerve: 
The lumbar plexus differs from the brachial plexus in that it does not form an intricate 
interlacement of nerves, rather several nerve distributions arise from one or more of the 
spinal nerves, in the following manner: the first lumbar nerve (Fig 1.2), frequently 
supplemented by a branch from T12, splits into an upper and lower branch; the upper 
and larger branch divides into the iliohypogastric, supplying anterior and lateral 
cutaneous innervation of the gluteal region, and ilioinguinal nerves, supplying the 
anterior area of the groin; the lower and smaller branch unites with a branch of the L2 to 
form the genitofemoral nerve innervating the skin medially to the groin.  
 
A large portion of L2 with a portion of L3 becomes the lateral femoral cutaneous nerve 
(Fig 1.2) that in turn branches into anterior and posterior regions after passing through 
the femoral triangle of the inner upper-thigh and down into the leg. The anterior branch 
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innervates the anterio-lateral thigh region, and the posterior branch innervates the 
posterior-lateral aspect of the thigh. 
 
The remainder of L2 combines fully with the third and fourth lumbar nerves to become 
the femoral cutaneous nerve (Fig 1.2), the largest of the lumbar nerves. This has three 
branches: the anterior/intermediate cutaneous femoral nerve, supplying the anterior 
thigh region, the saphenous nerve, supplying the medial aspect of the calf and foot, and 
the medial cutaneous femoral nerve, supplying the medial aspect of the thigh. 
 
L2-L4 join together and form a distinct nerve to the femoral, called the obturator nerve 
(Fig 1.2) that has an anterior and posterior branch that exits the pelvis through the 
obturator foramen, and innervates the upper half of the medial cutaneous area of the 
thigh. In 29% of cases there is a ventral branch of the obturator called the accessory 
obturator that provides sensory innervation to the hip joint (Gray et al., 1980). 
 
The Sacral Plexus 
 
Roots: 
The sacral plexus is formed by the loops of communication between part of the L4, the 
lumbosacral trunk, the L5, and the first three sacral roots (S1-S3) (Fig 1.2). The sacral 
plexus innervates the skin on the back of the thigh, leg and around the anus and genitals 
(Gray et al., 1980). 
 
Peripheral nerve: 
A large majority of these nerve roots join together to form the largest nerve of the body, 
the sciatic nerve (L4, L5, S1, and S2, Fig 1.2), that emerges from below the piriformis 
muscle of the gluteal region and enters the leg. This nerve subdivides into the tibial, and 
the common peroneal nerve. The tibial further decussates into the sural nerve, medial 
and lateral plantar nerves, and the calcaneal nerve, further down in the leg and foot. The 
calcaneal nerve supplies the ball of the foot, the sural the lateral aspect of the foot and 
posterio-lateral leg, the medial and lateral plantar nerves (similar to the ulnar and 
median nerves in the brachial plexus) innervate the medial and lateral plantar surfaces 
of the plantar foot respectively. The common peroneal also branches further down the 
leg into the deep peroneal nerve that innervates the skin between the 1st and 2nd toe, the 
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superficial peroneal nerve that innervates the anterio-lateral shin region and foot 
dorsum, and the lateral sural cutaneous nerve that innervates the anterio-lateral calf just 
below the knee. The L6 root in rat has a variable contribution to the sciatic nerve (Asato 
et al., 2000;Rigaud et al., 2008;Shehab, 2009), with sometimes the L3 root contributing 
(Asato et al., 2000). 
 
The posterior femoral cutaneous nerve (Fig 1.2), is part of the sacral plexus also and is 
served by S1, S2, roots S3, and innervates the whole posterior aspect of the thigh, from 
gluteal region to the popliteal fossa. (Gray et al., 1980). 
 
The Pudendal Plexus 
 
The pudendal plexus is located ventrally to the posterior wall of the pelvis and is formed 
from the medial part of the sacral plexus. It culminates in two nerves: the pudendal (S2, 
S3, and S4 nerve roots) and perforating cutaneous/inferior cluneal (S2 and S4 nerve 
roots) (Fig 1.2). This nerve/plexus divides down in the pelvis into the inferior rectal 
nerve, the perineal nerve and the dorsal nerve of the penis/clitoris. These innervate the 
peri-anal skin, scrotum/labia majora and penis/clitoris respectively. 
 
The perforating cutaneous/inferior cluneal nerve also part of the pudendal plexus (Fig 
1.2) innervates the skin covering the gluteal region above the region supplied by the 
posterior femoral cutaneous nerve. This nerve is absent in 33% of cases and its role can 
be taken by a branch from the posterior femoral cutaneous (Gray et al., 1980). 
 
The Coccygeal plexus 
 
The coccygeal plexus is the most caudal part of the spinal cord and sacral plexus. It 
consists of just one nerve: the anococcygeal nerve. It is formed from the coccygeal root 
with communicating filaments from the fourth and fifth sacral roots, uniting to form the 
coccygeal plexus (Fig 1.2). This consists of a few fine filaments which pierce the 
sacrotuberous ligament to supply the small amount of skin in the region of the coccyx 
(Gray et al., 1980). 
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Figure 1.2: Lumbosacral plexus and sensory system of the leg, foot, pelvis, genitals, and anus in 
human. Plexus constitutes T12-Coc1. The major cutaneous sensory nerves consisting of lateral femoral 
cutaneous, femoral cutaneous, obturator, sciatic, posterior femoral cutaneous, perforating cutaneous, 
pudendal and anococcygeal (indicated in blue). These nerves also have motor function, including other 
nerve branches (indicated in black). Adapted from (Gray et al., 1980). 
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1.5: Brachial and lumbo-sacral plexus injuries 
 
Ramon y Cajal (Ramon and May, 1928) first documented the characteristic of 
regeneration after injury within the peripheral nervous system, noting the appearance of 
‘ball-like appendages’ (buds) at the central end of transected axons within the sciatic 
nerve, contrary to the limited capacity seen in the CNS (Ramon and May, 1928). In the 
case of spinal roots, he discovered that the dorsal component had a capacity to 
regenerate toward, but not through, the root entry zone after a central root injury. This is 
thought to be due to two main factors: firstly, the non-permissive environment of the 
CNS through the development of astrocytic glial scars and secretion of inhibitory 
molecules such as chondroitin sulphate proteoglycans (Fawcett, 2006;Yiu and He, 
2006), and secondly the lack of intrinsic growth potential within the axon (Caroni, 
1997). This growth potential relies on the formation of a growth-cone, by localized 
protein turn-over at the terminal end of transected axons, and is controlled by the 
upregulation of regeneration-associated genes such as small proline-rich repeat protein 
1A (SPRR1A) and growth associated protein (GAP43) (Snider et al., 2002). This is 
regulated by extensive intracellular signalling pathways specifically within neurones of 
a certain age (embryonic/neonatal) and type (peripheral) (Chierzi et al., 2005;Verma et 
al., 2005). In contrast to the CNS, lesions to the mature sciatic nerve in animal models 
leads to Wallerian degeneration of the distal fibres, and a robust regenerative response 
in the proximal fibres of the transected nerve (Fawcett and Keynes, 1990).  
 
Spinal root avulsions involve a lesion to the peripheral nervous system at the CNS 
transition zone, and can result in trauma to both CNS and PNS (Carlstedt, 2009). The 
extent of CNS disruption is dependent upon avulsion proximity to the root entry zone, 
and therefore a wide variety of neuropathology can be presented to the clinic. Also they 
have the potential to affect both ventral and dorsal root components, resulting in motor 
and/or sensory disruption initially, cell death of motor neurones (Koliatsos et al., 
1994;Bergerot et al., 2004;Bigbee et al., 2007), and neuropathic pain (Berman et al., 
1998). These neuropathies usually occur from high-energy traction forces to the limbs, 
and approximately 1000 new cases appeared in 2008. The injury most commonly, in 
80-90% of avulsion cases (Flores, 2006), involves damage to the roots (C5-T1) of the 
brachial plexus (Terzis et al., 2001;Carlstedt, 2009), and are caused notably by motor 
bike accidents (Rosson, 1987) or obstetrical complications that involve shoulder 
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dystocia (Hoeksma et al., 2000). American and European studies show that 10-20% of 
all peripheral nerve lesions involved the brachial plexus (Flores, 2006). Brachial plexus 
avulsion can present as two main types: upper and lower (Carlstedt, 2009). Upper 
avulsions involving C5-C8 occurs from excessive lateral neck flexion away from the 
shoulder, leading to loss of rotation capacity in the shoulder muscles, arm flexors and 
hand extensor muscles and results in Erb’s palsy. Lower avulsions involving C8 and T1 
occurs through sudden traction force on the arm away from the shoulder with 
subsequent paralysis of intrinsic muscles of the hand and flexors of the wrist and 
fingers resulting in Klumpke’s palsy.  
 
Lumbosacral root avulsions commonly involve roots L4, L5, and S1 (Huittinen, 1972) 
and often result from lap-belt motor vehicle injuries (Tubbs et al., 2006), or trauma to 
the pelvis (Tung et al., 2005). Studies into the prevalence of lumbo-sacral neurological 
injury, showed an incidence rate of 30 to 46% in cases of unstable pelvic fractures 
(Huittinen, 1972), and that pain occurs in 10-25% of injuries to the nerve (Sindou et al., 
2001). 
 
Clinically, avulsion is diagnosed where the root is both stretched (neuropraxia) and torn 
(ruptured) from the cord. Root avulsions can be caused by central tensile force such as 
twisting of the head and neck, or an applied force of a lap belt against the momentum of 
the body, leading to the spinal cord being pulled cranially away from the roots. This 
results in avulsion with roots still held by attachments to the interverebral foramen. If 
the limb is pulled from the body in traction injuries, such as motor bike and obstetrical 
accidents, the nerve roots are pulled from the cord and in some cases leading to 
displacement of the roots outside the spinal canal requiring more complex surgical 
intervention (Carlstedt, 2009). 
 
In humans, paralysis, muscle atrophy, and excruciating, intractable deafferentation pain 
occurs within 48 hours of brachial (Bruxelle et al., 1988;Berman et al., 1996;Uetani et 
al., 1997)}(Berman et al., 1998;Htut et al., 2006) and lumbosacral plexus/cauda equina 
avulsions (Sampson et al., 1995;Sindou et al., 2001;Stevanato et al., 2007). In cases of 
sacral avulsions such as conus medullaris and cauda equina injuries, a lower motor 
neurone autonomic dysfunction also occurs, including atonic bladder and flaccid anal 
sphincter control, and in males a loss of reflexogenic erection (Kingwell et al., 2008).  
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Accompanying pain is characterised as crushing with intermittent shooting pains down 
the deafferented limb (Berman et al., 1998) coupled with generation of border-zone 
hypersensitivity and allodynia across affected-unaffected dermatomes (Htut et al., 
2006;Havton and Carlstedt, 2009). The pain is resistant to most pharmacotherapies 
(Parry, 1980), and can lead patients to suicidal behaviours (Zhang et al., 2008) or revert 
to amputation for therapy (Piva et al., 2003). The most widely accepted effective 
treatment for relief of this neuropathic pain is a DREZ lesion called DREZotomy 
(Nashold, Jr. and Ostdahl, 1979;Sampson et al., 1995;Sindou et al., 2005;Teixeira et al., 
2007). However initial pain relief is variable (47.8%-90%), as is the follow-up 
prognosis (26.1%-73.9%) at 12 months (Sampson et al., 1995;Sindou et al., 2005) 
(Chen and Tu, 2006;Zhang et al., 2008), with a risk of low limb paralysis presenting 
(Piva et al., 2003). The DREZ lesion targets the ventro-lateral part of the central dorsal 
rootlets, medial Lissauers tract, and laminae I-V of the dorsal horn (Zhang et al., 2008), 
designed to selectively destroy the nociceptive fibres and terminations of the lateral 
bundle of the dorsal rootlet (Sindou et al., 2001). Nowadays, either DREZotomy or 
ventral root reconstructive surgery is used as therapy for alleviating neuropathic pain, 
with the later having the benefit of restoring functional motor recovery (Carlstedt et al., 
1995). Recently high cervical spinal cord stimulation has been shown to be effective at 
pain relief after brachial plexus avulsion, which DREZotomy or antidepressant and 
anticonvulsant pharmacotherapy failed to relieve (Piva et al., 2003;Lai et al., 2009), by 
activating descending inhibitory pathways. However patients needed permanent 
implantation of the stimulator devise to maintain efficacy. Reconstructive surgery 
constitutes re-implantation of the root (Carlstedt, 2009;Havton and Carlstedt, 2009), via 
nerve transfers for pre-ganglionic transection and nerve grafts for post-ganglionic 
transection (Berman et al., 1998;Anand and Birch, 2002). This has had clinical success, 
with respect to recovery of motor function after spinal root avulsion in the brachial 
plexus (Carlstedt et al., 1995;Carlstedt et al., 2000;Carlstedt et al., 2004;Carlstedt et al., 
2009), having been developed in pre-clincal models in primates and rodents (Carlstedt 
et al., 1986;Carlstedt et al., 1993;Bergerot et al., 2004;Nogradi et al., 2007). Similar 
reconstructive surgery for the lumbosacral plexus also yields some lower extremity 
functional improvement (Lang et al., 2004;Sivaraman et al., 2008). Importantly, this 
surgical procedure even when delayed by 1 year diminishes the severity of the pain 
prior to the onset of motor functional recovery (Berman et al., 1996;Berman et al., 
1998;Carlstedt et al., 2004;Htut et al., 2006;Kato et al., 2006). Furthermore, patients 
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who have undergone reconstructive surgery are more likely to be effectively treated 
with carbamazepine and amitriptyline (Berman et al., 1998), drugs that previously were 
shown to have limited efficacy in avulsion pain (Parry, 1980;Berman et al., 1996;Piva et 
al., 2003). Successful functional motor recovery and the effectiveness of pain relief is 
directly related to age of patient and delay of surgical intervention (Carlstedt et al., 
2000;Kato et al., 2006), and CNS plasticity is likely to be the overwhelming factor for 
this success. This plasticity does have its disadvantages. Avulsion of C5 root, the origin 
of the phrenic nerve, accompanied with surgical reimplantation, can lead to the 
phenomenon of the ‘breathing arm’: a spontaneous contraction of arm muscles in 
synchrony with inspiration, believed to be due to inappropriate regeneration and 
plasticity of the phrenic motor pool axons into the peripheral nerves of the arm 
(Carlstedt et al., 2004;Htut et al., 2006;Carlstedt, 2009).  
 
In animal models it has been made clear that re-implantation alone will not bring about 
an optimal functional recovery, as motor neurones continue to die and axonal 
regeneration through the implanted root is poor (Bergerot et al., 2004;Nogradi et al., 
2007), and additional therapy is required. One such intervention could be providing a 
medium for the motor axons to regenerate through before entering the more growth 
promoting environment of the peripheral nerve. Olfactory ensheathing cell (OEC) 
transplantation into the VREZ with ventral root re-implantation after rhizotomy (Li et 
al., 2007) has shown an improvement of axonal growth through the CNS-PNS 
transition zone by 4 fold; however, functional recovery was not found due to lack of 
peripheral muscle unit-axonal re-connection. In multiple lumbar ventral root avulsion 
(VRA) rat models, permanent motor deficit can be attributed to irreversible motor 
neurone cell death, where 50-80% of the motor pool is lost after 2 weeks (Koliatsos et 
al., 1994;Bergerot et al., 2004). In models of single lumbar ventral root avulsion, there 
is a loss of motor neurones in the affected segment but also an enhancement of the 
monosynaptic activity of reflex arcs of the adjacent uninjured motor neurones 
(Holmberg and Kellerth, 1996;Holmberg and Kellerth, 2000) after 12 weeks, 
suggesting a plastic compensatory mechanism that aims to maintain a functional 
locomotor activity in the limb.  
 
Minocycline, riluzole, glial cell line-derived neurotrophic factor (GDNF), and brain 
derived neurotrophic factor (BDNF) administration post VRA have all shown improved 
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motor neurone survival (Bergerot et al., 2004;Blits et al., 2004;Parsadanian et al., 
2006;Zhou and Wu, 2006;Hoang et al., 2008), with a 90% survival rate at 6 weeks (Wu 
et al., 2003). When combined with re-implantation better motor neurone survival 
occurs, and locomotor function can be restored (Bergerot et al., 2004;Nogradi and 
Vrbova, 2001;Nogradi et al., 2007), providing a critical window for therapeutic 
intervention into motor functional regeneration. This survival is associated with 
influencing anti-apoptotic intracellular signalling pathways involving c-Jun, and also 
the inhibition of nNOS expression (Novikov et al., 1995). However, withdrawal of 
neutrophic support directs motor neurones back to their original fate (Bergerot et al., 
2004), suggesting only a life support mechanism of action in these cases. In a more 
extensive avulsion injury to multiple roots within a plexus, the death of motor neurones 
may require reconstitution of the motor neuronal pool if any functional recovery is to 
occur. Embryonic postmitotic motor neurone grafts (Nogradi and Vrbova, 1996) have 
been shown to survive and extend axons through re-implanted ventral roots after 
avulsion and reach target muscles, providing possible therapy for patients that may have 
missed the ‘therapeutic window’ of cell death prevention. Interestingly, these motor 
neurone grafts successfully survive and elongate axons, only if the host motor neurones 
themselves die (Nogradi and Vrbova, 2001), suggesting an association of donor cell 
rejection in injured spinal cord to successful clearance of injured or dying cells.  
 
Avulsion injuries of cervical and lumbosacral dorsal roots, are a major challenge for 
rehabilitation, as these lesions result in an irreversible loss of sensory function (Havton 
and Carlstedt, 2009) and severe intractable pain (Sampson et al., 1995;Stevanato et al., 
2007). Avulsion of brachial plexus dorsal roots in rat leads to severe impairment of 
successful forepaw grasping (Ibrahim et al., 2009b) as well as bilateral below-level 
hypersensitivity (Rodrigues-Filho et al., 2003). Experimental treatment techniques 
under investigation for regeneration involve DREZ OEC-transplantation with dorsal 
root re-implantation after rhizotomy (Li et al., 2004), improving axonal growth through 
the CNS-PNS transition into the dorsal horn and up the dorsal columns for 10mm, 
corresponding to improvement of lost forepaw grasping over several weeks (Ibrahim et 
al., 2009a). Immediate intrathecal neurotrophin administration after dorsal root crush 
injury leads to specific subpopulations of injured sensory afferents crossing the DREZ 
(McPhail et al., 2005). NGF, NT3, and GDNF treatment lead to re-growth of damaged 
sensory axons through the root entry zone into the cord. Reconnections to dorsal horn 
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neurones were also found to be functional, and nociceptive sensitivity to noxious heat 
and pressure were restored (Ramer et al., 2000). Clinically, however the situation is less 
optimistic. Effective therapeutics are still required after surgical intervention for 
treatment of ongoing neuropathic avulsion pain (Berman et al., 1998), DREZotomy is 
only partially effective (Sampson et al., 1995), and allodynia has been shown to 
accompany regeneration (Htut et al., 2006). At present it unclear what, if any, effects to 
the dorsal horn neuronal pool occur after avulsion of the dorsal roots and what 
mechanisms can contribute to the sensory changes seen after dorsal root avulsion. 
 
1.6: Lumbosacral plexus injury in vivo 
 
This thesis has attempted to more closely model human avulsion injury in the 
lumbosacral region of the rat by tearing rather than cutting the roots. Clinically 
lumbosacral avulsion is far rarer injury than brachial plexus avulsion (Stevanato et al., 
2007;Carlstedt, 2009) as the plexus is protected within the bony pelvis, and the reason 
for designing animal models in the lumbosacral region needs to be made clear. So far in 
pre-clinical animal models of pain and peripheral nerve injury, quantitive sensory 
analysis techniques have been designed for assessing somatic behavioural changes in 
the hindpaw (lumbar region) and not forepaw (cervical region). These techniques are 
well established and used consistently in the literature for peripheral nerve injury 
models, and the assessment of neuropathic pain, and consist of von-Frey hair filaments 
(Seltzer et al., 1990), thermal probe assessments (Hargreaves et al., 1988), and other 
methods such as cold plates and chemical irritants (Bennett and Xie, 1988), and more 
recently an automated plantar asthesiometer (Dolan and Nolan, 2007), some of which 
are used in this thesis. In addition, and as described earlier, the detailed anatomy of the 
rat lumbosacral somatotopy, dermatomal innervation and physiology in the dorsal horn 
is far better understood than in the cervical/brachial region (Swett and Woolf, 
1985;Molander and Grant, 1985;Woolf and Fitzgerald, 1986;Molander and Grant, 
1986;Shortland et al., 1989;Takahashi et al., 1995;Takahashi et al., 2003). Surgery of 
the lumbar region is anatomically easier and less invasive than cervical surgery, with 
less muscle and surrounding tissue to dissect, and for lumbosacral avulsion injury there 
are less post-surgical implications, such as breathing difficulties.  
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In this thesis three models have been applied to model root avulsion: L3-L6 dorsal root 
avulsion, L3-L6 dorsal root rhizotomy, to fully injure the hind-paw, and L5 spinal root 
avulsion. Dorsal roots L3-L6 were avulsed or transected, affecting the two main 
hindlimb nerves: the sciatic nerve and the saphenous nerve, to compare the models. The 
sacral roots were not avulsed, as injury to these roots can result in post-surgical 
complications to parasympathetic autonomic function, such as bladder and bowel 
function. In addition, a single L5 ventral+dorsal root avulsion (spinal root avulsion) was 
chosen as the vast majority of lumbosacral avulsions involve mainly the L5 root 
(Maillard et al., 1992). This model also provides an opportunity to assess evoked 
behavioural responses produced by the adjacent L4 intact afferents as a way of 
modelling borderzone hypersensitivity shown in patients (Htut et al., 2006;Havton and 
Carlstedt, 2009). 
 
1.7: Thesis aims  
 
The first chapter of this thesis will aim to compare the in vivo model of avulsion 
currently in use in the literature, dorsal root rhizotomy (DRR), against a more direct 
injury to the spinal cord, dorsal root avulsion (DRA). The former model does not 
directly damage the dorsal horn of the spinal cord, a characteristic that often happens 
clinically. The spatial and temporal neuropathology of the dorsal cord after these 
different deafferentation injuries at early and late time points will be assessed to provide 
more information on the underlying consequences of root avulsion injury with possible 
mechanisms of the neuropathic pain.  
 
There is, at present, a lack of established animal models to test drug treatments for 
avulsion-pain. The second chapter will describe a behavioural avulsion model (L5 SRA) 
enabling quantitative testing of the development and characterisation of evoked, at-
level, neuropathic avulsion-pain. Behavioural sensory tests of both tactile and thermal 
modalities will be implemented, and histology of the adjacent (L4) and avulsed (L5) 
spinal segments and DRG will be analysed. 
 
At present some therapy for avulsion-pain shows efficacy, including DREZotomy 
(Nashold, Jr. and Ostdahl, 1979;Sindou et al., 2005) and antidepressants and 
anticonvulsants (Berman et al., 1998;Flores, 2006), however this is limited due to the 
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re-occurance of pain after ablative therapy, and side-effects and tolerance with drugs. 
The third chapter will aim to determine whether the antidepressant amitriptyline, and 
the anticonvulsant carbamazepine, administered to SRA injured rats produces results 
similar to that seen for patients with respect to neuropathic pain treatment. Results will 
clarify the effectiveness of the drugs pre-clinically as well as providing further proof-of-
concept of SRA-induced neuropathic behaviour.  
 
The last results chapter will aim to provide evidence for potential efficacy of the drugs, 
minocycline and riluzole, at present prescribed for other clinical conditions such as 
amyotrophic lateral sclerosis (ALS), neuroprotection after SCI, and acne, in the 
treatment of avulsion-pain. Minocycline has shown effective neuroprotective qualities 
pre-clinically for SCI (Lee et al., 2003;Wells et al., 2003;Teng et al., 2004) and root 
avulsion (Hoang et al., 2008), and analgesic properties for PNI (Raghavendra et al., 
2003;Ledeboer et al., 2005) and SCI (Hains and Waxman, 2006;Marchand et al., 2009). 
Riluzole has shown neuroprotective qualities in VRA models (Nogradi and Vrbova, 
2001;Bergerot et al., 2004;Nogradi et al., 2007), and has shown analgesic properties in 
PNI (Sung et al., 2003;Coderre et al., 2007). Both drugs may therefore be effective at 
reducing SRA-induced pain through similar mechanisms. Evoked behaviour and 
histological effects will be assessed in an immediate and maintained treatment regime in 
the SRA model. A delayed treatment regime will assess the potential for these drugs to 
effectively reverse and prevent the return of avulsion-pain behaviour.  
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Chapter 2: Methodology 
 
2.1: Animal housing and number 
 
142 adult male Wistar rats (Charles River, U.K.) of weight 150-350g were used in this 
thesis and were kept in standard housing conditions with 12 hour light/dark cycle, and 
given water and a standard rat chow pellet diet ad libertum. All animal procedures were 
in accordance with the Animal Scientific Procedures Act 1986 and UK Home Office 
regulations.  
 
• Dorsal root avulsion and rhizotomy immunohistology groups: 
 
In total 50 rats were involved in the DRA and DRR comparative immunohistochemistry 
analysis. 20 rats underwent L3-L6 unilateral dorsal root avulsion (DRA), and were left 
for 1 day (N=4), 2 days (N=6), 14 days (N=6), and 28 days (N=4) post injury, before 
sacrifice.  20 rats underwent L3-L6 unilateral dorsal root rhizotomy (DRR), and were 
left for 1 day (N=4), 2 day (N=6), 14 day (N=6) and 28 day (N=4). 6 rats underwent 
laminectomy, for 1 day (N=3) and 14 day (N=3) for sham surgery comparisons. 4 rats 
were processed for naïve immunohistochemical comparison. 
 
• Flow Cytometry groups: 
 
28 rats also underwent surgery for flow cytometric analysis. Rats underwent DRA and 
were left for 2 days (N=8) or 2 weeks (N=4) post injury before sacrifice.  A DRR group 
were sacrificed at 2 day (N=8) or 2 week (N=4). Rats underwent unilateral 
laminectomy, and sacrificed at 2 days (N=4).  6 rats were also sacrificed without 
surgery for naïve flow cytometric comparison.  
 
• Spinal root avulsion behavioural groups: 
 
64 rats were used for behavioural analysis of a spinal root avulsion injury.  
 
Naïve (N=6), sham operated (N=6), and L5 unilateral spinal root avulsion (SRA) (N=6) 
rats were behaviourally tested daily for 14 days and then sacrificed. Additionally rats 
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underwent SRA and were administered (i.p daily for first week then every other day for 
second week) riluzole (N=6; 4mg/kg. Sigma-Aldrich, UK.), minocycline (N=6; 
40mg/kg. Sigma-Aldrich, UK.), and HCl-vehicle (N=6; 0.1M identical volume) and 
were sacrificed on day 14. All tissue was then processed for immunohistochemical 
analysis. 
 
SRA rats were also given 3 isolated doses (days 11, 18, and 21) of carbamazepine (N=6; 
32mg/kg, and 64mg/kg. Sigma-Aldrich, UK.), amitriptyline (N=6; 30mg/kg, and 
64mg/kg. Sigma-Aldrich, UK.), and 45% 2-hydroxypropyl-beta-cyclodextrin-vehicle 
(N=6, identical volume. Sigma-Aldrich, UK.) and behaviourally assessed for 30 days 
(for Carbamazepine and Amitriptyline). Delayed minocycline (N=5 40mg/kg) and 
riluzole (N=5 4mg/kg) treatment groups were assessed over a period of 4 weeks with 
treatment given in the second and third weeks of the study. Tissue was collected but not 
processed for presentation in this thesis. 
 
2.2: Surgery 
 
Dorsal root avulsion and dorsal root rhizotomy: 
 
Male Wistar rats were deeply anaesthetised with 4% isofluorane (Abbott Animal 
Health, U.K.) in 1.5L/min of O2, and a hemi-laminectomy of the lumbar L4-L6 region 
of the cord was performed involving incision of the dorsal skin surface, exposure of the 
L1-3 vertebrae, removal of the dorsal vertebral processes and incising the dura mater. A 
local anaesthetic application of 2% xylocaine (Abbott Animal Health, U.K.) was made 
to the exposed dorsal surface of the lumbar cord, before the corresponding L3-L6 dorsal 
roots were identified and isolated with fine jeweller forceps (Fine Science Tools, U.K.). 
These roots were then carefully pulled from the cord, modelling an avulsion injury, or 
transected (rhizotomised) with fine micro-scissors (Fine Science Tools, U.K.). Sham 
laminectomy surgery was also performed which included all of the above procedure, 
including exposing the dorsal surface of the cord and incising the dura, but excluding 
avulsion or rhizotomy of the roots. Overlying muscle and skin were resutured with 3.0 
ethicon sutures, and topical auromycin antibiotic (Abbott Animal Health, U.K.) applied 
to the external surface. 
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Spinal Root avulsion: 
 
For sensory behavioural analysis to be performed post injury, an injury paradigm of 
avulsion that allows for evoked responses was required. A single spinal root avulsion 
model was designed where only the L5 root is avulsed, leaving the L4 root and 
corresponding plantar paw dermatome intact. Male Wistar rats again were anaesthetised 
with 4% isoflurane in 1.5L/min of O2.  An incision was made ipsilaterally to the iliac 
crest, the L5 lateral vertebral process identified and removed exposing the L5 spinal 
root. The L5 spinal root is then isolated with curved watchmaker forceps distally from 
the DRG and then carefully pulled from the cord. In this way both the L5 dorsal and 
ventral roots are avulsed from the cord.  Sham surgery included all of the above 
procedure, excluding avulsion of the L5 spinal root.  Overlying muscle and skin were 
resutured with 3.0 ethicon sutures, and topical antibiotic applied to the external surface. 
A major benefit of this model over multiple DRA and DRR surgery is that a lumbar 
laminectomy is not required as a surgical control, and so that spinal column does not 
become distorted, and trauma is directed only to the nerve roots and entry zones, more 
closely mimicking the neuropathy seen clinically. 
 
2.3: Behavioural analysis 
 
Injury paradigm: 
 
The benefits of the SRA injury model over multiple DRA and DRR is that it provides 
an opportunity for a deafferentation neuropathy to be analysed through evoked 
behavioural responses. The L4 and L5 spinal roots innervate the plantar surface of the 
rat hind paw, and the dermatome border runs diagonally along the rat hind paw plantar 
surface, from the middle digit through the distal surface of the heel. To test the 
development of evoked border-zone sensitivity, a condition seen clinically after 
brachial and/or lumbar plexus avulsion injury (Htut et al., 2006;Havton and Carlstedt, 
2009), it is this area of the hindpaw that will be stimulated. The red circle in Figure 1 
indicates the area of testing which best avoids pressure pads and is most central on the 
hindpaw for equal and consistent distribution of body weight through the paw.  Three 
tests were used to analyse sensory and motor deficits after SRA; a horizontal ladder, 
mechanical stimulation, and thermal stimulation. 
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Acclimatisation: 
 
54 male Wistar rats of 150-175g were acclimatised to the animal unit and cages for 2 
days before handling. After such time they were acclimatised to the behavioural room, 
ladder preparation, and Perspex test boxes (Ugo Basile, Italy) for 2 days before stimulus 
testing. Each test was performed in the morning (unless stated otherwise) at the same 
time before cages were cleaned to prevent external factors effecting behaviour (Vissers 
et al., 2003). Animals would always be tested from the least stressful and intensive test 
(ladder) first, and the most intensive stimulus (thermal) last, to prevent effects of one 
test interfering with another and to minimise stress. It was assumed that acclimatisation 
was reached when exploratory behaviour of the rats ceased and grooming began in the 
test boxes. Each animal was tested for no more than 2 hours before being placed back in 
home cages to minimise stress and to allow feeding. Animal groups were blinded 
throughout the experiment. 
 
 
Figure 2.1: Behavioural testing of the rat plantar hind paw. Diagram modified from Takahashi et al., 
2003. The area for mechanical and thermal testing is at the border of the L4 and L5 dermatomes, avoiding 
paw pads as indicated by the red circle. Blue numbers indicate locomotor foot fault scoring. A 5-point 
system was designed and depended upon plantar foot placement on the ladder rung. Scoring was thus: 1 = 
normal plantar step with toe grip on rung, 2 = mid-plantar placement without toe grip on the rung, 3 = 
heel placement on rung, 4 = foot slips off rung and 5 = foot completely misses a rung either at the toe or 
heel.  
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Horizontal ladder test: 
 
To test the development of motor deficits after avulsion of the L5 ventral root a 
horizontal ladder set-up was used. A ladder was propped no more than 6 inches over a 
table and attached to a cardboard cylinder and dark box at one end (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rats underwent 2 weeks training on the ladder every other day. Rungs were evenly 
spaced allowing the rat to remember rung spacing. This allows testing the ability of the 
animal to recruit spared lower motor units of the L4 ventral horn to perform a pre-
trained task. This is opposed to changing the rung spacing every day. This tests a rats 
ability to accurately recruit, control, and alter coordination of higher motor neurone 
activity of the brainstem and spinal cord, for each rung spacing, and is used notably in 
spinal cord injury paradigms (Maier et al., 2008;Metz and Whishaw, 2002). After the 
training period each rat that was placed at one end of the ladder would naturally and 
independently walk across the ladder in a quadrupedal motion (each ipsilateral hind-
paw placement occurs every other rung), rarely misplacing a step, and finally entering 
the cylinder. On the day of base-lining (day 0) the rats were set across the ladder three 
*  *  * *  *  * 
Figure 2.2: The horizontal ladder test for locomotor function. After a few days of exposure the animal 
voluntarily walks across the ladder into a tunnel at the far end. Red asterisks denote the rungs on which 
the injured hindlimb will be scored for foot faults in frame-by-frame video analysis. 
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times and video recorded from the left side from a raised position (Figure 2). Surgery 
was then performed either on the same day or next day. Post operative tests were 
performed on days 1, 3, 5, 7, 9, 11 and 14 for untreated groups: naïve, sham SRA, and 
SRA, and sacrificed on day 14. Drug treatment groups did not undergo locomotor 
testing. 
 
Quantitative video analysis was only performed at the end of the experiment to prevent 
bias. Videos were slowed down for detailed frame-by-frame analysis of the ipsilateral 
hindpaw placement in two ways. The first type of analysis quantified the total number 
of rung missteps out of 6. The second answered the question of what type of foot 
placement is most prominent across 6 rungs (foot fault score). 6 rungs were assessed 
ipsilaterally (Figure 2.2). Figure 2.1 describes the score the rat will receive when 
balancing on a certain area of the plantar surface.  
 
Mechanical plantar aesthesiometer (‘Von Frey’): 
 
For behavioural assessment of tactile hypersensitivity readings were taken using an 
automated plantar aesthesiometer (Ugo Basile, Italy). This consists of a movable 
actuator that lifts a blunt probe at a controlled force rate onto the plantar paw surface. 
This rate was set at 1.7 grams/second with a cut off weight of 50 grams and latency of 
30 seconds. This experimental set-up benefits from the removal of observational bias, 
human error, and variable force applied by the investigator experienced with manual 
Von Frey hairs. The mechanical aesthesiometer has greater accuracy (to nearest 0.1 
gram) and the weight incurred on the plantar paw increases at a linear rate from 0 to 
50g, whereas manual hair numbers have an exponential force increase, with large force 
differences at higher hair values between adjacent hairs. Rats were acclimatised and 
baselined, and then tested post operatively, in a similar way to the manual hair 
investigation. The probe made contact with the same plantar area, and increased force 
until the foot was voluntarily withdrawn. A positive response was determined as a 
single voluntary flexion withdrawal of the foot, with or without foot licking or biting, 
from the meshed flooring during the increasing weight of the probe. Each limb was 
tested 3 times with an interval of 5 minutes to prevent habituation to the stimulus, and 
readings were taken ipsilaterally and contralaterally and averaged. Post operative tests 
were performed on days 1, 3, 5, 7, 9, 11 and 14 for untreated groups: naïve, sham SRA, 
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and SRA, and sacrificed on day 14. For post operative time points in treatment groups 
see section 2.1.4. 
 
Thermal plantar test (‘Hargreaves’): 
 
The automated thermal plantar test in accordance with previous literature (Hargreaves 
et al., 1988) consists of a glass panel raised 8 inches above a table, on top of which are 
placed the Perspex test boxes. An infrared aesthesiometer probe (Ugo Basile, Italy) 
makes contact with the glass, and when active, heats up the glass and plantar paw 
surface of the rat above it providing a noxious heat stimulus. Infrared intensity was set 
at 50 units corresponding to 150mW of power applied per cm2. A safety cut off was set 
at 20 seconds latency to prevent tissue damage, and indicated non-responsiveness. Rats 
were daily acclimatised to the test boxes for ten minutes prior to testing until 
exploratory behaviour stopped. Once baselined rats were then tested post operatively in 
an identical way to the automated mechanical aesthesiometer. A consistent withdrawal 
response was maintained at approximately 8 seconds at baseline. Post operative tests 
were performed on days 1, 3, 5, 7, 9, 11 and 14 for untreated groups: naïve, sham SRA, 
and SRA, and sacrificed on day 14. For post operative time points in treatment groups 
see section 2.1.4. 
 
Weight measurements: 
 
The marker of spontaneous neuropathic pain, autotomy, did not occur in the SRA 
model, as the hind-paw was only partially de-afferented. Instead weight loss or rate 
reduction (Willenbring et al., 1994) was analysed. A reduction in growth rate after 
surgery was taken as a sign of a loss of appetite or motivation to feed, indicative of a 
developing spontaneous and chronic pain state. Weight was measured every other day, 
before behavioural testing, for the duration of the training period and post-injury period. 
Attention was taken to make sure rats did not lose more than 15% of their original body 
weight and remained in a healthy condition. Weight changes were graphically 
represented as a histogram of mean daily weight gain. 
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2.4: Pharmacotherapy 
 
Two treatment paradigms for neuropathic pain were assessed in this work. Firstly the 
prevention of hypersensitivity development by immediate pharmacological 
intervention, and secondly, the treatment or reversal of an established neuropathic pain 
state. These methods of treatment have translational possibilities in either acute or 
chronic root avulsion injured patients respectively. Antidepressant, anticonvulsant, 
neuroprotective, and anti-neuroinflammatory drugs were assessed. All drugs were 
administered to the animals intra-peritoneal and the experimenter was blinded 
throughout the experimental procedure. 
 
Single dose treatment groups: 
 
Conventional neuropathic pain treatments were explored as a treatment option for an 
established neuropathic deafferentation pain. Amitriptyline (Amitriptyline 
Hydrochloride, Sigma-Aldrich, UK.) dissolved in saline (30mg/ml), and carbamazepine 
(Sigma-Aldrich, UK.) dissolved in 45% 2-hydroxypropyl-beta-cyclodextrin (30mg/ml, 
Sigma-Aldrich, UK.) were administered at 32mg/kg on post operative days 11 and 13, 
and at 64 mg/kg on days 18 and 21, alongside a vehicle treatment group, after 
confirmation of the establishment of hypersensitivity at 5 and 7 days. One hour after 
treatment thermal and mechanical hypersensitivity was assessed in the way described in 
section 2.1.3. On days 14 and 20 animals were behaviourally assessed but without 
further treatment to ascertain whether hypersensitivity had returned in the absence of 
treatment. Animals were sacrificed on day 21. 
 
Immediate treatment groups: 
 
Two separate drugs were assessed for therapeutic efficacy immediately after injury as a 
treatment paradigm for prevention of neuropathic pain development. Minocycline 
hydrochloride (Sigma-Aldrich, UK.) was dissolved in saline (100mg/ml) and 
administered at 40mg/kg, and riluzole (Sigma-Aldrich, UK.)  was dissolved in 0.1M 
HCl (10mg/ml) and administered at 4mg/kg, immediately after injury and every day for 
7 days (days 0-6 p.o.), then every other day up to 14 days (days 7, 9, 11, and 13 p.o.), 
along with a vehicle group. Immunohistochemical effects were assessed in two 
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deafferentation models: DRA and SRA at day 14. Behavioural effects were assessed on 
post-injury days 1, 3, 5, 7, 9, 11 and 14, each time 24 hours after drug administration. 
 
Delayed treatment groups: 
 
In addition to pre-emptive treatment of minocycline and riluzole, a post-operative 
treatment regime was studied to ascertain efficacy of these drugs in ameliorating 
neuropathic pain during treatment, and permanently during drug withdrawal. Drugs 
were prepared and administered in accordance with the pre-emptive treatment, but 
given at day 7 every day for a week (days 7-13 p.o.), then every other day for a 
subsequent week (days 14, 16, 18, and 20 p.o.). Behavioural effects were assessed on 
post-injury days 3-27, each time 24 hours after drug administration. 
 
2.5: Sacrifice and dissection 
 
The animals were sacrificed by CO2 asphyxiation until breathing ceased and 
responsiveness to toe pinch was not detectable. The skin over the sternum was gripped 
with forceps and incisions made in the abdomen until the diaphragm was fully exposed. 
The xiphoid process of the sternum was clamped and held up so the diaphragm could be 
cut. The ribcage was cut bi-laterally and xiphoid process clamped back in a position so 
as to expose the whole thoracic cavity, with the heart accessible and still beating. A 
small incision to the left ventricle was made with fine micro scissors and a perfusion-
drip needle inserted and clamped into place. The right atrium was identified and an 
incision made with fine micro scissors, and 0.9% saline was flushed through the hepatic 
circulation. After 200ml of saline had passed through the circulation, and the exiting 
fluid from the right atrium and liver was clear of blood, the animal was perfused with 
400-500ml of chilled 4% paraformaldehyde (Sigma-Aldrich, UK.) in 0.1M PBS at pH 
7.4, until the tissue and limbs were rigid.  
 
The animals were dissected and vertebrae carefully opened with curved malleus nippers 
(Fine Science Tools, Heidelburg. Germany). The L4-L6 dorsal root ganglia were 
identified from there location relative to the iliac crest (L6 closest, L5 and L4 rostrally). 
The DRG were isolated and dissected with fine micro scissors (Fine Science Tools, 
Heidelburg, Germany) and roots traced back to the DREZ at the corresponding 
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segmental level. In this way the lumbar cord, from L3 to L6, could be accurately 
removed. The cords and DRG were then ‘post-fixed’ (4% PFA in 0.1M PBS at pH 7.4.) 
for 2-3 hours to ensure full fixation. Tissue was then removed from the fixative and 
submerged in a graded sucrose solution (10%, 20%, then 30% in 0.1M PBS) for 12 
hours in each concentration, or until the tissue had sunk to the bottom of the container 
indicating elimination of water from the tissue. The ventral and dorsal roots of the 
spinal cord were trimmed up to the DREZ, dural layer removed, the external surface of 
the cord dried on a paper towel, and vertically embedded in optimum cutting 
temperature (OCT) gel through freezing. The spinal cord was then sectioned on a Leica 
CM 1900 cryostat (Leica, Milton Keynes. U.K.) into 18μm thick transverse sections. 
Ten to fifteen sections were mounted per Superfrost slide (V.W.R. International, 
Lutterworth. U.K.), each adjacent section separated by approximately 340μm. L4 and 
L5 DRG were longitudinally sectioned into 8µm thick sections, with 6 sections 
sequentially presented on the slide. Slides were air dried for 2 hours and stored in a 
slide box containing cryoprotectant (120ml ethylene glycol, 200ml PBS, and 200ml 
sucrose) at -20°C until further use. 
 
2.6: Cell suspension preparation for flow cytometry  
 
After sacrifice and removal of the L3-L6 spinal cord (as described in section 2.1.5), the 
cord was placed in Ham’s F12 medium (Gibco, Paisley. U.K.) on ice. The cord was 
then divided into ipsilateral and contralateral halves under a microscope through a 
scalpel incision through the posterior median sulcus and anterior median fissure. 
 
Each half of the cord was placed in a 24 well plate at 37.5°C for 30 minutes with 800ul 
of F12 + 100ul of Type 1 Collagenase (Worthington. Reading. U.K.) added. The 
collagenase was diluted and filtered from powdered stock in the ratio 0.125g in 10ml of 
F12, after which the media was topped up with 100ul of fresh Type 1 collagenase and 
the cords left again for 30 minutes at 37.5°C. After this time the collagenase was 
removed by pipette and the tissue was twice washed in 1M Dulbeco’s PBS (P.A.A. 
Yeovil. U.K.). 1ml of BSF2 was added to each well and the tissue carefully dissociated 
through manual pipette titration, maintaining the cellular integrity but ensuring cell 
separation. These suspensions were then centrifuged at 1000rpm for 30 minutes. After 
removal of the supernatant, the pellet was resuspended in 1ml of 1M Dulbeco’s PBS 
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and centrifuged at 600rpm for 5 minutes in preparation for propidium iodide (PI. 
Invitrogen, Pailey, UK.) single staining and neurone-specific nuclear protein (donkey α-
mouse NeuN, Chemicon, Chandlers Ford, Uk.) in conjunction with 4,6-diamidino-2-
phenylindole (DAPI. Invitrogen, Paisley, UK.) double labelling. 
 
2.6.1: Propidium Iodide staining for cell death analysis 
 
After cell suspension preparation, the supernatant was removed with a manual pipette 
and 100μl of 5μg/ml PI (in 0.1M PBS) in 400μl of cell suspension was added to each 
sample tube in preparation for analysis with an LSR11 flow cytometer (BD 
Biosciences, Oxford. U.K.). PI is a DNA nuclear stain that is impermeable to unfixed-
cells with intact membranes. It specifically labels cells with permeabilised membranes, 
or in other words, cells that have undergone (but not specifically undergoing) apoptotic 
or necrotic cell death. In this way, flow cytometry provides a count of dead cells per 
sample analysed.  
 
2.6.2: NeuN and DAPI staining for identification of cell specific death 
 
After cell suspension preparation, the supernatant was removed and 1ml of DAPI 
(1:15000) was then added to the pellet for 5 minutes at room temperature. After this 
incubation, the suspension was again centrifuged at 600rpm/5min, supernatant removed 
with a pipette controller pipetboy (Pipettboy Acu, Scientific Laboratory Supplies, 
Nottingham, U.K.) and the cells resuspended in 10ml of 1M PBS PH 7.4. After another 
centrifuge/wash cycle, and removal of supernatant, the cells were fixed in 1ml 70% 
ethanol (ETOH) + 2% glucose for 30 minutes at room temperature. After this time the 
suspension was centrifuged at 600rpm/5min, supernatant removed, resuspended in 1M 
PBS PH 7.4, again centrifuged at 600rpm/5min, and supernatant removed. 1ml of the 
primary antibody donkey α-mouse NeuN was added to the cells at a concentration of 
1:1000. The suspension is incubated for 30 minutes at 37.5°C. After which time the 
suspension was centrifuged at 600rpm/5min supernatant removed, resuspended in 0.1M 
PBS PH 7.4, and centrifuged at 600rpm/5min. The remaining pellet was suspended in 
1ml of donkey α-mouse fluorescein isothiocyanate (FITC 1:400) (Jackson 
ImmunoResearch Labs, Suffolk. U.K.), and again incubated for 30 minutes at 37.5°C. 
Two more centrifuge and PBS wash cycles (see above) occurred before the suspension 
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was placed on ice. 500μl of the suspension was then isolated for flow cytometric 
analysis with an LSR11 flow cytometer.  
 
2.6.3: Preparation of controls for gating parameters 
 
Negative staining controls were used for PI flow cytometry. 400μl samples of unstained 
cell suspension (see section 2.2.1) in 100μl 0.01M PBS were analysed. The scatter plot 
produced gives a gating parameter for positive against negative staining known as the 
P1 box (see section 3.4.1a), that can be kept constant throughout the experiment, and 
accurately divides stained and non-stained cells. Gating parameter controls were also 
prepared for NeuN/DAPI labelled cell suspensions. These consisted of unstained (see 
section 2.2.1), primary antibody only, secondary antibody only, and DAPI only cell 
suspensions (modified from section 2.2.1b). The resultant scatter plots classified the 
positive against negative fluorescent staining gate parameters of FITC and DAPI lasers 
within the flow cytometer. In this way focused analysis of the positively stained cell 
suspensions is performed (see section 3.4.1b). 
 
2.7: Terminal deoxynucleotidyl transferase-mediated dUTP nick end (TUNEL) 
labelling 
 
Slides were washed twice in 0.01M PBS-Tween20 for 15 minutes after removal from -
20°C cryoprotective storage. The sections were then encircled with a hydrophobic PAP-
pen prior to incubation in equilibrium buffer [potassium cacodylate 200mM, pH 6.6 at 
25oC, Tris-HCL 25mM, pH 6.6 at 250C, DTT 0.2mM, BSA 0.25mg/ml, and cobalt 
chloride 2.5mM (Promega. Wisconsin. U.S.A)], 100ml per slide for 10 minutes at room 
temperature. The equilibration buffer was then tapped off, and approximately 100µl of 
the freshly made incubation mix (98µl equilibrium buffer, 1µl of biotinylated 
nucleotide mix, and 1µl of TdT enzyme (Promega. Wisconsin. U.S.A) was applied to 
each slide. Parafilm (Promega. Wisconsin. U.S.A) was placed over the top of the slide 
to ensure direct and even distribution of the enzyme mix and the tissue through removal 
of any air-liquid interface. These slides were incubated for 1 hour at 37°C in a humid 
chamber, ensuring they did not dry out. The slides were then incubated twice in 2x 
Standard Sodium Citrate (SSC) buffer (diluted from 20x SSC (Promega. Wisconsin. 
U.S.A.) in distilled water) for 15 minutes each, denaturing the TdT enzyme and ending 
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the reaction. The SSC was removed through 3 washes in PBS for 5 minutes each. The 
slides were then incubated for 2 hours in extra-avidin conjugated FITC (Ex-Av FITC 
1:400. Sigma, Poole, U.K.) at room temperature in a humidifier, after which time the 
slides were again washed 3 times in 0.01M PBS for 5 minutes and coverslip mounted 
with 0.01M PBS-glycerol (1:8) and nail varnish seal. These were then stored at 4°C in 
the dark until analysis.  
 
2.8: Single immunohistochemical staining protocol  
 
Slides were removed from cryoprotective storage, rinsed in two washes of PBS-
Tween20 for 15 minutes each and prepared in the same manner as described above for 
TUNEL staining. 10% normal donkey or goat serum (NDS/NGS) was applied to the 
tissue for 1 hour in preparation for antibody incubation. NDS was used if the secondary 
was derived from donkey, and NGS used if the secondary was derived from goat. The 
excess serum was tapped off the slide, the primary antibodies were added. The primary 
antibodies used to label primary afferent terminals, glia, neurones, leukocytes, and 
vasculature are listed and described in Table 2.1. Detrimental effects of root injury apon 
the spinal cord and peripheral nerves will be ascertained using these 
immunohistochemical markers. 
 
The dilutions indicated were made from stock antibody aliquots of 1:5 or 1:10, stored at 
-80°C, through serial dilutions with 0.01M PBS-0.2%TritonX-0.1%NaAzide. Primaries 
were incubated for 24 hours at room temperature in a humidifier to prevent the slides 
from drying out. After this time the slides were washed thrice for 5 minutes each in 
0.01M PBS-Tween20, and the secondary antibody added. 
 
For studies involving L3-L6 DRA and DRR spinal cord (Results 1) either donkey α-
mouse, donkey α-rabbit specific tetramethylrhodamine-5 isothyocyanate (TRITC 
1:400) (Jackson ImmunoResearch Labs, Suffolk. U.K.), or Ex-Av FITC (1:400) 
(Sigma, Poole. U.K.), were applied specific to the species of primary. The slides were 
incubated for 2 hours in a dark humidifier at room temperature, and then washed 3 
times for 5 minutes each in 0.01M PBS, and mounted in accordance with Chapter 2.3. 
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For studies involving L5 SRA spinal cord and DRG (Results 2-3) either donkey α-
rabbit Alexa Fluor 594 (1:1000), goat α-mouse Alexa Fluor 594 (1:000), or donkey α-
rabbit Alexa Fluor 488 (1:1000) (Invitrogen, Paisley. U.K.), were used and correspond 
to a spectrum emission wavelength of TRITC (red-594) and FITC (green-488). In 
addition Ex-Av FITC (1:400) (Sigma, Poole, U.K.) was also used for IB4-biotin DRG 
staining.  
 
The rhodamine and fluorescien secondaries were replaced by Alexa Fluors during the 
project due to laboratory centre preference, superior staining quality, and quicker 
incubation time (1 hour). However image analysis between old and new secondary 
antibodies was kept separate. 
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2.9: Double immunohistochemical labelling protocol 
 
For identification of sensory cell bodies within a DRG section, NeuN was applied 
alongside the specific subpopulation or injury marker, such that anti-mouse NeuN was 
used alongside biotin-IB4, anti-rabbit CGRP, anti-rabbit ATF3, and anti-rabbit TRPV1, 
and anti-rabbit NeuN was used alongside anti-mouse N52. The two primary antibodies 
Primary antibody Abbreviation Concentration 
and species 
Distributor Description of specificity 
Rat-CD68 ED-1 1:1000 
Mouse 
Serotec. Oxford. 
U.K. 
Specific to activated microglia and the 
majority of tissue macrophages, and 
also weakly by blood granulocytes. 
Rat Endothelial Cell 
Antigen 
RECA-1 1:100 
Mouse 
Serotec. Oxford. 
U.K. 
Specific to a cell surface antigen present 
on the endothelia of the vasculature.  
Ionized calcium-
binding adapter 
molecule-1 
Iba1 1:1000 
Rabbit 
Wako. Neuss. 
Germany. 
Specific for a Ca2+-binding peptide 
produced by activated monocytes and 
microglial cells. 
Glial Fibrillary 
Associated Protein 
GFAP 1:1000 
Mouse 
Chemicon. Chandlers 
Ford. U.K. 
Specific to intermediate filament 
proteins within astrocytes processes, 
and satellite cells. 
Calcium binding 
protein- S100 
S100 1:1000 
Mouse 
Chemicon. Chandlers 
Ford. U.K. 
Specific to glial and ependymal 
astrocyte cell bodies, including 
cytoplasm and nucleus. 
Neurone-specific 
Nuclear Protein 
NeuN 1:1000 
Mouse 
Rabbit 
Chemicon. Chandlers 
Ford. U.K. 
Specific to mature neuronal cell bodies 
but not proliferative cells. 
Calcitonin Gene-
Related Peptide 
CGRP 1:2000 
Rabbit 
Sigma. Poole.U.K. Specific marker of the terminals of 
small unmyelinated peptidergic 
afferents in the dorsal horn. 
Biotinylated- 
Griffonia 
(Bandeiraea) 
Simplicifolia 
Isolectin-B4 
IB4-biotin 1:200 
Lectin 
Affiniti. Exeter. U.K. Specific to unmyelinated non-
peptidergic afferent terminals in lamina 
II-i. Also a marker for agglutinate B-
type red blood cells, microglia, and 
blood vessels. 
Rat neutrophils Anti-
neutrophil 
1:1000 
Rabbit 
Gift from Prof H. 
Perry, Southampton 
University (Bolton 
and Perry 1998) 
Raised against rat neutrophils, at 
Southampton University. 
Heavy (200kDa) 
Neurofilament  
N52/NF200 1:16000 
Mouse 
Sigma. 
Poole. U.K. 
Specific marker for myelinated large A-
fibre sensory afferents in the DRG. 
Transient receptor 
potential cation 
channel, subfamily 
V, member 1 
TRPV1 1:2000 
Rabbit 
Chemicon 
Chandlers Ford. U.K. 
Specific marker for receptor present in 
small and medium sized sensory 
neurones, which is activated by heat, 
capsaicin, and vanilloid compounds. 
Activating 
transcription factor 3 
ATF3 1:200 
Rabbit 
Santa-Cruz 
Wembley. U.K. 
Specific marker for cellular stress or 
injury. 
Table 2.1: Primary antibodies and lectins used  
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were made up in solution together whilst maintaining the dilution quoted in Table 1, 
and applied to the slide in an identical way as single labeling for 24 hours, then three 5 
minute washes in 0.01M PBS+Tween20. The two corresponding Alexa Fluor secondary 
antibodies were applied separately for 1 hour each. Each secondary was applied for an 
hour and then washed off in three washes of 0.01M PBS+Tween20 for five minutes 
each and mounted as described in sections 2.3/2.4.  
 
For cases of identifying cell specific cell death, a TUNEL assay in conjunction with cell 
specific immunohistochemistry was performed. Astrocytes, microglia, neutrophils and 
neurones were labelled and analysed in this way. In all cases TUNEL staining was 
undertaken first (see section 2.3), prior to normal donkey serum being applied, so as not 
to interfere with the sensitive TdT-fragmented DNA binding. Before the secondary 
antibody ExAv FITC (1:400) is added, after 3 sets of 5 minute washes in 0.01M 
PBS+Tween20, either α-mouse S100, α-rabbit Iba1, α-rabbit ‘anti-neutrophil’, α-mouse 
ED1, or α-mouse NeuN (all dilutions indicated in Table 1) were added to the slide. 
These were then incubated at room temperature in a humidifier for 24 hours. After 
which time the slides were washed 3 times for 5 minutes each in 0.01M PBS+Tween20, 
before Ex-Av FITC (1:400) and α-rabbit TRITC (1:400) or α-mouse TRITC (1:400) 
(dependent upon the primary antibody species) were sequentially applied to the slide. 
The slides were incubated with the first secondary antibody for 2 hours at room 
temperature in a humidifier, covered from light with foil for 2 hours. After such time, 
the slides were washed 3 times for 5 minutes each in 0.01M PBS+Tween20 and the 
next secondary applied to the slide and the process repeated. The coverslipping 
procedure is identical to the method for TUNEL (see section 2.3) and general 
immunohistochemistry (see section 2.4), and the slides were stored at 4°C in the dark 
prior to analysis.  
 
2.10: Toluidine blue staining protocol 
 
In many cases identification of cell types via immunofluorescence is dependent upon 
epitope expression within a cell. If this epitope is not available due to the fixation 
process, or is in low quantities in the cell, or the antibody has poor specificity, then 
staining will be variable. For identification of general morphological changes and 
neuronal and glial cell numbers within the dorsal horn after injury, independent of 
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antibody-epitope binding, a metachromatic dye called toluidine blue was used that 
stains cell cytoplasm. Slides were removed from cryoprotective storage and rinsed in 
two washes of 0.01M PBS-Tween20. The slides were then dipped into 0.1% (w/v) 
toluidine blue in 0.1 PB PH 7.4, and incubated for 30 seconds. After which they were 
dipped briefly in distilled-H2O. The slides were then dehydrated through the alcohols: 
70%, 90%, and 100%, twice in each dilution for 2 minutes. The slides were than 
incubated in xylene, twice for 2 minutes, in fume cupboard. The slides were mounted 
with coverslips in synthetic resin Depex Polystyrene (DPX. Sigma-Aldrich, UK.) and 
allowed to dry in the fume cupboard. 
 
2.11: Microscopy 
 
Photography:  
 
All fluorescence microscopy was undertaken 1-2 days after the immunohistochemical 
incubation, to reduce effects of faiding of fluorescence from the fluorochromes, but was 
not essential for toludine blue staining. Photographs of all immunohistochemical 
markers were taken with a digital camera (Hamamatsu Photonics. Welwyn Garden 
City. U.K.) connected to the microscope, at a constant exposure time of 1.223 seconds 
to allow comparison across groups in staining intensity. Areas of cord and segmental 
level were all kept consistent between animals and experimental groups. For L3-L6 
DRA and DRR, 6 sections were selected randomly but with the intent of obtaining a 
range of segmental levels within the whole deafferented area, and the dorsal horn 
photographed. In the case of ED1 staining both dorsal horn and DREZ/dorsal columns 
were photographed as infiltration of blood borne macrophages occurs through the 
damaged DREZ in root injury models, as well as across microvascular endothelial 
tissue in the deeper dorsal horn. For L5 SRA, 3 to 4 sections were selected from both 
L5 and L4 regions for comparable analysis of injured versus uninjured segmental 
levels. Differences in segmental level were identified anatomically (Molander et al., 
1984).   Magnifications of photographs for analysis were either 10x or 20x optical 
zoom. For DRG images, photographs were taken of sections with equal distributions of 
neuronal bodies at either 10x or 20x optical zoom at a constant exposure time of 1.223 
seconds.  
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Percentage staining: 
 
For immunohistological staining that could not be accurately measured or represented 
by counts alone, a percentage positive staining was calculated for GFAP, IB4, CGRP, 
Iba1, ED1, and RECA-1. Each photograph was grey-scaled through Adobe Photoshop 
CS2, removing background staining intensity and non-specific staining, and cropped to 
isolate the entire area of interest. For CGRP and IB4 these were the medial portion of 
the superficial laminae. For GFAP and Iba1 the medial portion of the dorsal horn was 
analysed. For RECA, medial portions of the dorsal and ventral horns, as well as lamina 
X (central canal) were analysed. These photographs were manipulated by intensity 
gradient scaling with Qwin V3 (Leica, Milton Keynes. U.K.). This involves converting 
the grey scale into a binary pixel measure. All positively stained pixels, measuring 
above background levels, is set as 1 (positive), and staining below this is given 0 
(negative), for the marker of interest. Areas of cavitation and necotic tissue that could 
give false positive and false negative staining could be cropped from the image before 
analysis. In the Q-win programme, a frame area of 200000 pixels2 is placed in the area 
of interest for IBa1, GFAP, RECA-1 and ED1 and the area covered must be exclusively 
tissue. For IB4 and CGRP, this box is 10000 pixels2 and all four corners must be in 
contact with positive staining, to prevent false negative calculation from incorrect 
placement. This box and the area of the cord are kept constant, examples of which are 
shown in figure 2.3 for each of the different markers. Sections with extensive cavitation 
or distortion are not analysed, and the adjacent section is taken instead. Positive staining 
quantity therefore, is given as number of positive pixels of the total pixel number in the 
given area; a percentage. This data manipulation allows easy comparison between 
injury groups.  
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Counts: 
 
Counts for DRG subpopulations using CGRP, IB4, N52, ATF3, and TRPV1 were taken 
directly from the microscope. Each section was counted sequentially until 400 NeuN 
 
  
 
  
Fig 2.3: Method of Q-win percentage density staining calculation for CGRP, IB4, ED1, RECA-1, 
GFAP, and IBa1. In all cases photos have been greyscaled, removing background staining leaving only 
positive staining. Yellow boxes represent positive staining within the area of interest for each 
immunohistochemical marker. These boxes are kept constant in size and placement for each marker. A. Q-
win analysis for IB4 staining in lamina II. A box of 10000 pixels2 is placed within an area of positive 
staining. B. Q-win analysis for CGRP in lamina I. Similarly to IB4, a box of 10000 pixels2 is placed. C-E. 
Q-win analysis for IBa1, GFAP, and RECA-1 staining in the dorsal horn respectively. A box of 200000 
pixels2 is used. F. Q-win analysis for ED1 staining in the dorsal columns, using a 200000 pixel box. 
Similar analysis was undertaken for the dorsal horn. Scale= 100μm  
A 
F E 
D C 
B 
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positive cells with a visible nucleus were identified. Within these sections the total 
number of DRG subpopulation was counted, providing a percentage of total cells 
recorded.  
 
Positive cell counts for TUNEL nuclei and neutrophils were taken directly from the 
slide through a Leica DM-RB Fluorescence Microscope (Leica. Milton Keynes. U.K.). 
Counts were restricted to the dorsal horn and dorsal columns (including the dorsal root 
entry zone) for TUNEL and neutrophils. DAPI was used alongside TUNEL to prevent 
false positive counts. Counts were averaged from 5-6 sections per animal, to give a 
mean count for each animal throughout the injury zone. For NeuN counts within DRA, 
DRR, SRA, sham-SRA, and naive spinal cord, a magnification of x10 was used to take 
photographs of the dorsal horn, and total numbers of positive neurones were counted in 
lamina I to III (Figure 2.4) according to anatomical boundaries (Molander et al., 1984) 
for all time points. A line, parallel to the superficial laminae was drawn in the dorsal 
horn using photoshop (Adobe) approximately 270μm from the extremity of the dorsal 
grey matter to isolate the area of quantification. Total counts from lamina I-III were 
preferred to isolate boxed areas, as this method of quantification analyses the total 
neuronal pool. To clarify whether neurones were lost after root injury, or whether it is 
just the NeuN epitope being reduced within neurones, the general histological dye 
toluidine blue was used. A selection of neurones within the centre of the dorsal horn 
were counted rather than total number, as the dorsal horn could not be delineated in 
many cases, as glia are also label with this dye. A 263μm by 158μm box was drawn 
around the medial section of the dorsal horn incorporating a section of laminae I-III and 
kept consistent between sections, and neuronal numbers were counted. Neurones could 
be distinguished from glia due to their more rounded and larger appearance. Also Tol 
Blue counts within the dorsal horn could only be taken at 1 and 2 days, as staining 
intensity of glia around dorsal root entry zone and superficial dorsal horn after these 
early time points obscured neuronal identification. Counts were also taken in the ventral 
horn for SRA, sham-SRA, and naïve animals of motor neurones in L5 and L4, using 
NeuN and Tol Blue staining. Motor neurones are distinguishable from interneurones as 
much larger and distinctly located in ventro-lateral areas in the L4 and L5 segments 
(Fig 2.4). Few motor neurones are also found in the ventro-medial areas in L5 that are 
also counted, and become more numerous in L6 (Fig 2.4).  
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2.12: Statistical analysis 
 
All data is graphically presented as a time series after injury. Analysis was undertaken 
by the statistical method ‘repeated measures’ ‘two-way analysis of variance’ 
(ANOVA), using SPSS version 15.0 (SPSS UK Ltd. Woking. U.K.), due to the 
continued nature of data collection across time points within a group. The Shapiro-
Wilks normality test was used to indicate a Gaussian distribution within groups. 
Fisher’s Least Significant Difference (LSD) post-hoc test was used, as it is the most 
widely used and of medium conservativeness to differences in data, to identify 
significant difference amongst the data groups in question. All P-value significance is 
indicated within corresponding graphs, presented as an asterisk by the repective data 
Fig 2.4: Method of dorsal horn and motor neurone selection. 2 week SRA spinal cord stained with 
NeuN at L4 (A) and L5 (B) segmental levels, and Tol Blue at L4 (C) and L5 (D) segmental levels. I and 
C represent ipsilateral and contralateral sides. Blue dotted lines represent the area of quantification of 
dorsal horn neurones. This line is placed parallel to extremity of superficial dorsal horn at 130μm. Motor 
neurones could be easily identified with NeuN and Tol Blue staining and were contained within the areas 
denoted by the red dotted lines. Scale= 400μm 
A B 
C D 
I C 
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point using the notation: P<0.05 (*/#/x/+), P<0.01 (**/##/xx/++), and P<0.001 
(***/###/xxx/+++).  
 
For immunohistochemical analysis of DRA and DRR sham, and naïve groups, day zero 
is the naive group, and sham groups are presented as a comparison for the individual 
time points of 1 and 14 days post injury. Both ipsilateral and contralateral values are 
represented. Comparisons are made between ipsilateral vs contralateral (*), injury vs 
naïve (#), injury vs sham (x), and DRA vs DRR (+), above the respective data point. 
 
For behavioural groups comparisons were made in several ways: 1) Untreated: SRA-
untreated, SRA-sham, and naïve; 2) Immediate treatment: SRA-riluzole, SRA-
minocycline, and SRA-HCl vehicle; and Single dose treatment: SRA-carbamazepine, 
SRA-amitriptalyine, and SRA-cyclodextrin-vehicle; and 3) Delayed and treatment 
withdrawal: SRA-minocycline and SRA-riluzole.  
 
1) The SRA group was compared against naïve and sham groups for specific time 
points and between injured and uninjured hindlimbs within groups, using 
significant difference notation: against baseline (#), ipsilateral vs contralateral 
(x), injury vs naïve (*), and injury vs sham (+) above the respective data point. 
 
2) The immediate minocycline and riluzole drug treatment groups, and single dose 
treatment groups of amitriptyline and carbamazepine, were compared against 
vehicle their pre-operative baseline values and between injured and uninjured 
hindlimbs using significant difference notation: against vehicle (*), against 
baseline (#), ipsilateral vs contralateral (x).  
 
3) The delayed minocycline and riluzole drug treatment groups were compared 
against their pre-operative baseline levels (#), and between injured and 
uninjured hindlimbs (x).  
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Chapter 3: Histological assessment of dorsal root avulsion and dorsal 
root rhizotomy, as rat models of root avulsion injury. 
 
 
3.1: Introduction 
 
3.1.1: Current models for avulsion  
 
Rhizotomy is the surgical severance of spinal nerve roots between the DREZ and dorsal 
root ganglia (DRG), and unlike avulsion, is not a traction severance of the nerve root 
and does not lead to direct damage to the spinal cord. It is conducted experimentally 
and therapeutically rather than presenting in a pathophysiological setting. Clinical uses 
are to alleviate intractable pain from joints or other peripheral targets (Loeser, 1972), 
such as in cases of multiple sclerosis to alleviate trigeminal neuralgic neuropathic pain 
(Kondziolka et al., 1994), as well as treatment for radiation-induced plexopathy pain 
(Teixeira et al., 2007). It is also undertaken to alleviate symptoms of neuromuscular 
conditions, such as severe muscle spasms presented in cerebral palsy (Hodgkinson et 
al., 1997) and spastic diplegia (Tilton, 2009). However, this treatment can itself often 
lead to post operative neuropathic pain states (Hesselgard et al., 2007), and in some pre-
clinical laboratories can induce neuropathic pain (Eschenfelder et al., 2000;Asato et al., 
2000;Song et al., 2003), although this is controversial (Sukhotinsky et al., 2004). Due to 
the severity of this deafferentation, this treatment technique is now not used in isolation, 
and has been modified with the addition of stereotactic radiosurgery (Teixeira et al., 
2007), intrathecal baclofen (Tilton, 2009), and deep brain and central nervous system 
stimulation (Patwardhan et al., 2006).  
 
In preclinical research rhizotomy is often used as a model of dorsal root injury. When 
modeling fully deafferented limbs, due to the nature of the injury, hyperalgesic and 
allodynic responses cannot be elicited to evoked sensory tests. However, qualitative 
measures such as autotomy, including vigorous scratching of the deafferented limb, can 
be detected after unilateral brachial plexus rhizotomy (Kriz and Rokyta, 2000) and 
lumbosacral rhizotomy (Lombard et al., 1979). This extreme behaviour is thought to be 
due to false nociception from abnormal central activity of the dorsal horn and represent 
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spontaneous pain (Kauppila, 1998). However, this extreme behavior could be a 
response to an anethetised and flaccid limb (Rodin and Kruger, 1984). In this case, the 
animal does not recognize the limb as part of its body scheme and attacks it as a foreign 
object impeding locomotion. An aditional problem with this evaluation method is that 
there is no scale dictating the level of pain induced (Kauppila, 1998). Minor 
environmental factors such as stress and animal husbandry (Kauppila and Pertovaara, 
1991) can affect the behavior, and ethical reasons prohibit extensive autotomy through 
the requirement of humane end points to experiments. Weight loss, grooming, and 
exploratory behavior (Vos et al., 1994) have also been used as measures of spontaneous 
pain. Both evoked sensory and observational qualitative methods are used as 
behavioural measures of neuropathic pain (Coderre and Melzack, 1986). However, the 
presence and extent of autotomy as well as other qualitative measures of pain are at best 
variable. Indeed autotomy has also been shown to be markedly reduced in animals with 
higher levels of serotonin and dopamine in the spinal cord (Feria et al., 1992). 
Autotomy also shows strain dependency (Rubinstein et al., 2003), and only occurs in 
adult rodents (Vaculin et al., 2005). This suggests an ontogenetical dependence in CNS 
maturity on the susceptibility for autotomy. However, the proposition that autotomy is a 
result of neuropathic pain has met with controversy, as adult brachial plexus injury 
patients do not show autotomy. In addition, autotomic presentations in non-human 
primate lumbar-avulsion models can be abolished by simple care of wounds (Pioli et 
al., 2003), and by altering simple housing conditions (Berman and Rodin, 1982).  
 
As stated previously rhizotomy models are inconsistent when it comes to inducing 
behavioural hypersensitivity. Sheen and Chung ((Sheen and Chung, 1993)) first showed 
that DRR does not always lead to evoked neuropathic pain behaviour, and suggested 
afferent connections of the DRG cell body to cord are required for evoked pain 
sensations. This has been corroborated more recently (Sukhotinsky et al., 2004). Also in 
agreement, mechanical and cold allodynia, as well as spontaneous pain, induced by 
tight ligation of L5 and L6 spinal nerves, is completely attenuated by rhizotomy of 
these injured dorsal roots (Yoon et al., 1996). Contrary to this are studies showing that 
dorsal root crush, rhizotomy, ligation or partial dorsal root rhizotomy produces transient 
thermal and mechanical allodynia and hyperalgesia (Colburn et al., 1999;Eschenfelder 
et al., 2000;Nakamura and Myers, 2000;Song et al., 2003;Rothman et al., 2005), and 
other studies demonstrating that rhizotomy does not reverse spinal nerve ligation-
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induced pain behaviour (Asato et al., 2000;Sheth et al., 2002). Infact neuropathic pain 
behaviour has been shown to be maintained for up to 4 weeks, with no difference in 
presentation between injuries distal to the DRG (PNI/SNT) or proximally to it (DRR) 
(Winkelstein et al., 2001a). In some cases groups have shown an acute development of 
allodynia after dorsal root transection, but returns to baseline after 7 days (Sheth et al., 
2002;Rothman et al., 2005). The development of neuropathic pain behaviour after DRR 
in some models, gives reason as to why in some scenarios (Sheth et al., 2002) it cannot 
as a therapy relieve PNI-induced pain; as this is replacing one pain (PNI-induced) for 
another (rhizotomy-induced) (Sukhotinsky et al., 2004). The inconsistencies between 
DRR-induced pain outcomes between laboratories may be due to variable injury 
models, rat strains, or method of data collection, but at present it is unclear why DRR 
elicits tactile allodynia in some hands but not others. This variability suggests that 
dorsal root rhizotomy may be an unsuitable model for avulsion-pain, as the later injury 
consistently induces pain (Parry, 1980;Bonnard and Narakas, 1985;Bruxelle et al., 
1988).  
 
In the context of dorsal root injury, there are different sequences of events compared to 
SCI and PNI. This is most noticeable with respect to degeneration, with the latter injury 
leading to Wallerian degeneration of the distal nerve axons at much greater rate than 
with a central lesion (Vargas and Barres, 2007). This distinction is also applicable to 
regenerative properties of injured or severed nerve fibres, with the peripheral nerve 
having an ability for regrowth, reconnection and functional repair, due to intrinsic and 
extrinsic growth permitting factors (Johnson et al., 2005),  that are not present in the 
CNS (Jackowski, 1995). There is also evidence (Colburn et al., 1999;Winkelstein et al., 
2001a) suggesting the site of both root and nerve injury in relation to the DRG impacts 
on the magnitude of the subsequent spinal glial activation, cytokine expression, but 
interestingly not neuropathic pain behaviour (Winkelstein et al., 2001a). The most 
notable difference with rhizotomy and avulsion root injuries is the damage to the spinal 
cord, specifically the dorsal horn (Ovelmen-Levitt et al., 1984). The primary trauma to 
the dorsal horn, dorsal columns and DREZ after root injury, can be observed through 
histological analysis of toluidine blue staining. Damage is evident in the medial portion 
of Lissauer's tract with avulsion injury and subsequently gliosis in the substantia 
gelatinosa. In some cases the superficial laminae are absent and interneurones of lamina 
III have atrophied (Ovelmen-Levitt et al., 1984). This indicates a dramatic disruption to 
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post-synaptic neuronal populations and extensive necrotic and apoptotic cell death.  
Micro-vascular disruption and endothelial cell loss can also be observed after 
transection of the dorsal surface of the spinal cord (Imperato-Kalmar et al., 1997), 
accompanied by the activation and infiltration of monocytes and leukocytes (Fleming et 
al., 2006;Thacker et al., 2007). This infiltration generates acute lesion expansion and 
injury exacerbation as well as facilitating endogenous repair processes such as axonal 
sprouting and remyelination (Jones et al., 2005). Functionally on injury, damaged 
sensory terminals emit a barrage of action potentials, which lasts for many seconds, or 
even minutes, onto dorsal horn neurones (Seltzer et al., 1991). Several weeks after root 
transection however, extensive receptive field expansion is seen in the deep laminae to 
the spared input (Ovelmen-Levitt et al., 1984); deafferented cells show a spontaneous, 
repetitive and continuous patterning of axon potential propagation from extracellular 
recordings in the dorsal horn (Dalal et al., 1999). Lack of sensory innervation from a 
deafferented nerve, or an acute barrage of action potentials from transected roots, may 
evoke a change in the original pattern of neural processing within the dorsal horn and in 
its central projections (Melzack et al., 2001), leading to prolonged heightened neuronal 
responses. Indeed after dorsal rhizotomy in the cat (Loeser and Ward, Jr., 1967), unitary 
activity recordings of deep laminae neurones were found to be hyperactive compared to 
non-deafferented neurones. This hyperactivity was also found to be present in human 
patients (Guenot et al., 2003) and rats (Guenot et al., 2002) with brachial plexus 
avulsion, and this discharge pattern is abolished through DREZotomy (Guenot et al., 
2003). This hyperactivity is thought to contribute to the maintenance of spontaneous 
deafferentation pain (Dalal et al., 1999) as well as neuropathic behaviour, such as 
autotomy, in vivo (Seltzer et al., 1991). 
 
3.1.2: Secondary consequences to dorsal root avulsion 
 
Consequences of injury to the spinal cord are not limited to the initial insult; be it from 
compression, root injury and peripheral nerve injury. Degeneration for example has 
been shown to continue for years after initial insult (Totoiu and Keirstead, 2005). 
Secondary injury within the CNS is the response of the intrinsic nervous system and 
extrinsic vascular system to the initial trauma. Both inflammatory and immune 
responses from non-neuronal cells in the blood, such as the recruitment of destructive 
neutrophils and macrophages (Popovich et al., 1997;Popovich and Jones, 2003), and 
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within the CNS, such as reactive microglia (Fleming et al., 2006;Milligan and Watkins, 
2009) are believed to be involved. These cell types produce ‘zones’ of pathological 
change that spread out from the initial trauma, and also progress within the site of 
injury. Processes such as inflammation, gliosis, oxidative damage and excitotoxicity 
lead to necrosis and apoptosis, axonal swelling and damage, Wallerian degeneration, 
and the formation of cystic cavities (Hagg and Oudega, 2006). Many of these secondary 
processes have been characterised after SCI and PNI, and have been successfully 
manipulated therapeutically (Baptiste and Fehlings, 2006). However very little work 
has concentrated upon the understanding the progressive effects of root avulsion injury 
within the spinal cord, and as such therapeutic intervention at the cellular level is 
limited. Presented here is a review of secondary injury phenomena, some degenerative, 
others regenerative, and their possible involvement in dorsal root avulsion. 
  
3.1.2.1: Glial changes 
 
Glial cells are important players in the functioning of the nervous system both before 
and after injury. The main types of CNS glial cells are astrocytes, microglia and 
oligodendrocytes. Each has a distinct role: oligodendrocytes play a role in myelinating 
and supporting CNS axons, microglia provide innate immunity for the CNS by actively 
assessing the state of the spinal cord, excavating dead neurones, plaques and infectious 
antigens, and astrocytes provide structural support to neurons and regulate potassium 
and calcium ion concentration, and extracellular pH (Fawcett and Asher, 1999). 
Astrocytes also importantly regulate the amount of synaptic glutamate available to 
neurons through the expression of Na+-dependent transporter proteins (Rat homologues: 
GLAST and GLT1. Human homologues: EAAT1 and EAAT2) on their surfaces, 
preventing excitotoxicity (Anderson and Swanson, 2000).  
 
Upon damage, the central nervous system undergoes an injury response, called ‘reactive 
gliosis’ or glial scarring, the main function of which is neuroprotective by limiting the 
size of the injury. However this process is detrimental to recovery, due to the 
impedence of axon regrowth (Fawcett and Asher, 1999;Fawcett, 2006). The final 
structure of a glial scar, which takes 6 weeks to fully develop in vitro (Polikov et al., 
2006), is predominantly astrocytic; however, nearly all non-neuronal cells of the CNS 
are involved (Ohlsson et al., 2004). The main players are oligodendrocytes, meningeal 
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cells, astrocytes, and microglia. Glia are actively recruited in response to injury through 
infiltration and/or migration to the injury site, and their numbers are greatly increased 
through proliferation of the resident population in the CNS (Liu et al., 2000a;Scholz 
and Woolf, 2007).  
 
Astrocytes play the major role in creating and maintaining the integrity of the structure 
of the ‘non-permissive’ glial scar, forming a barrier to external or foreign matter. They 
can be identified by labelling proteins they express such as, glial fibrillary acidic protein 
(GFAP), a member of the class III intermediate filament protein family, or by the 
calcium binding protein, S100β. Upon root injury and spinal nerve transection 
astrocytes hypertrophy by 3-4 days within the ipsilateral dorsal horn (Murray et al., 
1990;Colburn et al., 1999). Astocytes do not proliferate (Murray et al., 1990) but 
increase expression of GFAP across 28 days in direct comparison to microglia (Tanga et 
al., 2004;Tanga et al., 2006). Neonatal root injury shows less propensity for astrogliosis 
(Murray et al., 1990), and may provide rational as to why plasticity and indeed recovery 
after root re-implantation is more effective in infants (Carlstedt et al., 2000;Kato et al., 
2006). As described the main role of reactive astrocytes is to maintain the structural and 
functional integrity of the scar (Fawcett, 2006). If astrocytes are prevented from 
becoming reactive (through administration of antiviral ganciclovir), SCI in rats leads to 
wide spread tissue disruption, pronounced cellular degeneration, failure of wound 
contraction, and motor impairment, far beyond that of equivalent untreated rats 
(Faulkner et al., 2004). To accomplish this essential scar formation astrocytes produce 
and express chondroitin sulphate proteoglycans (CSPG), cytotactin/tenascin, neurocan, 
brevican, and versican and may other extracellular matrix components (Beggah et al., 
2005). However, these non-permissive proteins are adverse to natural growth-cone 
elongation and targeting (Yiu and He, 2006), and inhibitory to successful re-targeting 
and repair of transected axons after CNS lesioning (McKeon et al., 1991) or dorsal root 
crush (Chong et al., 1999). Chondroitinase ABC, an enzyme that breaks down CSPGs, 
has been shown to improve regenerative neuronal growth through scar tissue and 
functional recovery, in animal models of SCI (Bradbury et al., 2002) and root injury 
(Cafferty et al., 2008). In addition 7-14 days after PNI, glutamate transporters, GLT-1 
and GLAST, downregulate their expression profiles on astrocytes (Xin et al., 2009). The 
vesicular glutamate transporter, VGLUT 1, found in neurones and astrocytes (Montana 
et al., 2004) are also downregulated by DRR and sciatic nerve transection by 12 days 
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(Brumovsky et al., 2007). This reduction in transporters increases extracellular 
glutamate, leaving dorsal horn neurones susceptible to excitotoxicity and cell death, 
and/or hyperexcitabilty resulting in neuropathic pain. 
Other glia within the spinal cord, for example oligodendrocytes, also express important 
inhibitory molecules such as myelin inhibitory molecule N1-250/NogoA (GrandPre et 
al., 2000), myelin-associated glycoprotein (MAG) (Fawcett and Asher, 1999), 
oligodendrocyte myelin glycoprotein (OMgp), Semaphorin 4D and Tenascin-R (Yiu 
and He, 2006), proteoglycans (Beggah et al., 2005), and NG2 (Keirstead and 
Blakemore, 1999), to aid successful scarring but also impeding regeneration (Fawcett, 
2006). Meningeal cells that cover the external surface of the CNS rapidly migrate to the 
site of trauma after a penetrating injury to neuronal tissue (Fawcett and Asher, 1999). 
They condense together to form a protective layer around the injury along side 
astrocytes, inhibitory to neurite outgrowth, called the glial limitans. This inhibition is 
likely to come from the production of NG2 and the multifunctional protein tenascin 
(Levine and Nishiyama, 1996) as well as the production of the chemorepellant, 
semaphorin 3A (Niclou et al., 2003). After dorsal root transection, a contributor to the 
growth inhibitory environment of the DREZ, as well as the deep grey matter and dorsal 
columns, is likely to be meningeal cell activity (Chong et al., 1999).   
Microglia have a different role to astroytes within the CNS scar, and play an essential 
role in the spinal cord and brain as an active immune defence for the central nervous 
system. Under resting conditions they are quiescent, but continuously sample the local 
environment looking for signs of damage or infection, removing dead cells and 
pathogens (Rock et al., 2004). Microglia can be labelled with an antibody to ionized 
calcium adaptor binding protein-1 (Iba1), a protein product of the gene, allograft 
inhibitory factor-1 (Aif1). This protein is constituatively expressed in microglia, and is 
upregulated during activation of this cell type. Microglia become activated through a 
number of receptor-agonist signals from neurones or by other glial cells that include 
ATP-P2X4/X7/Y6 signalling, CX3C1 (fractalkine)-CX3CR1 signalling, and HSP (Heat 
shock protein)-TLR (Toll-like receptor) signalling (Tsuda et al., 2003;Obata et al., 
2008;Milligan and Watkins, 2009;Inoue et al., 2009). When for example, spinal root 
damage occurs, microglia become activated and participate in phagocytosing 
degenerating debris (Hoffmann et al., 1993;Hashizume et al., 2000a;Liu et al., 2000a). 
Indeed, in the rhizotomised dorsal funiculus of the kitten, microglia have been shown to 
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contain myelin and lipids (Franson and Ronnevi, 1989), and astrocytes and microglia 
transport debris from the neuropil to the blood via endothelial cells (Holtzer et al., 
1998). Microglia, identified by OX42 labelling, are upregulated through proliferation 
around primary afferent terminals and motor neurones 24 hours after sciatic nerve 
transection, dorsal root rhizotomy and spinal root avulsion, peaking around a week after 
(Eriksson et al., 1993;Colburn et al., 1999;Liu et al., 2000a;Penas et al., 2009). 
However after dorsal root rhizotomy microglia present much less compliment activity 
and reactivity than after PNI (Liu et al., 1998;Colburn et al., 1999). It has recently been 
concluded that the microglial/macrophage response after disease, injury, or 
inflammation to the nervous system is not a homogenous one (Cameron and Landreth, 
2010), and can occur via a ‘classical’ pathway (M1) involved in inflammation and 
immune response, or an ‘alternative’ pathway (M2) for anti-inflammatory processes 
such as wound healing and phagocytosis (Kigerl et al., 2009). It is understood that 
microglia have the capacity for aiding neuroregeneration or collateral sprouting, 
perhaps through phagocytosis of myelin debris and growth factor expression 
(Aldskogius, 2001), and this could well occur through the M2 pathway (Kigerl et al., 
2009). The M1 pathway however is neurotoxic (Kigerl et al., 2009), mediated via free 
radicals, cytokines, and complement component expression (Aldskogius and Kozlova, 
1998). Functionally, after spinal cord injury in mice, activation of microglia via 
therapeutic administration of IL-12, assisted in remylination and lead to improved 
recovery (Yaguchi et al., 2008). However the ability of microglial-phagocytosis in the 
CNS is less than observed in the periphery; controlled by monocyte-macrophages 
(Aldskogius and Kozlova, 1998), taking 14 days to complete primary afferent terminal 
phagoctyosis after dorsal root rhizotomy (Liu et al., 1998). This slow clearance may 
explain the absence of effective regeneration in the CNS compared to the PNS.  
Complement-3 (C3) component expression strongly facilitates monocyte-macrophage 
phagocytosis in the PNS (Aldskogius and Kozlova, 1998). C3 is not induced in 
microglia-macrophages of the dorsal horn after rhizotomy (Liu et al., 1998) but is 
expressed in microglial-macrophages of the dorsal horn after sciatic nerve cut (Liu et 
al., 1998), suggesting anterograde degeneration is not a stimulus for the generation of a 
complement-induced fully-phagocytotic microglial (M2) phenotype; rather DRG cell 
body connectivity to the dorsal horn is the crucial difference. It may be this factor, 
among many others, that controls neuroregenerative capacity. It is suggested that if 
microglia can be pharmacologically influenced to undergo activation via the M2 
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pathway, this may provide a neuroprotective strategy and reducing neuroinflammation 
in SCI (Kigerl et al., 2009), and could also be applicable to root injury. 
 
In recent years, a major role for microglia and astrocytes has emerged in the onset and 
maintenance of neuropathic pain (Raghavendra et al., 2003;Watkins and Maier, 
2003;McMahon et al., 2005;Nesic et al., 2005;Tsuda et al., 2005;Tanga et al., 
2006;Inoue and Tsuda, 2009). The roles of astrocytes and microglia may be slightly 
different in peripheral compared to spinal cord injury models. It is suggested that 
microglia are important for the onset of neuropathic pain in peripheral nerve injury 
(Raghavendra et al., 2003), with the development of a maintained chronic pain state, the 
result of a replacement of activated microglia with activated astrocytes. This is 
confirmed in sciatic nerve injury, where microglial activation preceeds astrogliosis 
(Cavaliere et al., 2007). An interesting point is dorsal root rhizotomy produces only 
transient microglial reactivity (Eriksson et al., 1993;Colburn et al., 1999) of much less 
magnitude than PNI, and leads to further scepticism over whether the injury leads to 
neuropathic pain behaviour (Sukhotinsky et al., 2004). Conversely, in spinal cord injury 
models, microglia have a much larger and prolonged role, having been shown necessary 
for the maintenance of chronic pain states (Hains and Waxman, 2006) alongside 
chronically ‘over-activated’ astocytes (Nesic et al., 2005). Noxious stimuli, disease or 
trauma to neurones can cause release of excitatory neurotransmitters like glutmate, and 
a milieu of neuroactive compounds like heat shock proteins (HSPs), fractalkine, 
prostaglandins (PGE-2), reactive oxygen species (ROS) such as nitric oxide (NO), pro-
inflammatory cytokines (TNFα, IL1β, IL6), and ATP. These compounds activate glial 
cells in close proximity, which in turn generate and release more proinflammatory 
mediators which increase AMPA and NMDA receptor conductivity and number in 
neurones, contributing to the maintenance of the pain (Watkins et al., 2001;McMahon 
et al., 2005;Milligan and Watkins, 2009) and may induce cell death through 
excitotoxicity mechanisms. Although the glial reaction is largely confined to the sites of 
injury, activated microglia can migrate to areas of the spinal cord that are not directly 
affected by trauma and contribute to the sensitization of neurones, thereby contributing 
to evoked pain sensations like hyperalgesia and allodynia (Beggs and Salter, 2007). It is 
unclear however what role these glial cells have to play after dorsal root avulsion and 
corresponding neuropathic avulsion-pain. 
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3.1.2.2: Neuronal changes 
 
The changes that occur to the neuronal population of the spinal cord will be catagorised 
into presynaptic, i.e. to primary afferents, and postsynaptic, i.e. to dorsal horn neurones. 
 
Presynaptic 
The time course of degeneration of the transected afferent nociceptor fibre terminals in 
the dorsal horn can be measured through substance-P (SP) labeling within lamina I, II, 
and V, with notable decrease by 7 days (Zhang et al., 1993), and is most marked at 10-
11 days (Tessler et al., 1980) after complete DRR of the lumbosacral plexus. 
Neurofilament degeneration is prominent at 3-4 days post rhizotomy, and absent 
beyond 7 days (Ralston, III and Ralston, 1982) This terminal degeneration is not 
exclusive to root deafferentation, but also occurs prominently at 30 days post peripheral 
nerve transection within lamina I-IV, lissauers tract, dorsal funiculus, gracile nucleus, 
and to a less extent in lamina V and VI (Arvidsson et al., 1986), suggesting DRG 
connection is not enough to prevent primary afferent terminal degeneration in the long 
term, and most likely through loss of target derived growth factors is key. Interestingly 
at 2 weeks, ipsilateral loss of CGRP positive terminals is incomplete in the deafferented 
dorsal horn, even after rhizotomy of 5 lumbar segmental levels in the cat (Traub et al., 
1989), suggesting the presence of a lengthy segmental collateral supply of peptidergic C 
fibres. This could also represent resident CGRP-positive second order dorsal horn 
neurones, that are know to be present in the rat lumbar cord (Conrath et al., 1989).  
 
Alongside the loss of synaptic input from deafferented fibres, there is also evidence to 
suggest a gain of synapses through three charaterised pathways: plasticity of descending 
supraspinal circuits, local interneuronal circuits, and sprouting of adjacent spared root. 
This increase in synaptic densities has been shown after unilateral DRR within the 
ipsilateral dorsal horn, and described as an anatomical compensatory recovery 
mechanism (Murray and Goldberger, 1986;Zhang et al., 1993;Zhang et al., 1995) that 
may contribute to functional recovery of some reflexes and locomotion, but also central 
sensitization mechanisms and hypersensitivity of dorsal horn neurones (see chapter 4). 
More specifically some of the sprouting involves a proliferation of SP and serotonin 
(5HT) containing terminals in lamina I, II and Clarke’s nucleus, usually 2 weeks after 
multiple unilateral rhizotomies (Tessler et al., 1980;Polistina et al., 1990;Wang et al., 
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1991;Zhang et al., 1993). This compensatory form of sprouting originates from the 
terminals of supraspinally descending 5HT systems like the raphe nuclei and the 
reticular formation (Shapiro, 1997), or in the case of SP, interneuronal or propriospinal 
fibre sprouting segmentally at the level of lesion (Tessler et al., 1980;Tessler et al., 
1981). Descending tracts from the raphe nucleus facilitates or inhibits nociceptive 
processing in lamina II via inhibitory 5HT-1A receptors present on interneurones, and 
rubrospinal tracts facilitates motor efferents. It may be via the latter tract sprouting by 
which the functional recovery of locomotion seen after extensive DRR could occur, 
through a mechanism of ‘reactive reinnervation’ (Zhang et al., 1993). There is also 
evidence to suggest adjacent intact roots may sprout into lamina II after dorsal root 
rhizotomy (Zhang et al., 1995) recovering the lost terminals. This occurs by 35 days 
post rhizotomy, with CGRP terminal densities increasing by 7 fold compared to the 
maximal loss seen at 5 days (McNeill et al., 1991). There is however some debate over 
whether deafferentation can induce spared root sprouting (Mannion et al., 1998), or if 
primary afferent sprouting even exists after injury (Shehab, 2009). Further evidence for 
primary afferent sprouting evidence will be covered in chapter 4.  
 
Postsynaptic 
One of the most notable effects of deafferentation injuries within the postsynaptic 
neuronal population is the amount and rate of cell death that occurs. Peripheral nerve 
injury models have shown cell death to occur in the superficial dorsal horn at 7 days but 
not 3 and 14 [(Azkue et al., 1998;Scholz et al., 2005) but see (Polgar et al., 2004) for 
contradictory data], and a much more delayed and progressive loss of DRG neurones 
across 32 weeks (Vestergaard et al., 1997;Tandrup et al., 2000). The mechanism of the 
transynaptic cell death in the dorsal horn is likely hyperactivity of peripheral nerves 
leading to glutamate excitotoxicity. Indeed increased activity of injured peripheral 
fibres induces activity-dependent apoptosis of dorsal horn neurones (Coggeshall et al., 
2001). This cell loss can be prevented by caspase inhibitors, which reduces dorsal horn 
hyperexcitability and neuropathic pain associated through maintaining lamina II 
interneurones (Scholz et al., 2005). The effect upon the postsynaptic neurones of the 
dorsal horn is dramatic after dorsal root injuries, with spontaneous discharges of the 
dorsal horn neurones after unilateral brachial plexus rhizotomy (Dalal et al., 1999), 
possible ‘umasking’ of previously unresponsive neurones (Basbaum and Wall, 1976), 
correlating with the onset of neuropathic pain behaviour in the rat (Guenot et al., 2002). 
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This hyperactivity may lead to excitotoxcity of neurones. However, it is unclear 
whether dorsal horn neurones die after root transection. Indeed complete lumbosacral 
plexus dorsal rhizotomy does not lead to dorsal horn cell death, quantified in Clarke’s 
nucleus, as measured by cresyl violet histological counts (Sanner et al., 1993). 
Interestingly, rhizotomy can prevent retrograde cell death in Clarke’s Nucleus induced 
by hemisection of spinocerebellar tract axons (Sanner et al., 1993), suggesting in spinal 
cord injury, primary afferents could exacerbate an axotomy injury perhaps through 
glutamate excitotoxicity. In PNI models there is still debate as to whether cell loss is 
even specific to dorsal horn neurones, with TUNEL-positive cells being identified as 
microglia, or even if it is causal to the development of allodynia and hyperalgesia 
(Polgar et al., 2005). The above literature suggest apoptotic cell death in the dorsal 
horn, whether it is specifically glial or neuronal, is activity dependent, and an 
ectopically active spared nerve or DRG-dorsal horn neurone contact is required to 
induce it (Coggeshall et al., 2001;Scholz et al., 2005). Therefore it will be interesting to 
see if dorsal horn neurone apoptosis is present in a full lumbosacral plexus-avulsed 
dorsal horn, or if indeed neuronal loss even occurs.  
 
Ventral root avulsion (Koliatsos et al., 1994;Carlstedt and Cullheim, 2000;Bergerot et 
al., 2004) leads to motor neurone death in vivo peaking by 14 days.  This may well be a 
response to accumulation of free radicals and consequently oxidative damage (Martin et 
al., 1999). NO, produced in an enzyme reaction with L-arginine and nitric oxide 
synthase (NOS), regulates immune function, blood vessel dilation, as well as serving as 
a neurotransmitter/neuromodulator in the processment and nociceptive stimuli (Reuss 
and Reuss, 2001;Cizkova et al., 2002). It has been implicated in the development of 
neuronal plasticity and hyperactivity in dorsal horn neurones and DRG after PNI 
(Cizkova et al., 2002). In free-radical chemical configuration, and excess, NO leads to 
cellular oxidative stress responses, DNA damage, and apoptosis. Neuronal NOS 
(nNOS) can be used as a marker for the molecule NO in naïve tissue, and is 
concentrated in lamina I-III and autonomic regions of the rat dorsal horn (Reuss and 
Reuss, 2001). Its expression increases in both DRG and spinal neurones after SCI 
(Vizzard, 1997) or PNI (Ma et al., 2000;Cizkova et al., 2002;Keilhoff et al., 2002). 
After ventral root avulsion NOS expression increases in motor neurones, and is 
associated with cell death (Wu, 1993), and inhibition of NOS through nitroarginine 
administration reduces this cell loss (Wu and Li, 1993;Ayata et al., 1997). However 
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DRG, spinal interneurone, and motor neurone survival, regeneration, and 
revascularisation are severely compromised in peripheral nerve injured NOS (neuronal, 
endothelial and inducible isoforms) knock-out mice (Keilhoff et al., 2003). Further 
NOS-positive surviving motor neurones (35% of total pool) can be found 9 weeks post 
ventral root avulsion, colocalised with Heat Shock Protein 27 (HSP27) (He et al., 
2003). HSP27 is a chaperone protein, and may assist radical scavenger systems from 
removing excess toxic NO. NO may control a fine balance of anti-apoptotic and pro-
apoptotic actions depending on its oxidative state or presence of scavenger systems in 
certain cells, and may not be the underlying determinant of cell death in models of 
nerve injury. nNOS is upregulated in injured and intact DRGs after selective dorsal root 
rhizotomy (Qin et al., 2004), but is reduced in dorsal horn neurones 5 days after such an 
injury alongside Substance P terminals, suggesting its spinal expression is regulated by 
peripheral afferent connection (Reuss and Reuss, 2001). Little is known about the role 
of nNOS or NO in dorsal horn neurone specific cell death in dorsal root avulsion 
models however, or indeed if it contributes to neuropathic pain. Nitic Oxide’s ‘double 
edged sword’ role in neuronal survival and death is confusing, and may not provide 
adequate assessment of dorsal horn neuronal population after rhizotomy or avulsion.  
 
3.1.2.3: Vascular changes 
 
CNS lesions, especially shearing and stretching, lead to direct mechanical damage to 
the microvasculature, especially in the grey matter. This direct disruption of the blood 
brain barrier, causes hemorrhaging of the vasculature (Maikos and Shreiber, 2007), 
altered blood flow and ischemia (Senter and Venes, 1978). For example after a spinal 
cord compression injury, endothelial cells of the vasculature are lost as early as 1 and 2 
days in mice (Benton et al., 2008a;Benton et al., 2008b) and rat models (Imperato-
Kalmar et al., 1997). An important regenerative response is observed after SCI, with 
increased vessel number and thickness 4 days post injury in the rat (Imperato-Kalmar et 
al., 1997), and 3 days in the mouse (Benton et al., 2008a), at both the injury site and at 
more rostral and caudal sites. This is associated with a unique IB4 intravascular binding 
surrounding the lesion site, and the up-regulation of ADAM8 in endothelial cells 
suggestive of neovascualture and angiogensis (Benton et al., 2008a;Mahoney et al., 
2009). Matrix metalloproteinases (MMP) present in the extracellular matrix and on 
inflammatory cells activate and cause the release of VEGF and fetal growth factors that 
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lead to plasticity of endothelial cells (Mautes et al., 2000). In the mouse, expression 
levels of platelet/endothelial cell adhesion molecule-1 (PECAM-1) found on endothelial 
cells, consistently recovers across 14 days after spinal cord injury (Benton et al., 
2008a), and this closely correlates with an accumulation of connective tissue in the 
primary injury cavity, and regeneration of ascending sensory fibres (Inman and 
Steward, 2003a) and descending corticospinal fibres (Steward et al., 2008). However, in 
stark contrast, angiogenesis is not mainted in the rat or other mammals after SCI (Inman 
and Steward, 2003a;Inman and Steward, 2003b) and at 7 days the number of vessels 
declined and cystic caverns containing CSF form in the epicenter (Imperato-Kalmar et 
al., 1997). After ventral root avulsion in cats (Holtzer et al., 1998), endothelial cells 
contained vacuoles filled with fibrous-like substances, and microvasculature was 
surrounded by glia and phagosomes containing myelin, suggesting transport of necrotic 
debris from the neuropil to the blood occurs via endothelial cells after injury. This role 
of vasculature endothelial cells after injury must be beneficial for protective scarring; 
however, it is still unclear if vascular plasticity is benefitial or detrimental to the 
traumatized spinal cord (Mautes et al., 2000). It is clear that this biphasic response in 
the rat vasculature (Imperato-Kalmar et al., 1997), and maintained cavatiation in 
mammals of higher order than mice, suggests angiogenesis is incapable of 
counterbalancing chronic progressive degeneration of vasculature after SCI. So far rat 
models of dorsal root rhizotomy and sciatic nerve transection show no obvious 
reduction in vasculature staining by 7 days, suggesting direct trauma to the spinal cord 
is needed to induce a vascular response (Liu et al., 1998). Further work however is 
necessary to identify the effects of dorsal root avulsion on vasculature maintenance. 
 
3.1.2.4: Inflammation 
 
During the period of vascular disruption and endothelial cell loss, production of 
cytotoxic reactive species within the spinal cord neuropil can occur. This causes rapid 
activation of resident glial cells, but also infiltration of monocytes through extravasation 
via endothelial cells (Fawcett and Asher, 1999;Thacker et al., 2007) resulting in an 
inflammatory response (Fleming et al., 2006). This response is associated with 
endothelial degredation via MMPs expressed on inflammatory cells (Mautes et al., 
2000). This causes an acute extravasation of mast cells, granulocytes, T-cells, 
monocytes, and neutrophils from the blood stream, peaking at 3 days (Popovich et al., 
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1997;Thacker et al., 2007). This produces further upregulation of cell adhesion 
molecules, chemokines, cytokines (Morganti-Kossmann et al., 2002), and interleukins 
(Hashizume et al., 2000a). These inflammatory mediators can have detrimental effects 
on cell survival (Popovich and Longbrake, 2008), by the production of reactive oxygen 
species that damages healthy tissue (Carlson et al., 1998), and can cause neuropathic 
pain (Thacker et al., 2007). Conversely macrophages and resident microglial-derived 
macrophages have been shown to be beneficial to functional recovery and axon 
regeneration (Stoll, 2002;Gensel et al., 2009); both neutrophils and macrophages, for 
example, have a role in phagocytic debris clearance of necrotic tissue and myelin, 
which creates cystic caverns that are eventually walled off from healthy tissue by 
astrocytic processes containing the lesion site and preventing the spread of damage. 
Activated microglia and monoctyes release cytokines and growth factors that support 
neurone and oligodendrocyte survival and remyelination (Popovich and Longbrake, 
2008), and are antibacterial and are important for adaptive immunity involving T and B 
lymphocytes (Ankeny and Popovich, 2009). For these reasons the neuroinflammatory 
response has been defined as a ‘double-edged sword’, with both positive and negative 
functions on the injured spinal cord. In mice and rats there is a distinctly different 
immune response to SCI (Inman and Steward, 2003b;Sroga et al., 2003). Mice have a 
delayed and prolonged T-cell infiltration beginning at 14 days, compared to the acute 
and transient infiltration seen in rat CNS lesions at 3-7 days. Mice have a greater MHC 
class II expression and fibrocytes in the injury site. These differences likely contribute 
to the greater propensity for wound healing, survival, and regenerative capacity in mice, 
than rats and higher mammals (Inman and Steward, 2003a), and indicates further the 
essential role the immune system plays in CNS recovery. 
 
After SCI for example, leukocytes become tethered to the endothelial cells of the 
microvasculature of the spinal cord through selectins. Endothelial cell-adhesion 
molecules and MMPs then interact with leukocyte integrins to facilitate extravasation to 
the lesion site (Gris et al., 2004). After thoracic cord compression injury, 
myeloperoxidase activity has been shown to peak at 24 hours (Carlson et al., 1998) 
representing an acute neutrophil invasion. Ling (1979) was the first to observe, through 
intravenous colloidal carbon injection and light microscopy, monocyte-derived 
macrophages in blood vessel lumina, in the neuropil, and crossing the endothelial 
membrane between 3 and 7 days after DRR (Ling, 1979b), and stab injury to the brain 
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(Ling, 1979a). The author also described a substantial population of microglial-derived 
macrophages (Ling, 1979b). Recently both dorsal root rupture (a modified avulsion 
injury) and rhizotomy have been shown to induce aggregation of macropahges from the 
injury site at the dorsal root into the dorsal funiculus, with high expression of p38-
MAPK and TNFα at 48 hours, suggesting active and inflammatory properties of these 
monocytes, that may aggrevate the injury (Nomura et al., 2005). Indeed after human 
brachial plexus avulsion injury and chronic constriction injury in the rat macrophages 
expressing the enzyme cycloxygenase-2 (COX-2), have been shown within the DRG, 
peripheral nerve and spinal cord, that induce PGE-2 production, contributing to 
inflammation and neuropathic pain (Durrenberger et al., 2004). As a therapeutic 
intervention against blood-borne inflammation, inhibitors of the endothelial-monocyte 
adhesion molecules P-selectin (Taoka et al., 1997) and CD11d/CD18 integrins (Gris et 
al., 2004;Oatway et al., 2005) administered after SCI, have been shown to improve 
motor and autonomic scores, reducing neuropathic pain behaviour, increasing 
neuroprotection, myelination and axonal sparing. These in vivo data provide direct 
evidence for the role of neutrophils and macrophages in the exasserbation of secondary 
neuronal injury (Carlson et al., 1998), as well as in the generation and maintenance of 
neuropathic pain (Thacker et al., 2007). However, in the case of root avulsion injuries, 
leukocyte inflammatory effects such as those described for SCI are yet to be 
characterized in the dorsal horn. 
 
3.1.3: Aims 
 
The secondary injury consequences described after dorsal root rhizotomy including 
reactive gliosis and vascular extravasion of cytokines and leukocytes, have the primary 
aim of isolating the lesion site, preventing further damage, clearing debris and 
preserving remaining neuronal function. However, the increased presence some of these 
components create a potential problem: they may contribute to neuropathic pain and 
further neuronal loss. Maintaining a fine balance between these neuroprotective and 
neurotoxic effects after dorsal root injury is therefore therapeutically essential. 
However, it is still unknown to what extent and across what time scale dorsal root 
avulsion can initiate neurodegeneration, inflammation, and dorsal horn neuronal loss, 
and whether rhizotomy as an in vivo model produces a similar spinal response. 
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The aims of this project are as follows: 
 
• To compare the effects of tearing of the roots (avulsion injury) to a surgical cutting 
of the roots (rhizotomy), in terms of the effects in the spinal cord dorsal horn and dorsal 
columns. This comparison will extend to activity of glia subpopulations, including 
phagocytic leukocytes, disruption of the microvasculature, and degeneration of 
nociceptors. The aim is to see if a traumatic traction injury, which can damage the CNS, 
produces a more severe response in the dorsal horn than an artificial surgical root lesion 
that does not affect the spinal cord and does not occur naturally in patients. Avulsion 
injury may then be a more appropriate model to study mechanistic changes in brachial 
plexus injured patients. 
 
• To establish if neuronal cell loss does indeed occur in the spinal cord due to 
deafferentation of the dorsal root, and to characterize which cellular subpopulations are 
preferentially affected. Cellular apoptotic cascades will be assessed through quantitative 
analysis of cell death using TUNEL analysis (Gavrieli et al., 1992) and fluorescence-
assisted flow cytometric analysis, within specific regions of the spinal cord. The cellular 
origin of this apoptosis will be identified through double labeling 
immunohistochemistry to various markers associated with neuronal and non-neuronal 
populations.
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3.2: Results 
 
3.2.1: Quantitative loss of primary afferent connection within the dorsal horn after 
dorsal root deafferentation 
 
CGRP and IB4 immunohistochemistry (ir) was used to analyse the time course of 
reduction in terminal afferent staining in the deafferented spinal cord. In this way 
comparisons with previous work on the time course of terminal degeneration (Ralston, 
III and Ralston, 1982) and deafferentation (Traub et al., 1989) in rhizotomy models can 
be compared. 
 
3.2.1.1: Peptidergic (CGRP) afferent terminals 
 
Naïve tissue (Fig 3.1) showed intense CGRP-positive granular-like staining uniformly 
within the superficial laminae (I and II). Immunostaining was also seen in the deep 
laminae (V) and around the central canal (X). Quantitative analysis was performed from 
only in the superficial laminae (Fig 3.2). Naïve tissue presented 32.7% (+/- 1.33) 
density staining in the superficial laminae (Fig 3.2). 
 
CGRP-ir reduction from naïve levels is significant bilaterally at 1 day in all injury 
models (Fig 3.1). Density staining values are reduced in DRA [15.3% (+/-3.83) 
ipsilaterally and 21.0% (+/-0.88) contralaterally], DRR [16.5% (+/-1.15) ipsilaterally 
and 20.4% (+/-1.94) contralaterally], and sham [21.8% (+/-3.19) ipsilaterally and 24.5% 
(+/-2.50) contralaterally] (Fig 3.2). Ipsilaterally DRA is significantly lower than sham, 
but there is no difference between DRR and DRA, or between cord sides within injury 
models (Fig 3.2). 
 
The loss at 1 day is maintained at 2 days in both injury groups (Figs 3.1 and 3.2).  
However, DRA ipsilateral levels [13.0% (+/-2.58)] are now significantly lower than the 
respective contralateral side [21.4 (+/-2.45)] (Fig 3.2). There is no significant difference 
between DRR and DRA CGRP-ir ipsilaterally or contralaterally (Fig 3.2). 
 
The most extensive loss of CGRP-ir occurs at 14 days post injury (Fig 3.1). Both DRR 
and DRA show reduced ipsilateral CGRP-ir to 4.44% (+/-0.45) and 1.58% (+/-0.19) 
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respectively, with DRA significantly more reduced than DRR (Fig 3.2). Contralaterally 
no further reduction in CGRP-ir is observed (Figs 3.1 and 3.2). No significant 
difference was observed at 14 days between sham cord sides, with no further reduction 
from day 1 sham (Figs 3.1 and 3.2).  
 
Only residual CGRP-ir remains ipsilaterally at 28 days post injury (Fig 3.1). Density 
staining is reduced to 0.43% (+/-0.13) and 1.9% (+/-0.80) within the ipsilateral 
superficial laminae of DRA and DRR tissue respectively. Significant difference 
between the two injury models is not found ipsilaterally (Fig 3.2). Further contralateral 
loss in DRA is present (Fig 3.1) with a density staining of 11.4% (+/-3.50) with notable 
scarring in the dorsal horn (Fig 3.1 and 3.2). Further contralateral loss in DRR is not 
seen (Figs 3.1 and 3.2). Contralaterally, DRA CGRP-ir is significantly lower than DRR 
(Fig 3.2).  
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3.2.1.2: Non-peptidergic (IB4) afferent terminals 
 
Naïve tissue presented intense positive staining within lamina II and Lisseaur’s Tract 
only, with a patchy non-granular appearance (Fig 3.3). No staining was observed in 
deeper laminae. Control groups presented 49.5% (+/- 2.14) density staining in the 
superficial lamina (Fig 3.4). 
 
Similar to results from CGRP quantitative analysis, IB4-ir reduction is apparent and 
statistically different bilaterally at 1 day in all injury models including sham (Figs 3.3 
and 3.4). IB4-ir for DRA, ipsilaterally, was significantly lower than sham (Fig 3.4). No 
difference between injury models, or between cord sides within injury models, was 
found at this time point.  
 
Fig 3.2: Quantitative analysis of CGRP density in the superficial dorsal horn. CGRP 
immunoreactivity is shown as mean percentage positive staining of analysed area, as measured by Q-
win program, at 0, 1, 2, 14, and 28 days post dorsal root injury. Comparisons are made between 
ipsilateral vs contralateral (*), injury vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown 
above the respective data point. N. numbers: naïve (4), 1 day sham (3), 1 day DRA (4), 1 day DRR (4), 
2 day DRA (6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day DRR (6), 28 day DRA (4), 
28 day DRR (4).  
 
  83 
IB4-ir reduction is maintained at 2 days (Fig 3.3). Only in DRA animals, was 
significant further ipsilateral reduction between 1 and 2 days (Fig 3.4). A significant 
difference was also observed between ipsilateral and contralateral IB4-ir in DRA at 2 
days (Fig 3.4), but significance was not reached for DRR side comparison (P value = 
0.089).  
 
Similar to CGRP, the most significant ipsilateral reduction in IB4-ir in both 
deafferentation models compared to sham occurred at 14 days post injury (Figs 3.3 and 
3.4). At this time point, both DRR and DRA had severely reduced ipsilateral IB4-ir (Fig 
3.3) with values at 1.23% (+/-0.53) and 0.06% (+/-0.01) respectively (Fig 3.4), with no 
difference between these values. Contralaterally a significantly lower IB4-ir was 
apparent in DRA than DRR (Figs 3.3 and 3.4). No difference was observed at 14 days 
between sham cord sides, and no further reduction was presented from 1 day (Figs 3.3 
and 3.4). 
 
At 28 days post injury, ipsilateral staining was almost absent after deafferentation injury 
(Fig 3.3), with levels at 0.06% (+/-0.06) in DRA and 0.23% (+/-0.06) in DRR, with no 
significant difference between these values (Fig 3.4). Significant contralateral loss from 
14 days is apparent in both models, and DRA is significantly less than DRR (Figs 3.3 
and 3.4). 
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3.2.2: Quantification of glial activity within the dorsal horn after dorsal root 
injury 
 
3.2.2.1: Microglia 
 
In naïve lumbar cord, Iba1 staining of microglia was uniform throughout the entire 
transverse cord showing no preference for white or grey matter. The morphology of 
these cells was star shaped (ramified) in appearance. A cell body was clearly 
identifiable with dendritic processes radiating out in all directions (Fig 3.5). Through Q-
win analysis of the dorsal horn mean percentage positive staining was 3.96% (+/-0.23) 
(Fig 3.6).  
 
After injury these microglia undergo morphological changes, similar to developmental 
reactive microglia, as well as upregulation in number. Initially they lose their processes 
Fig 3.4: Quantitative analysis of IB4 density in the superficial dorsal horn. IB4 immunoreactivity is 
shown as a percentage positive staining of analysed area, as measured by Q-win program, at 0, 1, 2, 14, 
and 28 days post dorsal root injury. Comparisons are made between ipsilateral vs contralateral (*), injury 
vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown above the respective data point. N. 
numbers: naïve (4), 1 day sham (3), 1 day DRA (4), 1 day DRR (4), 2 day DRA (6), 2 day DRR (6), 14 
day sham (3), 14 day DRA (6), 14 day DRR (6), 28 day DRA (4), 28 day DRR (4).  
 
* 
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(becoming amebiod), then multiply within, or migrate toward, the ipsilateral dorsal 
columns and dorsal horn (Fig 3.5), which is confirmed statistically as increased density 
(Fig 3.6).  
 
At 1 day post injury there is no significant increase in intensity from naïve or sham (Fig 
3.6) in microglia staining in either injury model. However in the case of DRA microglia 
have started to under reactivity, losing their multiple processes, becoming polarized and 
orientating their bodies towards the zone of injury, notably the superficial dorsal horn 
and the DREZ (Fig 3.5).  
 
At 2 days post injury ipsilaterally, in DRA [9.57% (+/-0.75)] and DRR [7.90% (+/-
0.86)] a significant increase in microglial staining is apparent (Fig 3.6), without 
contralateral changes. There is no statistical difference in Iba1 intensity between DRA 
and DRR injuries (Figs 3.5 and 3.6). 
 
The most significant microglial effects occur at 14 days post injury, and bilaterally (Fig 
3.5 and 3.6). The microglia take on a markedly different morphology: rounded, swollen, 
and absent of processes (Fig 3.5), which is more prominent in DRA [20.1% (+/-1.80)] 
than DRR [10.8% (+/-0.86)] (Fig 3.6). Sham ipsilateral Iba1-ir is significantly increased 
from naïve to 7.73% (+/-0.25) (Fig 3.6). Both injury models show statistically greater 
ipsilateral Iba1-ir than sham. A significant contralateral increase in Iba1-ir, from sham 
and naïve levels, is present in DRA [10.6% (+/-0.58)] (Fig 3.6). A significant 
contralateral increase is present in DRR [6.61% (+/-0.51)] compared to naïve; however 
this is not significantly different to sham (Fig 3.6).  
 
At 28 days post injury no further increase in IBa1-ir is present ipsilaterally (Fig 3.5 and 
3.6). Indeed DRR immunoreactivity shows a decrease in Iba1-ir ipsilaterally (7.16% +/-
0.58) and contralaterally (3.99% +/-0.20). However in DRA a significant gain in 
contralateral immunoreactivity is observed at 14.4% (+/-0.62) such that a greater 
difference in microglial activity is present between injury models (Fig 3.6). Significant 
difference is maintained between cord sides and between deafferentation groups (Fig 
3.6). 
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3.2.2.2: Astrocytes 
 
GFAP-positive astrocytes in the naïve tissue are uniformly distributed throughout the 
cord in both grey and white matter, and are star shaped in morphology with short 
processes (Fig 3.7). Q-win analysis of the dorsal horn produced an 8.77% (+/-1.37) 
mean positive staining for GFAP (Fig 3.8).  
 
After injury to the roots, dorsal horn astrocytes respond rapidly by upregulating GFAP, 
undergoing hypertrophy, elongation and migration of processes towards the injury site, 
and finally forming a scar (Fig 3.7). They can undergo cell division and produce fine 
processes which migrate toward the locality of the lesion and interconnect via tight and 
gap junctions to form the eventual glial scar.  
 
Fig 3.6: Quantitative analysis of Iba1 staining in the dorsal horn. IBA1 immunoreactivity is shown as 
a percentage positive staining of analysed area, as measured by Q-win program, at 0, 1, 2, 14, and 28 days 
post dorsal root injury. Significant differences from naïve and between groups are indicated by asterisks. 
Comparisons are made between ipsilateral vs contralateral (*), injury vs naïve (#), injury vs sham (x), and 
DRA vs DRR (+), shown above the respective data point. N. numbers: naïve (4), 1 day sham (3), 1 day 
DRA (4), 1 day DRR (4), 2 day DRA (6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day DRR 
(6), 28 day DRA (4), 28 day DRR (4).  
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At 1 day post injury, a significant ipsilateral increase in GFAP-ir is present in DRA (Fig 
3.8) compared to naïve and contralateral, with astrocyte processes polarised toward the 
DREZ (Fig 3.7). No significant increase in GFAP-ir is evident in DRR or sham (Figs 
3.7 and 3.8).  
 
At 2 days post injury, DRA shows significant bilateral increase in GFAP-ir from naive, 
and significantly greater than DRR (Fig 3.8). DRR shows a significant ipsilateral 
increase in GFAP-ir compared to contralateral and naïve levels (Fig 3.8), and 
polarisation and hypertrophy of processes is first observed (Fig 3.7).  
 
At 14 days post injury there is a significant bilateral increase from 2 days, in both injury 
models (Fig 3.8). Astrocytes no longer have elongated and polarized processes, and 
resume their original star shapes, as well as forming notable structures around cavities 
(Fig 3.7). There is a significant bilateral GFAP-ir increase compared to naïve levels in 
sham tissue (Fig 3.7 and 3.8). DRA presents a significantly greater bilateral GFAP-ir to 
sham at 14 days, whereas in DRR tissue GFAP-ir is statistically greater than sham only 
ipsilaterally (Fig 3.8). There is significantly greater GFAP-ir in DRA than DRR, 
ipsilaterally [24.0% (+/-1.62) and 19.1% (+/-1.92) respectively] and contralaterally 
[20.7% (+/-0.52) and 13.5% (+/-1.83) respectively] (Fig 3.8).  
 
At 28 days post injury no further increase in GFAP-ir is apparent. Levels are 
maintained at 24.3% +/-0.83 (DRA) and 15.1% +/-1.17 (DRR) ipsilaterally, and 
contralaterally at 19.7% +/-1.02 (DRA) and 8.65% +/-0.37 (DRR) respectively. 
Significant difference between deafferentation models is maintained bilaterally. 
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3.2.3: Blood borne infiltration within the dorsal horn and dorsal root entry zone 
 
3.2.3.1: Macrophages 
 
Macrophages can be identified using an antibody to ED1 (labels human CD68 
glycoprotein).  This complement factor is a lysosomal membrane antigen expressed in 
mononuclear phagocytes, both blood borne-derived and microglial-derived.  
 
Naïve tissue revealed scarcely any macrophage staining within any areas of the cord 
(Fig 3.11). This was also the case for 1 and 14 day sham surgery (Figs 3.9 to 3.11). 
Some ED1 macrophages were present in 14 day sham ipsilateral dorsal horn (Fig 3.10), 
but when quantified did not reach significant difference from naïve tissue (Fig 3.11)  
 
At 1 day post DRA some sparse macrophage staining is observed (Figs 3.9 and 3.10), 
however significantly increased ED1-ir is statistically reached only within the ipsilateral * 
Fig 3.8: Quantitative analysis of GFAP staining in the dorsal horn. GFAP immunoreactivity is shown 
as a percentage positive staining of analysed area, as measured by Q-win program, at 0, 1, 2, 14, and 28 
days post dorsal root injury. Significant differences are indicated by asterisks to the right of the data point 
or error bar. Comparisons are made between ipsilateral vs contralateral (*), injury vs naïve (#), injury vs 
sham (x), and DRA vs DRR (+), shown above the respective data point. N. numbers: naïve (4), 1 day 
sham (3), 1 day DRA (4), 1 day DRR (4), 2 day DRA (6), 2 day DRR (6), 14 day sham (3), 14 day DRA 
(6), 14 day DRR (6), 28 day DRA (4), 28 day DRR (4).  
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dorsal horn compared to contralateral, with a mean percentage staining of 1.00% (+/-
0.35) (Fig 3.11). Compared to naïve however, this does not reach statistical significance 
(P=0.063). No significant ED1-ir is found in DRR or sham tissue.  
 
At 2 days post DRA increase in ED1-ir is significantly greater than naïve and 
contralateral values, in the ipsilateral dorsal horn [2.17% (+/-0.37)] and columns 
[2.66% (+/-0.49)] (Fig 3.11). DRR ED1-ir is also increased ipsilaterally in both dorsal 
horn [1.64% (+/-0.29)] and dorsal column [1.82% (+/-0.24)] compared to naïve and 
contralateral levels (Fig 3.11). The macrophages are granular in appearance, and are 
small, few in number, and irregularly dispersed between superficial and deep lamina, 
and the DREZ and dorsal columns (Figs 3.9 and 3.10). 
 
A statistically significant ED1-ir expression increase occurs after 14 days in the 
ipsilateral dorsal horn, but more so in the ipsilateral dorsal columns of DRA (Figs 3.9 to 
3.11). 14 day sham tissue shows no significant increase in ED1-ir. ED1-ir of DRA has 
significantly increased from 2 days, reaching 10.5% (+/-0.78) in the dorsal columns and 
3.62% (+/-0.86) in the dorsal horn (Fig 3.11). DRR ED1-ir has significantly increased 
in the dorsal columns to 4.06% (+/-1.06) compared to sham, naïve, and contralateral 
values, and in the dorsal horn 1.65% (+/-0.42) compared to naïve and contralateral 
values, without significance from sham in this case (Fig 3.11).  
 
At 28 days post DRA injury further increase is observed in the dorsal horn, ipsilaterally 
[5.46% (+/-1.40)] and contralaterally [1.78% (+/-0.54)], and more extensively in the 
dorsal columns, ipsilaterally [18.3% (+/-1.79)] and contralaterally [6.27% (+/-3.19)] 
(Figs 3.9 to 3.11). In DRR tissue no contralateral effect is observed (Figs 3.9 and 3.10), 
and further ED1-ir increase is observed only ipsilaterally in the dorsal columns [9.82% 
(+/-0.91)] (Figs 3.9 and 3.11). In all cases DRA initiates a far greater ED1-ir expression 
in the dorsal horn and columns than DRR at 28 days.  
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Fig 3.9: ED1 staining in the dorsal columns after root injury. ED1-positive macrophages are not 
found in 1 day sham tissue or naïve tissue (not shown). 1 day after DRA and DRR injury few 
macrophages are found in the DREZ. After 2 days in DRA and DRR ED1 is distributed as patches of 
staining throughout the dorsal columns, but mainly near the DREZ, with many macrophages found 
towards the pia mater. 14 day sham shows no ED1 positive macrophages. At 14 days in DRA tissue, 
swollen macrophages are clearly defined in the dorsal columns, and the tissue shows cavitation (white 
asterisk). At 14 days in DRR, ED1 positivity and tissue cavitation is also noted but not to the same extent 
as DRA. A few macrophages are found contralaterally in DRA tissue. 28 days post DRR and DRA tissue 
shows greatly increased ED1 immunoreactivity from previous time points, with ED1 staining throughout 
the dorsal columns. A significant contralateral ED1 staining is present in DRA tissue. There are 
significantly greater macrophages in the DRA than in the DRR tissue. Naïve tissue is not shown. 
Ipsilateral images are shown to the left, and contralateral to the right. Scale = 100μm. Examples of L5 
segmental level. 
 
* 
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Fig 3.10: ED1 staining in the dorsal horn after root injury. ED1-positive macrophages are not found in 
1 day sham tissue or naïve tissue (not shown). 1 day after DRA and DRR injury few macrophages are 
found in the dorsal horn, more so in the former. After 2 days in DRA and DRR ED1 is distributed in a 
punctuate fashion throughout the dorsal horn. No contralateral effect is noted at these early time points. 14 
day sham shows few ED1 positive macrophages in the dorsal horn. At 14 days in DRA tissue, punctuate 
ED1 staining is clearly defined in the dorsal horn. At 14 days in DRR, ED1 positivity is also noted but not 
to the same extent as DRA. 28 days post DRR and DRA tissue shows greatly increased ED1 
immunoreactivity from previous time points, with ED1 staining throughout the dorsal horn. A clear 
contralateral ED1 increase is noted in DRA tissue. There are significantly greater macrophages in the 
DRA than in the DRR tissue. Naïve tissue is not shown. Ipsilateral images are shown to the left, and 
contralateral to the right. Scale = 100μm. Examples of L5 segmental level. 
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Fig 3.11: Quantitative analysis of ED1 in the dorsal columns (A) and dorsal horns (B). ED1 
immunoreactivity is shown as a percentage positive staining of analysed area, as measured by Q-win 
program, at 0, 1, 2, 14, and 28 days post dorsal root injury. Comparisons are made between ipsilateral vs 
contralateral (*), injury vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown above the 
respective data point. N. numbers: naïve (4), 1 day sham (3), 1 day DRA (4), 1 day DRR (4), 2 day DRA 
(6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day DRR (6), 28 day DRA (4), 28 day DRR 
(4)   
 
A: 
B: 
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3.2.3.2: Neutrophils 
 
Naïve sections presented few, if any, neutrophils in the dorsal horn and columns. 
Neutrophils that were identified were almost exclusively associated with the 
microvasculature and were not within the grey or white neuronal matter. The 
mononuclear cells are typically rounded, 10-15μm in diameter, with intense staining of 
the cell membrane, with a weaker immunoreactivity in the cytoplasm (Fig 3.12). Mean 
numbers for neutophils within naïve tissue were 1.85 (+/-0.68) and 1.23 (+/-0.27) in the 
dorsal horn and columns respectively (Fig 3.13).  
 
At 1 day post injury neutrophils were found throughout the dorsal horn and dorsal 
columns (Fig 3.12). After DRA a significant increase in neutrophil number was 
quantified in the dorsal horn [95.1 (+/-8.36)] and dorsal columns [41.7 (+/-5.32)] 
compared to sham and naïve tissue (Fig 3.13), where counts peak at this time point. 
Neutrophils were also found in DRA tissue within the contralateral dorsal column [12.9 
(+/-2.15)] and dorsal horn [14.4 (+/-2.32)] at levels significantly greater than sham and 
naïve tissue (Fig 3.13). After 1 day post DRR significant neutrophil infiltration is found 
exclusively ipsilaterally, in the dorsal columns [17.0 (+/-2.10)] and dorsal horn [24.1 
(+/-3.85)] compared to naïve and sham tissue (Fig 3.13). Neutrophil counts were were 
significantly greater after DRA than DRR in both dorsal horn and columns, bilaterally. 
A small but significant neutrophil infiltration was quantified in 1 day sham, within the 
ipsilateral dorsal horn [7.90 (+/-1.66)] (Figs 3.12 and 3.13). 
 
At 2 days post injury no further increase in neutrophil number can be observed in DRA 
tissue, however further increase in infiltration occurs in DRR tissue (Fig 3.12). 
Neutrophil counts in DRR tissue reach 34.8 (+/-9.24) in the dorsal horn, and 37.9 (+/-
3.48) in the dorsal columns, significantly greater than naïve and corresponding 
contralateral sides (Fig 3.13). DRA tissue shows significantly more neutrophils in the 
dorsal horn than DRR; however, similar numbers are noted in the dorsal columns of 
these two injuries (Figs 3.12 and 3.13). At 2 days in both injury models, a significant 
contralateral neutrophil infiltration is apparent in the dorsal columns after DRA 
[12.7(+/-3.33)] and after DRR [13.5 (+/-3.43)] compared to naïve neutrophil counts 
(Fig 3.13). A small but significant increase in neutrophils is observed in the 
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contralateral dorsal horn after DRA [6.36 (+/-1.35)] compared to naïve levels, that is 
absent in DRR (Figs 3.12 and 3.13).  
 
At 14 days post injury, neutrophil number decreases dramatically in both models (Fig 
3.12). However ipsilateral values for DRA [6.75 (+/-0.75)] and DRR [9.58 (+/-1.54)] 
are still significantly higher than sham and naïve neutrophil numbers in the dorsal horn 
at this time point (Fig 3.13). In the dorsal columns ipsilateral DRR neutrophil counts 
[3.47 (+/-1.70)] reach significance against naïve, but this is not significant against sham 
neutrophil counts (Fig 3.13). In the dorsal columns of DRA tissue, neutrophils are 
present (Fig 3.12); however, counts do not reach significance against naïve or sham 
levels (P=0.82, Fig 3.13). At this time point there is a large quantity of anti-neutrophil-
ir staining present in the ipsilateral cord that is not associated with cellular morphology, 
but rather a particulate mater that is speckled in appearance (Fig 3.12), that was not 
quantified. Further analysis of neutrophil number at 28 days shows no significance 
difference from naïve levels (Fig 3.13), but the particulate anti-neutrophil-ir staining is 
still observed in the dorsal cord (Fig 3.12). 
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Fig 3.12: Neutrophils in the spinal cord after root injury. Neutrophils are spherical in appearance, 
with staining around the cell membrane. Few neutrophils are found in sham tissue either 1 day or 14 days 
post injury. 1 day after DRA, neutrophils are apparent throughout the entire dorsal cord, with a few 
present contralaterally. 1 day DRR tissue shows a smaller, but still significant, increase in neutrophil 
number in the dorsal horn and columns but with ipsilateral preference. 2 days after DRR a significant 
increase in neutrophils is noted in the dorsal columns, DREZ and within the degenerating root. At 2 days 
after DRA, neutophils have a similar concentration to 1 day levels. At 2 days post injury notable 
contralateral neutrophil infiltration is observed. At 14 days after injury the numbers of identifiable 
neutrophils is markedly reduced. However neutrophil-ir debris is found throughout the ipsilateral cord. In 
DRA tissue necrotic tissue and cystic cavities around the lesion site is notable. 28 day tissue is similar to 
14 day injury in both models, with no significant identifiable neutrophils and only particulate staining 
present around the injury site. Naïve tissue is not shown as staining was not present. Ipsilateral images are 
shown to the left, and contralateral to the right. Scale = 200μm. Examples of L5 segmental level. 
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Fig 3.13:  Neutrophil counts in the dorsal column (A) and dorsal horn (B) after injury.  Neutrophil 
immunoreactivity is shown as mean number of positive cells per section at 0, 1, 2, 14, and 28 days post 
dorsal root injury. Similar time course of neutrophil infiltration occurs in the dorsal columns as in the 
dorsal horn. Contralateral neutrophil counts were also detected, however not significantly greater than 
naïve. Infiltration was maximal at 1 day in the avulsion model and 2 days in the rhizotomy model. 
Comparisons are made between ipsilateral vs contralateral (*), injury vs naïve (#), injury vs sham (x), and 
DRA vs DRR (+), shown above the respective data point. N. numbers: naïve (4), 1 day sham (3), 1 day 
DRA (4), 1 day DRR (4), 2 day DRA (6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day DRR 
(6).  
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3.2.4: The integrity of the microvascular system of the lumbar spinal cord 
 
Damage to the dorsal horn microvasculature is shown histologically as a decrease in 
endothelial cell immunoreactivity as measured by RECA-1 antibody (Fig 3.14).  
 
Naïve rat spinal cord, labelled with RECA-1 and Q-win analysed, provided percentage 
density staining values of 5.89% (+/-0.28) of the dorsal horn (Fig 3.15). 
 
At 1 day after DRA a decrease in RECA-1-ir was observed ipsilaterally [3.49% (+/-
0.35)] compared to naïve and contralateral levels (Fig 3.15). A RECA-1-ir reduction 
was found in 1 day DRR ipsilaterally [4.71% (+/-0.28)], significant only from naïve 
levels (Fig 3.15). No contralateral reduction was found at this time point (Figs 3.14 and 
3.15). DRA tissue presents significantly less RECA-ir than DRR at 1 day (Fig 3.15). A 
significant reduction in RECA-ir was found in sham ipsilaterally [4.12% (+/-0.82)] 
compared to naïve (Fig 3.15). 
 
A statistically significant ipsilateral reduction is apparent at 2 days post DRA [2.51% 
(+/-0.35)] and DRR [2.93% (+/-0.62)] (Fig 3.15). A delayed contralateral effect is also 
significant at this time point with values of RECA-ir at 2.77% (+/-0.50) for DRA and 
4.01% (+/-0.37) for DRR (Fig 3.15). Difference between DRR and DRA RECA-ir at 2 
days (Fig 3.14) do not reach statistical significance (P=0.074) (Fig 3.15). 
 
At 14 days post injury a significant recovery in RECA-1-ir is presented in DRR animals 
(Fig 3.14), with staining reaching 5.18% (+/-0.53) ipsilaterally and 5.80% (+/-0.50) 
contralaterally, with no significant difference to sham or naïve levels. However there is 
no such improvement from 2 days in DRA [3.65% (+/-0.43) ipsilaterally and 3.55% 
(+/-0.51) contralaterally], and is still significantly less bilaterally than naïve and sham 
levels, and for the first time, DRR RECA-1-ir levels (Fig 3.15).   
 
No change is seen in either deafferentation group at 28 days from 14 days (Fig 3.14). In 
DRA tissue RECA-1-ir [(3.36% +/-0.46 ipsilaterally) and (3.54% +/-0.29 
contralaterally)] is significantly lower than naïve and DRR values bilaterally (Fig 3.15). 
DRR RECA-1-ir values are maintained from 14 days, and are not significantly different 
to naïve levels bilaterally (Fig 3.15).  
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3.2.5: Cell death and neuronal loss  
 
3.2.5.1: Fluorescence-activated cell-sorting (FACS) flow cytometry  
 
Cytometry was used to quantitatively examine cell viability within the naïve, sham, and 
DRR/DRA spinal cord. Information was collected on the total L3-L6 spinal cord, 
through fluorescence analysis of a free suspension sample of dissociated cells.  
 
Scattered light measurements determined the ratio of dead cells to live cells in the 
suspended sample of dissociated cells. As the cell suspension sample flowed through 
the cytometer each cell or cell particulate matter, was subjected to deflection by electric 
charge. This deflection can be forward or sideways, as is detected by the flow cytometer 
as events on a scatter plot. The extent of forward scatter (FSC) is dependent upon size 
of particle, and side scatter (SSC) is dependent upon cytoplasmic granulation (a cellular 
Fig 3.15. Quantitative analysis of RECA-1 in the dorsal horn. RECA-1 immunoreactivity is shown as 
a percentage positive staining of analysed area, as measured by Q-win program, at 0, 1, 2, 14, and 28 days 
post dorsal root injury. A significant decrease (~ 50%) in vasculature staining is evident at 2 days post 
DRA and DRR. which is maintained at 14 and 28 days post DRA only. DRR tissue shows significant 
vascular recovery at 14 days. No significant difference is found in RECA staining at 1 day compared to 
naïve. Comparisons are made between ipsilateral vs contralateral (*), injury vs naïve (#), injury vs sham 
(x), and DRA vs DRR (+), shown above the respective data point. N. numbers: naïve (4), 1 day sham (3), 
1 day DRA (4), 1 day DRR (4), 2 day DRA (6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day 
DRR (6), 28 day DRA (4), 28 day DRR (4).  
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marker for a dying or dead cell). In this way a detection of dead cells can be 
accomplished without fluorescence, described as flow cytometry (Fig 3.16A).  
 
A selection of these events was taken in favour of isolating whole cell counts 
(represented by the P1 box [Fig 3.16B-F and Fig 3.17B-F]). After scattering, these 
events were subjected to laser excitation, and a series of dichroic mirrors and filters 
directed the emission into channels for detection. As more than one fluorophore was 
used in some cases, the mirrors separate the emission spectrum characterising the 
different staining, such as DAPI and FITC. Each fluorophore detected was measured as 
an event and plotted on a scatter graph, constituting the fluorescence-activated 
component of the analysis.  
 
PI FACS: 
 
Figure 3.16A is a scatter plot example of all events from a sample of injured cord. The 
‘P1’ box represents a sample population of the largest events, typically whole cells 
rather than debris. This sample population can be divided into PI-positive (Red - 
dead/dying/broken membranes) and PI-negative (Black - alive/intact membranes) cells 
(Figs 3.16B-F). This provides a percentage of dead cells within this sample, 
representing the L3-L6 cord. The placement and size of the ‘P1 box’ (Fig 3.16A), as 
well as the grid-line dissectors (Figs 3.16B-F) are kept constant between experiments, 
and have been previously defined through adding the same dissociated spinal cord 
sample to the flow cytometer, absent of PI staining. 
 
Naïve tissue and 2 day sham tissue (Fig 3.16B) showed 0.83% (+/-0.21) and 2.05% (+/-
0.32) PI+ve cell percentages within samples of L3-L6 cord (Fig 3.18A).  
 
At 2 days after injury, DRA [10.3% (+/-2.03%)] and DRR [13.4% (+/-5.39%)] tissue 
show significant increases in PI+ve cells in the scatter plots (Figs 3.16C-D), from naïve 
and sham levels, but werere not significantly different from one another (Fig 3.18A).  
 
At 14 days post injury PI+ve cells decreased from 2 days (Fig 3.16E and 3.16F). PI+ve 
cells within tissue samples in both DRA [0.68% (+/-0.16)] and DRR [1.87% (+/-0.21)] 
were not significantly higher than naïve or sham PI+ve cell percentages (Fig 3.18A). 
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Fig 3.16: Sample of raw data read-out from flow cytometric analysis of PI within the L3-L6 spinal 
cord. A: Typical initial forward (FSC) and side scatter (SSC) plot of total events taken from 2 day DRA 
tissue. Event number represents whole cells, as well as cell debris. The box (P1) represents the population 
of largest sized events, i.e. whole cells. Cells at the top of this box are mainly apoptotic or dead. The P1 
box is kept consistent throughout the experiment. B: P1 box of 2 day sham showing little dead cells (in 
red). Crossing lines represent the barriers between PI-positive and negative whole cells. Top right 
represents whole cell PI counts, and bottom right represents PI negative cells. C: 2 day DRA, P1 box 
showing dead cells. D: 2 day DRR, P1 box showing dead cells. E: 14 day DRA, P1 box showing little 
dead cells. F: 14 day DRR, P1 box showing little dead cells. 
 
A: All events within the sample 
B: 2 day sham 
C: 2 day DRA D: 2 day DRR 
E: 14 day DRA F: 14 day DRR 
Whole cells 
Mainly cell 
debris 
PI+ve dead cells 
PI-ve alive cells 
M
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y 
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ll 
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NeuN FACS: 
 
Further analysis of the type of dead cells analysed by PI staining was accomplished. In 
this case DAPI was used in a similar way as PI to give the percentage of dead cells. 
However these cell types were further analysed with NeuN staining, to ascertain if the 
dead cells are neuronal. 
 
Similarly to PI flow cytometry, unstained sample controls were used to determine DAPI 
and FITC positive staining (Fig 20a). After the initial scatter plot was formed these 
gates were kept constant throughout the experiment. These gating parameters divides 
the P1 boxes into 4 quadrants labelled Q(1-4)-2, with quadrant Q2-2 DAPI and FITC 
positive representing dead neurones. Quadrant Q4-2 represents live neurones. The 
remaining quadrants represent non-neuronal cells. Therefore a ratio of alive to dead 
neurones can be found within the sample through the equation (Q2-2/Q4-2) x 100. 
 
Naïve tissue presented 12.1% (+/-1.00) and sham 7.23% (+/-1.30) NeuN/DAPI+ve cell 
percentages within the respective samples (Fig 3.18B). This figure is higher than that 
seen with PI and is most likely due to the greater damage caused by more mechanical 
dissociation steps in the procedure.  
 
At 2 days post injury, NeuN/DAPI+ve colocalisation percentages rose significantly 
(Figs 3.17C-D) from naïve and sham values, to 36.8% (+/-2.55) in DRA tissue samples 
and 29.9% (+/-3.16) in DRR tissue samples (Fig 3.18B). DRA showed a significantly 
greater NeuN/DAPI+ve percentage staining than DRR (Fig 3.18B) in concurrence with 
immunohistochemical counts of NeuN (see section 3.2.5.2).  
 
Similar to PI scatter plot data at 14 days, scatter plots of NeuN/DAPI showed decreases 
in positive cell percentages (Fig 3.17E and 3.17F). Levels decreased to 12.9% (+/-1.76) 
in DRA tissue samples and to 15.6% (+/-2.46) and were not significantly different to 
sham or naïve values, and were not significantly different between injury groups (Fig 
3.18B). 
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Fig 3.17: Sample of raw data from flow cytometric analysis of NeuN/DAPI within the L3-L6 spinal 
cord. Further analysis of P1 boxes from original forward and side scatter event plots. A: Control tissue 
sample absent of staining and subjected to fluorescent light of wavelength 440nm (DAPI excitation) and 
530nm (FITC excitation). Quadrants can then be set as to a positive stain. Q1-2 represents positive DAPI 
and Q4-2 represents positive NeuN-FITC. Q2-2 represents colocalisation and population of dead 
neurones. Q2-2/Q4-2 gives the percentage dead neurones in P1 box within the spinal cord sample. B: 
Quadrant plot for 2 day sham showing a shift of the population toward DAPI positive. C: Quadrant plot 
for 2 day DRA showing a shift toward DAPI positive. D: Quadrant plot for 2 day DRR. E: Quandrant 
plot for 14 day DRA. The majority of events have shifted below the DAPI positive gate. F: Quadrant 
plot for 14 day DRR. The majority of events have, similarly to 14 day DRR, shifted to below the DAPI 
positive gate.  
A: Controlled gating arrangement B: 2 day sham 
C: 2 day DRA D: 2 day DRR 
E: 14 day DRA F: 14 day DRR 
DAPI +ve (Dead cells) 
FITC
-N
euN
+ve 
(N
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Figure 3.18: Flow cytometric analysis of cell death in the spinal cord using Propidium iodide (A) 
and NeuN/DAPI (B) colocalisation.  Cell death is shown as a percentage of total count, at 0, 2, and 14 
days post dorsal root injury. A: PI positive cell death of the L3-6 lumbar cord is significantly greater 
than sham and naïve tissue within the injury models at 2 days, with no difference between DRA and 
DRR, and no increase in cell death in sham. At 14 days percentage cell death returns to baseline levels. 
B: Percentage neuronal cell death of the L3-6 lumbar cord is significantly more than sham and naïve 
tissue within the injury models at 2 day, with DRA greater than DRR, with no increase in neuronal cell 
death in sham tissue. At 14 days, percentage cell death returns to naïve levels. Comparisons are made 
between injury vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown above the respective data 
point. N numbers are: naïve (6), sham (4), 2 day DRA (8), 2 day DRR (8), 14 day DRA (4), and 14 day 
DRR (4) 
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3.2.5.2: Immunohistochemical analysis of NeuN neuronal loss 
 
NeuN positive cell counts in the naïve dorsal horn averaged 410 (+/-11.4) per section 
(Fig 3.20), with staining located mostly in the cytoplasm, and in some cases the nucleus 
also. Neurones are organized in layers, or a lamina distribution, with clustering of small 
neurones in lamina I, fewer in lamina II, and larger neurones with dendritic-like 
processes in lamina III-V (Fig 3.19). Some neurones can be found outside the grey 
matter, and these constitute cells of the lateral spinal nucleus (Gwyn and Waldron, 
1968; Molander et al., 1984) that respond to noxious stimulation and are involved in 
pain processment (Menetry et al., 1980; Dagci et al., 2008) (Fig 3.19). 
 
At 1 day post injury NeuN decreased significantly in the ipsilateral dorsal horn of DRA 
animals (Fig 3.19) compared to naïve and sham, with counts at 308.2 (+/-25.5) 
ipsilaterally (Fig 3.20). Contralateral levels [359.6 (+/-15.7)] showed a trend toward 
reduction (Fig 3.20). Significance was not reached between cord sides (P=0.058) (Fig 
3.20). Significant decrease in NeuN counts bilaterally were calculated for DRR, at 
322.7 (+/-4.70) ipsilaterally and 350.6 (+/-1.70) contralaterally against naïve, with 
ipsilateral significantly less than contralateral and sham (Fig 3.20). No significant 
differences were found between DRA and DRR injury models after 1 day (Fig 3.20).  
 
At 2 days post injury NeuN counts were reduced to 285.7 (+/-18.8) in the ipsilateral 
dorsal horn of DRA, which was significantly less than naïve levels, the respective 
contralateral side, as well as ipsilateral DRR [334.6 (+/-20.2)] (Fig 3.20). DRR tissue 
does not show significant difference between cord sides at 2 days (Fig 3.20). Tissue 
cavities are apparent in the areas of NeuN loss in DRA, but not in DRR (Fig 3.19). Both 
injury models showed a small but significant contralateral loss of NeuN number 
compared to naïve tissue (Fig 3.19). 
 
At 14 days post injury, no further decrease in NeuN is apparent in either injury, and 
sham tissue shows no NeuN reduction (Figs 3.19 and 3.20). Cavities within the dorsal 
horn that were observed in 2 day tissue, have become ‘walled off’ from neuronal 
populations most likely through tissue scaring (Fig 3.19). Ipsilateral NeuN counts in 
DRA [284.6 (+/-15.2)] and DRR [335.5 (+/-15.7)] are significantly less than sham and 
naïve levels, with DRA significantly less than DRR. Contralateral counts in DRA, 
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although showing some NeuN reduction (Fig 3.19) are not significantly reduced from 
sham or naïve (P=0.10) due to a large standard error. However contralateral DRR 
counts are significantly lower than both naïve and sham levels at 14 days (Fig 3.20). 
 
At 28 days post injury further significant NeuN decrease occurs in DRA but not DRR 
(Fig 3.19 and 3.20). In DRA, both ipsilateral [143.6 (+/-22.6)] and contralateral [279.3 
(+/-23.3)] NeuN counts are significantly lower than naïve and DRR, with ipsilateral 
DRA significantly lower than contralateral DRA levels (Fig 3.20). Mean NeuN positive 
neurone loss in laminae I-IV, over 28 days after DRA injury, is 56.4% ipsilaterally and 
30.1% contralaterally, whereas in DRR it is 19.6% and 14.5% in respective cord sides. 
NeuN populations are greatly reduced in the superficial lamina and deeper laminae, 
leaving a band of NeuN+ve cells in the intermediate laminae. In some cases scarring 
has become so severe that neuronal groups have become separated and isolated from 
the main neuronal population. Patches of neurones can be observed, some of which 
appear isolated to the white matter (Fig 3.19). 
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Fig 3.20: NeuN counts in the dorsal horn after injury. NeuN immunoreactivity is shown as a mean 
number of positive cells in laminae I-IV at 0, 1, 2, 14, and 28 days post dorsal root injury. NeuN staining 
decrease within the dorsal horn follows a 2 step process. Reduction is first apparent at 1 day, increasing to 
2 days, with avulsion presenting a greater loss than rhizotomy. Significant further reduction is then only 
apparent in the avulsion model after 4 weeks, bilaterally. Comparisons are made between ipsilateral vs 
contralateral (*), injury vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown above the 
respective data point. N. numbers: naïve (4), 1 day sham (3), 1 day DRA (4), 1 day DRR (4), 2 day DRA 
(6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day DRR (6), 28 day DRA (4), 28 day DRR 
(4).  
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3.2.5.3: Histological analysis of toluidine blue neuronal loss  
 
Toluidine blue staining of naïve cord showed cell bodies in the grey matter, but also 
lightly in the white matter, suggesting both glia and neurones are stained. In naïve 
tissue glia could be distinguished from neurones due to their smaller size and less 
intensity of staining (Fig 3.21); however, at later time points reactivity, hypertrophy, 
and swelling in size of many glia and leukocytes prevented easy identification.  
 
In naïve tissue (Fig 3.21), toluidine blue positive cell counts within the boxed area of 
the dorsal horn averaged 100.7 (+/-4.97) cells (Fig 3.22).  
 
At 1 day post injury a significant reduction in neuronal number was found in the dorsal 
horn of DRA (Fig 3.21) with 80.5 (+/-4.03) cells (Fig 3.22). Ipsilateral DRA tissue had 
significantly less cells than naïve, sham [96.9 (+/-5.15)], contralateral DRA [95.8 (+/-
1.76)], and ipsilateral DRR [92.0 (+/-1.97)] at this time point (Fig 3.22). No significant 
reduction of toluidine blue stained cells was found in DRR or sham. No contralateral 
reduction in number was observed. 
 
At 2 days post injury a significant decrease in toluidine blue counts from naïve levels 
was present bilaterally in DRA [80.2 (+/-2.41) ipsilaterally and 90.9 (+/-1.73) 
contralaterally], with statistical difference between cord sides. DRR was statistically 
lower than naïve bilaterally, with ipsilateral counts [81.8 (+/-3.60)] statistically lower 
than contralateral counts [92.0 (+/-2.68)]. No significant difference was found between 
injury models at this time point, and this reduction at 2 days was not significantly 
different from corresponding 1 day tissue in either case. Darker staining is notable 
around the pia mater in DRA tissue and dorsal horn (Fig 3.21). 
 
At 14 days post injury, accurate counts of toluidine blue positive neurones were not 
able to be made, as neurones could not be clearly distinguished from glia. Glia 
surrounding the injury site within the dorsal horn, columns and root entry zone had 
become intensely stained for toluidine blue in both DRR and DRA so that the dorsal 
horn and neurones could no longer be distinguished. This glial staining was even more 
prominent at 28 days (not shown) preventing correct neuronal counts at this time point 
also.  
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Fig 3.22: Toluidine blue counts in a sample of the dorsal horn after injury.  Tol Blue counts are 
shown as a mean number of positive cells in a 4.16cm2 boxed area in the superficial dorsal horn at 0, 1, 
and 2 days post dorsal root injury. Counts decreased within the dorsal at 1 and 2 day. Reduction is first 
significant at 1 day after DRA, maintaining after 2 days, with avulsion presenting a greater loss than 
rhizotomy. Significant reduction in counts is only found after 2 days in DRR. 14 day and 28 day tissue 
could not be accurately quantified. Comparisons are made between ipsilateral vs contralateral (*), injury 
vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown above the respective data point. N. 
numbers: naïve (4), 1 day sham (3), 1 day DRA (4), 1 day DRR (4), 2 day DRA (6), 2 day DRR (6). 
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3.2.5.4: Immunohistochemical analysis of cell death in the spinal cord 
 
Single labelling 
 
TUNEL staining was used to characterize the end stage apoptotic event of DNA 
fragmentation within cells of the spinal cord after DRA and DRR injury. TUNEL-
positivity was confirmed with the nuclei counter stain DAPI, and counts were made in 
the dorsal horn and dorsal columns. 
 
Very few TUNEL positive nuclei were found in naïve sham (1 or 14 days) tissue. 
Values for naïve were 0.8 (+/-0.37) in the dorsal columns and 0.8 (+/-0.2) in the dorsal 
horn (Fig 3.24). Values for ipsilateral sham were 1.13 (+/-0.13) in the dorsal columns 
and 1.33 (+/-0.66) in the dorsal horn (Fig 3.24).  
 
An ipsilateral increase in TUNEL counts is observed by 1 day (Fig 3.24). TUNEL 
positive nuclei were small and round in appearance with granular staining in the centre 
(Fig 3.23). They were found throughout the dorsal horn, dorsal root entry zone and 
dorsal columns, preferentially ipsilaterally (Fig 3.23). 1 day DRA tissue showed a 
significant increase from naïve, ipsilateral sham, and DRA contralateral tissue, with 
24.5 (+/-1.61) and 14.5 (+/-3.22) mean counts in the dorsal horn and column 
respectively (Fig 3.24). 1 day DRR tissue showed significantly much lower numbers of 
TUNEL-positive nuclei than DRA, with 6.76 (+/-2.89) and 4.02 (+/-1.07) in the 
ipsilateral dorsal horn and dorsal column respectively (Fig 3.24). This is statistically 
greater than contralateral DRR, ipsilateral sham, and naïve tissue. At this time point 
there is a significant difference between the injury models, with avulsion showing 
greater numbers of TUNEL-positive cells in the dorsal columns, but significant 
difference is not reached in the dorsal horn (Fig 3.24). 
 
At 2 days, TUNEL numbers have significantly increased from 1 day. Levels now reach 
28.1 (+/-2.30) and 40.6 (+/-6.32) per section in the avulsion model, and 16.0 (+/-1.90) 
and 18.2 (+/-3.37) per section in the rhizotomy model, for the dorsal columns and horns 
respectively. Within the dorsal columns, for both injury models, a significant 
contralateral effect is seen from naive, with counts at 5.42 (+/-1.50) for rhizotomy and 
4.69 (+/-1.47) for avulsion; these are not significantly different from each other. Similar 
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to 1 day, the avulsion model showed significantly greater TUNEL counts than 
rhizotomy in the ipsilateral dorsal columns and dorsal horn, with greater tissue damage 
and cystic cavities (Fig 3.25c).  
 
At 14 days no significant TUNEL staining was found in DRR or DRA injury models 
compared to naïve or sham (Fig 3.24). 
 
  
 
 
 
 
 
 
Figure 3.23: TUNEL staining in the ipsilateral dorsal horn and dorsal columns. A: 1 day DRA 
TUNEL positive cells are present in the ipsilateral dorsal horn, and column with tissue necrosis and cavity 
formation apparent. B: 1 day DRR presents few TUNEL counts in the dorsal horn and column. C: 2 days 
DRA shows TUNEL positive cells thoughout the superficial dorsal horn and dorsal columns. Ouline of 
dorsal horn is delineated by white lines. D: TUNEL positive nuclei (Green) double labelled with DAPI 
(Blue) for positive confirmation (asterisk). Scale = 50μm 
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Figures 3.24: TUNEL-labelled cell counts in the dorsal columns and dorsal horn after injury 
respectively. TUNEL positive counts are shown as a mean number of positive cells per section at 0, 1, 2, 
and 14 days post dorsal root injury. TUNEL positive cells were found only at 1 and 2 days post injury, 
with 2 days significantly greater than 1 day. DRA presented significantly greater numbers of apoptotic 
nuclei than DRR at 1 and 2 days. Significant contralateral TUNEL labelling presented in both injury 
models only in the dorsal column, and only at 2 days. TUNEL labelling at 2 and 4 weeks (data not shown) 
showed no significant difference in counts from naïve baseline. Comparisons are made between ipsilateral 
vs contralateral (*), injury vs naïve (#), injury vs sham (x), and DRA vs DRR (+), shown above the 
respective data point. N. numbers: naïve (4), 1 day sham (3), 1 day DRA (4), 1 day DRR (4), 2 day DRA 
(6), 2 day DRR (6), 14 day sham (3), 14 day DRA (6), 14 day DRR (6).  
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Double labelling 
 
To identify whether neurones, glial cells, or infiltrating leukocytes are dying by 
apoptosis after root injury, double labelling immunocytochemistry was performed with 
a variety of markers and TUNEL in 1 and 2 day DRA tissue.  
 
Neuronal: 
 
NeuN-TUNEL colocalisation was not apparent in the cord at either 1 or 2 day time 
points (Fig 3.25). 
 
 
 
Astroglial: 
 
As astrocytes have been shown to undergo differentiation and proliferation during 
gliosis after injury to the CNS, it is possible that they may be undergoing apoptosis at 
these same time points to control the rate and extent of glial scarring within the lesion 
site of the DREZ and superficial laminae. TUNEL-S100 staining provided co-
localisation of the apoptotic cell bodies and nucleus of astrocytes. However no 
apoptotic astrocytes were found in the cord at 1 or 2 days time points (Fig 3.26). 
 
 
 
Figure 3.25: NeuN(red)–TUNEL(green) co-localisation in the ipsilateral dorsal horn. A: NeuN 
staining of 1 day DRA. B: TUNEL positivity. C: Merge shows no co-localisation. Scale = 200μm 
 
 
 
 
 
 
Figure 3.26: S100(red)-TUNEL(green) co-localisation in the ipsilateral dorsal columns. A: S100 
staining of 1 day DRA. B: TUNEL positivity in the dorsal horn C: Merged image showing no double-
labelled astrocytes. Scale = 100μm 
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Microglia: 
 
Across 1 and 2 days of peak TUNEL expression in DRA tissue, many apoptotic nuclei 
co-localised with Iba1 for microglia. These nuclei were found almost exclusively within 
the lesion site in the dorsal column and superficial laminae, but only accounted for a 
small proportion of TUNEL positivity.  Only the morphologically ‘reactive’ population 
of microglia, with a typical rounded appearance lacking processes which may also be 
ED1 positive, were TUNEL positive (Fig 3.27).  
 
 
 
 
Macrophage: 
 
ED1-TUNEL colocalisation was also found at 1 and 2 day time points in both DRA and 
DRR (Fig 3.28). These were found within the lesion site and superficial dorsal horn 
and, similarly to Iba1, accounted for only a small proportion of TUNEL positive nuclei. 
They may be the same population as Iba1 as ED1 labels activated microglia. 
 
 
 
 
 
 
Figure 3.27: Iba1 (red) -TUNEL (green) colocalisation in the ipsilateral dorsal horn. A: Iba1 staining 
of dorsal horn (+) and dorsal columns (*) in 1 day DRA. B: TUNEL positivity. C: Merged image of the 
box regions outlined in A and B. Some double-labelled microglia are apparent (arrow). The majority of 
TUNEL positive cells do not co-localise with Iba-1. Scale = 100μm 
 
 
 
 
 
 
* 
+ 
Figure 3.28: ED1 (red) –TUNEL (green) colocalisation staining in the ipsilateral dorsal horn. A: 
ED1 staining in dorsal horn (+) and dorsal columns (*) in 2 day DRA. B: TUNEL positivity in the dorsal 
horn. C: Merged image of the box regions outlined in A and B. Some double-labelled macropahges are 
apparent (arrow). The majority of TUNEL positive nuclei do not colocalise with ED1. Scale = 100μm 
 
 
 
 
 
+ 
+ 
* 
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Neutrophil: 
 
Anti-neutrophil-TUNEL co-localisation was also exclusive in 1 and 2 day DRA tissue, 
providing evidence that it is the neutrophil population of cells that are responsible for 
the TUNEL staining at 1 and 2 day time points after root transection injuries (Fig 3.29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: Neutrophil(red)-TUNEL(green) co-localisation staining in the ipsilateral dorsal horn. 
A: Neutrophil staining of 1 day DRA. B: TUNEL positivity in the dorsal horn. C: merged image showing 
almost all TUNEL positive cells are neutrophils (white asterisk) with very few single labelled TUNEL 
nuclei (blue astersik). Scale = 50μm 
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3.3: Discussion 
 
3.3.1: Summary  
 
The new findings of this study can be summarised as follows: 
 
No difference is observed across 28 days ipsilaterally between DRA injury and DRR 
injury with respect to primary afferent terminal labelling with CGRP or IB4. However 
across 28 days a more severe contralateral loss of primary afferent terminal labelling 
occurs after DRA compared to DRR. 
 
A more intense astrocytic reaction occurs ipsilaterally in the dorsal horn after DRA 
injury at 1 day increasing up to 14 days, and maintained up to 28 days bilaterally, 
compared to a delayed and significantly less severe astrogliosis in DRR and only 
ipsilaterally. Microglial effects are delayed compared to astocyte effects after root 
injury. Significant increases in microglial labelling in both models occurs at 2 days, 
with greatest microgliosis observed at the later time points of 14 and 28 days. A more 
intense microglial reaction occurs bilaterally at 14 and 28 days in DRA dorsal horn, 
compared to more modest effects in DRR.  
 
An ipsilateral infiltration of both neutrophil and macrophage blood borne cells are 
present in both the dorsal horn and the dorsal column after both deafferentation injuries. 
A time and injury dependent increase in macrophage staining is shown within the 
ipsilateral dorsal regions, starting in DRA ipsilateral dorsal horn at 1 day compared to 2 
days in DRR. Significant macrophage recruitment in the dorsal columns is delayed in 
both models to 2 days, but produces a more substancial infiltration than within the 
dorsal columns at the two later time points. Intense macrophage staining is observed in 
DRA dorsal horn and columns at 14 and 28 days, and is significantly greater than in 
corresponding DRR tissue. By direct comparison, the other leukocyte population 
analysed, neutrophils, infiltrate at 1-2 days with minimal numbers at 14 days, and none 
at 28 days. DRA injury leads a greater infiltration of neutrophils across 1 and 2 days 
than DRR.  
 
  122 
Microvascular RECA-1 labelling is reduced bilaterally by 1 day in DRA dorsal horn, 
and is maintained up to 28 days. A similar reduction in RECA-1 staining occurs at 1 
day post DRR, however a recovery of staining back to naïve levels of density staining is 
observed by 14 days.  
 
There is a reduction in NeuN labelling beginning at 1 day in both DRA and DRR that is 
maintained up to 14 days. There is a more severe ‘second wave’ of NeuN-ir reduction 
by 28 days that is bilateral, but this is only found in the DRA model. DRA therefore 
leads to a more severe neuronal deterioration than DRR across this time period. This 
loss is confirmed by NeuN FACs and also toluidine blue counts, suggesting cells are 
indeed lost rather than a decrease in epitope for the anitbody.  
 
At 1-2 days post DRA and DRR, apoptotic expression was found by TUNEL staining 
within the dorsal horn and columns (Chew et al., 2008), that is absent at 14 days, and 
this was supported with PI flow cytometry. TUNEL staining was restricted ipsilaterally 
within the dorsal horn and column, and quantitative analysis showed that DRA is more 
severe at inducing apoptosis than DRR. Colocalisation studies showed apoptosis to be 
restricted to the non-neuronal cell population, mainly the neutrophils but also some 
microglia and macrophages.  
 
Significant contralateral effects were shown to occur in all cell types and staining 
protocols. This contralateral effect was usually delayed, showing effect at 14 and 28 
days predominantly, and of less magnitude than ipsilateral to injury. In all markers 
analysed, DRA lead to a greater contralateral effect than DRR. 
 
These results suggest that DRR, commonly used as an in vivo model of avulsion, gives 
a milder representation of the traumatic state of the dorsal horn compared to true 
avulsion injury. This is true with respect to glial activity, the state of the vasculature, as 
well as amount of blood borne inflammatory and phagocytic infiltration. However 
primary afferent degeneration and neuronal reduction do not seem to differ. This is the 
first time neuronal loss after avulsion has been demonstrated, beginning at 1 day, and 
progressing substantially over 14 to 28 days. 
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3.3.2: Methodological considerations 
 
Certain considerations need to be taken into account when analysing and discussing the 
data presented in this report.  
 
Firstly, issues arise from the surgical procedure: the hemi-laminectomy will lead to 
some contralateral damage to the afferents innervating the vertebral muscles, the 
vertebrae themselves, and the skin and muscle afferents of the overlying skin, as these 
tissues are structurally contiguous across the spinal cord and column. Therefore some 
reduction in CGRP and IB4 in 1 and 14 day sham animals, and the loss contralaterally 
in all models, may be due to bilateral damage to dural, vertebral, and skin/muscle 
afferents. The dura itself is innervated by CGRP positive nociceptive primary afferents 
(Bove and Moskowitz, 1997;Strassman and Levy, 2006) and P2X2/3 positive 
nociceptor primary afferents (Staikopoulos et al., 2007) that colocalise with IB4 
(Bradbury et al., 1998). The lumbar vertebral joints are also innervated by CGRP 
positive afferents (Morinaga et al., 1996). This may also explain the significant increase 
in sham astrocytic and microglial reactivity at 14 days, consistent with previous 
findings (Colburn et al., 1997;Hashizume et al., 2000a;Bigbee et al., 2007). Cutting the 
dura and prolonged disruption of the blood brain barrier, may lead to disruption of pH 
homeostasis in the cord that activates astrocytes bilaterally. This is shown as an increase 
in astrocyte GFAP-ir without hypertrophy, elongation of processes, or differentiation. 
Further, extensive hemi-laminectomy surgery (L5 to S1) has been shown to induce 
mechanical hyperalgesia up to 15 days with deformity of the spinal cord observed upon 
dissection (Kosta et al., 2009). 
 
Another issue with the surgical procedure is that avulsion is the physical tearing of the 
roots from the cord. This may create problems with reproducibility and morphological 
differences in the sections of the dorsal horn between animals, with variable mechanical 
distortion of the cord, and variable amounts of injury to the spinal cord (Brown-Séquard 
Syndrome). These morphological differences were less common in rhizotomised dorsal 
horn as the injury is not a traction force that directly affects the spinal cord. 
 
Secondly, issues may arise from the method of analysis of the spinal cord. The 
conclusions drawn from this data are based mainly on immunofluorescence analysis 
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only, the limitation of which is the reliance upon epitope expression. For the results that 
describe a reduction in antibody staining such as NeuN, it could be that injury to the 
dorsal horn could cause a reduction in cellular expression of the corresponding epitope 
within cells that may not be dead or dying, thereby giving an incorrect estimate of the 
number of cells lost. For this reason, the general metachromic dye, toluidine blue, that 
does not rely on epitope expression for staining, was employed. However this too has 
its limitations, as it is not specific to neurones, and can label glia and leukocytes like 
cresyl violet, that have hypertrophied in response to tissue damage (Sanner et al., 1993). 
This staining of glia was shown to increase in intensity in 14 and 28 day tissue, making 
it impossible to distinguish neurones or the shape of the dorsal horn. However the same 
trends were observed with these different methods at 1 and 2 days post injury giving 
strength to the notion that these injuries cause cell death. 
 
Further issues arise in immunohistological identification with generic antibodies. The 
ED1 antibody, specific to the CD68 complement factor, is expressed on activated 
microglia as well as macrophages, making them difficult to distinguish between as they 
have similar morphology (Ling, 1979b). Similarly, the lectin IB4 binds to microglia, 
perivascular cells and group-B blood erythrocytes, albeit with a lesser efficacy, as well 
as a sub class of C-fibres. This overlap could potentially interfere with intensity staining 
analysis after injury, and this was controlled for by exclusion of randomly selected 
tissue sections that showed this staining within the selected area of analysis.  
 
Limitations with TUNEL labeling also exist. The apoptotic caspase cascade takes 
approximately 2-4 days depending on cell type (Cooray et al., 2003). Therefore 
apoptotic immunohistochemical detection of cells is dependent on the point of the 
cascade analysed. TUNEL labelling isolates the population of cells undergoing end 
stage apoptosis; therefore TUNEL staining will provide only a snapshot of the total 
spectrum of apoptotic cells within the cord. Potentially at any time point analysed there 
is an underestimation of the total apoptotic population, so counts are relative and not 
absolute. 
 
Thirdly, several limitations involve the flow cytometric analysis: 1) It was not possible 
to analyse only the dorsal horns of the spinal cord, as they could not be accurately 
dissected from the spinal cord. Therefore, the percentage dead cells would be of all 
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regions within the cord, including both white and grey matter, from L3 to L6. 2) The P1 
scatter plot does not provide a clear cellular population difference between dead and 
alive for either PI single labelling or NeuN/DAPI colocalisation. This is due to the 
constituency of the dissociated tissue sample. Cells of different shapes and sizes are 
present in the spinal cord, some of which may have been broken down into fragments of 
different sizes through the titration procedure. This is shown on the scatter plot as a 
blended population of dead to alive, neuronal to non-neuronal, that is entirely dependent 
upon gating controls. These gates are generated by analysing naïve tissue and single 
labelled suspensions, as defined in the methodology, and then applying them to the 
injured tissue samples. Results from NeuN/DAPI colocalisation in naïve and sham 
tissue show approximately 12% and 7% dead neuronal population respectively, that is 
also present, but to a lesser extent in PI flow cytometric analysis. A likely explanation 
for this neuronal loss, is the detrimental effect to cellular integrity of the increased 
number of centrifuge and mechanical wash cycles most notably in NeuN/DAPI 
methodology. In this way a proportion of the neuronal population within all 
NeuN/DAPI FACs analysed groups are killed through this procedure, rather than the 
deafferentation surgery, overestimating the absolute loss.  
 
3.3.3 Primary afferent terminals 
 
Immunohistochemical analysis of the primary afferent terminals within the dorsal horn 
after deafferentation has shown a time dependent reduction in CGRP and IB4 levels.  
This begins at 1 day bilaterally, with an afferent terminal immunoreactivity loss of 
around 25-35% for peptidergic terminals 29-53% for non-peptidergic terminals in both 
deafferentation models and sham. Ipsilateral immunoreactivity shows a trend toward 
more loss than the respective contralateral side, but does not reach significance in any 
model including sham, suggesting that some reduction in terminal staining is primarily 
due to the laminectomy. These results are contrary to previous findings, where no 
contralateral effects were described using DRR or DRA models (Gibson et al., 
1984;Traub et al., 1989;Muneton-Gomez et al., 2004). The differences in this work and 
previous literature may be due to the method of analysis, with previous literature using 
the contralateral side as an intrinsic control for ipsilateral effects rather than a separate 
group in itself. Only rhizotomy models are used in the literature, and this work has 
shown contralateral effects are more extensive after DRA, and therefore could have 
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been overlooked previously. Also, here, a more quantitative technique of primary 
afferent terminal density staining calculation was used. Contralateral effects are further 
discussed in section 3.8. 
 
The further ipsilateral reduction of CGRP-ir and IB4-ir at 14 days in DRA and DRR is 
consistent with previous findings (Gibson et al., 1984;Traub et al., 1989;Tie-Jun et al., 
2001;Muneton-Gomez et al., 2004). This loss is due to the degeneration of terminals 
distal to the injury point, which begins at 8 hours (Coimbra et al., 1984) and is complete 
by 7 days (Ralston, III and Ralston, 1982), as well as loss of anterogradally transported 
vesicles containing CGRP and the glycoprotein that binds IB4. Only isolated punctate 
staining of CGRP and IB4 were found after 14 days post injury in both models. This 
terminal labelling represents spared terminals originating from intact long range 
afferents arising rostrally (>L3) and caudally (<L6) to intact lumbar and sacral roots 
(Shortland and Wall, 1992;Muneton-Gomez et al., 2004). 
 
The only differences in the time course of peptidergic and non-peptidergic afferent 
terminal loss were found at 28 days, with DRA showing significantly less 
immunoreactivity than DRR on the contralateral side. This suggests that ipsilaterally 
the mode of deafferentation does not affect the rate of terminal staining intensity loss in 
the spinal cord.  
 
3.3.4: Glial activity 
 
3.3.4.1: Microglia 
 
Reactive gliosis occurs when resident microglia become phagocytic, enabelling removal 
of damaged axons, neurones, and myelin. This report shows microglia undergoing a 
morphological change across time after root injury, which has been shown previously in 
a SCI model (Popovich et al., 1997;Watanabe et al., 1999). Temporally, microglia 
change from a ramified form, with processes and small soma, to an activated form 
without such processes, identical to macrophages, but with swollen soma (amoebic-
like) consistent with previous descriptions (Ling, 1979b). Importantly these changes are 
maintained up to 28 days in DRA where they are maximal, which is in contrast to 
minimal microglial activity in DRR dorsal horn. 
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Both deafferentation models lead to dorsal horn microglial reactivity, with ramified 
microglia becoming amoebic-like surrounding the injury site. This metamorphosis is 
observed at 1 day but significance is not reached until 2 days after injury, and directed 
ipsilaterally, as evidenced by an increase in Iba1 staining for both DRR and DRA, with 
no difference between them. Proliferation may also be a mechanism by which 
percentage density staining is increased (Liu et al., 2000a). A small proportion of 
microglia undergo apoptosis at 1 and 2 days as they begin to engulf neuronal debris; 
phagocytosis is a known trigger for apoptosis (Watson et al., 1996;Hacker et al., 
2002;Kirschnek et al., 2005). It is likely the purpose of apoptosis is to safely remove 
cytotoxic phagocytic cells, preventing them from exacerbating symptoms within a 
lesion site. 
 
A significant increase in microglia occurs in DRA bilaterally at 14 days, which is not 
present after DRR. The severity of the microglial reaction at 14 days in DRA is almost 
double that of DRR, both ipsilaterally and contralaterally. This is the first descriptive 
and quantitative comparison of microglial reactivity in these deafferentation models, 
and suggests the type of trauma can influence the time course and extent of the dorsal 
horn microglial activity. The difference in microglial reaction between injury models 
may be due to the direct damage to the spinal cord that occurs from root avulsion 
injury, whereas rhizotomy, like PNI, does not. In both deafferentation models, the 
response within the lesion site to the injury is similar initially, where microglia become 
activated and phagocytose necrotic debris. However, in the case of DRA, the microglial 
response is greatly increased in the lesion site from 2 to 14 days, continuing to 28 days.  
This suggests avulsion causes a greater autoimmune response in the later stages of 
injury, which is absent in rhizotomy models. Contralateral effects observed previously 
in SCI (Hains and Waxman, 2006), PNI (Arguis et al., 2008), and focal burn injury 
(Chang et al., 2010), are prominent in DRA tissue, but minimal in DRR tissue, and are 
likely due to a number of factors discussed separately in section 3.8. 
 
As microglia are implicated in the maintenance of chronic neuropathic pain states in 
spinal cord injury (Hains and Waxman, 2006), and DRA leads to spinal cord trauma 
and maintained microglial activity, it could be plausible to suggest similar mechanisms 
involving microglia may underlie the intractability of these neuropathic pains. 
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Conversely rhizotomy leads to minimal microglial activity across 28 days corroborating 
previous data (Eriksson et al., 1993;Colburn et al., 1999), does not generally lead to 
neuropathic pain in vivo (Sheen and Chung, 1993;Yoon et al., 1996;Sukhotinsky et al., 
2004), and is used to relieve peripheral nerve pain clinically (Loeser, 1972) (Chapter 4: 
results, for further details).  
 
The spinal cord injury incurred after DRA, and the robust and maintained microglial 
activity that follows may well be the distinction between why avulsion leads to severe 
intractable neuropathic pain, and rhizotomy does not. The results here support the 
hypothesis that a rhizotomy model does not accurately represent the microglial reaction 
that may occur in the chronic stages of brachial plexus avulsion injury, and is important 
evidence when trying to ascertain the mechanisms behind neuropathic avulsion pain. 
 
3.3.4.2: Astrocytes 
 
The results of this chapter describe a two-step process of reactivity in both models. A 
significant increase in astrocytic process elongation toward the injury site can be seen at 
1 day after DRA. This is earlier than the astrocytic reaction after DRR, which occurs at 
2 days and is significantly less than DRA at this time point. This suggests the severity 
of astrocytic reactivity is dependent upon the type of deafferentation injury, once again 
providing contrast between these two models of brachial plexus injury.  
 
GFAP expression continues to increase at 14 days, consistent with previous findings in 
SCI models (Popovich et al., 1997;Nesic et al., 2005), peripheral nerve injury models 
(Garrison et al., 1991;Raghavendra et al., 2003) and rhizotomy models (Beggah et al., 
2005;Murray et al., 1990). It is known that astrocyte differentiation is progressive after 
PNI, peaking at 14 days (Echeverry et al., 2008), and it may be this differentiation that 
constitutes the further increase in immunofluorescence at this time point in both DRA 
and DRR. This may represent the change in activity of astrocytes during gliosis and 
their involvement in forming the non-permissive glial scar and preventing further 
degeneration of axons (Nomura et al., 2002). GFAP expression increases may be 
essential in maintaining some neuropathic pain conditions, certainly in PNI 
(Raghavendra et al., 2003), by taking over the role of microglia in sustaining synaptic 
changes within the dorsal horn of damaged and intact peripheral nerve terminals (Tanga 
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et al., 2004). However, although GFAP expression increases are seen in the spinal cord 
after SCI, coinciding with neuropathic pain behaviour (Nesic et al., 2005), astrocytes 
may not be responsible for the neuropathic pain perceived in this injury, as inhibition of 
microglial activity with minocycline at 4 weeks post SCI attenuates dorsal horn 
neuronal hyperresponsiveness and restored nociceptive thresholds (Hains and Waxman, 
2006). A more likely role for astrocytes in the dorsal horn after dorsal root injury is in 
scar formation, as astrocyte morphology of interconnecting processes at 14 and 28 days 
may indicate. This is essential after avulsion injury to reform the barrier between CSF 
and the dorsal root entry zone with a greater need for scarring, and this is shown as a 
more substantial GFAP density than in DRR tissue at these time points.     
 
Contralateral GFAP increase, that has been observed before in unilateral spinal nerve 
crush (Hatashita et al., 2008), occurs in both root injury models but is more substantial 
after DRA, probably due to the extent of SCI trauma inflicted in this model. These 
effects probably have a similar aetiology as with microglia and are discussed in section 
3.8. 
 
3.3.5 Leukocyte infiltration 
 
3.3.5.1: Macrophages 
 
At the early injury time points of 1 and 2 days, ED1-positive cells are small and 
granular in appearance, and possibly represent resident activated microglia, or tissue 
macrophages, or those from within the spinal cord microvasculature. Many surround 
the pia matter and DREZ, with only a few present in dorsal horn laminae and columns, 
in accordance with previous literature on root rupture and root rhizotomy at this time 
point (Nomura et al., 2005;George and Griffin, 1994a). The most significant increase in 
macrophage expression is at 14 days, especially in the dorsal columns after DRA and 
DRR. The macrophages are swollen, with staining principally surrounding the cell 
membrane, and encompass areas of vacuolisation, consistent with previous data 
(Fleming et al., 2006;George and Griffin, 1994a). Across later time points swollen 
macrophages infiltrate the dorsal column, with further vacuolization and tissue damage 
to this area, apparent. ‘Wallerian’ degeneration of ascending sensory fibres occurs in 
the dorsal columns after L4-L6 dorsal root rhizotomy, in a proximo-distal fashion, at a 
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rate of 3mm per hour in the rat (George and Griffin, 1994b). This data suggests that 
macrophages are phagocytosing damaged axons and myelin of ascending A-α/β fibres 
within the dorsal funiculus. Macrophages within the spinal cord are known to contain 
phagocytosed myelin after rhizotomy (Ling, 1979b). Secondly, the production of 
myeloperoxidase within macrophages, as well as neutrophils (Taoka et al., 1997), is 
neurotoxic, and may lead to tissue vacuolisation (Fleming et al., 2006). Surprisingly, a 
macrophage reaction has been shown in the ipsilateral dorsal column of ventral root 
avulsed rats expressing neuropathic pain behaviour (Bigbee et al., 2007), coupled with 
degeneration of primary afferent collaterals (Bigbee et al., 2008). This suggests that 
avulsion of the ventral root and therefore damage primarily to lower motor neurone 
axons, can detrimentally induce macrophage reactivity within ascending primary 
afferent fibre tracts. This may well occur through Wallerian degeneration of the 
transected motor axons interacting, through cytokines and inflammatory mediators, 
with sensory fibres within the same peripheral nerve (Bigbee et al., 2008). Interestingly, 
a generalized SCI, such as contusion, also leads to initial targeting of macrophages 
within only the dorsal columns (Carlson et al., 1998). A more diffuse ED1 expression 
throughout the segmental cord is found only at later time points (Carlson et al., 1998). 
This suggests dorsal root injury, ventral root injury, as well as spinal cord trauma, 
causes specific deteroriation of the ascending dorsal column sensory pathway, and is 
linked to macrophage extravasation and phagocytosis. However, the possibility that 
these ED1 cells originate from microglial populations, as shown previously after DRR 
injury (George and Griffin, 1994a) cannot be excluded.  
 
In contrast to the dorsal columns, DRR and DRA macrophages within the dorsal horn 
have a subtle difference in appearance. They were not swollen and notably phagocytic, 
and did not surround regions of vacuolisation and cavities, and in the majority remained 
remained cellularly intact. Numbers of these smaller macrophages continue to increase 
across 28 days, but density staining remains substantially lower than in the dorsal 
column due to this separation in size. This perhaps implies a different, non-phagocytic, 
role of macrophages within this area of neuronal cell bodies, perhaps of a more 
persistent immune response similar to microglia. It is known macrophages produce 
reactive oxygen species, myeloperoxidase and NOS (Carlson et al., 1998), which 
suggests a role in neuroinflammation. As for apoptotic macrophages at 1 and 2 days 
post injury, similar to microglia, only a few were observed. It is likely that when 
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macrophages become phagocytic they also undergo a programmed cell death 
(Kirschnek et al., 2005). However, due to the overlap of the ED1 epitope with 
microglia, and the fact that only a small proportion of macrophages are colocalised with 
TUNEL, it is unclear whether these apoptotic macrophages are a different population to 
activated microglial-macrophages.  
 
Macrophage density staining progressively increases over the course of 14-28 days after 
DRA and DRR, most clearly within the dorsal columns showing vastly swollen cell 
bodies. This increase is consistent with the findings from rat SCI (Casella et al., 
2006;Trivedi et al., 2006), human SCI (Fleming et al., 2006), rat PNI (Gupta and 
Channual, 2006), and rat DRR (George and Griffin, 1994a). The expression of 
macrophages has a delayed contralateral effect at 4 weeks DRA. In this case an 
overspill from the increasing ipsilateral infiltration of macrophages could give rise to 
this contralateral effect, similar to the bilateral glial activation shown at 14 and 28 days. 
However, this delayed contralateral macrophage infiltration was also found in dorsal 
root ganglion cells after unilateral nerve ligation (Dubovy et al., 2007), where 
‘overspill’ could not anatomically occur. This suggests either a general systemic 
upregulation of blood borne macrophages, targeted to specific contralateral segmental 
region of the cord, or perhaps a transneuronal control of macrophage infiltration (see 
section 3.8). 
 
This report provides new evidence of a clear distinction between the two types of 
deafferentation injuries. After DRR within the dorsal horn, macrophage density remains 
unchanged from 2 to 28 days, at a low density, similar to previous findings (Ling, 
1979b), whereas in DRA injured dorsal horn ED1 continues to rise beyond 2 days, at 
both 14 and 28 days, with a contralateral expression at 28 days. Within the dorsal 
columns both models show progressive macrophage recruitment across 2 to 28 days, 
but with DRA showing far greater bilateral ED1-ir than DRR. It is known that p38 
MAP Kinase phosphorylation, an intracellular pathway associated with inflammation 
and neuropathic pain (Tikka et al., 2001), is greatly increased within macrophages after 
dorsal root rupture (mechanical stretch without avulsion), but only minimally after 
rhizotomy (Nomura et al., 2005). This suggests that a traction injury to the root and 
spinal cord leads to much more robust macrophage activation and infiltration into the 
spinal cord. Therefore the severity of deafferentation trauma, as is the case in glial 
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activity, is the factor behind the differential macrophage recruitment in DRA and DRR. 
The greater extent of spinal cord tissue damage caused by avulsion, compared to 
rhizotomy, increases macrophage recruitment within the dorsal horn and columns, and 
that this infiltration in the former injury is capable of extending across to the 
contralateral cord.  
 
3.3.5.2: Neutrophils 
 
The slow and steady increase of macrophage recruitment and activation is clearly 
contrasted with neutrophil infiltration. Neutrophils are apparent in the dorsal horn and 
columns in the acute phase of injury only, at 1 and 2 days, with very few positive cells 
at 14 and 28 days, consistent with previous data on SCI (Carlson et al., 1998). Original 
findings of this report show that DRA causes a greater neutrophil infiltration at 1 day in 
both dorsal horn and column of the ipsilateral cord and within the ipsilateral dorsal horn 
at 2 days compared to DRR. Neutrophils are recruited to the site of injury through 
adhesion to the surface of the vascular endothelium and transendothelial migration 
(Moalem and Tracey, 2006), and then targeted to the injury site by the expression of 
chemoattractant chemokines from inflamed tissue and immune cells such as microglia 
(Milner and Campbell, 2002). From here they can sensitize nociceptors through release 
of cytokines and reactive oxygen species (Moalem and Tracey, 2006), phagocytose 
foreign or native necrotic debris (Watson et al., 1996), and attract macrophages to the 
site of injury (Trivedi et al., 2006). This is the first time neutrophil infiltration has been 
shown, and quantified, in dorsal root deafferentations within the spinal cord.  
 
The specificity of infiltration to the ipsilateral dorsal horn and dorsal column at early, 
but not later, time points is in parallel with the magnitude, time course, and side 
specificity of TUNEL expression, as well as cell loss counts from PI flow cytometry. 
Colocalisation reveals that, almost exclusively, TUNEL-positive nuclei are neutrophils. 
This result is consistent with the short life cycle of neutrophils (approximately 9 hours), 
regulated by apoptosis (Maianski et al., 2004), which is influenced by both intrinsic and 
extrinsic factors within normal and patho-physiological conditions (Trivedi et al., 
2006). Neutrophil apoptosis can be accelerated both in the presence and in the absence 
of survival factors by activation of distinct members of the tumor necrosis factor/nerve 
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growth factor receptor family. A trigger for neutrophil apoptosis is phagocytosis 
(Watson et al., 1996) of either foreign or native debris (Popovich and Jones, 2003).  
 
Neutrophil apoptosis in pathophysiological conditions plays an important role in the 
elimination of these cells from inflamed tissue without the release of hazardous 
intracellular contents (Simon, 2003). Macrophages phagocytose neutrophils while 
releasing anti-inflammatory mediators, thus controlling the extent of neutrophil 
mediated tissue damage (Savill et al., 2002). This explains why neutrophil infiltration 
and apoptosis occurs shortly after injury, within 1-2 days, before macrophage 
expression, whereas at 2 weeks the cord is absent of neutrophils but in an abundance of 
macrophages. The particulate neutrophil staining at 14 and 28 days most likely 
represents particles of phagocytosed neutrophil membrane.  
 
The number of infiltrating neutrophils into the ipsilateral dorsal horn also depends on 
the deafferentation model. DRR resulted in fewer neutrophils in the dorsal horn than 
DRA, again suggesting that dorsal horn tissue damage is less severe in the former 
injury. The similar numbers of neutrophils in the dorsal columns at 2 days suggests 
similar tissue damage occurs in this area after both deafferentation models. The 
contralateral neutrophil count, predominantly in the dorsal columns, at 1 and 2 days are 
likely to occur from an ipsilateral ‘overspill’ in a similar way as observed with 
macrophages at 28 days. For further details refer to section 3.8.  
 
3.3.6 Vascular loss 
 
RECA-1 staining was used as a representation of loss of endothelial staining and 
microvasculature. Endothelial staining at 1 day after sham surgery was reduced in 
accordance with previous literature (Anderson et al., 1978), but was not maintained at 
14 days suggesting a laminectomy effects the microvasculature of the dorsal horn only 
transiently. Endothelial reduction at 1 day post DRA and DRR may therefore be due to 
the cumulative effect of both transient ischemia after hemi-laminectomy as well as a 
result of injury to the root and radicular artery coursing with it. After 2 days vascular 
staining loss is maximal in both DRA and DRR dorsal horn, with vessels thin and 
broken within the cord. These results are consistent with SCI (Casella et al., 2006), 
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where RECA-1 expression is reduced after 8 hours, continuing to 2-4 days. The 
mechanisms behind the decrease in vascular integrity across at 2 days remain unclear.  
 
One possibility is ischemia, through disruption of the ipsilateral posterior radicular 
arteries, which supply the posterior spinal artery of the spinal cord, and course along the 
dorsal and ventral roots and eventually supply blood to the spinal cord grey matter, as 
well as the single dorsal spinal vein, which overlies the posterior median sulcus in the 
rat, that provides venous drainage of the dorsal cord. Ligation of radicular arteries 
causes considerable ischemic spinal cord lesions, that are most pronounced at 7 days 
(Tsitsopoulos et al., 1995). Another possibility is a loss of microvascular tissue through 
gliosis and cytotoxicity. Nesic et al., ((Nesic et al., 2005)) suggested that chronically 
overactivated astrocytes after SCI may cause loss of the blood brain barrier integrity 
within the cord. Wang et al., ((Wang et al., 1996)) showed that endothelial cell necrosis 
could be induced through oxidative and non-oxidative mechanisms initiated after 
neutrophil adhesion and activation. The peak infiltration time of neutrophils and the 
maximal extent of vascular loss do indeed coincide in both deafferentation models; 
however, this unlikely to be the sole cause of vascular loss as leukocyte infiltration is 
strictly ipsilateral, whereas vascular loss is bilateral in the dorsal horn.  
 
It is unclear as to the reasons why a unilateral root injury would lead to a bilateral 
vascular loss, and indeed so early after injury as most other contralateral effects such as 
glial activation, neuronal loss, and macrophage infiltration, occur much later. 
Contralateral vascular effects have been shown before (Sommer and Myers, 1996), with 
narrowing of the endoneurial lumina of the contralateral sciatic nerve 14 days after 
unilateral ligation. Contralateral vasculature degeneration is unlikely to be due to direct 
damage to arterial input to the lumbar spinal cord, which originates from a contralateral 
posterior spinal artery and radicular artery that would be protected from the hemi-
laminectomy and the ipsilateral deafferentation. However occlusion of the single dorsal 
spinal vein leads to bilateral ischemia of the dorsal spinal cord incuding oedema, 
hemorrhage and gliosis from 1 day post injury, becoming more severe across 28 days 
(Zhang et al., 2001). Deafferentation, especially avulsion, may lead to damage of this 
major vein directly through trauma or through scar formation and expansion, as well as 
inflammation over the dorsal surface of the cord, and could permanently disrupt the 
venous drainage of the dorsal cord bilaterally.  
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After spinal cord hemisection (Imperato-Kalmar et al., 1997) or contusion (Casella et 
al., 2002;Loy et al., 2002) a potential recovery mechanism within the microvasculature 
can be observed after an initial vascular deterioration, beginning at 4 days and 7 days 
respectively as measured by RECA-1. This phenomenon is thought to be due to ‘a 
disintegrin and metalloprotease protein 8’ (ADAM8) initiation of angiogenesis 
(proliferation and migration of endothelial cells) (Mahoney et al., 2009). However, in 
the case of SCI, this angiogenesis is unable to repair the vasculature and beyond 7 days 
the microvascular integrity continues to decline (Imperato-Kalmar et al., 1997;Casella 
et al., 2002;Loy et al., 2002). New findings in this report show that after DRR a 
significant recovery of vascular staining occurs by 14 days, suggesting that rhizotomy 
does not permanently affect the vascular supply of the spinal cord, confirming previous 
literature (Liu et al., 1998). This recovery maybe initiated through compensatory 
shunting of blood supply, from other arteries such as the contralateral radicular arteries 
after the initial loss (Maliszewski et al., 1999), or less damage incurred by the dorsal 
spinal vein after rhizotomy compared to avulsion. Previous literature suggests the more 
likely reason for vascular recovery is angiogenesis and proliferation of endothelial cells, 
creating a neo-vasculature (Mahoney et al., 2009), however further studies using 
angiogenic markers (such as ADAM8) or neo-vascular markers (such as IB4), or 
markers for growth factors such as vascular endothelial growth factor (VEGF) are 
needed to confirm this. This angiogenic recovery has also been shown in the 
endoneurium of the sciatic nerve after ligation by 7 days (Sommer and Myers, 1996).  
Comparatively no maintained recovery of vasculature was seen in DRA up to 28 days, 
similarly to SCI. It is likely that the tensile stress placed on the cord through the tearing 
of the root, resulting in stretch and distortion of the avulsed cord, leads to permanent 
rupturing of the microvasculature and vasospasm (Mautes et al., 2000). The subsequent 
loss of tissue integrity, vast phagocytic invasion, scarring and vacuolisation in the case 
of avulsion overshadows any potential angiogenic recovery mechanism or blood supply 
diversion. This leaves this neovasculature unstable and susceptible to degeneration and 
phagocytosis (Imperato-Kalmar et al., 1997;Mautes et al., 2000). 
 
There are secondary consequences to the loss of microvasculature. Vascular loss with 
corresponding ischemia within the lesion, may be a mechanism by which the avulsed 
cord could become necrotic (Mautes et al., 2000), through deposition of platelets and 
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formation of thrombi and mediation of multiple secondary injury inflammatory 
cascades (Nelson et al., 1977). Secondary neuronal loss recorded in 28 day DRA tissue 
may well be explained by this maintained vascular loss, as both endothelial cells and 
neurones deteriorate across similar time periods after SCI (Dusart and Schwab, 
1994;Imperato-Kalmar et al., 1997;Casella et al., 2006), and cavity formation occurs 
after angiogenesis fails to re-establish neo-vasculature (Loy et al., 2002). Further, loss 
of vascular integrity may be a pathway by which monocyte-macrophages may enter the 
cord from the blood, and loss of vascular integrity after SCI coincides with macrophage 
infiltration, as well as glial scarring and microglial activation (Dusart and Schwab, 
1994;Casella et al., 2006). This is especially evident in DRA where a maintained loss of 
vascular staining could facilitate further macrophage infiltration at 14 and 28 days, and 
also coincides with maximal astrocyte and microglial densities. Perhaps the recovery of 
vascular integrity in DRR by 14 days may have prevented such an increase in secondary 
damage at these later time points.  
 
It is not possible to say in this report whether endothelial cells are in fact dying, as 
TUNEL colocalisation studies were not performed, and therefore only circumstantial 
evidence can be put forward to suggest a role of degenerating vasculature in the chronic 
stages of deafferentation injury. Indeed it is also premature to describe the vascular 
system as damaged, as the observations here could simply be a reduced expression of 
the RECA-1 epitope. However this report is the first evidence showing different 
microvascular effects after rhizotomy compared to avulsion. These different vascular 
effects suggest that rhizotomy may not give an accurate representation of the severity of 
the vascular loss in an avulsed spinal cord, which shows similarity to SCI.  
 
3.3.7 Neuronal loss 
 
This report has used immunohistochemistry, flow cytometry, and histology to 
investigate the effect of two different deafferentation injuries on the neuronal 
population of the dorsal horn. Data shows that a transneuronal loss of dorsal horn 
neurones occurs immediately after deafferentation, and that it is greatly increased in 
avulsed animals. A ‘second-wave’ of NeuN loss occurs in the case of DRA, at 28 days 
post injury. This data for the first time provides evidence suggesting root avulsion 
injury, like SCI, is a chronic, progressive trauma, and this time frame of 14-28 days of 
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further neurodegeneration may provide a substantial therapeutic window for chronic 
neuroprotective treatment clinically.  
 
NeuN reduction after both DRR and DRA follows the pattern of downregulation found 
in the vasculature, and is similar in time course to previously reported findings in spinal 
cord hemisection (Dusart and Schwab, 1994), spinal cord contusion (Casella et al., 
2006), and spinal cord compression (Huang et al., 2007). In the case of root injury, an 
initial reduction in NeuN in the dorsal horn at 1 day in both models is significant from 
both sham and naïve, and is maintained at 2 days at approximately 30% in DRA and 
18% in DRR, with ipsilateral NeuN loss more severe than contralateral. This NeuN 
reduction at these early time points was confirmed with toluidine blue counts within the 
dorsal horn as well as flow cytometry analysis within the spinal cord. This death, as 
defined by NeuN/DAPI flow cytometry is approximately 25% after DRA and 18% after 
DRR at 2 days (Chew et al., 2008), and 20% in both deafferentation models in toluidine 
blue staining. These values represent the percentage of all neurones that have died from 
the moment of the injury up to 2 days, depending on the rate of neuronal phagocytosis 
and debris clearance of macrophages. The percentages calculated from these three 
different analyses are similar, with differences due to different methods of analysis. For 
this reason it can be concluded that death of neurones does occur rather than just a 
down-regulation of the NeuN epitope in injured neurones. Interestingly, this neuronal 
loss is, in the early injury time period, not specific to the type of deafferentation 
imposed on the cord, suggesting that the method of deafferentation is not a factor in 
early stage neuronal loss. This is in direct contrast to other spinal events such as 
infiltration of phagocytes, vascular disruption and glial reactivity.  
 
The negative TUNEL-NeuN colocalisation at 1 and 2 days suggest two possibilities of 
the initial fate of neurones after deafferentation injury: Firstly the loss of neurons, 
observed by all methods, may occur through non-apoptotic mechanisms. Secondly, that 
cell death within the neuronal population, via apoptosis, may occur before 1 day. It is 
the case in spinal cord contusion injury that TUNEL positivity presents in neurones at 4 
hours, peaking at 8 hours, and is absent by 24 hours (Liu et al., 1997).  
 
The numbers of dead neurones in flow cytometric analysis at 14 days are not 
significantly different to naïve. This suggests two things: Firstly, the neurones that died 
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by 1-2 days have been cleared, most likely through phagocytosis involving the 
neutrophil and macrophage populations. Secondly, no further neuronal loss occurrs 
between 2 and 14 day time points in either model. The absence of further dead neurones 
at 14 days in NeuN/DAPI flow cytometry is also confirmed with NeuN 
immunohistochemistry, and is consistent with SCI models (Huang et al., 2007). 
Scarring around the lesion and the dorsal columns suggests that intrinsically the cord 
has prevented further neuronal loss by containing the lesion site through an astrocytic 
glial reaction, maintaining the integrity of the remaining intact dorsal horn. This 
coincides with the upregulation of GFAP in astrocytes, and the appearance of 
interconnected astrocytic processes in both deafferentation models. 
 
Further analysis shows a ‘second-wave’ of NeuN reduction, with a significant 
contralateral effect, occurring by 28 days after DRA but not after DRR. Although this 
reduction has not been confirmed with toluidine blue or flow cytometric analysis, it 
could be suggested that further release of cytotoxic, free radical, and excitatory amino 
acids from increasing glial and phagocytic species with the injury site as well as 
sustained loss of vascular integrity are contributing to the secondary cell loss. This 
chronic neuronal reduction of approximately 56% at 28 days certainly coincides with 
the maximal macrophage induction, and microglia and astrocyte reactivity. Visually, 
tissue scarring and further cystic cavity formation have engulfed the dorsal horn and 
column in 28 day DRA. Interestingly, further increase in glial and macrophage species 
in the dorsal horn and columns of DRR animals are minimal at 28 days, coinciding with 
no further neuronal loss. Scarring and cavity formation has been shown to occur after 
SCI at 28 days accompanied with >80% neuronal loss, using NeuN (Huang et al., 
2007). A neuronal loss of 20% was found after PNI (Scholz et al., 2005) in the dorsal 
horn over 28 days, with apoptosis implicated as the cause. As for an explanation of the 
30% contralateral neuronal loss at this time point, excitotoxic effects within the 
ipsilateral dorsal horn, trans-neuronally or in an “over spill” mechanism may affect the 
contralateral dorsal horn also. Again this coincides with an increase in glial activity, 
macrophage recruitment, and vascular loss in the contralateral dorsal horn at 28 days. 
The aetiology of the neuronal loss by 28 days has not been assessed in this work, but is 
likely to be either necrotic, or apoptotic, at time points that have not been analysed in 
this report.  
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3.3.8 Contralateral effect 
 
Contralateral effects were detected for primary afferent terminal loss, microglial and 
astrocyte reactivity, macrophage and neutrophil infilatration, and neuronal and vascular 
loss. These effects were usually delayed, and more severe in the DRA model compared 
to DRR. Contralateral effects after unilateral root injury are not observed in previous 
research literature. However, as mentioned above, these effects may have been missed 
in previous studies, as authors use the contralateral side as an internal control for 
ipsilateral rhizotomy comparison, rather than a naïve control. Contralateral effects in 
the dorsal horn, across similar time points as mentioned in this chapter, have been 
shown to occur in microglia (Colburn et al., 1997;Sweitzer et al., 1999;Milligan et al., 
2003) and astrocytes (Colburn et al., 1997;Hatashita et al., 2008) after unilateral 
inflammation and PNI. Bilateral allodynia has been reported in unilateral rat injury 
models of dorsal root crush (Rothman et al., 2009), dorsal root ligation (Hunt et al., 
2001) unilateral focal burn injury (Chang et al., 2010), spinal nerve ligation (Arguis et 
al., 2008), and spinal nerve crush (Hatashita et al., 2008). The ‘mirror-image’ pain in 
these cases was causally linked to contralateral increases in satellite cell activation and 
TNFα expression in the contralateral DRG (Hatashita et al., 2008); as well as activation 
(Chang et al., 2010) and proliferation (Rothman et al., 2009) of microglia, and astrocyte 
hypertrophy in the dorsal horn (Hatashita et al., 2008). In all cases the contralateral 
effects were delayed, always proceeded, and were of a lesser magnitude than ipsilateral. 
These phenomenon have two possible explanations that are clinically relevant when 
understanding certain contralateral pain syndromes (Sotgiu et al., 2004). Firstly, some 
authors suggest the spinal cord upregulation could be simply an “overspill of reactivity” 
from the ipsilateral side (Koltzenburg et al., 1999;Hatashita et al., 2008). Activated glia 
can influence nearby cells in a paracrine fashion (Milligan and Watkins, 2009), via gap 
junction communication as in astrocytes, or cytokines and inflammatory mediator 
release as in microglia. If this occurs near the grey commissure and posterior median 
sulcus, it is plausible that contralateral glia could be influenced and activated by 
ipsilateral glia. Alternatively, a transneuronal mechanism involving commissural fibre 
activity could be responsible for this phenomenon (Attal et al., 1990;Koltzenburg et al., 
1999;Sotgiu et al., 2004). Dorsal horn neurons and interneurone axons are known to 
cross the cord contralaterally, such as the spinothalamic and ventral spinocerebellar 
tracts (Willis and Coggeshall, 1991;Willis and Westlund, 1997;Almeida et al., 2004). If 
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these neurons are hyperexcitable or injured and releasing excitatory amino acids, ATP, 
or fractalkine for example, this could also activate contralateral glia. For vascular loss, 
as explained previously, contralateral effects could well be due to indirect mechanisms 
such as ischemia through damage to the posterior venous outflow. Contralateral effects 
are more severe after avulsion suggesting the direct mechanical trauma, rather than 
deafferentation, to the spinal cord after DRA may be responsible for the magnitude of 
these effects.  
 
3.3.9: Conclusion 
 
This chapter identifies important differences in the degenerative events in the spinal 
cord proceeding deafferentation via root rhizotomy, used in pre-clinical root avulsion 
modeling, and ‘true’ root avulsion. When quantifying reactive processes such as 
microglial and astrocyte upregulation, infiltration of leukocytes or degenerative 
phenomena in neurones and endothelial cells, avulsion results in a more severe response 
than rhizotomy in all cases. A delayed contralateral effect after avulsion is prominent in 
primary afferent terminal, dorsal horn neuronal, and endothelial loss, as well as glial 
and leukocyte upregulation. This may have been overlooked in previous literature due 
to the use of rhizotomy models. This new evidence highlights a role for neutrophil 
reactivity at the early stages of injury (1-2 days), and macrophage, microglial, and 
astrocyte reactivity, in the later stages of avulsion injury (14-28 days). Degenerative 
phenomena follow these processes, with initial neuronal and vascular disruption at 1-2 
days through both modes of deafferentation, but a further neurodegeneration and a 
maintained vascular degeneration at 28 days only after avulsion. These differences 
provide evidence for arguing rhizotomy, used most often for in vivo modeling of 
deafferentation, is a milder model of brachial and lumbosacral plexus avulsion injury 
for assessing degenerative phenomena in the spinal cord.  
 
Neuronal loss does occur after deafferentation initially, but does not significantly 
change between 1 and 14 days. A second wave of neuronal loss occurs between 14 and 
28 days after avulsion but not after rhizotomy. The extent and time course of dorsal 
horn neuronal loss after avulsion injury, with a delayed and more severe “second wave” 
of loss that coincides with further degenerative phenomena, may provide a therapeutic 
window to target and prevent exacerbation of symptoms after brachial plexus injuries. 
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Chapter 4: A new rodent behavioural model of avulsion pain. 
 
4.1: Introduction 
 
4.1.1: Neuropathic pain 
The International Association for the Study of Pain (www.iasp-pain.org) defines 
neuropathic pain as ‘pain initiated or caused by a primary lesion or dysfunction of the 
nervous system’, different from nociceptive pain that typically results as a response to 
tissue damage outside of the nervous system. Neuropathic pain can be broadly described 
as a pathological symptom of injury, inflammation, or disease to the peripheral or 
central nervous system. It is usually chronic in duration, such that it lasts longer than 3 
months. Various diseases can lead to neuropathic pain including trigeminal neuralgia 
(Cheshire, 2005), diabetic neuropathy (Veves et al., 2008), multiple sclerosis (Pollmann 
and Feneberg, 2008), cancer (Blumenthal, 2009), and HIV (Verma et al., 2004), to list 
but a few. The nature of neuropathic pain can be broadly divided into three unique 
sensory abnormalities or dysesthesias: 1) Allodynia-a painful sensation from a typically 
non-noxious stimulus. 2) Hyperalgesia- a highly exaggerated nociceptive response. 3) 
Spontaneous pain- a painful sensation from an area of anaesthetic (Anesthesia 
Dolorosa) tissue, which is not driven by peripheral stimulation. These characteristics 
may act in combination, or only one may be present. Indeed in phantom limb pain or 
anesthesia dolorosa where evoked sensation is not applicable, only spontaneous pain 
can be a symptom. These symptoms do not take into account the emotional, cognitive 
changes that also take place in a person with neuropathic pain, including depression and 
stress. Patient descriptions of neuropathic pain sensations include pricking, cold, 
freezing, numb and wretched, pressing and burning sensations (Herr, 2004). These 
dysesthesias can be continuous, such as a burning sensation, and/or paroxysmal that are 
likened to electric shock. 
 
The Neuropathic Pain Network (www.neuropathicpainnetwork.org) estimates the 
prevalence of neuropathic pain in the United Kingdom at 3 million people, with similar 
numbers in other European countries such as France, Spain and Germany. Between the 
UK and the US there are estimated to be 15 million sufferers of neuropathic pain. In a 
recent survey across 3 UK cities the prevalence of pain of a neuropathic origin was 8% 
  142 
(Torrance et al., 2006). A questionnaire sent to the general population of France 
recorded a prevalence of 31.7% for chronic pain, with 6.9% prevalence of neuropathic 
pain (Bouhassira et al., 2008). Although these studies are not ideally controlled, as they 
depend solely upon unblinded patient self diagnosis, they suggest an alarming number 
of the general population suffer from this disorder. 
 
4.1.2: Models of neuropathic pain 
 
Peripheral Nerve Injury (PNI) 
 
Work in animal models has contributed greatly to our understanding of neuropathic pain 
mechanisms, and involve several variations of nerve injury. They have provided quick 
and easy tools to assess therapeutic efficacy of new drugs as pre-clinical screens. The 
first model of neuropathic pain, specifically spontaneous, was designed by Wall et al., 
((Wall et al., 1979)), with complete sciatic and saphenous nerve transection. This 
produced an anesthesia dolorosa in the affected limb, and resulted in atendency for the 
rodents to attack and mutilate the anesthetized limb which the authors described as 
autotomy, and a scaling system was designed to describe the extent of neuropathic pain. 
Many issues arise with this model, such that higher order mammals do not show self 
mutilation, and alternative interpretations have been proposed for autotomy (Rodin and 
Kruger, 1984). 
 
Partial denervated PNI models have been designed to allow for evoked sensory testing 
as a more quantitative measure of neuropathic pain development (Bennett and Xie, 
1988;Seltzer et al., 1990;Kim and Chung, 1992;Decosterd and Woolf, 2000;Lee et al., 
2000). In these models autotomy rarely occurs, indicating a fully denervated sensory 
peripheral field through nerve injury is required for self mutilation. These have resulted 
in reproducible sensory deficits that have been typically defined as allodynia, 
hyperalgesia, and spontaneous pain. However they also show considerable differences 
in magnitude and duration of symptoms (Dowdall et al., 2005). The first model, 
designed by Bennett and Xie ((Bennett and Xie, 1988)) was a chronic constriction 
injury (CCI), accomplished by tying loose ligatures around the sciatic nerve of the rat at 
mid-thigh level. The ligatures evoke intraneural edema, and the nerve self-strangulates, 
initially leading to a loss of most A-fibres (Carlton et al., 1991;Obata et al., 2003), later 
  143 
followed by C-fibres, equaling out the ratio (Coggeshall et al., 1993;Gabay and Tal, 
2004). The process of Wallerian degeneration of injured motor and sensory fibres, and 
the corresponding secretion of inflammatory mediators, triggers spontaneous activity in 
non-injured fibres (Wu et al., 2002). The model results in the development of chemical 
and heat-evoked hyperalgesia and allodynia and spontaneous pain 2 or more days after 
surgery, peaking at 10-18 days, and lasting up to 2 months (Bennett and Xie, 
1988;Dowdall et al., 2005), that is thought to be due to ectopic activity of A-fibres (Tal 
and Eliav, 1996) and central sensitization in the dorsal horn (Koltzenburg et al., 1994). 
Interestingly the effect of different composition of ligatures lead to different behavioural 
outcomes (Maves et al., 1993), with chronic gut ligatures leading to a far more severe 
behaviour and loss of axons than silk or plain gut, suggesting a chemical component 
may also play a neuropathic role. The main problem with this injury is the requirement 
of the nerve to become inflamed and ‘strangle itself’, and this can be highly variable. In 
most case the percentage of damaged DRG neurones, as identified by ATF3 positivity, 
range from 7-51% (Obata et al., 2003) as can the incidence of neuropathy 10-80%. 
 
Seltzer et al., ((Seltzer et al., 1990)) designed the partial sciatic nerve ligation model 
that is produced by piercing the rats sciatic nerve at the upper thigh level with a needle 
and suture, and tightly ligating and thus transecting about ⅓ to ½ of the nerve axons. 
This leads to a partial deafferenation of the rat hind paw, and induces mechanical 
allodynia, thermal hyperalgesia and indication of spontaneous pain, within a few hours 
and maintained presence for up to 7 months. Through neonatal capsaicin treatment and 
selective nociceptor (C and Aδ) destruction, a role of A-fibres in mechanical 
hypersensitivity and C-fibres mediate thermal hyperalgesia were defined in this model 
(Shir and Seltzer, 1990). However, the authors (Shir et al., 1998) found difficulty in 
replicating the neuropathic pain induced in this model, when used in different 
laboratories. The neuropathic behavior is greatly susceptible to changes in rat strain, 
vendor, age, gender, weight, diet, and personnel. There are likely to be additional 
conflicting factors with the extent of axonal injury (one third to half) and accuracy of 
surgery applied to the sciatic nerve, as well as uncontrolled co-mingeling of injured and 
intact axons. The sciatic nerve ligation model has recently been modified into a ‘spared 
sciatic nerve injury’ model. This involves tight ligation of only 2 of the 3 branches of 
the sciatic nerve, most often the tibial and common peroneal, leaving the sural intact 
(Decosterd and Woolf, 2000;Lee et al., 2000). In this way the co-mingling of distal 
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axons with degenerating axons, and the effects of Wallerian degeneration on intact 
axons is restricted, and enables a more reliable behavioural testing on adjacent nerve 
injured and ‘intact’ skin territories than the partial sciatic nerve injury model. 
 
The spinal nerve ligation (SNL) otherwise known as the ‘Chung’ model (Kim and 
Chung, 1992) is perhaps the most well know and most reproducible nerve injury model, 
and can be modified accordingly. SNL can involve a tight ligation of the L5 and L6, L5 
alone, or S1-S4 spinal nerves, close to the respective ganglia and transection without the 
formation of a neuroma. The hind paw or tail is therefore partially deafferented (through 
sciatic and sacral nerves) by 50%. Mechanical and heat-evoked hyperalgesia, and 
spontaneous pain, were evident immediately and maintained up to 4 months post injury 
(Choi et al., 1994). The neuropathic pain was shown to be sympathetically dependent 
(Choi et al., 1994;Kim and Chung, 1992), as lumbar sympathectomy almost completely 
abolishes it. Indeed after SNL injury sympathetic sprouting of noradrenergic terminals 
around the effected DRG has been shown to be functionally coupled and aberrantly 
active (McLachlan et al., 1993), a phenomenon common to all PNI models and a 
symptom of neuropathic pain (see section 4.1.3). The unique feature of SNL, unlike the 
spared sciatic injury model, is that the DRG cells of injured and intact afferents are 
completely separated, allowing their contribution to neuropathic pain to be separately 
assessed.  
 
Several groups have tried to understand the contribution of the intact and injured spinal 
nerves and spinal segments in SNL neuropathic pain, and there is still much debate 
(Sheen and Chung, 1993;Yoon et al., 1996;Eschenfelder et al., 2000;Li et al., 
2000;Sukhotinsky et al., 2004). Selective L5-L6 dorsal root rhizotomy or anaesthetic 
block 5 days after L5 and L6 spinal nerve ligation abolished the injury-induced evoked 
pain behavior (Sheen and Chung, 1993;Yoon et al., 1996;Sukhotinsky et al., 2004). This 
suggested afferent activity from the injured L5-L6 DRG must coordinate and maintain 
the neuropathic pain that is processed through the intact L3 and L4 afferent fibres and 
spinal segments. Ectopic discharges from the L5 and L6 DRG, perhaps mediated 
sympathetically (Choi et al., 1994) as peripheral targets are no longer intact, sensitize 
the dorsal horn neurones making them more susceptible to activation from intact 
adjacent afferents. Sensitization of the dorsal horn can be reversed by inhibiting these 
ectopic discharges with local anesthetic applied to the rhizotomised roots (Yoon et al., 
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1996;Sukhotinsky et al., 2004). There is however, evidence to the contrary, where pre-
emptive or delayed (5-7 days) L5 DRR does not ameliorate L5 SNL pain (Eschenfelder 
et al., 2000;Li et al., 2000). In both of these cases peripheral interaction between injured 
(L5/L6) and intact (L3/L4) nerves via Wallerian degenerative phenomena, and 
increased L3/L4 afferent activity were implicated as the cause for neuropathic pain after 
SNL. This controversy can be explained; in some cases (Colburn et al., 
1999;Eschenfelder et al., 2000;Li et al., 2000) L5 DRR alone produced a robust 
allodynic response up to 7, 20, and 57 days post injury in respective articles, whereas in 
the hands of separate investigators (Sheen and Chung, 1993;Yoon et al., 
1996;Sukhotinsky et al., 2004;Obata et al., 2006b) it did not produce neuropathic pain. 
Therefore in the hands of some investigators DRR may simply replace the L5/L6 SNL-
induced neuropathic pain; however, it is still unclear which afferents, intact or injured, 
are most important in neuropathic pain. 
 
Additionally, and perhaps surprisingly, rhizotomy or avulsion of the L5 ventral root can 
lead to glial activation in the dorsal horn (Colburn et al., 1999;Bigbee et al., 2007), 
increase p75 expression in satellite cells and Schwann cells of the DRG, linked to 
sympathetic sprouting (Zhou et al., 1996), and up-regulation of NGF, BDNF, and ED1 
within the DRG, and BDNF in the dorsal horn (Obata et al., 2004). Such increase in 
activity and expression could be the cause of the neuropathic pain behaviours induced in 
this injury model (Sheth et al., 2002;Li et al., 2003;Obata et al., 2004). Prolonged 
treatment with NGF-antiserum attenuated ventral root-induced mechanical allodynia (Li 
et al., 2003). These phenomena occur most likely through Wallerian degenerative 
interaction between injured motor axons and intact primary afferents of the mixed 
nerve. However, similar to dorsal root rhizotomy, some investigators have shown no 
neuropathic pain responses to ventral root rhizotomy (Colburn et al., 1999). Ventral root 
avulsion (L6-S1), a more clinically representative model of true avulsion also leads to 
astrogliosis, microglial activation, macrophage infiltration, and axon degeneration, in 
the dorsal column and horn, with neuropathic pain behaviour maintained up to 7 weeks 
(Bigbee et al., 2007;Bigbee et al., 2008). Immediate reimplantation of the ventral root 
ameliorated these symptoms (Bigbee et al., 2007;Bigbee et al., 2008), but it is unclear 
what mechanism underlies this phenomenon.  
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The reason why dorsal or ventral root rhizotomy produces neuropathic pain in some 
groups but not others is unclear, as clinically (White and Sweet, 1969;Loeser, 
1972;Hosobuchi, 1980;Gybels and Sweet, 1989) rhizotomy is used to relieve peripheral 
neuropathic pain. This may be due to a number of methodological factors (Shir et al., 
1998;Sheth et al., 2002), as well as the extent of laminectomy surgery (Kosta et al., 
2009). As suggested in chapter 3, because rhizotomy is unreliable at producing 
neuropathic pain behaviour, and does not represent the clinical condition, it is therefore 
an unsuitable model for the study of neuropathic pain and nerve/root injury. 
 
Spinal Cord Injury (SCI) 
 
Spinal cord injury also leads to the generation of neuropathic chronic pain states, and 
clinically has a prevalence of >65% in patients (de Miguel and Kraychete, 
2009;Miladinovic, 2009). Models for spinal cord injury have been designed specifically 
for regenerative research rather than chronic pain, and less attention has been given to 
mechanism of chronic pain in SCI.  The most common model is the contusion devise 
first described by Allen (Allen, 1911) as a simple weight that is dropped from a varying 
height. This crude method has now been optimized through precision controlled devises 
such as the Infinite Horizons Contusion (IHC) device (Precision Systems and 
Instrumentation, Lexington, KY) and the MASCIS/NYU impactor, designed by Wise 
Young, John Gruner, and Carl Mason at New York University Medical Centre in 1991. 
The IHC instrument enables the application of standard-force injuries through 
electronically controlled impaction, and force levels can be varied accordingly. The 
MASCIS impactor is more widely applied to studies on chronic neuropathic pain 
(Hulsebosch et al., 2000). It precisely measures the movement of a 10-gram rod onto the 
laminectomised dorsal surface of the thoracic cord. The height of the rod dropped can 
be accurately controlled. After impact computer readout gives information on impact 
trajectory, impact velocity, cord compression distance and time.  In this case the 
intensity of impact can be varied to produce optimum hyperalgesic responses without 
excesses and permanent functional loss in the forepaws (‘above-lesion’), hindpaws 
(‘below-lesion’), and in the trunk/girdle area (‘at-level-lesion’), as well as spontaneous 
measures of chronic pain such as reduced activity and exploratory behavior (Siddall et 
al., 1995;Mills et al., 2001;Hulsebosch et al., 2000;Hulsebosch et al., 2009). In these 
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cases neuropathic behavior is related to the recovery of function and is therefore 
delayed by several weeks.  
 
Hemi-transection injuries to the spinal cord at the thoracic level have also lead to 
mechanical and thermal allodynia bilaterally in forelimbs and hindlimbs after 4 weeks 
(Christensen and Hulsebosch, 1997a;Bennett et al., 2000). Anterolateral lesions of the 
spinothalamic tract in monkeys and rats resulted in excessive grooming and mechanical 
allodynia in the contralateral limb (Ovelmen-Levitt et al., 1995;Vierck, Jr. and Light, 
2000).  
 
Another model of chronic neuropathic pain after SCI is ischemia, involving an 
intravascular photochemical laser beam reaction that occludes blood vessels at the T10 
vertebra (Hao et al., 1991b;Hao et al., 1991c;Hao et al., 1991a). Acute ischemia is 
produced at the T10 spinal cord level accompanied with transient neuropathic behavior 
including trunk mechanical allodynia, as determined by increased vocalization to light 
brushing of the flank, and spontaneous pain as determined by non-evoked vocalization, 
peaking at several hours and dissipating at several days (Hao et al., 1991a). This 
allodynia was coupled with increased sensitivity of wide dynamic range dorsal horn 
neurones to stimulus (Hao et al., 1991c), and behavior could be abolished with pre-
treatment of NMDA antagonist MK-801 (Hao et al., 1991b).  
 
A clip compression model in which the thoracic spinal cord is compressed by a 35 g or 
50 g clip that results in mechanical hyperalgesia in the hindlimbs that coincided with a 
reduction in serotoninergic immunoreactivity below the level of lesion (Bruce et al., 
2002), suggesting in this model below level neuropathic pain behaviour was due to loss 
of inhibitory tone.  
 
Quisqualic acid injection (an AMPA/kainate and metabotropic receptor agonist) into the 
deep dorsal horn results in specific excitotoxic loss of deep dorsal horn neurones and 
produces spontaneous (excessive grooming) and evoked (mechanical allodynia and 
thermal hyperalgesia) neuropathic pain behaviour (Yezierski et al., 1998), with the 
authors suggesting, albeit without direct evidence, that loss of inhibitory neurones and 
hyperexcitability of spared superficial dorsal horn neurones the mechanism of 
neuropathic pain behaviour. 
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In the Hulsebosch lab, this chronic neuropathic pain behaviour in spinal cord injury 
models have been directly related to dorsal horn neurone hyperexcitability (Christensen 
and Hulsebosch, 1997a), as well as increases in CGRP immunoreactivity (Christensen 
and Hulsebosch, 1997b), metabotrophic glutamate transporters (Mills and Hulsebosch, 
2002), and NGF (Gwak et al., 2003) have been shown in the dorsal horn. Common 
themes present between peripheral and central injury and the resulting neuropathic pain, 
such as increased excitability to peripheral stimulation and central sensitisation. Indeed 
the hyperalgesia and allodynia seen in these animals after either transection injuries or 
contusion injuries have been attenuated with CGRP receptor antagonists (Bennett et al., 
2000), gabapentin (Hulsebosch et al., 2000), or anti-NGF (Gwak et al., 2003).  
 
4.1.3: Mechanisms of neuropathic pain 
 
Neuropathic pain can loosely be attributed to the disruption of a system ‘neuromatrix’; 
‘a neuro-signature pattern of nerve impulses generated by widely distributed neural 
networks’ (Melzack et al., 2001). The mechanisms by which this disruption to the 
nervous system leads to neuropathic pain are not entirely clear at present, but are 
becoming better understood in recent years. Physiological mechanisms include ectopic 
firing, phenotypic changes, peripheral sensory degeneration, and disinhibition that can 
lead to a phenomenon of central sensitisation (Woolf, 2004;Latremoliere and Woolf, 
2009). Central sensitisation is the state of heightened excitability of central dorsal horn 
neurons and is the proposed mechanism by which allodynia and hyperalgesia develop 
after injury. This can be activity-dependent, caused by spontaneous firing of peripheral 
C- and A-fibre axons, or transcriptionally-dependent caused by increases in expression 
levels of BDNF, SP, NK1, COX2, cytokines and other mediators (Woolf, 2004). 
Extracellular recordings from the dorsal horn in various root injury, PNI, and SCI 
models have revealed changes in electrophysiological properties of dorsal horn 
neurones (Ovelmen-Levitt et al., 1984;Ovelmen-Levitt, 1988;Dalal et al., 1999;Drew et 
al., 2001;Hains et al., 2003b;Lampert et al., 2006). However the cellular mechanisms 
that occur pre- and post-synaptically, that are responsible for these physiological effects 
are extensive and only recently have become more clear. 
 
Pre-synaptically 
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Spontaneous firing of intact C-fibre nociceptors within adjacent spinal nerves is 
understood to be responsible for the spontaneous pain that is experienced in neuropathic 
PNI and inflammatory pain states (Ali et al., 1999;Wu et al., 2001;Djouhri et al., 2006), 
giving further evidence for the role of the intact afferent in neuropathic pain. There is 
also evidence to suggest directly injured Aβ-fibres in PNI may also drive neuropathic 
pain of an evoked nature, such as allodynia and hyperalgesia through ectopic activity, 
as shown by c-Fos expression in the dorsal horn (Molander et al., 1994;Shortland and 
Molander, 1998;Bester et al., 2000), and shown electrophysiologically in the dorsal root 
(Han et al., 2000;Liu et al., 2000c) and dorsal horn (Kohno et al., 2003), suggesting 
both injured and adjacent intact nerves are key to the pathophysiology of central 
sensitisation. Ectopic activity may be caused in part by alteration in the arrangement 
and density of voltage gated sodium channel subunits (Dib-Hajj et al., 2009). In 
particular, the sodium channel subunit Nav1.3, controlling high frequency action 
potential firing through rapid repriming of the tetrodotoxin-sensitive (TTX-S) current 
and expressed at low levels in adult DRG, is upregulated in DRG cell bodies following 
nerve injury, leading to enhanced responses and a larger persistent current (Waxman et 
al., 1994;Dib-Hajj et al., 1999;Dib-Hajj et al., 2009). The tetrodotoxin-resistant (TTX-
R) sodium channel subunits Nav1.8 and Nav1.9, expressed almost exclusively in rodent 
nociceptive neurones (Kerr et al., 2001;Djouhri et al., 2003;Silos-Santiago, 2008), are 
responsible for resting inactivation and hyperpolarized state of the sodium channel. 
These are downregulated in the injured DRG after axotomy (Dib-Hajj et al., 
1999;Sleeper et al., 2000;Decosterd et al., 2002) further increasing the propensity for 
hyperexcitability. Sodium channel expression remains unchanged however in adjacent 
intact DRGs (Decosterd et al., 2002). Knock out studies for both NaV1.3 -/- mice 
(Nassar et al., 2006), and NaV1.8-/- mice (Kerr et al., 2001) have provided conflicting 
evidence for the role of these sodium channels, as the development of ‘normal’ 
neuropathic pain behaviour after PNI occurs up to 14 days. Interestingly NaV1.8-/- 
mice, show no behavioural signs of NGF-induced thermal hyperalgesia (Kerr et al., 
2001), suggesting TTX-R sodium channel expression is essential in inflammatory pain 
but not neuropathic. An explanation for these conflicting methodologies is that sodium 
channel expression changes are not essential for the development and maintainence of 
evoked pain behaviours, but may modulate the symptoms of neuropathic pain through 
altering the membrane properties of injured axons. Alternatively it could be that no 
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single channel is responsible for the generation of neuropathic pain, and rather aberrant 
expression of many different sodium channel subtypes after injury may result in 
hyperexcitability (Nassar et al., 2006). As for root injury, after L4/5 rhizotomy (Sleeper 
et al., 2000) no change in NaV1.8 or 1.9 expression was found in the injured DRG at 9-
12 days. However, a decrease in these sodium channels was noted in injured DRG 4-8 
days in patients with brachial plexus avulsion, with recovery to naïve levels over a 
period of 3 months (Coward et al., 2000) suggesting time post injury or type of root 
injury may be a factor in sodium channel expression. An accumulation of NaV1.8 and 
NaV1.9 was also found across these time points post injury in developing root 
neuromas (Coward et al., 2000), as well as in peripheral neuromas developed 22 days 
after in vivo saphenous nerve section, with increasing ectopic activity over time (Roza 
et al., 2003). This suggests TTX-R channels and accumulation in the transected end of 
the nerve or root rather than within the DRG may be responsible for ongoing 
spontaneous pain.  
 
There is debate as to whether structural changes occur after PNI, namely uninjured 
afferent terminal sprouting. Liu and Chambers ((LIU and CHAMBERS, 1958)) were 
the first to suggest the phenomenon of collateral sprouting of adjacent intact afferents in 
the dorsal horn after partial deafferentation. As mentioned previously, deafferented C-
fibres have atrophy within lamina II after PNI (Arvidsson et al., 1986) and rhizotomy 
(Tessler et al., 1980;Zhang et al., 1993). As a result of C-fibre injury, Aβ-fibres sprout 
into laminae I and II, a region usually devoid of such afferent terminals that contains 
pain-sensing dorsal horn neurones, and this is corroborated extensively in the literature 
(Woolf et al., 1992;Lekan et al., 1996;Mannion et al., 1996;Shortland et al., 
1997;Doubell et al., 1997;Nakamura and Myers, 2000;Ma and Tian, 2001;Hu et al., 
2004). There is however controversy over whether the sprouting is isolated to only the 
injured population of A-fibres (Shortland et al., 1997) or can be induced in adjacent 
intact A-fibres (Mannion et al., 1996). The mechanism of intact Aβ-fibre sprouting may 
be due to injury-induced C-fibre transganglionic degeneration or atrophy that 
‘conditions’ A-fibres into a regenerative growth state (Mannion et al., 1996). After L5 
root rhizotomy, A-fibre sprouting from L4 does not occur, suggesting that simply 
creating synaptic space in the dorsal horn through terminal depletion is not enough 
stimuli to cause sprouting: rather Wallerian degenerative interaction between injured 
and intact afferents of the same nerve is the trigger (Mannion et al., 1998). A-fibre 
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sprouting after PNI is still a controversial topic however, due to recent articles 
questioning the selectivity of the tracer toxin used to identify ‘new’ terminals (Tong et 
al., 1999;Bao et al., 2002;Shehab et al., 2003;Shehab, 2009). C-fibres that do not 
normally transport cholera toxin B (CTb), taken up exclusively by A-fibres, do so after 
injury, and it is these C-fibre terminals that are labeled in lamina II (Tong et al., 1999). 
If CTb labeling is applied to the nerve before injury, some A-fibre sprouting does occur 
but it is much less pronounced than previously thought (Bao et al., 2002).  
 
After multiple lumbar rhizotomies, the appearance of previously unresponsive neurones 
in the deafferented dorsal horn appear suggesting ‘unmasking’ of exsisting connections 
may also be a structural change associated with deafferentation and perhaps neuropathic 
pain (Basbaum and Wall, 1976). Disinhibition and loss of GABAergic and glycinergic 
inhibitory currents, possibly through excitotoxic cell death of interneurones (Scholz et 
al., 2005) although controversial (Polgar et al., 2003;Polgar et al., 2004;Polgar et al., 
2005;Polgar and Todd, 2008) may also lead disinhibition and central sensitization. 
Primary afferents themselves can provide the dorsal horn with an inhibitory influence 
(Woolf and Wall, 1982;Woolf, 1983), and this can undergo a disinhibition after injury. 
Primary afferent terminals are known to send inhibitory collateral terminal branches to 
other primary afferent terminals, and can be ‘primed’, by a conditioning stimulus, to 
inhibit the response of primary afferents to a proceding stimulus through ‘habituation’. 
This is A-fibre mediated inhibition of nociceptive C-fibre terminals (Woolf and Wall, 
1982), but can also occur from C-fibres (Woolf, 1983). After sciatic nerve section in the 
rat, this A-fibre-mediated C-fibre inhibition is diminished at 7-14 days, even though 
afferent volleys from these transected axons can still be evoked (Woolf and Wall, 
1982). This suggests another mode of synaptic reorganisation in response to nerve 
injury, which could exacerbate the symptoms of neuropathic pain through loss of dorsal 
horn inhibitory tone.  
 
 
Sympathetic sprouting within the dorsal root ganglia may also occur (McLachlan et al., 
1993), appearing as basket-like structures around large-diameter axotomised sensory 
neurones, and hypothesized to be the cause of some neuropathic pain states. 
Sympathetic sprouting has been shown after L5/L6 ligation linked with the development 
and maintanence of mechanical allodynia, as sympathectomy abolishes symptoms 
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(Chung et al., 1996). It is activity dependent, initiated by ectopic discharges of injured 
neurones (Dong et al., 2002) as well as intact neurones, as spared DRGs adjacent to 
spinal nerve ligated DRGs have also shown increased alpha-adrenergic sensitivity (Ali 
et al., 1999). Wallerian degeneration is also causally linked to sympathetic sprouting, 
and if both are purposefully delayed by genetic modification in mice (C57B1/wld) both 
CCI-induced mechanical allodynia and thermal hyperalgesia are attenuated (Ramer et 
al., 1997). Sympathetic sprouting contributes clinically to a condition known as 
complex regional pain syndrome (Seltzer and Shir, 1991), charaterised by severe pain, 
as well as autonomic changes such as swelling in the skin, vasospasm, and rapid nail 
and hair growth. 
 
Phenotypic changes occur within the peripheral nervous system following injury. These 
changes in transcription lead to alterations in membrane properties, growth, excitability 
and transmission (Woolf, 2004;Latremoliere and Woolf, 2009). A-fibres start to express 
peptides characteristic of nociceptors such as substance P (SP) brain-derived 
neurotrophic factor (BDNF), neuropeptide Y (NPY), and galanin. BDNF is known to be 
a potent neuromodulator of pain, and is synthesised by small-medium sized, CGRP-+ve 
DRGs, within the cell body and transported to the terminals in the dorsal horn, where it 
is released into the dorsal horn, sensitizing neurones (Obata and Noguchi, 2006). BDNF 
is upregulated in medium-large diameter neurones of the injured DRG after L5 DRR 
and L5 VRR, and maintained up to 7-14 days, but do not show neuropathic pain 
behaviour (Ernfors et al., 1993;Li et al., 2006;Obata et al., 2006b). BDNF is also 
upregulated in both the intact L4 DRG, and injured L5 DRG, up to 28 days after 
selective L5 spinal nerve ligation (Fukuoka et al., 2001;Obata et al., 2006b). However, 
no such upregulation is found in the L4 DRG after L5 rhizotomy (Obata et al., 2006b). 
This suggests Wallerian degeneration in the injured nerve (absent in rhizotomy), and 
interaction with intact fibres within the mixed nerve, is necessary for BDNF 
upregulation in the intact adjacent DRG, and corresponding anterograde transport to the 
dorsal horn.  
 
BDNF is also upregulated up to 28 days in the injured L4 and L5 DRG after sciatic 
nerve transection, coexpressed with NPY (Michael et al., 1999). NPY is not normally 
present in adult naïve DRG but is present in the dorsal horn with especially dense 
concentrations in the superficial laminae (Hokfelt et al., 2007). NPY is upregulated in 
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large sized myelinated neurones and in the deep dorsal horn 7-14 days after nerve injury 
(Wakisaka et al., 1991;Noguchi et al., 1993). NPY is released by primary afferent 
terminals and has pre- and post-synaptic receptor targets in the dorsal horn. The Y1 
receptor can be found on primary afferent terminals and on excitatory interneurones, 
and activate potassium channels, thereby attenuating excitatory transmission and 
exerting anti-nociceptive effects (Hokfelt et al., 2007). Indeed YR1-/- mice show 
exaggerated evoked behavioural nociceptive responses (Hokfelt et al., 2007;Wiley et al., 
2009). However, NPY also has Y2 receptors on small nociceptive primary afferents, 
which are upregulated in cells of all sizes after axotomy (Zheng et al., 1997), and may 
mediate some aspects of neuropathic pain through enhanced neuronal excitability 
(Abdulla and Smith, 1999;Hokfelt et al., 2007). NPY-/- mice show exaggerated 
spontaneous pain behaviour (autotomy) after sciatic nerve transection, although there is 
no difference in evoked behavioural responses from wild-type (Shi et al., 1998).  
 
Galanin expressed in DRG and dorsal horn interneurones (Liu and Hokfelt, 2002) is 
also upregulated in a mixed population of DRG neurones after sciatic nerve injury 
(Noguchi et al., 1993), and similarly to NPY has opposing actions on pain processing 
depending on which receptor (GAL1 or GAL2) is activated. Upregulation of galanin in 
DRGs after nerve injury may result in anti-nociceptive effects in the dorsal horn via 
inhibitory GAL1 receptors on dorsal horn neurones, and pro-nociceptive effects via 
excitatory GAL2 receptors on primary afferent terminals (Liu and Hokfelt, 2002). 
However after nerve injury the GAL1R is downregulated, but the GAL2R less so and 
galanin is over expressed, perhaps shifting this balance toward pro-nociception (Liu and 
Hokfelt, 2002). GAL1R-/- mice do show increased evoked behavioural nociception and 
neuropathic pain (Wiesenfeld-Hallin et al., 2005). However the main role of galanin 
may well be neuroprotection and neuroregeneration after nerve injury, as GAL-/- mice 
show increased cell death after nerve injury, in specifically nociceptive populations of 
DRG neurones (Holmes et al., 2005). 
 
Receptor expression changes also occur after nerve injury and may underlie some 
neuropathic pain states. The transient receptor potential channel TRPV1, previously 
know as vanilloid receptor 1 (VR1) is expressed primarily in small diameter sensory 
nociceptors and is known to drive peripherally generated thermal hyperalgesia in 
inflammatory injury models (Ji et al., 2002). It is upregulated by NGF-driven activation 
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of p38 MAPK (Ji et al., 2002) in mainly uninjured A-fibre, but also uninjured C-fibre, 
DRG neurones after spinal nerve injury (Hudson et al., 2001;Fukuoka et al., 2002), and 
partial sciatic nerve ligation (Hudson et al., 2001;Ma et al., 2008) as well as in the pre-
synaptic membrane of the dorsal horn after peripheral inflammation (Luo et al., 2004), 
coinciding with neuropathic pain behaviour to thermal stimulation. This ‘spared nerve’ 
TRPV1 upregulation in A-fibres could be responsible for thermal allodynia, and 
upregulation in C-fibres responsible for thermal hyperalgesia. The receptor is 
downregulated in all injured DRG neurones after spinal nerve injury (Hudson et al., 
2001;Fukuoka et al., 2002), sciatic nerve injury (Hudson et al., 2001;Staaf et al., 2009), 
and axotomy (Michael and Priestley, 1999;Hudson et al., 2001), suggesting expression 
is dependent apon peripheral connectivity. The purinergic receptor P2X3 is coexpressed 
with the TRPV1 receptor on small nociceptive primary afferents in the DRG and 
terminals of the dorsal horn (Wirkner et al., 2007). It is upregulated after chronic 
constriction injury to the sciatic nerve (Novakovic et al., 1999), but are downregulated 
after axotomy and rhizotomy in 50% of neurones (Bradbury et al., 1998), with a subset 
of small and large DRG remaining P2X3 positive, that likely provide the P2X3r-
mediated component of neuropathic pain (Kage et al., 2002). Prostaglandin receptors 
(EP1 and EP4) have also been shown to upregulated in the injured DRG after partial 
sciatic nerve ligation alongside TRPV1, and correlates with neuropathic pain, and both 
expression and pain can be ameliorated with a selective COX2 inhibitor (Ma et al., 
2008).  
 
Recent studies have focused on the role of neurotrophins in the pathophysiology of 
neuropathic pain. Hyperalgesia to noxious cold has been observed in GFRα2-/- mice, 
alongside a 70% reduction in non-peptidergic cutaneous nerve endings (Lindfors et al., 
2006), suggesting a role for GDNF in the maintenance of nociceptor subpopulations. 
Also, intrathecal administration of NGF lowers nociceptor thresholds in naïve animals 
(Ramer et al., 2003). However, intrathecal administration of GDNF does not alter 
nociceptive thresholds (Ramer et al., 2003). Alternatively, when administered 
subcutaneously, GDNF, along with neurturin (NTN) and artemin (ART) (Malin et al., 
2006) each cause peripheral TRPV1 sensitisation and acute thermal hyperalgesia, 
suggesting some neurotrophins may have distinctly different roles centrally compared 
to peripherally. 
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Changes in non-neuronal populations such as satellite glial cells and macrophages 
within the DRG have been shown after nerve injury (Hu et al., 2007) and could also 
mediate neuropathic pain behaviour. GFAP positive satellite cells of the DRG have 
been shown to react to peripheral nerve injury or inflammation, by activation, 
proliferation, and release of mediators, and increased gap junction coupling that 
contribute to pain (Woodham et al., 1989;Dublin and Hanani, 2007;Xie et al., 2009). 
Following sciatic nerve crush or transection or DRG compression, a perineuronal 
satellite cell reaction in injured DRGs can be seen after 3 days (Woodham et al., 1989) 
and up to 7 days (Fenzi et al., 2001), that decreases sharply at 10 and 21 days but 
staying above control levels (Zhang et al., 2009). When quantified, 88% of neurones in 
the injured ganglia expressed GFAP perineuronally compared to 15% in the 
contralateral (Woodham et al., 1989). Ectopic sensory neurone activity after injury, 
with increases in levels of neuronal growth factors, has been implicated as a mechanism 
by which satellite cells become activated (Xie et al., 2009), and blocking sodium 
channel activity with TTX reduces both GFAP and NGF expression in DRG after SNL 
(Xie et al., 2009). CCI or transection of the sciatic nerve leads to robust macrophage 
infiltration around neuronal soma in the DRG (Hu et al., 2007), and mechanical and 
thermal hyperalgesia. The low affinity neurotrophic receptor p75 is upregulated in glia 
within the DRG after PNI, in close association with sympathetic nerve sprouts (Zhou et 
al., 1996), and cutaneous neurones (Hu and McLachlan, 2003), suggesting glial 
synathesis of p75 might be another mechanism of control of sympathetic sprouting, 
neuronal ectopic activity and neuropathic pain. 
 
 Post-synaptically 
 
Activation of NMDA receptors within dorsal horn neurones, in response to enhanced 
and prolonged peripheral stimulation and pre-synaptic glutamate release is the most 
well know mechanism of central sensitisation. The process involves increased pre-
synaptic activity, excess neurotransmitter release, maintained activation of AMPA 
receptors, increased post synaptic sodium influx and maintained depolarisation, 
voltage-dependent removal of a magnesium ion block in the NMDA channel, prolonged 
calcium influx through the NMDA channel, phosphorylation of the NMDA receptor via 
PKC, and maintained channel opening via calmodulin-dependent PKII (CaMKII) 
leading to dorsal horn neuronal hyperexcitation (Petrenko et al., 2003b). Postsynaptic 
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changes in specific subunit expression occurs in response to nerve injury; for example, 
the NR2A subunit expression is reduced in the dorsal horn after PNI and joint 
inflammation, increasing the contribution of the NR2B subunit in neuronal activity 
(Karlsson et al., 2002). This may play a role in neuronal hyperexcitability as NR2B 
shows greater sensitivity to glutamate (Karlsson et al., 2002). However, knock-out mice 
lacking NR2A still present similar evoked withdrawal thresholds at baseline, and after 
sham, PNI, and formalin injection injuries (Petrenko et al., 2003a), with the authors 
suggesting a developmental compensatory mechanisms from other channels may be 
occurring. Sodium channel subunit expression, specifically NaV1.3, has been shown to 
be increased in dorsal horn neurones after SCI (Hains et al., 2003a), and PNI (Hains et 
al., 2004) with corresponding generation of neuropathic pain behaviours. Pain is 
thought to be due to the increase in persistent sodium ramp currents in the dorsal horn 
(Lampert et al., 2006). As stated previously, delayed anti-sense knock-down of NaV1.3 
reverses pain behaviours induced by PNI and SCI (Hains et al., 2003a;Hains et al., 
2004), but global or nociceptive specific NaV1.3 deletion during embryo development 
shows no change in neuropathic phenotype upon injury (Nassar et al., 2006), leaving 
the relative significance of NaV1.3, as well as NR2B, as a major contributor of dorsal 
horn excitability and neuropathic pain, uncertain.  
 
Similar to its generation and release from primary afferents, BDNF is also generated 
and released from microglia after activation via ATP-P2X4r signaling after PNI (Coull 
et al., 2005;Milligan and Watkins, 2009), coinciding with the generation of allodynic 
behaviour. BDNF acts on neurones by causing a membrane depolarization shift, and 
reversal of GABAergic currents in lamina I dorsal horn neurones into excitatory (Coull 
et al., 2005), intensifying central sensitization (Lu et al., 2007). This ‘disinhibition’ may 
occur through reduction in expression of Cl--cotransporter K+-Cl- exporter 2 channels 
(KCC2) after both PNI (Coull et al., 2003) and SCI (Lu et al., 2008), that are 
responsible for driving chloride ions out of cells, causing normally subthreshold A and 
C inputs to evoke action potentials from superficial dorsal horn neurones, some of 
which could be nociceptive. Another mechanism of disinhibition may occur from loss 
of the descending opioid system (Zimmermann, 2001). For example, 4 months after 
dorsal root rhizotomy a 60% reduction in µ- and δ-opioid receptor binding sites 
occurred in the dorsal horn (Zajac et al., 1989), and the incidence of autotomy in rats 
after sciatic nerve section was correlated with decreased β-endorphins in the brain and 
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spinal cord (Panerai et al., 1987). Further, the spontaneous activity of the dorsal horn 
neurones of rats with multiple dorsal rhizotomies were far less sensitive to systemic 
morphine administration than arthritic rats (Lombard and Besson, 1989), suggesting a 
deafferentation neuropathy reduces opioid sensitivity in dorsal horn neurones. These 
results can be explained by location studies of the µ- and δ-opioid receptor binding 
sites, indicating 75% of which are located pre-synaptically on C-fibre terminals 
(Dickenson and Suzuki, 2005), and will be lost after deafferentation. A more direct loss 
of inhibitory tone can occur through death of GABAergic neurones or loss of GABA 
neurotransmitter, found after PNI (Ibuki et al., 1997;Moore et al., 2002) and SCI (Drew 
et al., 2004;Meisner et al., 2010).  
 
Our understanding of pathological pain has primarily revolved around neuronal 
mechanisms. However more recently the involvement of spinal cord glia in central 
sensitization has come to light. Astrocytes and microglia have recently been recognized 
as powerful modulators of pain in PNI and SCI (Raghavendra et al., 2003;McMahon et 
al., 2005;Nesic et al., 2005;Hains and Waxman, 2006;Crown et al., 2008;Hulsebosch et 
al., 2009;Milligan and Watkins, 2009). Increased pre-synaptic firing in the dorsal horn 
after PNI, and neuronal loss in central nervous system injury within the spinal cord, 
leads to release of ATP, fractalkine (CX3CL1), heat shock proteins, substance P, 
glutamate, reactive oxygen species (ROS), cysteine-cysteine chemokine ligand 21 
(CCL21), monocyte chemoattractant protein 1 (MCP-1/CCL2) (Zhang and De, 
2006;Thacker et al., 2009), and many other mediators from neurones (McMahon et al., 
2005;Marchand et al., 2005). This in turn results in microglial activation through the 
calcium-sensitive p38 MAP Kinase - CREB phosphorylation pathways via extensive 
neuronal-glial interactions (Tikka et al., 2001;Crown et al., 2008;Hulsebosch, 
2008;Inoue and Tsuda, 2009). This intra-cellular signalling leads to surface expression 
of MHC class II molecules and activation of complement type receptors (e.g. CX3CR1) 
on the microglial cell membranes, which corresponds with a distinct change in 
morphology and phenotype (Popovich et al., 1997). Inhibition of this MAP Kinase 
phosphorylation pathway attenuates hypersensitivity post SCI (Crown et al., 2008). 
These neuronal-glial interactions involve such receptors as CX3CR1 (fractalkine 
receptor) (Milligan et al., 2004), CCR2 (CCL2 receptor), CXCR3 (MCP-1/CCL2 low 
affinity receptor) (Murphy et al., 2000), ATP receptors (Tsuda et al., 2003;Tsuda et al., 
2005;Tsuda and Inoue, 2007), Toll-like receptors (specifically TLR3 and 4) (Tanga et 
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al., 2005), and matrix metalloproteinase 9 (MMP9)/Pro-IL-1β cleavage (Kawasaki et 
al., 2008). Receptor activation leads to microglial cell proliferation (Narita et al., 2006), 
increase in membrane bound receptors, and cytokine production (Crown et al., 
2006;Crown et al., 2008). One major pathway of microglial activation that has been 
studied is via the ATP receptor P2X4, located on the surface of microglia, and these 
receptors are upregulated after nerve injury (Ulmann et al., 2008). Pharmacological 
blockade of the P2X4 receptor (Tsuda et al., 2003) and P2X4-/- mice lack the mechanical 
and thermal hyperalgesia induced by PNI (Ulmann et al., 2008;Tsuda et al., 2009), but 
do not exibit major defects in nociceptive pain, suggesting a role of purinergic receptors 
in purely neuropathic pain. Upon activation microglia release neuronal mediators, such 
as BDNF and NO, that hyperexcite neurones, release ROS and TNF that can lead to 
apoptosis of neurones, and release of inflammatory cytokines, such as IL-1β, IL-6, and 
TNFα, that activate neurones as well as adjacent microglia through MAPK/ERK 
phosphorylation and CREB intracellular signaling (Hulsebosch et al., 2009). Microglia 
also synthesize and released prostaglandins that directly regulate signaling between 
themselves and neurones via EP2 receptors shown in spinal cord contused rats, and 
heighten dorsal horn neurone sensitivity (Zhao et al., 2007).  
 
The role of astrocytes in neuropathic pain is less clear. They have been shown to have 
an involvement in ‘at-level’ neuropathic pain after SCI (Nesic et al., 2005), and are also 
activated by a milieu of mediators released from injured neurones and microglia and 
respond by phosphorylating, and thereby activating, p38 MAPK (Crown et al., 2008). 
However, astrocytes do not proliferate in response to nerve injury, unlike microglia 
(Narita et al., 2006). Also dorsal horn astrocyte activation is slower in onset than 
microglia; typically taking 4 days to become apparent after L5 spinal nerve transection, 
and increasing over 28 days (Tanga et al., 2004;Tanga et al., 2006), compared to 
microglial activation at 1 day and declining after 7 days after sciatic nerve transection 
(Eriksson et al., 1993), with mRNA of some microglial markers expressing as early as 4 
hours post L5 spinal nerve transection (Raghavendra et al., 2003;Tanga et al., 2004), 
associated with the development of neuropathic pain behaviours. After PNI a delayed 
but prolonged MMP-2/IL-1β cleavage in astrocytes maintains their activation, and 
corresponding neuropathic pain, whereas MMP-9 IL-1β expression in microglia is only 
transient (Kawasaki et al., 2008). The difference in time of activation between these 
glia, have been implicated in a ‘microglia-astrocyte replacement mechanism’ that 
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maybe essential in the maintenance of neuropathic pain in PNI (Colburn et al., 
1997;Raghavendra et al., 2003;Tanga et al., 2006) by mobilization of internal calcium, 
release of glutamate (via GLUT1), ATP release and enhancement of synaptic signaling 
(Wang et al., 2009). Indeed, inhibition of microglial activity pharmacologically with 
minocycline pre-emptively prevents the development of PNI-induced neuropathic pain 
behaviour, but post-emptively has no effect in reversing it (Raghavendra et al., 2003). 
There is still some debate, however, to the distinct roles of microglia and astrocytes, in 
central verses peripherally mediated neuropathic pain (Winkelstein and DeLeo, 
2002;Hains and Waxman, 2006), as well as ‘at-level’ and ‘below-level’ SCI-induced 
neuropathic pain (Crown et al., 2008;Gwak et al., 2009). Further, the extent of 
microglial reactivity has been shown to be linked to the severity of neuronal injury 
whereas, this is not the case for astrocytes, such that more severe nerve and root 
ligations produce greater dorsal horn microglial activity (Winkelstein and DeLeo, 
2002), and neuropathic pain behaviour (Winkelstein et al., 2001b).  
 
Clear role differences between microglia in the initiation of hypersensitivity after PNI, 
and astrocytes in the maintenance role in the longer term are not so easily defined in 
centrally mediated pain. For example, one month after SCI, activated microglia in the 
superficial and deep dorsal horn essentially control the generation and development of 
chronic pain, as defined behaviourally and electrophysiologically (Hains and Waxman, 
2006)(Hains and Waxman, 2006), in conjunction with astrocytes (Hains and Waxman, 
2006;Gwak and Hulsebosch, 2009). This is in direct comparison to the decline in 
microglial activity at 1 week post PNI (Eriksson et al., 1993), with a delayed but 
prolonged astrocyte activity (Tanga et al., 2006) maintaining neuronal hypersensitivity 
up to 11 days (Raghavendra et al., 2003). This is an important finding when considering 
brachial plexus preganglionic injuries can induce Brown-Sequard syndromes (traumatic 
disruption of ipsilateral spinal cord) in the avulsed segment (Stephen et al., 1997;Nordin 
and Sinisi, 2009). If root avulsion occurs at or within the DREZ, this may manifest in 
distinctly different microglial activity than would occur after a more distal avulsion or 
peripheral rupture. Indeed DRA injury that causes trauma to the spinal cord, leads to 
maintained upregulation of both astrocytes and microglia immunoreactivity in the 
dorsal horn across 28 days (Chapter 3), similarly to SCI (Hains and Waxman, 2006), 
suggesting glial activity is mediated centrally after injury to CNS tissue. However DRR 
that causes no trauma to the spinal cord, leads to no further increase in microglial or 
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astrocyte activity beyond 14 days, and in many cases no neuropathic pain behaviour 
(Sukhotinsky et al., 2004). Colburn et al., ((Colburn et al., 1997)) showed that DRR 
produced less dorsal horn gliosis than even PNI, suggesting glial activity in injury 
models where no CNS trauma occurs, may depend upon DRG connection.  
 
The leukocytic immune system may also have an important role in pro-nociception and 
central sensitization after SCI (Trivedi et al., 2006) and PNI (Thacker et al., 2007). 
Macrophage, neutrophil, and T-lymphocyte cells populate the dorsal horn after PNI (Hu 
et al., 2007;Thacker et al., 2007), DRR (Ling, 1979b;Nomura et al., 2005), SCI 
(Popovich et al., 1997;Carlson et al., 1998), and brain stab injury (Ling, 1979a). This 
occurs through mobilization of local neuronal populations and infiltration from the 
blood. These cells release cytokines and key inflammatory mediators, such as IFNγ, 
IL1β and TNFα that can influence neuropathic pain behaviour by sensitizing neurones 
(Thacker et al., 2007). IL1β, for example, is released from immune cells through ATP-
P2X7 receptor interaction, and receptor knock-out reduces IL1β production in mice, 
abolishing hypersensitivity to mechanical and thermal stimuli after partial nerve ligation 
(Chessell et al., 2005). IFNγ reduces GABAergic currents through IFNγ receptor 
activation in the superficial dorsal horn and lateral spinal nucleus, increasing 
nociceptive neuronal activity (Vikman et al., 1998;Vikman et al., 2003). TNFα induces 
neuronal hypersensitivity via intra-cellular signaling pathways including p38-MAPK 
and NFκβ through its membrane receptors p55 (TNFR1) and p75 (TNFR2), that are 
constitutively expressed in DRG, afferent terminals, and dorsal horn neurones of 
laminae I and II (Holmes et al., 2004). TNFα is upregulated within the DREZ and 
dorsal funiculus at 48hrs post DRR and DRA, colocalising with p38 MAPK positive 
activated macrophages (Nomura et al., 2005). TNFR1 and R2 are upregulated in 
neurones, astrocytes and oligodendrocytes of the spinal cord as early as 15 minutes, 
peaking at 8 hours, after SCI (Yan et al., 2003), and in satellite cells, astrocytes, and 
DRG neurones after PNI (Ohtori et al., 2004), contributing to TNFα-mediated 
neuropathic pain. TNFα is notoriously involved in neuropathic and inflammatory pain, 
but it also has an essential role in neuroprotection and growth via activation via TNFR2 
and, conversely, cell death via TNF1 activation, during both development and injury 
(Kraft et al., 2009). Knocking out TNFαR1 reduces inflammation and tissue injury, but 
inhibition of TNFα reduces functional recovery, after SCI injury (Kim et al., 
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2001;Demjen et al., 2004;Genovese et al., 2008), suggesting appropriate receptor 
targeting of the TNFα signaling pathway is necessary to optimize recovery and 
ameliorate neuropathic pain after injury. 
 
Neutrophils are the earliest inflammatory cell to infiltrate, and dominates the acute 
tissue inflammation process, through phagocytosis and release of cytokines and 
lipoxygenase products that can induce hyperalgesia (Levine et al., 1985). Substantial 
neutrophil extravasation into the contused spinal cord peaks at 3 hours as measured by 
MPO (Taoka et al., 1997), and in the injured sciatic nerve peaks between 8 and 24 hours 
as measured by an antibody to neutrophils (Perkins and Tracey, 2000), and may be 
responsible for initiating hyperalgesia in these cases. Selective cytotoxic antibody-
mediated depletion of neutrophils at the time of sciatic nerve injury delayed neutrophil 
infiltration into the injured nerve, and delayed thermal hyperalgesia development 
(Perkins and Tracey, 2000). Administration of the cytotoxic antibody, 8 days post 
sciatic nerve injury, had no effect on pre-existing hyperalgesia, indicating neutrophils 
are important early in hypersensitivity development (Perkins and Tracey, 2000). 
Neutrophils also summon macrophages into the damaged tissue through secretion of 
macrophage-inflammatory protein-1 and IL-1β (Trivedi et al., 2006), which largely take 
over the role of prolonged immunity. IL-69-ED2 positive macrophages (MHC class II-
presenting macrophages) and CD3 positive T-lymphocytes have been shown to be 
recruited to the dorsal and ventral horn 14 days after spinal nerve transection correlating 
with mechanical allodynia (Sweitzer et al., 2002). Activated macrophages may be pro-
nociceptive through the release of algesic mediators such as nitric oxide, PGs, and 
proinflammatory cytokines like TNFα, IL-1β, and IL-6, which sensitise primary 
afferents and dorsal horn neurones directly (Moalem and Tracey, 2006). Conversely, the 
application of activated macrophages alone to the exposed peripheral nerve does not 
induce mechanical allodynia, and blocking macrophage activation with an antibody or 
depleting systemic macrophages with clodondrate 2 days prior to L5 spinal nerve 
transection, did not attenuate mechanical allodynia (Rutkowski et al., 2000). Other 
authors using partial sciatic nerve ligation have shown clodronate treatment 
immediately after surgery, with a follow up does 2 days later, is effective at reducing 
macrophages and hyperalgesia (Liu et al., 2000b), and the differing results may well be 
due to different dosing regimes used. On the whole, these findings suggest leukocytes 
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may have a role in neuropathic pain generation and maintainence, but likely act in 
tandem with CNS macrophages/microglia. 
 
4.1.4: Avulsion pain  
 
Patient descriptions of traumatic root avulsion dyesthesias are remarkably consistent, 
and include extreme pain detectable as burning, aching, shooting, or crushing, that is 
unbearable and intractable, described as ‘like putting your hand in a deep fat fryer’, 
lasting in some cases decades (Parry, 1980;Birch, 1996;Berman et al., 1998). The 
majority of patients (80-91%) report severe chronic pain at some point in the course of 
their condition (Parry, 1980;Bonnard and Narakas, 1985;Bruxelle et al., 1988;Woolf, 
2004;Bertelli and Ghizoni, 2008), and certain environmental influences such as 
differing weather conditions and local cooling (Parry, 1980) as well as stress and illness 
(Berman et al., 1996) can exacerbate these symptoms. Age is another influencing factor 
on outcome, with younger patients much less susceptible to chronic pain and showing 
greater functional recovery (Anand and Birch, 2002;Bertelli and Ghizoni, 2006), most 
likely as greater propensity for cortical plasticity (Carlstedt et al., 2009) and lower 
motor neurone regeneration (Carlstedt, 2008). Pain appears within 48 hours after injury 
(Berman et al., 1996), and no later than 1 month (Berman et al., 1998). The pain seems 
to be correlated to the extent of the avulsion, such that the greater the number of roots 
avulsed, the greater the pain (Birch, 1996;Berman et al., 1998). The pain is 
hypothesized to be due to damage to the dorsal horn and/or disinhibition of neurones 
within the substantia gelatinosa (Loeser and Ward, Jr., 1967) and deeper laminae 
(Ovelmen-Levitt et al., 1984) as shown in cat experiments. Another dyesthesia is 
evoked border-zone hypersensitivity to thermal and mechanical stimuli, which occurs 
across intact and deafferented dermatomes, that increases in severity over time, with 
30% of patients complaining of symptoms at 6 months (Berman et al., 1998;Htut et al., 
2006;Havton and Carlstedt, 2009). Hypersensitivity is also common in adjacent intact 
dermatomes (Finnerup et al., 2009). Interestingly, pain occurs after ventral root avulsion 
both clinically (Berman et al., 1998;Htut et al., 2006), and experimentally (Bigbee et al., 
2007;Bigbee et al., 2008) with noticeable degeneration of primary afferent axons in the 
ipsilateral dorsal column. Quite unexpectedly the pain is ameliorated with early ventral 
root re-implantation (Berman et al., 1996;Berman et al., 1998;Carlstedt et al., 2004;Htut 
et al., 2006;Kato et al., 2006;Bigbee et al., 2007). The pain relief may be linked to re-
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establishing peripheral neurotrophic support (through BDNF, GDNF, and NGF) to the 
spinal cord via the ventral root (Bergerot et al., 2004;Carlstedt, 2008), thereby reducing 
neuro-degenerative and gliotic phenomenon that occur in the dorsal horn (Bigbee et al., 
2007). The authors state that Wallerian degeneration of avulsed motor axons still occurs 
even after ventral root re-implantation (Bigbee et al., 2008), suggesting pro-nociceptive 
and pro-inflammatory factors, released during axon degeneration within the peripheral 
nerve, are unlikely to be the cause of this pain. Therefore the more likely cause of the 
neuropathic pain, are central mechanisms in the spinal cord (Bigbee et al., 2008).  
 
There is controversy in the literature however about the role of the avulsed root in 
avulsion pain. Certainly allodynia and hyperalgesia experienced in brachial plexus 
avulsed patients must occur through hyper-excitability of the intact dermatomal 
receptive fields (Htut et al., 2006). As previously mentioned adjacent intact, and injured, 
afferents may acquire abnormal activity, and the corresponding spinal segment may 
undergo anatomical re-organisation pre- and post-synaptically, leading to evoked pain 
behaviours. However spontaneous pain may also originate from the same mechanisms. 
Bertelli and Ghizoni ((Bertelli and Ghizoni, 2008)) showed that brachial plexus injured 
patients complained more of spontaneous neuropathic pain if a root and DRG in the 
plexus remained connected to the spinal cord. Patients that had total pre-ganglionic 
brachial plexus avulsion had only minimal complaints of pain. This suggests that 
peripheral ectopic activity from the DRGs or neuroma from roots that are either avulsed 
post-ganglionically (a PNI), or remain intact, may also drive the spontaneous 
neuropathic pain in these patients, as well as central disinhibition (Loeser et al., 1968). 
When an anesthetic block was applied to these intact roots of brachial plexus avulsion 
patients, pain was ameliorated (Bertelli and Ghizoni, 2008). Alternatively if the post-
ganglionically avulsed nerve was repaired through nerve grafting, then again the pain 
was ameliorated (Bertelli and Ghizoni, 2008). The authors suggested therefore that 
avulsion pain is actually mediated through DRG-intact roots and spinal segment, rather 
than from the directly avulsed dorsal horns (Bertelli and Ghizoni, 2008), and this is 
certainly the cause for evoked hypersensitivity in the adjacent intact dermatomes 
(Finnerup et al., 2009). 
 
What is clear from the clinical literature (Berman et al., 1998) is that there is a need for 
improved modeling of neuropathic root avulsion pain. When patients present to the 
  164 
clinic, immediate treatment is required and it is unethical to withhold treatment for 
experimental sake or provide control groups in clinical trials, as it is well known that 
surgical intervention after root avulsion is beneficial (Birch, 1993). From recent clinical 
data (Bertelli and Ghizoni, 2008) it may also be important to clearly separate studies 
into pre-ganglionic avulsion (proximal to the DRG) nerve-transfer and post ganglionic 
avulsion (distal to DRG, PNI) nerve-grafting repair. However this is clearly difficult as 
most patients present a mixture of preganglionic and postganglionic avulsions after 
brachial plexus injury (Anand and Birch, 2002;Carlstedt, 2008), and they are repaired in 
different ways (Berman et al., 1998;Bertelli and Ghizoni, 2008). This clinical limitation 
may not allow for a clear understanding of the data when defining the mechanism of 
avulsion induced pain as separate from PNI.  
 
4.1.5: Modelling avulsion pain 
 
Spontaneous pain that manifests after avulsion injury is particularly difficult to model in 
animals, as definition relies on patient descriptions in a verbal analogue scale, or the 
‘McGill Pain Questionaire’ (Berman et al., 1998;Htut et al., 2006). Typically, in animal 
models after multiple root avulsion there is a loss of sensation in the affected limb that 
cannot be tested for by evoked behaviour. Semi quantitative methods for analysis of 
spontaneous pain in vivo have been used such as spontaneous foot lifting (Bennett and 
Xie, 1988;Djouhri et al., 2006), autotomy (Wall et al., 1979), ultrasound vocalization 
(Sakurada et al., 2007), nocifensive hindpaw behaviours (Kim and Chung, 1992;Choi et 
al., 1994;Kurvers et al., 1997;Roussy et al., 2009), and weight loss (Kurvers et al., 
1997). As previously stated some models of ventral root rhizotomy have lead to evoked 
hyperalgesia and allodynia (Yoon et al., 1996;Sheth et al., 2002;Li et al., 2003), 
however others have not (Colburn et al., 1999). DRR is also unreliable (Yoon et al., 
1996;Sheth et al., 2002;Sukhotinsky et al., 2004). Avulsion of the L6-S1 ventral root 
causes neuropathic pain behaviour, and neurodegenerative and inflammatory responses 
in the dorsal columns of the adjacent L5 segment (Bigbee et al., 2007). Another group 
has modeled a unilateral brachial plexus avulsion combined with assessment of hind 
paw evoked behavioural testing in rats (Rodrigues-Filho et al., 2003) and mice (Quintao 
et al., 2006), and acknowledged a below-level hypersensitivity to mechanical and cold 
stimuli occurring bilaterally that could be ameliorated with pharmacological 
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manipulation (Rodrigues-Filho et al., 2004). However, this ‘alternative limb pain’ is not 
noted in clinical literature of brachial or lumbosacral plexus avulsion. 
 
No literature to date has determined the effect of avulsion of dorsal roots on the evoked 
responses in the adjacent dermatome, as well as analyzing to correlate the 
neuroinflammatory and neurodegenerative effects in the adjacent dorsal horn. This may 
be a critical gap in literature as more than 80% of brachial plexus avulsions have some 
intact roots (Sindou et al., 2005) and as mentioned before recent clinical evidence 
suggests the involvement of the adjacent intact DRG and spinal segment in certain 
modalities of deafferentation pain (Bertelli and Ghizoni, 2008).  A new model 
developed in the laboratory (adapted from (He et al., 2000)) involves a single L5 spinal 
root avulsion. As the rat hindpaw is primarily innervated by L4 and L5 mainly 
(Takahashi et al., 2003), the surgery allows for testing of the L4/L5 border zone. This 
model is also more clinically representable, as there is no laminectomy exposure, 
including disruption of the dura, is required to access the roots. Indeed the laminectomy 
procedure has been shown recently to produce hyperalgesia (Kosta et al., 2009). The 
traction force on the mixed spinal root using this model will result in direct injury to the 
both the DRG and root, as well as the cord, better representing the clinical scenario, 
than previous models of DRA and DRR. In addition weight loss, an indicator of 
spontaneous pain, will be recorded, as well as any motor impairment and motor neurone 
loss accompanying the injury.   
 
4.1.6: Possible mechanisms of avulsion pain: 
 
There are major differences in dorsal horn histopathology between the deafferentation 
models of root rhizotomy and PNI, compared to true avulsion, which may underly the 
inconsistent and generally less severe neuropathic pain generation noted in the former 
(Yoon et al., 1996;Song et al., 2003;Sukhotinsky et al., 2004). For example DRR is a 
poor model for root avulsion with respect to the amount of cell death (Chew et al., 
2008), neuroinflammation, and vascular deterioration (Chapter 3). Clinically root 
avulsion patients complain of excrutiating intractable pain (Parry, 1980;Berman et al., 
1998) whereas rhizomtomy alleviates PNI-pain (Loeser, 1972;Gybels and Sweet, 1989). 
c-Fos immunoreactivity, an indirect marker of neuronal hyperactivity, is expressed in 
far greater quantity in the dorsal horn of root avulsed rats than nerve transected rats 
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(Zhao et al., 1998). Mechanical allodynia initiated by dorsal and ventral root ligation 
surgery is less effectively alleviated by pharmacotherapy than PNI-induced evoked pain 
(Winkelstein et al., 2001a). In patients 5% of PNI cases result in chronic pain, compared 
to 80% in brachial plexus avulsion (Bertelli and Ghizoni, 2008), and sustained long-
term disability and pain was more prominent in patients with root avulsion compared to 
PNI (Novak et al., 2009). These differences are likely due to different basic anatomical 
features such as, DRG-dorsal horn connection (Winkelstein et al., 2001a), as well as 
central effects in the dorsal horn such as dorsal horn hyperexcitability (Ovelmen-Levitt 
et al., 1984) and direct damage to the spinal cord (Berman et al., 1996;Stephen et al., 
1997) after avulsion. For example, maintenance of central sensitivity cannot be driven 
by ectopic firing of preganglionic deafferented roots, such as suggested for PNI, as 
DRG cell bodies are disconnected from the dorsal horn. Also Wallerian degeneration of 
the transected peripheral nerves may contribute to sensitization of intact adjacent fibres 
either at the level of the nerve, DRG, or the peripheral endings. However, after dorsal 
root injury, Wallerian degeneration occurs from the root stump up the dorsal columns in 
rats (George and Griffin, 1994b) and humans (Endo et al., 2009), begining in vivo after 
1 day and becoming prominent at 7 days (Wroblewski et al., 2000). Retrograde 
Wallerian degeneration or loss of DRG neurones in the distal part of the nerve does not 
occur after DRA or DRR at least by 14 days (Chew et al., 2008) most likely because the 
neurones still maintain peripherally mediated trophic support. This suggests that 
peripherally mediated sensitization of adjacent uninjured nerve fibres does not occur, 
and is not responsible for central sensitisation.  
 
It is not surprising that specific mechanisms of neuropathic pain in spinal root injuries 
are not well understood due to a complex etiology of peripheral and central injured 
components (Berman et al., 1998;Anand and Birch, 2002;Bertelli and Ghizoni, 2008). It 
is suggested that loss of inhibition of large sensory A-fibers after dorsal root damage 
may result in the deafferentation of nociception-transmitting neurons in the dorsal horn, 
and thus produce neuronal hyperactivity, hypersensitivity and abnormal spontaneous 
discharges with intermittent bursts of high-frequency activities (Loeser and Ward, Jr., 
1967;Loeser et al., 1968;Ovelmen-Levitt et al., 1984;Ovelmen-Levitt, 1988). Pre-
clinical research of brachial plexus injury models suggested the opioid endorphin 
system had a reduced sensitivity in a deafferented animal (Lombard and Besson, 1989), 
with a drastically (60%) reduced opioid receptor binding sites in the dorsal horn 4 
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months after DRR (Zajac et al., 1989). Recently some cellular mechanisms have been 
implicated in rat models of brachial plexus avulsion pain, including roles for 
upregulation of systemic TNFα (Quintao et al., 2006), neurotrophic factors, especially 
BDNF (Obata et al., 2006b;Obata and Noguchi, 2006;Quintao et al., 2008b), 
upregulation of central and peripheral bradykinin (B1 and B2) receptor levels (Quintao 
et al., 2008a) as well as cortical reorganization and CNS plasticity (Carlstedt, 
2008;Carlstedt et al., 2009).  
 
The previous chapter described glial activity, neurodegeneration, vascular degeneration, 
leukocyte infiltration, and cell death effects within the dorsal horn after L3-L6 dorsal 
root avulsion and suggested that these may contribute to the development of 
deafferentation pain. This chapter will attempt to corroborate these effects in a spared 
root avulsion model (L5 SRA) with behavioural changes indicative of neuropathic pain. 
 
4.1.7: Aims 
 
• The primary aim of this chapter is to determine whether hypersensitivity to 
stimulation can be evoked across the L4/L5 borderzone after single spinal root 
avulsion. More specifically it is important to establish when hypersensitivity 
occurs, and what type of stimulus (mechanical or thermal) can evoke this, and its 
duration. A surrogate measure of spontaneous pain, weight reduction, will be 
assessed. Motor impairment after L5 SRA will also be assessed. 
 
• To determine the potential mechanisms of avulsion induced hypersensitivity, 
histology of the intact DRG should provide evidence on whether there are 
peripheral components including glial activity (GFAP), evidence of injury 
(ATF3), phenotypic change to subpopulations (CGRP, N52, and IB4), and 
upregulation of receptors known to be involved in evoked hypersensitivity 
(TRPV1). Similar histological approaches implemented in chapter 3 will be used 
assess central mechanisms of injury within the L4 and L5 segments of the spinal 
cord across 14 days. This includes glial activity (IBA1, GFAP), neuronal loss 
(NeuN, Tol Blue), macrophage activity (ED1), and vascular disruption (RECA-
1).  
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4.2: Results 
 
4.2.1: Acute behavioural effects of L5 SRA across 14 days 
 
4.2.1.1: Motor incoordination 
 
One day after L5 SRA, rats were able to locomote the ipsilateral limb, in a similar range 
of motion to sham and naïve rats, and were able to walk across the horizontal ladder. 
The contralateral limb was not assessed. 
 
Total number of incorrect steps: 
Naïve and sham animals presented few misplaced ipsilateral steps on the ladder rungs 
across 14 days, and this was not significantly different from baseline (Fig 4.1).  
 
Across the horizontal ladder the SRA group made a significant number of incorrect paw 
placements (as defined in the methods) against sham and naïve levels, such that >60% 
of steps were misplaced on day 1 post injury (Fig 4.1). This incorrect plantar placement 
was maintained throughout the 14 day trial against sham, naïve and baseline values (Fig 
4.1). This method of assessing plantar misplacement provided evidence for locomotor 
impairment after SRA, but did not assess the level of severity of the plantar deficit.  
 
Foot fault score: 
Naïve and sham animals had an average foot fault score of 1, suggesting normal plantar 
placement across 14 days, and this was not significantly different from baseline at any 
time point (Fig 4.2).  
 
When scoring each of the misplaced ipsilateral paw steps for level of severity, rats that 
underwent L5 SRA had a mean misplaced ipsilateral step that was category 2 or below 
(see methods) (Fig 4.2). This refers to a mid-plantar placement without toe curl around 
the rung, the mildest foot fault on the score. Rarely did the SRA rats completely miss 
the rung or slip from the rung. This foot fault score was maintained across 14 days, did 
not increase in severity, and at every day measured, was significantly more severe than 
naïve and sham (Fig 4.2). 
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Figure 4.1: Mean number of foot faults across 6 rungs. From day 1 SRA rats develop an ipsilateral 
incorrect plantar paw placement across the rung. No change is detected with sham or naïve. Comparison 
against baseline (#), ipsilateral vs contralateral (x), injury vs naïve (*), and injury vs sham (+) are shown 
above respective data point. N=6 in each group. 
 
Figure 4.2: Severity of foot fault placement across 6 rungs. From day 1 SRA rats develop an inability 
to accurately perform plantar placement, such that mid-plantar placement without toe curl takes place on 
the majority of the rungs. Across 14 days no change occurs in the severity of misplaced plantar 
placement. No change is detected with sham or naïve. Comparison against baseline (#), ipsilateral vs 
contralateral (x), injury vs naïve (*), and injury vs sham (+) are shown above respective data point. N=6 
in each group. 
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4.2.1.2: Sensory deficits 
 
Thermal:  
After 14 days of acclimatisation all rats withdrew from thermal stimulus with latency of 
between 7.91s (+/-0.11) and 8.30s (+/-0.24), with no significant difference between 
groups or paw side (Fig 4.3). Across 14 days no change in withdrawal latency occurred 
in naïve or sham rats against baseline or contralateral paw (Fig 4.3A and 4.3B).  
 
After L5 SRA rats showed significant reduction in withdrawal latency against baseline 
values at 5, 7, 11, and 14 days (Fig 4.3D), against contralateral values at 7, 11, and 14 
days (Fig 4.3C), against naive values at 3, 5, 7, 11, and 14 days (Fig 4.3D), and against 
sham values at 11 and 14 days (Fig 4.3D). At 14 days SRA rats showed mean 
withdrawal latency to thermal stimulation of 6.05s (+/-0.22) ipsilaterally, significantly 
less when compared to naïve [8.00s (+/-0.11)] and sham [7.57s (+/-0.17)] (Fig 4.3D). 
 
Mechanical: 
After 14 days of acclimatisation all three groups of rats bilaterally withdrew from tactile 
stimulation between 25.4g (+/-0.41) and 26.9g (+/-1.79), with no significant difference 
between groups or paw side (Fig 4.4). Across 14 days no change in withdrawal 
threshold occurred in naïve rats against baseline or contralateral paw (Fig 4.4A). Sham 
rats showed significant hypersensitivity development from 5 days maintained up to 11 
days compared to naïve and baseline values (Fig 4.4D). Only at 5 days was ipsilateral 
significantly less than contralateral withdrawal thresholds (Fig 4.4B). 
 
One day after L5 SRA a reduction in ipsilateral withdrawal threshold was significant 
from baseline, sham, and contralateral values (Fig 4.4C and 4.4D). Loss of significance 
from contralateral and sham values was noted at 3 days for ipsilateral SRA (Fig 4.4C 
and 4.4D). At 5 days [15.5g (+/-0.87)] significant difference returned, compared to 
contralateral [21.5g (+/-1.41)] (Fig 4.4C), naïve [25.9g (+/-0.98)] (Fig 4.4D), and 
baseline [25.4g (+/-0.41)] (Fig 4.4D) values. Between 5 and 14 days SRA rats showed 
increasingly pronounced reduction in withdrawal thresholds against all groups 
compared (Fig 4.4C and 4.4D). At 14 days SRA rats had a mean ipsilateral withdrawal 
threshold of 10.9g (+/-1.84) compared to naïve [25.2g (+/-0.86)], and sham [25.9g (+/-
1.57)] (Fig 4.4D), and contralateral [25.3g (+/-1.61)]. 
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4.2.1.3: Reduced weight gain after SRA 
 
Over a period of 14 days naïve male Wistar rats, with a pre-surgical baseline weight of 
271.2g (+/-6.89), gain an average of 5.15 (+/-0.35) grams per day (Fig 4.5). Mean total 
weight gain across 14 days was 72.2 (+/-4.83) grams (Fig 4.5), which was in agreement 
with data from animal breeders (Charles River. Margate. UK).  
 
Wistar rats from the same litter, with a pre-surgical baseline weight of 271.2g (+/-6.89), 
that underwent sham surgery gained 4.98g/day (+/-0.47) (Fig 4.5). Mean total weight 
gain across 14 days was 69.7g (+/-6.57), which was not significantly different to naïve 
rats (Fig 4.5). 
 
However, identical Wistar litter mates, with a pre-surgical baseline weight of 266.8g 
(+/-10.5), that underwent L5 SRA, over the same 14 day period, gained only 3.86g (+/-
0.37) (Fig 4.5). Mean total weight gain across 14 days was 54.0g (+/-5.13). This 
average daily weight gain is significantly lower than naive levels, but statistical 
significance was not achieved against sham levels (P=0.056) (Fig 4.5). 
 
Pre-surgical baseline weights were not significantly different between groups. 
 
 
 
Figure 4.5: Daily weight gain in adult male Wistar rats after sham-SRA, SRA, or naïve surgery. 
Over a period of 14 days naïve and sham-SRA wistar rats gain 5.15g and 4.98g of weight per day 
respectively with no significant difference.  Over the same period of assessment in SRA injured wistar 
rats gain only 3.86g, significantly less weight per day than their naïve litter mates. Comparison injury vs 
naïve (#) is indicated above respective data point. N=6 in each group. 
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4.2.2: Chronic behavioural effects of L5 SRA 
 
After observing a significant hypersensitivity development across 14 days, it was 
important to assess the temporal profile of this behaviour. A 60 day trial of rats with L5 
SRA, using identical thermal and tactile stimulation, was conducted in absence of sham 
and naïve animals, as hypersensitivity had previously been confirmed against these 
controls. Baseline and contralateral values were used as control values at each time 
point.  
 
Before surgery, baseline thermal withdrawal thresholds were 9.57s (+/-0.38) 
ipsilaterally, and 9.38s (+/-0.45) contralaterally. Baseline mechanical withdrawal 
thresholds were 19.3g (+/-1.33) ipsilaterally, and 20.4g (+/-1.77) contralaterally. No 
difference was presented between cord sides and values were representative of previous 
data (Fig 4.3 and Fig 4.4).  
 
By 5 days ipsilateral hypersensitivity had significantly developed to thermal stimulation 
[5.97s (+/-0.43)] (Fig 4.6A) compared to baseline and contralateral levels, and tactile 
stimulation [15.01g (+/-2.23)] (Fig 4.6B) compared only to baseline levels. By 7 days 
ipsilateral hypersensitivity was significantly lower than contralateral values. These 
withdrawal values were not significantly different to values from the previous 
experiment at 7 days [5.57s (+/-0.51) and 15.0g (+/-1.21g)] (Fig 4.3 and Fig 4.4).  
 
At 25 days further significant withdrawal latency reduction was noted for tactile 
stimulation, such that values reached 8.42g (+/-0.59g), significantly lower than 
contralateral and baseline values (Fig 4.6B). This hypersensitivity was then maintained 
up to 60 days [8.31g (+/-0.64)] with no further change from day 25 values. Further 
thermal withdrawal latency reduction was not noted, and values were maintained across 
60 days at 4.27s (+/-0.35) (Fig 4.6A). At no time point did contralateral values 
significantly fluctuate from baseline (Fig 4.6). 
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Figure 4.6: Temporal time-course of hypersensitivity after SRA. (A) Over 5 days thermal 
hypersensitivity develops, and is maintained up to 60 days without contralateral effect. (B) Over 5-7 days 
tactile hypersensitivity develops. Between 7 and 25 days this hypersensitivity is greatly enhanced. 
Between 25 days and up to 60 days this hypersensitivity is maintained. No change in contralateral 
withdrawal threshold is significant. Comparison ipsi vs contra (x), and injury vs baseline levels (#) is 
indicated above respective data point. N= 6 in group. 
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4.2.3: Mechanisms of hypersensitivity development 
 
4.2.3.1: Peripheral component of SRA induced hypersensitivity 
 
Fourteen days after L5 SRA, quantification of phenotypic changes were made through 
profile counts using Neurofilament (N52), CGRP, and IB4 for the three subtypes of 
primary afferents within the intact ipsilateral and contralateral L4 DRG. 
 
Analysis indicated that no significant change occurred in these subpopulations against 
contralateral, sham, or naïve levels. No significant difference was found with TRPV1 
expression in the ipsilateral L4 DRG compared to sham, naïve, and contralateral levels. 
No increase in GFAP expression within satellite cells, from sham, naïve, and 
contralateral levels was found in the L4 DRG (Fig 4.7). 
 
The only antibody in which there was any significant difference in the L4 DRG was the 
injury marker activating transcription factor 3 (ATF3) (Fig 4.8 and Fig 4.9). The 
percentage of L4 DRG neurones expressing ATF3 in the nucleus were greater than 
naive and sham bilaterally, with ipsilateral SRA expression greater than contralateral 
(Fig 4.9A). ATF3 colocalised with both N52 positive and N52 negative neurones (Fig 
4.8E). There was also a small but significant expression compared to naïve in sham L4 
ipsilateral DRG (Fig 4.9B).  
 
All other density staining (GFAP) and counts for the ipsilateral and the contralateral 
DRG, were not significantly different between any of the groups (Fig 4.8 and Fig 4.9).  
 
Quantification within the L5 DRG was not attempted for any markers mentioned above, 
and only pictures were taken for visual consideration (Fig 4.7). This was unavoidable 
due to the methodological requirement of obtaining enough viable sections for analysis. 
There were no animals, within the SRA group, that when cryosectioned had the 
minimum 400 neurones per DRG required for quantification and percentage analysis 
(See methods). Indeed only very few sections had recognizable DRG cells within them. 
However it is worth noting descriptively, that on the sections were some neurones 
remained, these DRG cells stained for all 3 phenotypic markers of subpopulations (Fig 
4.7). TRPV1 labeling was seemingly absent in these ipsilateral L5 DRG neurones (Fig 
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4.7). GFAP was also highly expressed in satellite cells surrounding the remaining DRG 
neurones (Fig 4.7). 
 
 
Figure 4.7: Changes in neuronal DRG subpopulations after L5 SRA. Immunolabelling with IB4, 
CGRP, N52, and TRPV1 shows no phenotypic changes occurring in neuronal subclasses within L4 DRG 
after L5 SRA. No upregulation in GFAP in satellite cells indicated little direct damage to this DRG. 
However, when comparing L5 DRG, a remarkable loss of neurones of all subtypes is observed. In most 
sections positive DRG neurones cannot be located (images not shown). TRPV1 expression is absent. 
Satellite cells upregulate GFAP around remaining neurones. Scale=50µm 
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Figure 4.8: AFT3 expression in intact and avulsed DRG after L5 SRA. ATF3 is expressed in many of 
the remaining neurones within the ipsilateral L5 avulsed DRG. Some are large myelinated N52 positive 
(blue arrow), others unmyelinated N52 negative (white arrows). A few ATF3 positive neurones are found 
in the L4 ipsilateral intact DRG that are large, myelinated neurones (white arrows) Scale=50µm 
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Figure 4.9: Quantification of L4 neuronal subpopulations, injury marker expression, and satellite 
cell expression in ipsilateral (A) and contralateral (B) DRG. No difference between naïve, sham, and 
SRA, and ipsilateral versus contralateral sides for small unmyelinated peptidergic neurones (CGRP), small 
unmyelinated non-peptidergic neurones (IB4), large neurofilament positive neurones (N52), Vanilloid 
receptor (TRPV1) expression, or satellite activation (GFAP). A few (5%) ATF3 positive neurones are 
found ipsilaterally in sham, and bilaterally in SRA DRG. Comparisons between ipsilateral and 
contralateral (x),, injury vs naïve (*), and SRA vs sham (+) are indicated above respective data point. N=6 
in each group. 
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4.2.3.2: Central component of SRA induced hypersensitivity 
 
4.2.3.2.1: Dorsal horn neuronal counts 
 
Counts in the dorsal horn for neuronal populations were quantified using the antibody 
NeuN as described in section 2.7 and 3.2.5.2. Toluidine staining was not applied in this 
case due to the observation of non-specific staining at 14 days in DRA and DRR dorsal 
horn (Section 3.2.5.3) 
 
Counts of naïve dorsal horn neurones averaged 413.8 (+/-5.29) in L4 and 407.3 (+/-
5.94) per section in L5 (Fig 4.11). The cytoarchitecture of the L5 dorsal horn was 
distinct from L4 with shorter and fatter lamina distribution and shallower dorsal 
fasciculus and columns (Fig 4.10). The neurones followed a distinct lamina distribution 
in both segments (Fig 4.10). Sham dorsal horn NeuN counts did not significantly 
change from naïve in any area analysed (Fig 4.11).  
 
Fourteen days after SRA, a small but significant reduction in NeuN counts were 
observed in the L5 dorsal horn [376 (+/-7.72) per section] (Fig 4.11). This was 
significantly lower than sham, naïve, and contralateral values. NeuN loss was evident in 
the medial superficial laminae directly overlying Lisseaur’s tract and the DREZ. Small 
cavities were noted in the deafferentated area around the DREZ. However lateral areas 
of the superficial laminae, including the lateral spinal nucleus remain intact (Fig 4.10). 
Contralateral NeuN counts in either deafferented or intact segments were not 
significantly lower than naïve levels (Fig 4.11). 
 
Interestingly, NeuN counts also decreased in the dorsal horn of the intact L4 segment to 
389.3 (+/-4.39), significantly decreased from sham, naive, and contralateral values, but 
not significantly different to L5 segmental loss (Fig 4.11). NeuN loss was again evident 
below Lisseaur’s tract and DREZ, and dispersed through the deeper laminae (Fig 4.10). 
 
Primary afferent terminal loss, determined by IB4 staining of non-peptidergic C-fibres, 
was distinctive in L5, with loss of staining throughout lamina II, but some residual 
staining remained (Fig 4.12) in accordance with results from DRA and DRR (Section 
3.2.1b). A partial loss of IB4 staining in lamina II of the adjacent L4 segment was also 
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noted (Fig 4.12). Neuronal loss however was not anatomically correlated with primary 
afferent loss within either L5 or L4 segments, with NeuN+ve dorsal horn neurones 
present in these specific areas of deafferentation (Fig 4.12). 
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Figure 4.11: Quantification of mean number of dorsal horn neurones 14 days after SRA. A small but 
significant NeuN count reduction is present in both L5 and L4 segments aftr SRA injury compared to 
sham and naïve levels. Comparisons between ipsilateral and contralateral (*), injury vs naïve (#), and 
SRA vs sham (x) are shown. N=6 in each group. 
 
 
Figure 4.12: Colocalisation studies of primary afferent terminal loss and neuronal loss in L4 and L5 
segments 14 days after L5 SRA. L4 IB4+ve primary afferent terminals show a decrease within the 
lamina II ‘eyebrow’ (asterisk), representing deafferented L5 fibres that branch and synapse within the 
adjacent segment. L5 IB4+ve staining is minimal, due to the deafferentation of L5 fibres. Residual 
staining does remain and may indicate adjacent overlapping from primary afferent terminals from L4 or 
L6. In neither segment does primary afferent loss colocalise with noticeable neuronal loss (NeuN-IB4 
merge). Scale=100µm 
 
* 
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4.2.3.2.2: Ventral horn neuronal counts  
 
In addition to dorsal horn NeuN reduction after SRA, a prominent motor neuronal loss 
was found in the ipsilateral ventral horn. This was evident using either Toluidine Blue 
histology or NeuN immunohistochemistry (Fig 4.13 and Fig 4.14). α-motor neurones 
could easily be distinguished by eye using both histological methods (Fig 4.13), and the 
inclusion criteria has been previously described (Section 2.7). Ipsilateral values are 
represented as a percentage of contralateral counts (Fig 4.14). This representation of the 
data was preferred to actual counts due to the relatively low numbers of motor neurones 
per section, and the propensity for naïve motor neurone number to deviate between 
sections.  
 
Sham surgery did lead to a loss of ipsilateral motor neurones, as determined by either 
Tol Blue or NeuN labelling (Fig 4.13 and Fig 4.14). Mean contralateral motor neurone 
counts in SRA ventral horn using either NeuN or Tol Blue staining was not different to 
contralateral sham motor neurone counts (data not shown).  
 
After SRA the number of NeuN+ve motor neurones decreased in L5 by 69.1% (+/-6.8) 
of contralateral numbers. Loss was observed in three areas; dorsolateral and 
ventrolateral (L4 and L5), and ventromedial (caudal L5) pools (Fig 4.13 and Fig 4.14) 
(As described in section 2.7). NeuN+ve motor neurone percentages were also reduced 
in L4, and loss was 47.2% (+/-3.1) of contralateral side, but was significantly less 
severe than the loss in L5 (Fig 4.14). Motor neurone loss was noted in ventrolateral and 
dorsolateral motor neuronal pools, with greater loss in ventrolateral (Fig 4.13). 
 
When analysing Tol Blue+ve motor neurones, a marked difference compared to NeuN 
immunohistochemistry was noted. Loss was limited to 42.9% (+/-4.9) in L5 and 26.6% 
(+/-4.0) in L4 segments, still significant from Tol Blue sham levels in both cases (Fig 
4.14). The deafferented L5 ventral horn again had a greater loss of motor neurones than 
the intact L4 ventral horn (Fig 4.14). This loss was significantly milder than NeuN loss 
in similar segments (Fig 4.13). In both L4 and L5 ventral horns, some small spherical 
cells with faint Tol Blue staining were observed surrounding motor neurones (Fig 4.13), 
likely representing a glial cell population, similar to results from Tol Blue staining in 
the dorsal horn at 14 days after DRA and DRR (Section 3.2.5.3). 
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4.2.3.2.3: Vascular effects 
 
Microvascular effects were assessed in naïve, sham-SRA, and SRA tissue 14 days after 
injury using RECA-1 density staining and quantified with the Leica Q-win program, 
(see section 2.3.2). 
 
RECA-1 density staining in naïve dorsal horns was 4.45% (+/-0.51) in the L5 segment 
and 4.39% (+/-0.23) in the L4 segment (Fig 4.16A). In the ventral horns RECA-1 
density staining was 4.67% (+/-0.45) in L5 segment and 4.87% (+/-0.46) in the L4 
segment (Fig 4.16B). Sham-SRA dorsal and ventral horn vasculature staining levels 
were not significantly lower than naïve levels (Fig 4.16). 
 
After 14 days in SRA, RECA-1 vasculature labelling showed a marked reduction in 
intensity against sham and naïve levels, in both the deafferented L5 and intact L4 
Figure 4.14: Mean motor neurone loss in ventral horn 14 days after L5 SRA. Sham ventral horn 
shows no loss compared to contralateral side. L5 SRA leads to significant motor neurone reduction at 14 
days compared to sham in both L5 and L4 segments. When using NeuN stain, counts show a significantly 
greater reduction than Tol Blue in the same tissue. Comparisons between Tol Blue vs NeuN values (*), 
and SRA vs sham (x), and L4 vs L5 (+) are shown. N=6 in each group. 
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segments, in both dorsal and ventral horns (Fig 4.15). The number of microvascular 
vessels did not seem to decrease; only the intensity of the staining of endothelial cells 
was reduced along with the thickness and length of the vasculature. This was not just 
around the lesion site of the DREZ and VREZ, but throughout the L4 and L5 segments. 
 
Levels of RECA-1 intensity staining in the ipsilateral dorsal horn 14 days after SRA 
were 2.62% (+/-0.32) in the L5 segment and 2.93% (0.32) in the L4 segment, both 
significantly lower than naïve levels (Fig 4.16A). However only in the L5 segment 
dorsal horn were percentage density levels of RECA-1 significantly lower than that in 
the corresponding sham (Fig 4.16A).  
 
Levels of RECA-1 intensity staining in the ipsilateral ventral horn 14 days after SRA 
were 2.01% (+/-0.15) in the L5 segment and 2.44% (0.26) in the L4 segment. All 
segments had significantly reduced RECA-1 from naïve and sham levels. 
 
No significant difference was found in RECA-1 density staining between deafferented 
L5 and intact L4 segments in either ventral or dorsal horns (Fig 4.16).  
 
A contralateral effect was significant in comparison to sham and naïve levels, and levels 
of RECA-1 were not significantly different to ipsilateral levels in any comparison (Fig 
4.16). Contralateral RECA-1 staining, similar to ipsilateral, was more significantly 
reduced against corresponding naïve and sham values, in the ventral horn [L4 = 2.61% 
(+/-0.19), L5 = 2.28% (+/-0.24)] than in the dorsal horn [L4 = 3.28% (+/-0.34), L5 = 
3.14% (+/-0.23)] (Fig 4.16). 
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 Figure 4.15: Representative images of RECA-1 staining in dorsal and ventral horns in L5 and L4 
segments. Loss of vasculature labeling can be seen at 14 days after SRA in both L5 and L4 segments, 
bilaterally, and in both ventral and dorsal horns. The number of microvascular vessels seems unchanged, 
only a reduced staining of endothelial cells (RECA-1 marker) as well as shortening and thinning of 
vessels is noted. Scale=100µm 
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Figure 4.16: Quantification of RECA-1 staining in dorsal (A) and ventral (B) horns in deafferented 
(L5) and intact (L4) segments. There is no difference between naïve and sham for any area. Significant 
bilateral reduction in RECA-1 occurs 2 weeks after SRA in dorsal and ventral horns compared to naïve. A 
significant reduction from sham RECA-1 levels is apparent in ipsilateral L5 dorsal horn and bilateral L4 
and L5 ventral horns. No significant differences are seen between cord sides. Comparisons between injury 
vs naïve (#), and SRA vs sham (x) are shown. N=6 in each group. 
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4.2.3.2.4: Macrophage infiltration 
 
Qwin analysis of naïve, sham, and contralateral SRA tissue provided no evidence of 
ED-1 positivity in the dorsal columns, and no ED-1 was visualised in any other areas of 
the L4-L5 cord in these sections (Fig 4.17 and Fig 4.18). 
 
Fourteen days after SRA, ED-1 expression was found in the ipsilateral dorsal root entry 
zone and dorsal columns almost exclusively in L5 and L4 segments respectively (Fig 
4.17), with no contralateral expression (results not shown). When quantified this ED-1 
expression density in the DREZ and columns was significantly greater than sham levels 
in the dorsal columns [0.01% (+/-0.00) in L4, and 0.02% (+/-0.01) in L5], such that the 
L5 segment showed 3.95% (+/-1.23) and the L4 segment 1.37% (+/-0.36) density 
staining (Fig 4.18). However, unique to SRA injured cord, ED-1 was not significantly 
expressed in the dorsal horn, contrasting evidence from DRA and DRR, which show an 
anatomically separate macrophage population that surround the dorsal horn neurones 
compared to primary afferent fibres (Section 3.2.3a). A small amount of ED-1 positive 
staining was found in the ventral horn in both L5 and L4 segments, with some 
clustering around motor neurones (Fig 4.17). The presence of this ventral horn staining 
was inconsistent between segments and animals, and was not analysed for this reason.  
 
Significant differences in ED-1 density expressions were seen between deafferented L5 
and intact L4 segments (Fig 4.17 and Fig 4.18).  In the L5 segment ED-1 macrophages 
are found intensely in the DREZ, with a few migrating through the ipsilateral dorsal 
fasiculus and column, and also into Lisseaurs tract and very few in the medial portion of 
superficial laminae, where dorsal horn neuronal loss was indicated. Intense ED-1 
staining surrounds areas of cavitation (Fig 4.17). However in the L4 segment, dispersed 
ED-1 positive cells are presented in a much reduced number, and specifically within the 
ipsilateral dorsal column only (Fig 4.17). 
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Figure 4.17: Representative images of ED1 staining in DREZ, columns, and ventral horn in 
deafferented-L5 (A) and intact-L4 (B) segments. ED1 positive labelling can be seen 14 days after 
SRA in both L5 and L4 segments. Rarely were ED1 positive cells found in sham, or naïve tissue (not 
shown). Some small ED-1+ve cells were present in the ventral horn in both L4 and L5 segments, with 
some clustering around motor neurones. Macrophages were almost exclusively located around cystic 
cavities and the DREZ in L5 (asterisk), whereas they are more dispersed throughout the dorsal columns 
in the L4 segment. Scale=50µm 
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4.2.3.2.5: Astrocyte reactivity 
 
Astrocytes were identified through immunohistochemical labelling of GFAP and 
quantified for density staining. Q-win analysis of naïve dorsal horns provided density 
staining values of 3.41% (+/-0.31) for the L4 segment and 3.39% (+/-0.23) for the L5 
segment (Fig 4.20). Naïve ventral horn density staining values were 3.45% (+/-0.13) for 
the L4 segment and 3.76% (+/-0.29) for the L5 segment (Fig 4.20). No significant 
difference was found between cord sides, or segmental levels (Fig 4.20). 
 
Fourteen days after sham surgery, a significant increase in GFAP density staining was 
observed bilaterally in L4 and L5 for both ventral and dorsal horns, as analysed against 
naïve levels (Fig 4.19 and Fig 4.20). When quantified, no significant difference was 
found between ipsilateral and contralateral comparisons, or between sham-injured (L5) 
Figure 4.18: Quantification of ED-1 staining in the dorsal columns of deafferented (L5) and intact 
(L4) segments. ED-1 positivity was found only ipsilaterally in SRA animals. Almost no ED1 positivity 
was found in sham animals. Significant ED-1 density staining was found in L5 dorsal funiculus, dorsal 
column, and dorsal root entry zone, compared to sham ED-1 levels. ED-1 positivity was located in L4 
ipsilateral dorsal columns exclusively, which was significantly less than L5 density staining. Naïve and 
contralateral sides not quantified. Comparisons between and SRA vs sham (x) and L5 vs L4 (*) are 
shown. N=6 in each group. 
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and intact (L4) comparisons, and density staining values fell within a range of 4.83% 
(+/-0.34) and 5.66% (+/-0.32) within the L4-L5 cord (Fig 4.20). 
 
Fourteen days after SRA surgery, GFAP density staining was significantly upregulated 
in dorsal horn astrocytes ipsilateral to the deafferentation, in L5 as well as L4 segments, 
compared to sham, naïve, and contralateral levels (Fig 4.19 and Fig 4.20). Visually, a 
GFAP-positive network of astrocytes could be seen in the dorsal root entry zone, dorsal 
column of L5, with hypertrophy and increased GFAP expression in the dorsal horn of 
both L4 and L5 segments (Fig 4.19). Ipsilateral GFAP density staining reached 8.14% 
(+/-0.42) in the L4 segment and 8.11% (+/-0.40) in the L5 segment, and no significant 
difference was found between the deafferented L5 and intact L4 segments (Fig 4.20).  
 
GFAP density staining was also significantly upregulated in the ventral horns of both 
deafferented L5 and intact L4 segments, compared to sham, naïve, and contralateral 
levels (Fig 4.19 and Fig 4.20). Visually in the L5 segment astroctyes were greatly 
upregulated around motor neurone clustering tightly in the lateral aspect of the ventral 
horn (Fig 4.19). Within the L4 segment, astrocytes had ‘looser’ association with motor 
neurones, surrounding rather than ‘blanketing’ individual cells, but each astrocyte still 
shows a greatly increased GFAP expression (Fig 4.19). Ipsilateral GFAP density 
staining reached 7.56% (+/-0.21) in the L4 segment and 7.13% (+/-0.20) in the L5 
segment, and again no significant difference was found between the deafferented L5 
and intact L4 segments (Fig 4.20). 
 
A small but significant contralateral increase in GFAP density expression was found in 
both deafferented L5 and intact L4 segments of SRA animals compared to naïve, and in 
both dorsal and ventral horns, but was not significantly higher than sham levels (Fig 
4.20).  
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 Figure 4.19: Representative images of GFAP staining in dorsal and ventral horn in deafferented-L5 and intact-L4 segments. Increase in GFAP labeling can be seen 14 days after sham surgery in the dorsal 
and ventral horns, in both L5 and L4 segments. Further increase in GFAP labeling can be seen 14 days 
after SRA, surrounding motor neurones (asterisk) and superficial dorsal horn, Lisseaur’s tract, and dorsal 
root entry zone. There is also a contralateral increase in GFAP labeling 14 days after SRA. Scale=100µm 
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Figure 4.20: Quantification of GFAP staining in the dorsal (A) and ventral (B) horns of deafferented 
(L5) and intact (L4) segments. GFAP was increased in all areas, bilaterally, in sham and SRA tissue 
against naïve levels. Increase in GFAP in SRA from sham levels was significant in both L5 and L4 dorsal 
(A) and ventral (B) horns ipsilaterally. Comparisons between and injury vs naive (#), SRA vs sham (x), 
and ipsilateral vs contralateral (*) are shown. N=6 in each group. 
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4.2.3.2.6: Microglial reactivity 
 
Microglia were identified through immunohistochemical labelling of ionized calcium 
binding adaptor molecule 1 (Iba1) and quantified for density staining. Q-win analysis of 
naïve tissue equated L4 density staining values of 1.60% (+/-0.35) for dorsal horn and 
0.98% (+/-0.18) for ventral horn, and L5 density staining values of 1.58% (+/-0.38) for 
dorsal horn and 0.88% (+/-0.18) for ventral horn (Fig 4.22). No significant difference 
was found between cord sides, or segmental levels. 
 
In 14 day sham tissue, a significant increase in Iba1 staining was observed bilaterally in 
L4 and L5 ventral horns compared to naïve, but not in the dorsal horns (Fig 4.21 and 
Fig 4.22). A significantly greater Iba1 density was found ipsilaterally compared to 
contralaterally in L5, but a similar comparison in L4 did not reach significance. No 
difference was found between L4 and L5 segments. Density staining values fell within a 
range of 2.04% (+/-0.31) and 3.57% (+/-0.67) within the L4-L5 cord for sham. 
 
14 days after SRA, Iba1 density was significantly upregulated in dorsal horn microglia 
ipsilateral to the deafferentation, in L5 and L4 segments, compared to sham, naïve, and 
contralateral levels (Fig 4.21 and Fig 4.22A). In the L5 ipsilateral segment Iba1 
expression could be seen intensely in the DREZ that spreads throughout the superficial 
laminae (Fig 4.21). A marked difference in Iba1 expression can be seen in the intact L4 
ipsilateral segment with increased expression throughout the superficial and deep dorsal 
laminae and dorsal columns (Fig 4.21). Ipsilateral Iba1 density staining reached 9.01% 
(+/-1.11) in L4 and 10.1% (+/-1.22) in L5, with no significant difference between these 
segments (Fig 4.22A). In the contralateral dorsal horn of L4 and L5, a significant 
increase in Iba1 expression was found against naïve levels, but not against sham (Fig 
4.21 and Fig 4.22A). 
 
Iba1 expression was significantly increased in the ipsilateral ventral horns of L5 and L4 
segments 14 days after SRA, compared to sham, naïve, and contralateral levels (Fig 
4.21 and Fig 4.22B). In the L5 and L4 ipsilateral segments Iba1 expression was 
upregulated around motor neurones, clustering tightly in the lateral aspect of the ventral 
horn (Fig 4.21). Ipsilateral Iba1 ventral horn density staining reached 10.2% (+/-0.93) in 
L4 and 10.5% (+/-0.91) in L5, with no significant difference between these values (Fig 
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4.22B). A significant contralateral increase in Iba1 expression, against naïve, was found 
in L5 and L4 segments (Fig 4.21). However only in L5 [3.21% (+/-0.37)] was this Iba1 
expression greater than sham levels (Fig 4.22B). 
 
 
 Figure 4.21: Representative images of Iba1 density staining in dorsal and ventral horn in 
deafferented-L5 and intact-L4 segments. Increase in Iba1 labeling can be seen in sham dorsal and 
ventral horns, in both L5 and L4 segments. Further increase in Iba1 labeling can be seen in SRA 14 days 
after SRA, surrounding motor neurones in L4 and L5 segments, and within superficial dorsal horn, 
Lisseaur’s tract, and dorsal root entry zone in L5, and throughout the dorsal horn laminae in L4. A 
contralateral effect is also observed. Scale=100µm 
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Figure 4.22: Quantification of Iba1 staining in the dorsal (A) and ventral (B) horns of deafferented 
(L5) and intact (L4) segments. Iba1 was increased bilaterally in the ventral horn (B) after sham surgery, 
compared to naïve levels. 14 days after SRA levels of Iba1 were increased in all areas of the cord 
investigated, compared to naïve levels. Increase in Iba1 labeling in SRA was significant from sham in both 
L5 and L4 dorsal (A) and ventral (B) horns ipsilaterally, with a small but significant increase in the 
contralateral L5 ventral horn Comparisons between and injury vs naive (#), SRA vs sham (x), and 
ipsilateral vs contralateral (*) are shown. N=6 in each group. 
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4.3: Discussion 
 
4.3.1: Summary 
 
The new findings of this study can be summarised as follows: 
 
Avulsion of the L5 spinal root leads to only a minor incorrect plantar placement of 
ipsilateral paw at 1 day that does not progress in severity across 14 days. A reduced 
weight gain is observed across 14 days in SRA rats, suggestive of ongoing, or 
spontaneous, pain. Avulsion of the L5 spinal root also leads to behavioural 
hypersensitivity to thermal and tactile stimulation. Thermal hypersensitivity peaks by 5 
days and remains unchanged thereafter. Tactile hypersensitivity develops rapidly and 
increases over the first month before plateauing and remaining unchanged thereafter.  
 
Avulsion of the L5 spinal root does not lead to significant phenotypic changes in 
subpopulations of DRG neurones in the adjacent L4 segment, or activation of satellite 
glia. Expression levels of the receptor TRPV1, associated with thermal hypersensitivity, 
remain unchanged. An increase in ATF3 is observed in the L4 DRG, but its biological 
significance remains to be determined.  
 
An ipsilateral dorsal horn neuronal loss accompanies hypersensitivity at 14 days after 
SRA injury; however, it is mild (~5% in L4 and ~8% in L5), associated with cavitation 
and trauma around the lesion site, and is not anatomically correlated with primary 
afferent loss in the deafferented regions. The neuronal loss in L4 may be associated with 
the spread of tissue damage from L5. 
 
A more significant motor neurone loss is found in SRA animals at 14 days, but values 
are dependent upon the method of histological identification. NeuN labelling gives a 
more severe ipsilateral motor neurone loss of ~69% in L5 and ~47% in L4. Tol blue 
histological dye counts show only ~43% loss in L5 and ~27% loss in L4, suggesting 
epitope expression may well be a dependent factor in the accuracy of determining 
neurodegeneration. The loss of motor neurones in L4, is in accordance with the 
anatomical rostro-caudal spread of motor fibres from ventral horn to root, suggesting a 
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population of L5 motor efferents originating in the L4 segment (Nicolopoulos-Stournas 
and Iles, 2004). 
 
L5 SRA leads to loss of microvascular staining in the dorsal and ventral horns of both 
L5 and L4 segments, bilaterally, in accordance with previous results on L3-L6 DRA 
studies at 14 days (see section 3.2.4). 
 
Macrophage recruitment 14 days after SRA injury is preferentially targeted at the zone 
of primary trauma, i.e. the DREZ and dorsal columns. Small particulate staining is 
noted in the ventral horns of L4 and L5, but it is inconsistent, and biological 
significance remains to be indentified. L5 macrophages are primarily associated with 
the DREZ, and densely cluster within this region. L4 macrophages are primarily 
associated with the dorsal columns and are much less densely packed as noted through 
density analysis imaging. 
 
Astrocytes in the L4 and L5 dorsal and ventral horns upregulate GFAP after SRA. A 
small but significant upregulation is noted contralaterally, as well as bilaterally in sham 
tissue. In the L5 segment astrocytes are intensely labelled in the DREZ around areas of 
cavitation, tissue trauma, and glial scarring. Astrocytes within the L4 dorsal horn are 
also upregulated but are less associated with tissue damage, and are spread throughout 
the dorsal horn. Astrocytes in the ventral horn surround motor neurones in L4, and 
densely cluster in the L5 region in areas that appear devoid of motor neurones. 
 
Fourteen days after SRA microglial activity is greatly upregulated in the region of 
primary trauma i.e. the DREZ of L5, most likely representing activated, phagocytic 
microglia. This expression extends into the dorsal column and dorsal horn. Increased 
microglial expression is observed in both the L4 and the L5 dorsal horns, in both 
number of cells and intensity of Iba1 expression. Prominent microglial activation, with 
increased number, increased Iba1 expression intensity, and clustering is found in the 
ventral horn of both L5 and L4 segments, and is associated with the lateral motor 
neurone pools. A small but significant Iba1 upregulation is noted contralaterally in L5 
and L4 dorsal and ventral horns. Iba1 expression increase is observed only in the ventral 
horn after sham surgery. 
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4.3.2: Behavioural effects of L5 SRA 
 
4.3.2.1: L5 SRA leads to an incorrect hind paw plantar placement  
 
Avulsion of the L5 spinal root leads immediately to an ipsilateral hind paw locomotor 
impairment. This impairment is maintained across 14 days, but is classified as only a 
mild plantar misplacement. L5 ventral root avulsion leads to a loss of fine control of 
plantar placement. Rats are able to successfully make a coordinated step, via swinging 
the affected limb and placing weight supported stance on the rung of the ladder. This 
suggests that loss of the L5 motor root is not sufficient at fully denervating the hind 
paw. The motor output from the L6 and L3 roots are capable of controlling hindlimb 
swing and stance phases of locomotion, with L4 compensating for the loss of L5 by 
maintaining plantar placement. Importantly, as each of the three joints of the hind limb 
are still innervated, the rat can still effectively withdraw the limb when stimulated by 
mechanical or thermal stimuli. It has been shown that motor neurone plasticity occurs in 
the adjacent spared ventral motor neurones after single ventral root rhizotomy in the cat 
(Holmberg and Kellerth, 2000), with monosynaptic reflexes enhanced by >200% 
(Holmberg and Kellerth, 1996). This motor neurone plasticity has been further 
characterised in rat dorsal root rhizotomy (Cuppini et al., 1999;Cuppini et al., 2002) 
with individual motorneurone peripheral receptive fields within the deafferented 
segment enlarged five to six times (Cuppini et al., 1998). This increase in synaptic 
density is likely to occur through activity dependency and sensory input from 
monosynaptic reorganisation (Holmberg and Kellerth, 1996;Cuppini et al., 2002). This 
plasticity may strengthen remaining monosynaptic reflex arcs and aid in locomotor 
compensation in the limb, which explains why only mild paresis is detected in L5 SRA. 
 
When both L5 and L4 ventral roots are avulsed the rat is unable to flex the ankle and 
initiate plantar paw placement, and it scores a 5 on every rung (data not shown). 
However, the animal still has hip and knee flexion, and attempts to make a coordinated 
step. Therefore, it is indeed the L4 root that compensates for L5 motor loss of the hind 
paw, and that L3 and L6 roots functionally control hip and knee movement only. 
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4.3.2.2: L5 SRA leads to a reduced gain in weight 
 
Reduction in weight gain has previously been used as a surrogate measure of a 
neuropathic pain syndrome for sciatic nerve (Willenbring et al., 1994) and trigeminal 
nerve injury (Imamura et al., 1997). Here, it is similarly used as a measure of 
spontaneous or ongoing pain after avulsion injury. A significant reduction in animal 
weight is found in SRA injured animals across 14 days compared to naïve with a trend 
against sham. It is unlikely that SRA animals undergo unique metabolic changes that 
lead to reduced body weight compared to sham litter mates. Loss of muscle mass in the 
avulsed limb, known to occur at longer time points in the range of 350-400mg across 12 
weeks (Gu et al., 2005), is unlikely to play a part in gross weight changes. Access to 
food is unlikely to change in SRA rats, as locomotion was not significantly impared in 
these animals across 14 days. The most likely explanation is loss of appetite due to 
ongoing behavioural changes associated with SRA neuropathy, indicative of chronic 
pain. 
  
4.3.2.3: L5 SRA leads to a delayed and maintained hypersensitivity 
 
This report does not use the terms hyperalgesia or allodynia to describe the 
hypersensitivity developed after SRA. Hyperalgesia is defined by the International 
Association for the Study of Pain (IASP) as ‘an increased response to a stimulus which 
is normally painful’, and allodynia defined by IASP ‘pain due to a stimulus which does 
not normally provoke pain’. In these cases this terminology has been useful for 
clinicians to describe the nature of a symptom that is presented to them in the clinic. 
The description is defined by the patient’s reaction to the question ‘is this painful’ rather 
than a withdrawal response. The rat on the other hand has no such capability, and 
withdrawal latency is the only quantitative measure available. Previous literature has 
defined an allodynic response to Von Frey hair testing as 0-1g threshold for peripheral 
nerve crush (Decosterd and Woolf, 2000), 1g threshold for L5/L6 spinal nerve ligation 
(Chaplan et al., 1994) and 2-5g threshold for chronic constriction of the sciatic nerve 
(Luo et al., 2002), using the ‘up-and-down’ analytical method (Dixon, 1980). To 
compare, in the case of L5 SRA minimal threshold withdrawal is a lot higher, at 6.44g 
across 60 days, using a slightly different tactile stimulus, the automated plantar 
aesthesiometer. This does not require the ‘up-and-down’ testing parameter to indicate a 
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50% response rate used for Von Frey hairs, and instead gives an exact value of hair 
weight and latency withdrawal. It would therefore be more appropriate to define 
significant lowering of threshold withdrawal as hypersensitivity, and ‘suggestive’ of a 
possible neuropathic pain state, rather than allodynia. Thermal hyperalgesia on the other 
hand is defined by Hargreaves et al., ((Hargreaves et al., 1988)), using the nociceptive 
thermal plantar test as a decrease in threshold and SRA rats show on average a 25-30% 
decrease in threshold.  
 
Avulsion of the L5 mixed spinal root results in delayed development of thermal 
hypersensitivity over 3 days, and an immediate development of mechanical 
hypersensitivity. This time scale is in accordance with clinical findings of avulsion pain 
development (Berman et al., 1996). Hypersensitivity is maintained at least up to 60 days 
post injury, and becomes progressively more severe in the case of tactile stimulation. 
The hypersensitivity is located at the borderzone of L4/L5 but it is unclear how far this 
spreads medially or laterally on the plantar surface. The withdrawal of the limb is 
usually accompanied by adverse behaviours such as lifting and licking or biting of the 
innervated side of the paw, and agitated movement around the testing box. This type of 
behaviour is in accordance with previous literature (Kim and Chung, 1992;Choi et al., 
1994). Many peripheral nerve neuropathic pain models exist (Wall et al., 1979;Bennett 
and Xie, 1988;Seltzer et al., 1990;Kim and Chung, 1992;Decosterd and Woolf, 2000). 
This model is the first example of a clinically representable and reproducible 
hypersensitivity development after spinal root avulsion injury. No contralateral effects 
were noted either in thermal or mechanical withdrawal thresholds. A transient 
mechanical hypersensitivity is observed ipsilaterally after sham surgery. This has been 
shown previously by similar surgical root exposure (Hashizume et al., 2000a). As this 
hypersensitivity is generally observed as mild, and is reversed at 14 days, this activity is 
unlikely to be biologically significant in the long term. 
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4.3.3: Histological effects of L5 SRA 
 
4.3.3.1: L5 SRA does not lead to phenotypic or degenerative phenomena in the 
intact adjacent L4 DRG 
 
Phenotypic changes in CGRP, IB4, and N52 are not present in the intact DRG after 
adjacent L5 avulsion. This is consistent with previous literature on spared nerve injury 
(Hammond et al., 2004), and implies hypersensitivity seen in this case is not driven by 
changes in DRG phenotype, or selective loss of a subpopulation. However using in situ 
hybridization CGRP mRNA has been shown to be upregulated in the intact L4 DRG 
neurones after L5 spinal nerve ligation (Fukuoka et al., 1998), but without changes in 
overall cell size or number, or changes in any other peptides such as NPY, VIP, galanin, 
or SP. This previous literature, and data now provided in this thesis, suggests that 
peripheral nerve injury, but not a central root injury, can induce transcriptional changes 
to the adjacent DRG, and this is most likely linked to Wallerian degeneration in the 
former that is absent in the latter. However phenotypic changes cannot be excluded 
from the L4 DRG as marker such as BDNF, NGF, NPY, Galanin, or NOS have not 
been analysed. 
 
Data in this thesis shows no change in the percentage of L4 DRG neurones expressing 
TRPV1 at 14 days post L5 SRA, in contrast to the upregulation of this receptor in 
spared DRG after PNI as a result of Wallerian degeneration and cytokine interaction 
with uninjured axons (Hudson et al., 2001;Fukuoka et al., 2002;Obata et al., 2006a). 
This result does not of course rule out possible upregulation of TRPV1 receptors in 
neurones already expressing this receptor, as intensity staining analysis was not 
performed; however, there was no obvious qualitative change by eye. It can be inferred, 
from these results, that the thermal hypersensitivity seen across 60 days after SRA is 
mediated by other means than changes in populations of TRPV1 expressing primary 
afferent neurones in the adjacent uninjured DRG, such as changes in the CNS.  
 
No increase in GFAP staining was seen in the intact L4 DRG at 14 days. Satellite cell 
activation is believed to be a mediator of neuropathic pain after PNI (Hu and 
McLachlan, 2003) and inflammatory pain (Dublin and Hanani, 2007), but activity peaks 
early at 3-7 days then decreases after (Woodham et al., 1989;Fenzi et al., 2001;Zhang et 
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al., 2009), perhaps suggesting 14 days is too late to observe satellite cell activity after 
SRA injury. However as hypersensitivity in the SRA model is maintained for much 
longer periods (>60 days), and in the case of tactile hypersensitivity becomes more 
severe beyond 18 days, peripheral satellite cell activity is unlikely to be an essential 
mediator of maintained neuropathic pain behaviour after avulsion.  
 
The ATF3 findings are of great interest as the ipsilateral L4 DRG is referred to in PNI 
literature as ‘uninjured’ (Hudson et al., 2001;Hammond et al., 2004). Sciatic nerve 
crush (Averill et al., 2002), and L5 spinal nerve transection (Shortland et al., 2006a), 
results in ATF3 expression in almost all injured DRG neurones by 1 day. Interestingly 
in the spared L4 DRG in the L5 spinal nerve transection, as well as the sham, ~11% 
ATF3 expression is found colocalised with upregulation of NOS, galanin, and NPY 
(Shortland et al., 2006a). These authors suspected that the surgical procedure of 
exposing the L5 spinal nerve caused direct damage, albeit mild, to the sensory afferents 
of L4. The data in this thesis shows a ~5% ATF3 expression increase in L4 DRG after 
L5 mixed root avulsion. Part of this small increase may be due to surgical exposure, as 
sham animals also expressed low levels of ATF3 (~1-2%). Furthermore, a small 
contralateral ATF3 expression is seen in the L4 DRG after SRA, suggesting the surgical 
incision and spread of the paraspinal muscle tissue with retractors during surgery may 
affect the primary afferents that innervate those dermatomes, bilaterally. This is not 
functionally significant however. It is likely both the exposure of the L5 spinal root, in 
sham and SRA, and the surgical disruption of overlying tissue during exposure, leads to 
a slight but significant increase in ATF3 expression in these cases. The ATF3 increase 
in these cases is unlikely to be functionally significant as it affects a small number of 
afferents. What is unknown, however, is the effect of surgical exposure on the L5 DRG, 
as this DRG was not analysed.  
 
The reason for the discrepancy between the negative findings in L4 DRG after L5-SRA, 
compared to other literature on spared nerve PNI, can be explained through differences 
in model. Obata et al., (Obata et al., 2006b) found that when comparing a ‘peripheral’ 
nerve injury model (L5 spinal nerve transection) with a ‘central’ root model (L5 dorsal 
and/or ventral root rhizotomy) markedly different levels of BDNF were found in the 
DRGs. 7 days after L5 DRR or L5 spinal root rhizotomy, upregulation of BDNF was 
found in the L5 DRG but not L4, and neuropathic pain was absent from the affected 
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hindpaw. L5 VRR lead to hypersensitivity, and BDNF expression only in L5 DRG. 
Whereas 7 days after L5 spinal nerve transection, BDNF was upregulated in both L5 
and L4 DRG, and correlated with robust mechanical and thermal neuropathic behaviour 
(Obata et al., 2006b). The authors suggest that this discrepancy is due to the loss of 
direct connection of the DRG axons to the dorsal horn neurones in dorsal and spinal 
root rhizotomy, whereas peripheral injury and VRR maintains DRG connection. This 
root connection provides anterograde BDNF transport from the periphery nerve, to 
primary afferent terminals in the dorsal horn, where it can sensitize dorsal horn 
neurones. Indeed L5 DRR does reduce L5 dorsal horn BDNF-ir (Zhou and Rush, 1996), 
compared to L5 VRR (Obata et al., 2004) and L5 SNT (Michael et al., 1999) that leads 
to an increase. Upregulation of BDNF within the L4 DRG, and corresponding 
neuropathic pain, were proposed to be due to Wallerian degeneration of L5 sensory 
fibres after PNI, that is absent after dorsal root or ventral root injury (Obata et al., 
2006b). Also NGF, a factor that controls the expression of many proteins such as 
TRPV1, CGRP, substance P, and BDNF, is upregulated in both intact and injured C-
fibre DRG neurones after ‘spared’ PNI, but only in injured C-fibres DRG neurones and 
not adjacent intact afferents after rhizotomy (Obata et al., 2004). NGF is also 
upregulated in the spared DRG, and implicated in sprouting, 6 days after extensive 
adjacent lumbar ganglionectomies in the cat (Zhou et al., 2009). BDNF and NGF have 
been shown to increase in the L4 intact DRG after selective L5 spinal nerve ligation 
(Fukuoka et al., 2001;Obata et al., 2004), and coincided with the development of 
hypersensitivity. Selective antibody blockage of these two growth factors ameliorated 
the hypersensitivity. It is implied that peripherally driven hypersensitivity after spared 
PNI, as well as peripheral inflammatory pain, is in part mediated through decrease in 
NGF competition between injured and intact axons (Fukuoka et al., 2001)(Fukuoka et 
al., 2001), increase in p38 MAPK activity through NGF, leading to BDNF expression in 
the intact DRG soma and terminals of the dorsal horn, modulating the processing of 
nociceptive information (Obata and Noguchi, 2006).  
 
Retrograde growth factor transport occurring in the intact L4 after SRA cannot yet be 
ruled out, as levels of BDNF and NGF in the L4 DRG are yet to be elucidated. BDNF 
and NGF are clearly important markers yet to be analysed in the DRG after L5 SRA 
before exclusively ruling out their contribution to peripherally driven neuropathic pain 
behaviour. 
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4.3.3.2: L5 SRA leads to neurodegeneration and neuroinflammation in the intact 
L4 spinal segment that mirror the effects in the deafferented L5 spinal segment 
 
Effects within the intact L4 segment significantly mirror the effects within the 
deafferented L5 segment, such that no difference can be quantified for dorsal horn 
neuronal loss, reduced endothelial labelling, and astroglial and microglial activation.  
This gives evidence to the argument that central neurodegenerative and 
neuroinflammation effects within a region adjacent to a localised deafferentation insult, 
could be a mechanism by which evoked neuropathic pain behaviour after SRA is 
generated. The effects could have 2 centrally mediated mechanisms. Firstly, a direct 
spread of reactive gliosis and degenerative phenomena may occur from the L5 segment 
that overlaps into the adjacent L4, through paracrine glial-glial activation (Milligan and 
Watkins, 2009). Secondly, degeneration of the L5 primary afferent terminals that 
terminate within the L4 segment (Shehab, 2009), and loss of avulsed L5 motor neurones 
that are anatomically located in the L4 ventral horn (Nicolopoulos-Stournaras and Iles, 
1983) most likely lead to these histological events in the adjacent L4 segment. This is 
also evident when observing the caudo-rostral degeneration of primary afferent fibres 
that progress through spinal segments in the dorsal columns up to the dorsal column 
nuclei (George and Griffin, 1994b). As there is yet no evidence to suggest a phenotypic 
change, or primary afferent or sympathetic sprouting in the L4 DRG and terminals after 
L5 root injury; the gliotic events, the neurodegenerative, vascular degeneration, and 
macrophage infiltration in the L4 segment are likely to be due principally to the above 
two points. 
 
4.3.3.2.1: Ventral horn  
 
Motor neuronal loss 
 
At 14 days post L5 SRA a loss of motor neurones is found in the ventral horn of the L5 
avulsed ventral horn are consistent with previous literature using cresyl violet, choline 
acetyltransferase, SMI32, and CTB-retrograde tracing (Koliatsos et al., 1994;Hoang et 
al., 2003;Bergerot et al., 2004;Penas et al., 2009). Percentage cell loss varied between 
authors (33-80%) due to different number of roots avulsed but also different labeling 
techniques. Motor neurone loss is variable depending on the method of staining used to 
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identify the cells in this thesis. Approximately 69% of ipsilateral motor neurones were 
absent from the cord compared to contralateral counts using NeuN 
immunohistochemistry and ~43% using Tol Blue in the L5 segment. The greater loss at 
14 days using NeuN staining to identify cells is likely due to loss of epitope expression 
in motor neurones, leading to a greater reduction in positive cell counts. Previous 
authors have already suggested that NeuN expression, and also with ChAT and other 
antibody markers, may not accurately represent the amount of cell loss, but rather 
reflect the physiological state of the neuron (McPhail et al., 2004a). However this may 
not just be a problem with antigens, as it has also been noted when using cresyl violet 
compared to SM132 immunohistochemistry at 28 days post avulsion (Penas et al., 
2009); the former underestimates the motor neurone loss. This may be due to loss of 
Nissl bodies within surviving neurones after lesion that reduces cresyl violet staining. 
Not only is there a discrepancy with staining methods, but also with the type of 
transection injury, where after distal axotomy of the ventral root after an initial loss of 
ChAT at 7 days, most motor neurones re-express this marker and survive up to 1 month 
(Rende et al., 1995;Matsuura et al., 1997). It may be due to levels of phosphorylated-
neurofilament from the axons that axotomised motor neurones accumulate compared to 
avulsed motor neurones which define the extent of cell survival (Koliatsos et al., 
1989;Penas et al., 2009), this may in turn be due to proximity of injury to cell body and 
extent of remaining axon connected to it. In this work, the NeuN epitope may be 
downregulated in the injured motor neurones before they are either dead or 
phagocytosed from the tissue. The Toluidine Blue dye will label all cells irrespective of 
whether they are living, as long as there is cytosol, and the cell membrane is intact. This 
suggests that a large population of motor neurones ~26% (difference between values) 
may be present in the ventral horn after injury, but are in the process of dying or being 
phagocytosed, and cannot be visualized using immunohistological techniques. Indeed, 
there is further significant motor neurone loss between 14 and 28 days (Penas et al., 
2009). The best way to represent this population of motor neurones is to use double 
labeling histology techniques, employing for example diaminobenzidine (DAB) 
visualisation of NeuN, colabelled with Tol Blue.  
 
The surprising loss of 47% (using NeuN) and 27% (using Tol Blue) of motor neurones 
in the L4 segment after L5 SRA is unlikely to be due to loss of L4 motor efferent fibres. 
If L4 motor neurones were dying, the ipsilateral locomotor function, which is solely 
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reliant upon the L4 root after L5 SRA, would not be so well maintained across 14 days. 
This loss most likely represents the population of avulsed L5 motor neurones that are 
anatomically located within the L4 segment (Nicolopoulos-Stournaras and Iles, 1983). 
HRP labeling of the soleus muscle in neonate rats, has indicated that L5 ventral root 
rhizotomy leads to loss of the lumbar motor neuronal pool and transmitter 
concentration, throughout the L5 and L4 segments (Lowrie et al., 1985), suggesting a 
large rostro-caudal intermingling of L4/L5 motor efferents that are not segregated to 
corresponding spinal segments, at least in young animals. It may also be possible to 
infer that the remaining motor neurones in the L5 segment after 14 days, could actually 
be labeling of neurones from L6 or L4 motor efferents, rather than surviving L5 motor 
neurones. Therefore, one way to identify definitively the remaining ‘true’ population of 
injured L5 efferents, is to induce a delayed injury to the L4 root 1 day prior to sacrifice, 
and label ATF3 to identify the rostrocaudal distribution of the intact L4 motor neurone 
pool, as it is rapidly upregulated within 12-24 hours after injury (Tsujino et al., 
2000;Shortland et al., 2006a). 
 
Gliosis and phagocytosis 
 
The upregulation of markers for astrocytes and microglia in the ventral horn specifically 
around motor neurone pools after avulsion, is consistent with previous literature 
(Ohlsson et al., 2006;Penas et al., 2009). Microglial cells appear to wrap up the soma of 
avulsed motor neurones in L5 and L4 segments. Microglial reactivity spreads over to 
the L5 contralateral side, and to a smaller extent in L4, in accordance with previous 
literature of root ligation and avulsion (Winkelstein and DeLeo, 2002;Penas et al., 
2009), and this is most likely through increased commissural interneuronal activity, that 
coordinates bilateral locomotor function (Eide et al., 1999), or through diffusible agents 
such as cytokines produced in the ipsilateral spinal cord (Penas et al., 2009). Microglia 
presented in both ramified and amoebic form suggesting distinctly different roles, in 
phagocytosis of neuronal debris (Streit and Kreutzberg, 1988), neuroprotection and 
regeneration (Aldskogius, 2001;Streit, 2002), and conversely neurodegeneration (Brown 
and Neher, 2010). Phagocytic microglia have a specific NADPH oxidase called 
phagocytic oxidase (PHOX), that when activated by cytokines or TNFα, for example, 
lead to phagocytosis (Brown and Neher, 2010). Phagocytic microglia have been 
observed surrounding axotomised facial motor neurones (Streit and Kreutzberg, 
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1988;Angelov et al., 1995). Microglia transiently upregulate pro-inflammatory 
cytokines, such as IL-1β, IL-6, TNFα, and heat shock proteins, that as well as 
hyperexciting neurones (Milligan and Watkins, 2009), can also be neuroprotective to 
axotomised facial motor neurones (Raivich, 2001), and motor neurones after SCI 
(Reddy et al., 2008). However, after CNS injury or ischemia microglia also produce 
neurotoxic compounds such as free radicals (Boje and Arora, 1992), glutamate (Giulian 
et al., 1993b;Giulian et al., 1993a) and complement components (Bellander et al., 
2001;Ohlsson et al., 2003) that lead to neuronal cell death (Brown and Neher, 2010). 
The controversy in the literature over the role of microglia in certain injury models, may 
be explained by different activation states of microglia that as yet cannot be 
physiologically characterized by histological labels such as Iba1.  
 
There is a clear difference in the extent of microglial activity compared to astrocyte 
reactivity, with the former expressing higher ipsilateral levels than the latter after L5 
SRA, compared to respective sham and contralateral values. Astrocyte reactivity can be 
seen as extensions of dendritic branching around motor neuronal pools of L5, clustering 
and tightly wrapping around motor neurones in accordance with previous literature 
(Ohlsson et al., 2006;Penas et al., 2009). This tight astrocyte-motor neurone correlation 
was not as obvious in the L4 segment however, rather an upregulation of GFAP 
expression in resident astrocytes was the key to increased density staining in this case. 
A small contralateral increase in GFAP is also noted in both segments similar to 
microglia, and in accordance with previous literature (Winkelstein and DeLeo, 
2002;Penas et al., 2009), and is likely to have similar underlying mechanisms of activity 
that involve commissural fibres or diffusible molecules originating from the ipsilateral 
cord. This robust microglial activity compared to a weaker astrocyte response has been 
shown before in facial motor neurone pools after transection (Graeber et al., 
1988b;Graeber et al., 1988a), and sciatic nerve ligation (Narita et al., 2006), and ventral 
root injury (Penas et al., 2009). The reason behind this inequality in activity between 
these glia is due to the observation that only microglial cells undergo mitosis and 
extensive proliferation early after motor neurone injury (Graeber et al., 1988a;Narita et 
al., 2006;Penas et al., 2009), and that hypertrophy and lamella process development of 
astrocytes is delayed, and absent of mitotic proliferative development (Graeber et al., 
1988b;Penas et al., 2009). Activated astrocytes may have a role, unique from microglia, 
in synaptic detachment around axotomised motor neurone cell bodies (Svensson and 
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Aldskogius, 1993) after SRA, providing a viable perisynaptic environment for 
synaptogenesis (Emirandetti et al., 2006), and in this way provides structural support for 
avulsed motor neurones and traumatized ventral horns, and prevention of inappropriate 
synaptic activation. Astrocytes may therefore protect remaining motor neurones and 
spinal tissue during the latter scarring period after an initial axotomy, whereas microglia 
are involved in early debris clearance and continuing immunity. Indeed as no severe 
loss of motor function occurred across 14 days, these glial effects within the ventral 
horn do not indicate detrimental activity.  
 
Punctate ED1 positivity was found in the L4 or L5 ventral horn at 14 days post SRA, 
with occasional clustering around motor neurones as observed previously (Koliatsos et 
al., 1994). However, the staining did not show morphology corresponding to that known 
to occur during phagocytosis. Interestingly, sciatic nerve CCI or transection causes an 
ED1 positive macrophage response in the ventral horn, without signs of typical 
phagocytic morphology or, strangely, cell loss (Hu et al., 2007). After extensive L5-S2 
ventral root avulsion at 28 days ED1 positive macrophages were seen in the ventral horn 
(Ohlsson et al., 2006), and was small and punctuate, similar to the staining described in 
this thesis. These results suggest that macrophages have little function in phagocytosis 
of motor neurones themselves after injury, but more likely phagocytose degenerating 
sensory 1a afferent fibres synapsing with the motor neurones. The question remains 
however, as to how the large motor neurone cell bodies are removed from the spinal 
cord after they die. Perhaps this can be explained by implication of an autophagic 
process (Lee, 2009) of motor neurones after root avulsion, that has been shown to occur 
to motor neurones after ischemic injury in vivo (Baba et al., 2009) and glutamate 
excitotoxicity in vitro (Matyja et al., 2005). These hypotheses, however, remain to be 
tested. 
 
Sham exposure of the L5 root leads to a small GFAP and Iba1 staining intensity 
increase in the ventral horn bilaterally. Typical structural changes of the glial cells, 
noted in SRA tissue, does not occur, rather an increase in epitope expression within 
cells is the key to increased density staining, similar perhaps to contralateral effects in 
SRA tissue. Increase in microglial and astroglial intensity staining in the ventral horn 
has been noted before in sham peripheral nerve exposure rat models as early as 3 days 
(Colburn et al., 1997), and also at 1-14 days after sham root exposure (Winkelstein and 
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DeLeo, 2002). L5 spinal root exposure could therefore be classified as a peripheral 
nerve injury in itself, such that it leads to increased glial reactivity in the ventral horn. 
However the manifestation of a mild and transient mechanical hypersensitivity in sham, 
is likely controlled by dorsal horn glial activity (Section 4.3.3.3.2). No ventral horn 
neuronal loss or locomotor impairment was noted in sham, and therefore these ventral 
horn glial effects are unlikely to be biologically significant.  
 
Endothelial staining loss 
 
Reduction of vascular integrity in the ventral horn after L5 SRA is an interesting new 
finding, and mirrors bilateral RECA-1 loss in the dorsal horn after L3-L6 DRA and L5 
SRA. This suggests that it is not the scale of deafferentation that defines permanent 
endothelial degradation, but the nature of trauma, such that avulsion prevents natural 
recovery of the spinal cord vasculature. As described in Chapter 3, it is likely that 
tensile stress on the spinal cord driven through avulsion forces, damages the spinal cord 
leading to vasculature disruption, in a similar way to traumatic SCI. However just as 
dorsal root avulsion could damage the single posterior spinal vein, through direct 
traction trauma or scarring (Section 3.3.6) damage to the single anterior spinal artery 
and vein that course along the anterior median fissure, and supplies the corresponding 
ventral portion of the cord, may explain the loss of RECA-1 endothelial staining in the 
ventral horn bilaterally after L5 SRA. It also explains the effects in the intact L4 
segment, as the anterior spinal artery contributes 75% of blood supply to the whole 
spinal cord (Grace and Mattox, 1977), and occlusion at one segment could effect the 
adjacent. This loss of vascular integrity could exacerbate motor neuronal loss through 
necrosis or secondary injury cascades (Nelson et al., 1977;Mautes et al., 2000). 
However as detrimental contralateral effects were not noted in either locomotor function 
or motor neurone loss, it is unlikely that the effects of RECA-1 immunostaining are 
functionally significant. Further RECA-1 staining does not give an appropriate 
determination of vascular integrity and ischemic effects on the ventral cord. More 
detailed analysis of blood flow through the arteries and veins that surround the spinal 
cord is required before conclusively implying trauma to the vascaular system and 
ischemia within neuronal tissue. 
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4.3.3.2.2: Dorsal horn 
 
Neuronal loss 
 
A small neuronal loss after L5 SRA was found in the superficial dorsal horn of L5. 
Neuronal loss was anatomically correlated with tissue cavitation and scarring located 
near the DREZ. Most neurones will be lost through this direct trauma of root avulsion in 
SRA similar to DRA (Chew et al., 2008). However, the loss in L4, albeit much smaller, 
represents perhaps transynaptic cell death within an intact segment. This could occur 
through caspase-dependent apoptosis initiated by ectopic activity from the spared 
afferents of L4, such as has been implicated for L5 spinal nerve injury (Scholz et al., 
2005), however there is no evidence to suggest injury-induced changes to L4 DRG 
neurones. Another possibility could be that cell death is initiated by loss of L5 primary 
afferent terminals, that synapse with second order dorsal horn neurones in the L4 
segment, though glutamate excitotoxicity from degenerating post synaptic membranes. 
It is well established in the rat and cat that afferent fibres enter the lumbar cord, send 
projections rostrally and caudally that terminate in laminae of adjacent segments, with 
an extensive overlap (Molander and Grant, 1985;Swett and Woolf, 1985;Smith and 
Bennett, 1987;Culberson and Brown, 1984;Rivero-Melian and Grant, 1990). Partial loss 
of the IB4 terminal ‘eyebrow’ in lamina II of the adjacent L4 segment indicates overlap 
of L5 primary afferents. However, colocalisation of NeuN and IB4 did not reveal 
anatomically correlated dorsal horn and primary afferent loss, suggesting that, at least 
with non-peptidergic terminals, terminal degeneration is unlikely to affect dorsal horn 
neuronal viability. A fibres and peptidergic C-fibres also need to be analysed in this way 
to say exclusively there is no transynaptic degenerative link between deafferented L5 
terminals and dorsal horn neurones. An alternative mechanism of cell loss could be via 
neuroinflammatory mediators, reactive oxygen species, cytotoxins, or glutamate (Boje 
and Arora, 1992;Giulian et al., 1993b;Giulian et al., 1993a;Tsuda et al., 2005). This 
neuroinflammation, involving microglia, could occur from spread of reactivity from the 
L5 segment, or via degeneration of the L5 terminals in L4, activating resident L4 
segment microglia (see later section on gliosis). Further work needs to be completed to 
ascertain whether the neuronal loss is restricted to any subpopulation of dorsal horn 
neurones, such as inhibitory GABAergic interneurones, and as such it is difficult to 
suggest the implication of this neuronal loss on evoked neuropathic behaviour.  
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This is the first evidence for dorsal horn neuronal loss found in the intact segment after 
an adjacent avulsion injury, and may have both peripherally and centrally mediated 
mechanisms underlying it. Further techniques, such as electrophysiology recordings 
from the dorsal horn (Ovelmen-Levitt et al., 1984), caspase staining (Scholz et al., 
2005), TUNEL staining (Chew et al., 2008), histological dyes such as Tol Blue (Section 
3.2.5.3), antibodies targeting subpopulations of dorsal horn neurones such as GABA 
(Drew et al., 2004), and apoptotic inhibitor administrations (Scholz et al., 2005), are 
required to ascertain subpopulation specific neuronal loss and assess its implications on 
behavioural hypersensitivity. 
 
Gliosis and phagocytosis 
 
After PNI, inflammation, and SCI, microglia become activated by a number of 
diffusible molecular pathways (Inoue and Tsuda, 2009;Marchand et al., 2005;Marchand 
et al., 2005;Zhang and De, 2006;Thacker et al., 2009), and is now confirmed in spinal 
root avulsion injury, in both spared (L4) and deafferented (L5) segments. 
 
Similar to the avulsion model, DRA, an increase in glial activity is noted in the dorsal 
horn 14 days after SRA, including a small contralateral increase. However, it is clear 
that the greater number of dorsal roots avulsed in DRA (four) leads to a more 
substantial gliopathy in the dorsal horn than SRA (one). There are noticeable 
differences in the extent of amoebic transformation of microglia between avulsed L5 
and spared L4 segmental levels, with mainly amoebic structure in the former and 
ramified in the latter. This is in accordance with experimental SCI models, where two 
different activation states of microglia are indicated (Watanabe et al., 1999). After L5 
SRA the first role is most likely focussed on a phagocytic response to degenerating 
primary afferent fibres and/or necrotic tissue, which will be greater in the avulsed L5 
segment than the L4. However, there is a potential for neurotoxicity (Tsuda et al., 
2005;Brown and Neher, 2010), and a mechanism of neuronal death in the intact and 
avulsed dorsal horns after SRA. The second role of the microglial reaction is that of a 
pro-inflammatory/neuroprotective characteristic, with a ramified activated form, 
predominating in the L4 segment. Such microglial-neuronal interaction has been linked 
in previous PNI models to the synthesis and release of TNFα (Lambertsen et al., 2009), 
HSP (Reddy et al., 2008), cytokines (IL-6 and IL-1β) (Marchand et al., 2005), and 
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PGE2 (Zhao et al., 2007), that generates a hyperexcitable dorsal horn neuronal 
population. The prolonged microgliosis in the L4 dorsal horn at 14 days, is suggestive 
of a substantial role in maintained central sensitisation mechanisms in the SRA model, 
that is contrary to established thinking of the early ‘microglial-astrocyte replacement 
mechanisms’ in PNI (Eriksson et al., 1993;Colburn et al., 1997;Raghavendra et al., 
2003), and is more reminiscent of ‘microglial-maintained’ pain after SCI (Hains and 
Waxman, 2006). This is perhaps the most important point when elucidating the etiology 
of avulsion pain. The reaction of microglia, within the dorsal horn L4 segment, provides 
evidence to suggest the neuropathic pain behaviour after avulsion injury is more closely 
related to central SCI-pain than PNI-pain, and perhaps treatment of this ailment should 
be directed at these central mechanisms. 
 
Macrophage activity is temporally linked to the development of hyperalgesia following 
nerve injury. This has been shown in rats with CCI, administered with liposome-
encapsulated dichloromethylene diphosphonate to deplete circulating macrophages (Liu 
et al., 2000b), as well as genetically modifying mice (C57BL/WLD) that have delayed 
macrophage recruitment and Wallerian degenerative progression and development of 
thermal hyperalgesia (Myers et al., 1996;Ramer et al., 1997). Shown here, 14 days after 
SRA, is a very specific macrophage response in the dorsal cord, with acute localisation 
within the dorsal white matter. This is in contrast to L3-L6 DRA where deep laminae 
were positive for punctate ED1 staining, suggesting multiple dorsal root avulsions lead 
to a greatly increased macrophage infiltration probably by increasing the surface area of 
the primary injury site for extravasation from the blood. This white matter localisation 
specificity at 14 days after single SRA suggests a limited role in phagocytosis of 
demyelinating primary afferents and neuronophagia in the dorsal horn at this time point, 
and also suggests limited role in the modulation of dorsal horn neuronal processing and 
the development of hypersensitivity. This finding greatly assists in the characterisation 
of microglial lineage within the dorsal horn after this spared root avulsion, as 
phagocytic microglia constitutively express ED1.  These immunohistological results 
suggest that activated microglia within the dorsal horn (and this is also true for the 
ventral horn) are more likely focussed on inflammatory responses, neuroprotection and 
innate immunity, and as a side effect, neuronal hypersensitisation (Thacker et al., 2007) 
in this particular model of avulsion within the spared L4 segment. However at the site of 
injury in the L5 segment after SRA, and also in the deafferented cord after L3-L6 DRA, 
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microglial pathology may shift toward phagocytic functions, as there is considerable 
overlap between IBa1 and ED1 histochemistry and morphology.   
 
Sham surgery leads to upregulation of GFAP in the dorsal horn, similar to the ventral 
horn. Previous nerve and root exposure surgery has been shown to lead to increased 
astroglial activity at 1, 3, and 7 days (Colburn et al., 1997;Winkelstein and DeLeo, 
2002), and it is likely responsible for the transient hypersensitivity noted after this 
surgery (Colburn et al., 1997;Hashizume et al., 2000a). Astrogliosis in the ipsilateral 
dorsal horn after SRA, similar to microgliosis, is much less severe than that seen after a 
more substantial injury (L3-L6 DRA). Astrocytes increase their expression of GFAP, 
and form a noticeable scar in the L5 DREZ; however in the L4 segment no scar is 
noticeable but cellular GFAP is upregulated compared to sham and naïve levels. This 
suggests astrocytes are indeed active in the adjacent segment at 14 days, and may 
contribute to the maintenance of avulsion induced neuropathic pain, as they do in PNI 
(Colburn et al., 1997;Raghavendra et al., 2003) and SCI (Gwak and Hulsebosch, 2009). 
However, relative expression of GFAP in SRA compared to sham (approximately 8% 
versus 6%) is far less than for microglia (approximately 10% versus 3%), perhaps 
suggesting a less obvious role in the neuropathic pain behaviour. Indeed, intrathecal 
injections of activated spinal microglia causes thermal hyperalgesia in naive mice, that 
did not occur for activated astrocyte injections in identical experiments (Narita et al., 
2006). Further, astrocytes caudal to a lesion to the spinal cord, do not express the typical 
MAP-kinase signaling cascade responsible for activation, and do not influence ‘below-
level’ pain maintenance, whereas microglia do (Gwak et al., 2009). It may therefore be 
the case in SRA, that shows relatively greater microglial than astroglial reactivity, that 
the former cells play a more direct and important role in neuropathic avulsion pain than 
the latter, but by how much is difficult to say without specific cell inhibition.  
 
Endothelial loss 
 
Reduction of vascular integrity in the dorsal horn 14 days after L5 SRA is in 
accordance with the bilateral RECA-1 expression reduction in the dorsal horn after a 
more substantial root avulsion such as L3-L6 DRA (Section 3.2.4). The loss of 
endothelial staining in these two avulsion models is likely to have a similar etiology. 
Posterior spinal vein disruption or occlusion after L5 SRA, as well as vasospasm 
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resulting from mechanical trauma of the avulsion (Mautes et al., 2000), may again lead 
to bilateral vascular degeneration in L5 and L4 segments. It is difficult to say whether 
the loss of endothelial staining is likely to cause extensive ischemia, as RECA-1 
immunostaining reduction was not linked to any obvious vessel depletion as was clear 
at 14-28 days in DRA (section 3.2.4), and it is likely that the spinal cord is still 
adequately perfused. In the case of SRA RECA-1 immunostaining reduction more 
likely represents reduced endothelial cell integrity, which could result in increased 
extravasation of leukocytes, elevating the inflammatory response and exacerbating 
hypersensitivity. However, this remains to be tested further.  
 
Little is known about the effect of PNI or root injury on the spinal cord vasculature, 
whereas SCI models have been used exclusively to study detrimental effects on 
microvasculature (Noble and Wrathall, 1987;Noble and Wrathall, 1989;Imperato-
Kalmar et al., 1997;Casella et al., 2002;Loy et al., 2002). Three to twenty four hours 
after contusion injury to the spinal cord extravasation is maximal within and 
surrounding the lesion site (Noble and Wrathall, 1989), and at 14 days it is markedly 
reduced, suggesting cellular extravasation plays only an acute role in pathogenesis of 
SCI. Disruption of the blood brain barrier in the SRA model could lead to extravasation 
of other inflammatory/immune cells including the lymphocytes T-cells and B-cells that 
play an important part in the adaptive immune response, and are found in the contused 
spinal cord at 3-6 hours and persist for 7 days (Popovich et al., 1997), and in the 
chronically constricted nerve at similar time points (Gomez-Nicola et al., 2008). The 
role of these immune cells in initiating or maintaining a neuropathic pain state after 
experimental injury is sparsely studied; however, it is well known that these cells can 
also generate inflammatory cytokines and chemokines and contribute to the innate 
immune/inflammatory response (Marchand et al., 2005) as well as further heightening 
dorsal horn neuronal responses. Confirmation of spinal cord vascular degeneration and 
leukocyte extravasation after SRA would benefit from more detailed examination of the 
microvasculature structural changes, as shown previously with electron-microscopy 
after traumatic brain injury (Dore-Duffy et al., 2000), and through intravital microscopy 
after SCI (Stirling et al., 2009). 
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4.3.3.2.3: Contralateral effects 
 
Significant contralateral effects were seen in microglial and astroglial reactivity, and 
loss of endothelial staining, both dorsally and ventrally. This is similar to results from 
L3-L6 DRA (section 3.2), but of less magnitude. These effects most likely occur via the 
same mechanisms in these injuries; including inflammatory mediator overspill from one 
side of the cord to the other, transneuronal mediation via interneurones or sprouting, or 
increase in systemic circulating factors (section 3.3.8). Contralateral effects in this case 
are anatomically but not functionally significant, as no hypersensitivity is noted in the 
contralateral paw. This suggests that histological evidence of glial reactivity may not 
accurately portray their functional activity, such that upregulation of specific markers 
does not necessarily mean increase in neuronal interaction; and/or, that hypersensitivity 
may require a specific level of glial or neuronal activity to initiate.  
 
4.3.4: Conclusion 
 
This chapter has characterised a new model of lumbosacral avulsion injury, 
behaviourally and histologically. Avulsion of the L5 spinal mixed root leads to 
development of thermal and tactile hypersensitivity, reduced weight gain, but without 
severe locomotor impairment, across 14 days. Hypersensitivity is maintained up to 60 
days. These results are suggestive of a neuropathic pain condition, and may represent 
the clinical scenario of root avulsion-induced pain. Histology indicated that the 
mechanisms of hypersensitivity are likely central in origin, specifically within the L4 
dorsal horn. Significant neuronal cell loss, endothelial immunoreactivity reduction, 
increased microglial reactivity and to a lesser extent astrogliosis, and macrophage 
infiltration, similar, but with a lesser magnitude to L3-L6 DRA, is shown. Considerable 
differences in cellular responses between deafferented and spared segments may 
determine different functionality, and is especially true in the case of microglia. Results 
suggest that in an injury such as avulsion, where mixed trauma is widespread, cannot be 
defined by common doctrine of separate PNI-induced and SCI-induced central 
sensitization. The cellular changes characterized here, present a testable hypothesis for 
mechanism of action of avulsion pain, which may depend on microglial/macrophage 
activity or dorsal horn neuronal loss, for example, and can be investigated through 
therapeutic inhibition of these histological and behavioural events.  
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Chapter 5: Validation of the L5 SRA pain model using clinically relevant 
analgesics 
 
5.1: Introduction  
 
5.1.1: Current therapeutic treatment for avulsion pain 
 
Current treatment for avulsion induced neuropathic pain is centered on the 
understanding that neuropathic pain is caused by pathologically hyperexcitable dorsal 
horn neurones (Loeser and Ward, Jr., 1967;Loeser et al., 1968;Ovelmen-Levitt et al., 
1984). Most notably and still most effective is the coagulation procedure, DREZotomy 
(Nashold, Jr. and Ostdahl, 1979) of the superficial dorsal horn and root entry zone. 
Recently, reconstructive surgery through root grafting has had notable success at 
alleviating the pain (Berman et al., 1998;Terzis et al., 1999;Htut et al., 2006;Bertelli and 
Ghizoni, 2008), although motor functional restoration for brachial (Carlstedt et al., 
2000) (Carlstedt et al., 2004;Htut et al., 2006)and lumbosacral (Lang et al., 
2004;Sivaraman et al., 2008) roots is the main surgical objective. Even more recently 
spinal cord stimulation (SCS) above the site of lesion has shown to be effective at 
relieving brachial plexus pain after failed DREZotomy (Piva et al., 2003;Lai et al., 
2009) perhaps through activating the descending inhibitory systems and GABAergic 
inhibition. 
 
For patients that have failed to respond to DREZotomy and/or surgical repair, or have 
established neuropathic pain, the preferred option would be an effective 
pharmacological treatment regime. Additionally, for patients in the acute stages of the 
condition early pharmacological intervention would be used as a preventative measure 
for the development of neuropathic pain. So far, however, many drug types have had 
little therapeutic efficacy on their own (Parry, 1980;Piva et al., 2003). Recently in a 
rodent model of brachial plexus pain several drugs were used to characterise possible 
further treatment options (Rodrigues-Filho et al., 2004). These included an opioid 
agonist (morphine), an alpha2 adrenoceptor agonist (clonidine), an NMDA antagonist 
(ketamine), an anticonvulsant (gabapentin), a COX-2 inhibitor (celecoxib), a Na2+ 
channel blocker (lidocaine), a non-steriodal anti-inflammatory (diclofenac), a steroidal 
anti-inflammatory (dexamethasone), and an anti-depressant (imipramine). Morphine, 
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clonidine, ketamine and gabapentin prevented ‘below level’ avulsion-associated 
mechanical and cold allodynia suggesting many drugs currently on the market could be 
suitable candidates for clinical trials into avulsion pain. However this model does not 
accurately describe clinical avulsion pain, as patients do not complain of pain in the 
lower limb after brachial plexus avulsion, and therefore conclusion drawn from these 
results are, at best, limited. 
 
Certainly, some conventional drugs have been shown to be at effective, at least in the 
short term for the treatment of avulsion pain. These include the opiate, morphine, which 
has had some success at alleviating avulsion pain (Schmidt and Schmidt, 2004). The µ 
and δ opioid receptors are found pre-synaptically in the superficial dorsal horn C-fibre 
terminal zone (Dickenson and Suzuki, 2005). Therefore mechanisms of action of 
morphine could be in pre-synaptic neurotransmitter release inhibition from ectopic 
adjacent intact roots (Bertelli and Ghizoni, 2008;Finnerup et al., 2009), as well as supra-
spinally in the raphe nuclei, periaqueductal grey, and locus coeruleus (Dickenson and 
Suzuki, 2005) at the chronic stages of injury. This is however still unclear. 
Cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown 
efficacy in brachial plexus injury patients (Berman et al., 2004), through reducing pain 
scores and improving sleep, thereby improving quality of life.  
 
It has been the case for a long time that antidepressants (amitriptyline) and 
anticonvulsants/antiepileptics (carbamazepine, gabapentin, and pregabalin) have 
become the mainstay treatment of neuropathic pain conditions, including trigeminal 
neuralgia, cancer pain, diabetic and HIV neuropathy, and post operative pain (Rogawski 
and Loscher, 2004;Sindrup et al., 2005;Saarto and Wiffen, 2007). They are usually the 
first treatment regime for brachial plexus avulsed patients (Berman et al., 1998;Schmidt 
and Schmidt, 2004;Flores, 2006) but in most cases have only limited efficacy (Parry, 
1980;Berman et al., 1996;Piva et al., 2003). When high doses are used side effects such 
as rash, ataxia, and sedation are common (Rapeport et al., 1984), and for this reason 
these drugs have to be used in conjunction with other medications (Schmidt and 
Schmidt, 2004). Efficacy of these drugs is increased if the patient has undergone 
reconstructive surgery for the avulsed root (Berman et al., 1998), however in more 
chronic cases of avulsion, sometimes at 10 years, these drugs show no analgesic 
properties (Schmidt and Schmidt, 2004). 
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Amitriptyline 
 
Amitriptyline, a tricyclic antidepressant (TCA), was originally used for the treatment of 
depression; however the patient usually has to wait up to 2-4 weeks for effective relief. 
Typical adult doses for brachial plexus injured patients are 25-150mg orally daily, at 
night (Schmidt and Schmidt, 2004) to improve quality of sleep. Prolonged treatment is 
not recommended due to the propensity for its anticholinergic side effects including dry 
mouth, sweating, drowsiness, muscle stiffness, nausea, dizziness, constipation and 
urinary retention (Sindrup et al., 2005;Saarto and Wiffen, 2007). The analgesic 
properties of TCAs were noted more than 40 years ago and introduced as an effective 
treatment for painful diabetic neuropathy more than 30 years ago (Davis et al., 1977). 
The rational for the use of amitriptyline in neuropathic pain conditions may be due to its 
multimodal action at the level of the brain, brain stem, and the spinal cord, and its 
actions appear independent of its efficacy in depression relief (Sindrup et al., 
2005;Bomholt et al., 2005).  
 
Amitriptyline is able to effectively block both TTX-resistant and TTX-sensitive sodium 
channels in peripheral nerves (Brau et al., 2001;Dick et al., 2007;Leffler et al., 2007;Hur 
et al., 2008;Su et al., 2009), and this inhibition is likely to contribute to its analgesic 
effect. There are many other proposed modes of amitriptyline action for pain relief, 
including inhibition of NMDA receptors preventing central sensitization (Watanabe et 
al., 1993), NK1 receptor antagonism preventing substance P-mediated sensitization 
(Boselli et al., 2007), biogenic amine receptor antagonism reducing peripheral 
inflammation and odema (Sawynok and Reid, 2003), enhancement of endogenous 
adenosine tone producing antihyperalgesic effects to thermal stimulation (Esser and 
Sawynok, 2000), inhibition of M1 muscarinic acetylcholine receptors (Choi and 
Mitchelson, 1994) and nicotinic acetylcholine receptors (Freysoldt et al., 2009) 
implicated in C-fibre mediated nociception. There is also evidence to suggest a non-
neuronal effect of amitriptyline, such that it can cause upregulation of EAA transporter 
channels (1 and 2) in glia after PNI, increasing glutamate clearance from dorsal horn 
and alleviating mechanical allodynia (Mao and Yang, 2010). All these receptors have a 
role in nociceptive, neuropathic or inflammatory pain. However, the effect of 
amitriptyline is transient in these cases, and is directly linked with the clearance 
properties of the drug. There is also some evidence that the analgesic properties of 
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amitriptyline can be permanent if the treatment is maintained. For example, 
amitriptyline’s actions on opioid receptors, include increasing binding sites expressed in 
the spinal cord after prolonged (10mg/kg for 14 days) treatment (Hamon et al., 1987). 
Further evidence for amitriptyline’s actions on the endogenous opioid system, is that 
CCI-induced neuropathic pain, attenuated by amitriptyline treatment, is acutely reversed 
with the addition of delta or kappa-opioid antagonists (Benbouzid et al., 2008).  
 
Direct evidence for the analgesic qualities of amitriptyline come from neuropathic pain 
animal models, such as sciatic nerve crush, CCI, spared nerve injury, and spinal nerve 
ligation (Decosterd et al., 2004;De Vry et al., 2004;Bomholt et al., 2005;Song et al., 
2008;Su et al., 2009;Mao and Yang, 2010). There seems to be a dose dependent action 
of amitriptyline as well as stimulus dependent (mechanical or thermal) amelioration in 
neuropathic pain models. A range of doses have been explored for efficacy between 3-
30mg/kg i.p. (Decosterd et al., 2004;Bomholt et al., 2005) and 32-128mg/kg p.o. (De 
Vry et al., 2004) following the establishment of PNI-induced neuropathic pain. The 
results in these investigations showed that amitriptyline had no effect on alleviating 
established mechanical allodynia, but successfully attenuated thermal hyperalgesia dose 
dependently at 30mg/kg and above. All analgesic effects were short acting (180min 
maximum) corresponding to the drugs half-life and clearance qualities of these acute 
doses. However, amitriptyline at just 2mg/kg, delivered via intravenous injection, 
successfully inhibits the ectopic discharges within primary afferents after L5/L6 spinal 
nerve ligation, and ameliorates mechanical allodynia (Su et al., 2009). Prolonged 
treatment at 10mg/kg twice daily for 5 days also alleviates mechanical allodynia (Mao 
and Yang, 2010) suggesting analgesic effects directly depend on the type of nerve 
injury, dosing regimes, and mode of delivery. 
 
Carbamazepine 
 
Carbamazepine is an anti-convulsant drug used in the treatment of epilepsy. It is also 
licensed in the U.S.A. as a first line treatment for patients with trigeminal neuralgia, and 
is also effective in traumatic and diabetic neuropathic pain treatment, neuromuscular 
disorders, migraine, and psychiatric disorders (McQuay et al., 1995;Rogawski and 
Loscher, 2004). A typical dose for brachial plexus injured patients is 1200mg/day 
(Schmidt and Schmidt, 2004). The pharmacological mechanism of action of 
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carbamazepine is ‘cleaner’ than that of amitriptyline, and involves inhibition of sodium 
channel function in the periphery and centrally (Spina and Perugi, 2004). As such, 
carbamazepine exhibits its anti-epileptic and anti-nociceptive properties by selectively 
blocking high frequency TTX-resistant voltage gated sodium channels (Rogawski and 
Loscher, 2004;Dick et al., 2007;Hur et al., 2008).  
 
The use of carbamazepine in the treatment of trigeminal neuralgia pain is now well 
established after its first introduction in 1962 (BLOM, 1962), and nowadays provides 
70-80% of patients with acute pain relief; however, this figure is reduced to 50% when 
looking at long term efficacy (Spina and Perugi, 2004). Clinical trials have shown 
efficacy at doses between 100 to 1200mg per day for neuropathic pain conditions in a 
dose-dependent manner but, like amitriptyline, discontinuation is recommended after 2-
3 months to prevent toxicity and side effects such as drowsiness, nausea, and blurred 
vision (Spina and Perugi, 2004). Carbamazepine exerts a central and peripheral use-
dependent inhibition of sodium channels and is effective in both evoked and ectopic 
peripheral neuronal activity (Chapman et al., 1998). The success of carbamazepine in 
the treatment of trigeminal neuralgia has led to carbamazepine being tested in various, 
randomised, double-blind controlled trials for a range of neuropathic pain conditions, 
including diabetic neuropathy, post-herpatic neuralgia, stroke, and autoimmune 
demyelinating disorders such as Guillain-Barre syndrome (Jensen, 2002;Spina and 
Perugi, 2004), as well as in the treatment of brachial plexus injury pain (Berman et al., 
1998;Schmidt and Schmidt, 2004;Flores, 2006).  
 
PNI animal models have shed light on the effects of carbamazepine on behavioural 
neuropathic pain. After spinal nerve ligation, 22.5mg/kg subcutaneous carbamazepine 
treatment reversed mechanical allodynia, with its mechanism of action centred on 
inhibition of C- and A-fibre neuronal responses (Chapman et al., 1998). Thermal 
hyperalgesia was strongly attenuated, and mechanical allodynia moderately attenuated, 
by 32mg/kg i.p. carbamazepine treatment after CCI (De Vry et al., 2004) and 
mechanical allodynia was attenuated after chemotherapy-induced (vincristine 
administered) neuropathic pain (Lynch, III et al., 2004). However, carbamazepine has a 
relatively low therapeutic index (LD50/ED50) compared to other analgesics, which 
increases the potential for toxicity (Lynch, III et al., 2004). Like amitriptyline, a dose 
dependent efficacy is seen for carbamazepine, where an optimum therapeutic dose is 
  223 
between 32 and 64mg/kg i.p., and maximal therapeutic efficacy at a dose of 64mg/kg 
i.p. for treatment of sciatic nerve ligation-induced neuropathic pain (De Vry et al., 
2004). At this maximal dose however, 3/11 of the rats were unable to complete the 
behavioural testing due to side effects (De Vry et al., 2004). In patients drowsiness is a 
well recognised side effect and is the reason for prescribing the drug to be taken at 
night.  
 
5.1.2: Aims 
 
As a proof of concept of the L5 SRA as a model of avulsion injury, it was important to 
establish that current pain relieving drugs, in this case amitriptyline and carbamazepine, 
used for brachial plexus pain would have efficacy on the SRA model as previously 
shown in PNI models (Chapman et al., 1998;Decosterd et al., 2004;De Vry et al., 
2004;Bomholt et al., 2005), and to confirm effects seen in human brachial plexus injury 
(Berman et al., 1998;Schmidt and Schmidt, 2004;Flores, 2006). Doses of 32mg/kg and 
64mg/kg were chosen in accordance with previous literature on CCI injury and effective 
doses (De Vry et al., 2004;Bomholt et al., 2005). The aim was to assess the effects of a 
delayed, single dose treatment of i.p. administered amitriptyline and carbamazepine 
when behavioural hypersensitivity was already well established, following L5 spinal 
root avulsion. Differences in efficacy of amitriptyline and/or carbamazepine between 
two different doses, 32mg/kg and 64mg/kg, will be explored, against possible side 
effects of drowsiness and hypoalgesia. Suitable time points (3 and 6 days) between 
treatments would allow full clearance of the drugs from prior testing points. 
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5.2: Results 
 
5.2.1: Vehicle treatment after L5 SRA 
 
For the vehicle treated SRA group, ipsilateral thermal hypersensitivity was significantly 
established against both baseline values (9.57s +/- 0.38) and contralateral values (9.78 
+/-0.59) by 5 days post injury (5.97s +/-0.43) (Fig 5.1A).  
 
Ipsilateral mechanical hypersensitivity was significantly established against baseline 
values (20.3g +/-1.43) by 5 days (15.0g +/-2.23) and from both baseline and 
contralateral values (20.4g +/-1.77) at 7 days (15.8g +/-0.73) (Fig 5.1B). Withdrawal 
thresholds to tactile stimulation showed further reduction across the period of 25 days; 
where withdrawal values reached a low of 8.42g (+/- 0.59) (Fig 5.1B).  
 
Withdrawal thresholds to thermal stimulation remained significantly lower than baseline 
and contralateral hindpaw withdrawal values for up to 25 days (4.64s +/-0.45) (Fig 
5.1A), again consistent with previous data (section 4.2.1b).  
 
No changes to contralateral withdrawal thresholds were recorded in this vehicle group. 
Importantly, i.p. vehicle injection did not cause any change in the progression of 
ipsilateral neuropathic pain behaviour on the day of injection or any days prior, for 
either thermal or tactile stimulation. This is the case for all 3 injections. 
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Figure 5.1: Effects of vehicle treatment on behavioural hypersensitivity. Treatment with vehicle does 
not ameliorate ipsilateral behavioural hypersensitivity to thermal (A) or mechanical (B) stimulation at any 
3 administrations (indicated by the arrows). Significant differences are indicated for ipsi vs contra (x) and 
against baseline (#). N = 6/ group.  
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5.2.2: Amitriptyline treatment after L5 SRA 
 
Amitriptyline treated SRA rats became hypersensitive to mechanical stimulation by 5 
days (14.4g +/-1.76) compared to baseline and contralateral levels and reached 13.2s 
(+/-1.20) on day 7 (Fig 5.2A). Thermal hypersensitivity was apparent at 5 days (6.26s 
+/-0.36) compared to baseline, and maintained at 7 days (6.58s +/-0.53) (Fig 5.3A). 
 
First treatment: On day 11, 1 hour after treatment with 32mg/kg amitriptyline, 
ipsilateral withdrawal responses for thermal (6.36s +/-0.96) and mechanical (17.5g +/-
3.81) stimulation were not significantly difference from contralateral and baseline 
values (Fig 5.2A and 5.3A). No significant difference was seen against vehicle injection 
(Fig 5.2B and 5.3B). No contralateral change was noted. On day 13 hypersensitivity to 
both thermal and mechanical stimuli returned such that the ipsilateral withdrawal 
responses (mechanical: 11.9g +/-1.49, and thermal: 5.36s +/-0.67) were significantly 
lower than baseline and contralateral levels in each case (Fig 5.2A and 5.3A). 
 
Second treatment: On day 14, 1 hour after a second treatment with 32mg/kg 
amitriptyline ipsilateral withdrawal responses (18.7g +/-3.01 for tactile and 9.01s +/-
1.59 for thermal) were not significantly difference from contralateral and baseline 
values (Fig 5.2A and 5.3A). No significant difference was found between vehicle and 
amitriptyline for thermal hypersensitivity, but a significant amelioration of mechanical 
hypersensitivity against vehicle levels was found (Fig 5.2B). On day 18 both thermal 
and mechanical hypersensitivity again returned, such that the ipsilateral withdrawal 
responses (mechanical: 12.6g +/-1.03, and thermal: 5.39s +/-0.35) were significantly 
lower than baseline and contralateral levels in each case (Fig 5.2B and 5.3B). 
 
Third treatment: On day 20, 1 hour after a third treatment with an increased dose of 
amitriptyline (64mg/kg) all significant differences from contralateral and baseline levels 
were again abolished and returned to 21.4g (+/-1.14) for mechanical withdrawal and 
10.2s (+/-1.05) for thermal withdrawal (Fig 5.2A and 5.3A). There was a significant 
amelioration of ipsilateral hypersensitivity against vehicle levels (mechanical: 10.3 +/-
1.54, and thermal: 5.57s +/-0.31) (Fig 5.2B and 5.3B). On day 21 and day 25 
hypersensitivity, significant against all comparisons, returned to levels identical to 
vehicle (Fig 5.2B and 5.3B). 
  227 
 
 
 
 
Figure 5.2: Effects of amitriptyline on mechanical hypersensitivity. Treatment with amitriptyline 
significantly reverses tactile hypersensitivity against contralateral and baseline values (A) and against 
vehicle levels (B) 1 hour post administration (indicated by the arrows). It is most effective on a repeated 
dose of 32mg/kg and 64mg/kg, without significant contralateral effects. Significant differences are 
indicated for ipsi vs contra (x), against baseline (#), and against vehicle (*). N = 6 in each group. 
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Figure 5.3: Effect of amitriptyline on thermal hypersensitivity. Treatment with amitriptyline 
significantly reverses thermal hypersensitivity against contralateral and baseline values (A) and against 
vehicle levels (B) 1 hour post administration (indicated by the arrows). It is only effective on a repeated 
dose of 32mg/kg and 64mg/kg, without significant contralateral effects. Significant differences are 
indicated for ipsi vs contra (x), against baseline (#), and against vehicle (*). N = 6 per group. 
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5.2.3: Carbamazepine treatment after L5 SRA 
 
The carbamazepine-treated SRA group became significantly hypersensitive to 
mechanical stimulation at 7 days (15.3g +/-1.71) compared to baseline (21.5g +/-0.61) 
and contralateral (21.3g +/-0.64) levels (Fig 5.4A). Significant ipsilateral 
hypersensitivity to thermal stimulation was apparent at 5 days (6.34s +/-0.74) but only 
compared to baseline, and this was maintained at 7 days (6.14s +/-0.71) (Fig 5.5A). A 
contralateral thermal hypersensitivity was seen on days 5, 7, 13, 18, that was not present 
for mechanical stimulation, and was not related to drug administration (Fig 5.4A and 
5.5A). This contralateral effect to thermal stimulation is anomalous as it was not seen 
for other groups of rats. 
 
First dose: On day 11, 1 hour after treatment with 32mg/kg carbamazepine ipsilateral 
withdrawal responses (mechanical: 20.6g +/-2.15, and thermal: 7.15s +/-0.55) were not 
significantly different from contralateral and baseline values (Fig 5.4A and 5.5A). There 
was a significantly greater mechanical withdrawal threshold ipsilaterally for 
carbamazepine treated group compared to vehicle-treated at this time point (Fig 5.4B). 
However, no significant difference was noted for thermal withdrawal thresholds 
between treated and vehicle treated rats at this time point (Fig 5.5B). A change in 
contralateral levels was seen with this first treatment time point for thermal withdrawal 
such that it was no longer significantly different to the baseline value (Fig 5.5A). On 
day 13 hypersensitivity to both thermal and mechanical stimulation returned such that 
the ipsilateral withdrawal responses (mechanical: 15.1g +/-1.67, and thermal: 5.81s +/-
0.45) were significantly lower than baseline and contralateral levels in each case (Fig 
5.4A and 5.5A). For contralateral thermal withdrawal latency, this returned to 
significant difference from baseline (Fig 5.5A). 
 
Second dose: On day 14, 1 hour after a second treatment with 32mg/kg carbamazepine, 
ipsilateral withdrawal responses (mechanical: 20.9g +/-2.45, and thermal: 7.61s +/-1.11) 
again were not significantly difference from contralateral and baseline values in the case 
of mechanical hypersensitivity, however ipsilateral responses to thermal stimulation still 
showed significant hypersensitivity (Fig 5.4A and 5.5A). Again there was a 
significantly greater mechanical withdrawal threshold ipsilaterally for carbamazepine 
treatment group over vehicle (Fig 5.4B). However, no significant difference was found 
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ipsilaterally between vehicle treatment and carbamazepine treatment for thermal 
withdrawal levels (Fig 5.5B). Again, a change in contralateral levels was seen with this 
first treatment time point for thermal withdrawal such that it was no longer significantly 
different to the baseline value (Fig 5.5A). On day 18 hypersensitivity to both thermal 
and mechanical stimulation again returned such that the ipsilateral withdrawal responses 
(mechanical: 13.4g +/-1.29, and thermal: 5.84s +/-0.33) were significantly lower than 
baseline and contralateral levels in each case (Fig 5.4A and 5.5A). For contralateral 
thermal withdrawal latency, this returned again to a hypersensitive level compared to 
baseline (Fig 5.5A). 
 
Third dose: On day 20, 1 hour after a third treatment with an increased dose of 
amitriptyline (64mg/kg) all significant differences from baseline levels were again 
abolished and returned to 20.1g (+/-1.67) for mechanical withdrawal and 9.13 (+/-0.63) 
for thermal withdrawal (Fig 5.4A and 5.5A). Contralateral effects were seen for 
mechanical and thermal stimulation, with significantly increased withdrawal thresholds 
compared to baseline in both cases (Fig 5.4A and 5.5A). There was a significant 
amelioration of ipsilateral hypersensitivity against vehicle levels for both mechanical 
and thermal stimulation (Fig 5.4B and 5.5B). On day 21 and day 25 ipsilateral 
hypersensitivity, significant against all comparisons, returned to levels identical to 
vehicle, and contralateral values were not significantly different from baseline (Fig 5.4B 
and 5.5B). 
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Figure 5.4: Effect of carbamazepine on mechanical hypersensivity. Treatment with carbamazepine 
significantly reverses tactile hypersensitivity against contralateral and baseline values (A) and against 
vehicle levels (B) 1 hour post administration. It is effective at all doses. A significant contralateral 
hyposensitivity is noted 1 hour after 64mg/kg dose but is absent 24 hours later. Significant differences are 
indicated for ipsi vs contra (x), against baseline (#), and against vehicle (*). N = 6 in each group. 
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Figure 5.5: Effect of carbamazepine on thermal hypersensitivity. Treatment with carbamazepine 
significantly reverses thermal hypersensitivity against baseline values (A) and against vehicle levels (B) 1 
hour post administration. However a contralateral hypersensitivity prevents intra-group comparison 
between hindpaw responses in the carbamazepine group (A). Carbamazepine is only significantly effective 
at ameliorating hypersensitivity on a third and increased dose of 64mg/kg. Significant differences are 
indicated for ipsi vs contra (x), against baseline (#), and against vehicle (*). N = 6 in each group. 
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5.3: Discussion 
 
5.3.1: Effects of Amitriptyline and Carbamazepine on SRA-induced evoked 
neuropathic pain behaviour  
 
In accordance with section 4.2.1b, behavioural hypersensitivity to thermal and tactile 
stimulation becomes significant by 5-7 days after L5 SRA injury. This has provided an 
opportunity to test conventional therapeutic treatment for neuropathic pain, in an animal 
model of root avulsion injury that reliably produces an evoked hypersensitivity.  
 
In the case of thermal hypersensitivity, significant amelioration is found for both 
carbamazepine and amitriptyline in accordance with the previous literature (Decosterd 
et al., 2004;De Vry et al., 2004;Bomholt et al., 2005). The effective dose is 32mg/kg. 
This dose is higher than that which is required to ameliorate PNI-induced behavioural 
pain, and this observation perhaps indicates a greater severity and intractability of the 
neuropathy after root avulsion compared to PNI.  
 
For the amelioration of mechanical hypersensitivity, carbamazpeine is effective on the 
first dose at 32mg/kg. Further increase in carbamazepine dose to 64mg/kg causes no 
further change in evoked hypersensitivity ipsilaterally, and leads only to contralateral 
hyposensitivity in accordance with previous literature suggesting a sedatory effect (De 
Vry et al., 2004;Lynch, III et al., 2004). The effectiveness of amitriptyline treatment at 
ameliorating mechanical hypersensitivity induced by SRA 1 hour post injection, is in 
accordance with recent literature on spared nerve injury and spinal nerve ligation rat 
models (Su et al., 2009;Mao and Yang, 2010), but is contradictory with earlier literature 
that indicates it can only alleviate thermal hypersensitivity (Decosterd et al., 2004;De 
Vry et al., 2004;Bomholt et al., 2005). This discrepency may be due to different injury 
models used, the variable methods of cutaneous mechanical stimulation, and also due to 
different mode of drug delivery.  
 
In all cases the effects of the drugs are transient, lasting less than 24 hours relating to the 
clearance of the drugs. In man carbamazepine and amitriptyline have biological half-
lives of approximately 35 hours (Bertilsson, 1978) and 24 hours (Schulz et al., 1985) 
respectively, when delivered orally and on the first administration. In the case of 
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carbamazepine this becomes shorter after repeated doses, due to enzyme ‘auto 
induction’ of the drug in the liver (Bertilsson, 1978), and this is one pathway to 
tolerance and side effects, as doses have to be increased. In rats the CNS biological half-
life is much shorter, at 3.4 hours for carbamazepine (Graumlich et al., 2000) and 1.6 
hours for amitriptyline (Coudore et al., 1996) after i.p administration. This is due to 
greater metabolisms and clearance in the kidneys, mode of administration, and 
magnitude of dose. This means that to maintain efficacy, drug administration would 
have to be performed approximately every 2 hours, as efficacy is lost after this period.   
 
In the case of amitriptyline, significant analgesic effect requires repeated dosing at 
32mg/kg, although a trend is shown on the first dose for tactile hypersensitivity 
amelioration. It is unclear why a second identical dose is more efficacious, as the 
previous dose would have been systemically cleared preventing any synergistic 
response between doses. Carbamazepine, on the other hand, does not require a second 
dose for efficacy and further signifies the difference in complexity of mechanism of 
action between these two drugs; with amitriptyline involved in a polymechanistic 
approach to analgesia, acting on a multitude of receptors, and carbamazepine specific to 
sodium channels. Perhaps initial dosing at 32mg/kg of amitriptyline heightens 
downstream signaling processes incuding receptor transcription and translocation, such 
as been shown it the accumulation of opioid receptors in the spinal cord (Hamon et al., 
1987). This is more likely to create a permanent physiological effect, priming the spinal 
cord for the next dose. This may indeed be the mechanism of action of amitriptyline 
when used clinically for depression. Patients take low doses of these drugs (25-
150mg/day representative of ~2.14mg/kg for a 70kg man) in comparison to larger doses 
in pre-clinical rodent models, due to the side effects, but importantly they do not 
experience efficacy for the first few weeks, suggesting an indirect mechanism of action 
of amitriptyline on the CNS, which is likely increased receptor translation and 
expression. This is not the case for carbamazepine, with sodium channel inhibition the 
primary mechanism of efficacy, and is why a similar magnitude of dose between 
clinical (1200mg/day representative of ~17.1mg/kg in man) and pre-clinical rodent 
models is seen. 
 
Side effects 
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Behavioural side effects were noted at 64mg/kg doses for carbamazepine, without 
effects for the same volume in the vehicle treated group, or for amtriptyline. With 
64mg/kg of carbamazepine a significant hypoalgesia occurred contralaterally, with an 
increase in withdrawal to tactile stimulation significantly above basal levels. This is in 
accordance with De Vry et al., (De Vry et al., 2004) who showed withdrawal 
unresponsiveness and sedation in 3 out of 11 rats behaviorally tested at this dose for 
carbamazepine. This is not a systemic sedatory effect, as no hypoalgesia is noted after 
thermal stimulation at 64mg/kg, and may just be linked to channel inhibition associated 
with tactile sensation in the dorsal horn or in cutaneous receptors. This however remains 
to be tested. Without testing lower doses of these two drugs (e.g. 8 and 16mg/kg) 
obtaining a correct therapeutic index dosing for avulsion pain is difficult, but clearly a 
dose between 32 and 64mg/kg is effective at ameliorating the hypersensitivity. 
 
Contralateral effect 
 
The contralateral thermal hypersensitivity in the carbamazepine group on days 5, 7, 13, 
and 18, irrespective of treatment, may suggest that in some cases contralateral effects 
may occur with SRA similarly to PNI (Arguis et al., 2008;Hatashita et al., 2008), dorsal 
root injury (Hunt et al., 2001;Rothman et al., 2009), and others (Koltzenburg et al., 
1999;Chang et al., 2010). The amelioration of this contralateral hypersensitivity on days 
11, 14, and 20 after carbamazepine administration confirms this effect is not simply an 
anomaly or human sampling error. These effects are not as significant as seen 
ipsilaterally, and are not maintained at days 21 and 25, suggest a mild and transient 
contralateral effect. It is unknown why this contralateral effect is only found in this 
group, and only in this trial, and may be due to unrelated housing conditions and stress 
for these specific animals. 
 
5.3.2: Conclusion 
 
The analgesic effects of amitriptyline and carbamazepine in this model of avulsion 
injury confirms the analgesic effects seen pre-clinically in PNI (Decosterd et al., 
2004;De Vry et al., 2004;Lynch, III et al., 2004;Bomholt et al., 2005;Song et al., 
2008;Su et al., 2009;Mao and Yang, 2010), and clinically for many types of neuropathic 
pain conditions (Davis et al., 1977;Sindrup and Jensen, 2002;Rogawski and Loscher, 
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2004;Sindrup et al., 2005). The inability of these drugs to maintain efficacy beyond 
wash-out in SRA animals provides evidence for why these drugs are ineffective at 
alleviating root avulsion-induced neuropathic pain in the long term. Further, these 
effects provide a pharmacological validation of the establishment of the rodent SRA 
injury, as an experimentally viable model for the study of avulsion pain mechanisms. 
These results now enable pharmacological characterization of more experimental drugs 
that may potentially be of more therapeutic benefit for the treatment of avulsion injury 
pain. 
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Chapter 6: Effects of immediate and delayed minocycline and riluzole treatment of 
SRA-induced behavioural hypersensitivity 
 
6.1: Introduction 
 
6.1.1: Limitations of current neuropathic pain therapy 
 
Drugs described as ‘first line’ treatment of neuropathic pain, such as anticonvulsants 
(e.g carbamazepine), TCAs (eg. amitriptyline), serotonin reuptake inhibitors (eg. 
paroxetine) and opioids (eg. morphine), that act on neurones directly through receptor 
and channel expression and activity, show some level of efficacy for the treatment of 
SCI (Baastrup and Finnerup, 2008) and PNI (Stacey, 2005) pain; however, fail to 
produce long lasting pain relief in plexus avulsion injury patients (Parry, 1980;Berman 
et al., 1996;Piva et al., 2003;Schmidt and Schmidt, 2004), or produce unacceptable side 
effects at efficacious doses (Berman et al., 2004). After peripheral and central 
neuropathy these analgesics are purposefully prescribed at low doses, and for short 
periods of time, due to their extensive side effects and propensity for the generation of 
pharmacological tolerance (Mayer et al., 1999). For example opioids, that were first 
prescribed to treat pain due to their inhibitory action on neurones in the spinal cord and 
brain-stem, are now thought to be ineffective at maintaining therapeutic efficacy, due to 
their activity on glia (Hutchinson et al., 2007;Mika, 2008). The actions of chronic 
administration of opioids such as morphine, have been shown to cause hypertrophy of 
astroctyes and thermal hypersensitivity (Song and Zhao, 2001), linked to activation of 
surface µ-3 opioid receptors on astrocytes (Dobrenis et al., 1995), and the upregulation 
and migration of microglia via interactions between µ-3 opioid and P2X4 receptors 
(Horvath and DeLeo, 2009). This glial-mediated neuroinflammation in the spinal cord, 
similar to that seen after neurotrauma, is a mechanism that antagonises the analgesic 
effects of morphine leading to drug tolerance. This tolerance results in the need for 
increased dosage to maintain physiological efficacy, culminating in drug dependency 
and addiction. Drug withdrawal becomes a disorder in itself, as loss of primary opioid 
analgesia will lead to unabated microglial-mediated neuropathic pain. This hypothesis 
of morphine tolerance has been clarified pre-clinically, and shown to be permanently 
established at 6 days in both naïve and CCI mice (Mika et al., 2009), and glial responses 
and cytokine expression have been shown to occur as acutely as 5 minutes after a 15ul 
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morphine single intrathecal injection in naïve rats, and lasts for up to 100 minutes 
(Hutchinson et al., 2008). This opioid-induced cytokine-mediated neuropathic 
behaviour can be substantially delayed by the administration of pre-emptive treatment 
boluses of the neuroinflammatory inhibitors minocycline (microglia), pentoxifylline 
(cytokine), fluorocitrate (astrocytes), and riluzole (anti-glutaminergic) (Song and Zhao, 
2001;Habibi-Asl et al., 2009;Mika et al., 2009). 
As described previously in chapters 3-5, there is now a shift in the understanding of 
neuropathic pain mechanisms, at least in pre-clinical research, that these mechanisms 
are at least in part due to pathologically increased glial-neuronal communication within 
the dorsal horn of the spinal cord, through glial activation, proliferation, and 
inflammatory mediator release (Raghavendra et al., 2003;McMahon et al., 2005;Hains 
and Waxman, 2006;Hulsebosch, 2008;Echeverry et al., 2008;Inoue and Tsuda, 
2009;Milligan and Watkins, 2009). This understanding provided the rational for the use 
of ‘non-classical’ analgesic drugs to target and influence ‘pre-neuronal’ mechanisms 
such as microglial activation (Raghavendra et al., 2003;Ledeboer et al., 2005;Hains and 
Waxman, 2006;Marchand et al., 2009), as well as attempting to reduce extracellular 
glutamate (Sung et al., 2003;Coderre et al., 2007), in an attempt to indirectly modulate 
dorsal horn neuronal excitability. The immediate benefit in the use of these drugs 
assessed pre-clinically for efficacy in neuropathic pain, is that they are already marketed 
by pharmaceutical companies for treatment of other disorders. Two of these potential 
treatments may lay with the application of riluzole, an anti-glutamatergic drug, and 
minocycline, an anti-inflammatory drug, to target the glutaminergic system and 
microglia in neuropathic pain management.  
 
6.1.2: Therapeutic potential of minocycline for neuronal injury and disease 
 
There is now overwhelming evidence to suggest that neuroinflammation exerts an 
important role in the pathogenesis of several chronic neurodegenerative disorders such 
as Alzheimers disease, Parkinson’s disease, and Huntington’s disease (Glass et al., 
2010), as well as acute insults such as stroke, epilepsy, ischemia (Oprica et al., 2003) 
and, SCI (Popovich et al., 1997) and PNI (Colburn et al., 1997;Colburn et al., 
1999;Ohlsson et al., 2006). There is growing support now for therapeutic strategies 
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targeting inflammation as a key to prevention of neurodegeneration after neurotrauma 
(Popovich, 2000;Hausmann, 2003;Kim and Suh, 2009;Ankeny and Popovich, 2009). 
 
Minocycline is a semi-synthetic second generation tetracycline derivative, effective 
against gram-positive and gram-negative infections, by inhibiting protein synthesis at 
the ribosome level (Kim and Suh, 2009). It was first introduced in 1967, and is now 
commonly prescribed as an antibiotic for dermatological conditions such as acne 
vulgaris and rosacea (Kim and Suh, 2009). It also has a profoundly anti-inflammatory 
property, and is used clinically for treatment of rheumatoid arthritis (O'Dell, 1999). 
Minocycline exerts its anti-inflammatory properties by modulating microglia, reducing 
immune cell activation, reducing cytokine and chemokine release, and modulating 
matrix metalloproteinases (MMPs) (Stirling et al., 2005). It has good pharmacokinetics 
being highly lipophilic in nature, easily crosses the blood brain barrier with high tissue 
absorption, and has a longer half-life (11-23 hours) than other tetracyclines (Langevitz 
et al., 2000;Kim and Suh, 2009). More recently minocycline has been implemented in 
the therapeutic treatment of neurodegenerative diseases due to its anti-inflammatory 
properties but also due to anti-apoptotic/neurotrotective properties that are distinct from 
its anti-microbial actions (Kim and Suh, 2009).  
 
Minocycline was first shown to have neuroprotective qualities after ischemic stroke 
(Yrjanheikki et al., 1998), by increasing the survival of CA1 hippocampal neurones 
with treatments both pre- and post-emptively and reducing microglial activity. These 
therapeutic effects were causally linked to reduction of expression of inducible nitric 
oxide synthase (iNOS) mRNA, reduction of Il-1β-converting enzyme expression, and 
reduction of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production 
(Yrjanheikki et al., 1998;Yrjanheikki et al., 1999). Minocycline was shown to be 
functionally effective in rat models of thoracic contusive SCI (Lee et al., 2003;Wells et 
al., 2003), where immediate treatment at 45mg/kg i.p, with follow-up treatment every 
12 hours, effectively reduced lesion size, increased axonal sparing, and improved 
locomotor scores, with corresponding reduction of apoptotic markers such as TUNEL 
and caspase-3, and decreasing TNFα expression. Many authors have shown similar 
effects in vivo and in vitro (He et al., 2001;Tikka et al., 2001;Stirling et al., 2004;Festoff 
et al., 2006). The primary mechanism of minocycline’s anti-apoptotic action is the 
direct inhibition of cytochrome-C release from mitochondria, shown initially in 
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Huntington’s disease models (Chen et al., 2000), but also in contusive SCI (Teng et al., 
2004). Minocycline has been shown to reduce NMDA mediated excitotoxicity and 
microglial proliferation via inhibition of p38 MAP-Kinase in animal models of SCI, 
stroke, and Huntington’s disease (Hains and Waxman, 2006;Crown et al., 2008;Tikka et 
al., 2001;Tikka and Koistinaho, 2001). Minocycline administration for 2 weeks in 
experimental autoimmune encephalitis (EAE) ameliorates clinical severity by 
downregulation of MHC-2 expression on microglia and reactivity inhibition 
(Nikodemova et al., 2007). Minocycline’s actions are cell specific, having been shown 
to attenuate microglial but not astroglial activity after cerebellar focal lesions (Viscomi 
et al., 2008). Minocycline treatment has also been shown to be a potent macrophage 
inhibitor after dorsal column crush injury (McPhail et al., 2004b), reducing axonal 
dieback (Stirling et al., 2004), as well as alleviating the cell death of oligodendrocytes 
(Stirling et al., 2004;Yune et al., 2007). More specifically for root injury, minocycline 
has been shown to protect motor neurones from cell death after ventral L6 root avulsion 
injury (Hoang et al., 2008).  
 
There is, however, much controversy in the literature over the effectiveness of 
minocycline in SCI therapy, as well as the emergence of toxicity, with the inability to 
replicate initial BBB locomotor and histological observations of improvement after 
contusive thoracic SCI from the labs in Seoul (Lee et al., 2003) and Alberta (Wells et 
al., 2003), and at the Miami Project in Florida (Pinzon et al., 2008). Positive 
observations do not cross over into different models of injury either, such that 
minocycline has limited neuroprotection after balloon-compression SCI (Saganova et 
al., 2008), fails to mitigate neuronal degeneration after focal cerebellar lesion (Viscomi 
et al., 2008), and worsens both hypoxic-ischemic brain injury in neonatal mouse models 
(Tsuji et al., 2004), and dopaminergic neurone loss in mouse models of Parkinson’s and 
Huntingtons disease (Yang et al., 2003;Diguet et al., 2004a;Stefanova et al., 2004). 
Minocycline also has rare but significant side-effects at high and prolonged dosing 
regimens clinically, when used for acne vulgaris in patients, with terminal fulminant 
hepatic failure requiring liver transplantation (Losanoff et al., 2007), life-threatening 
hypersensitivity and autoimmune reactions (Shapiro et al., 1997;Ramakrishna et al., 
2009), as well as demineralization and discoloration of tooth enamel (Good and Hussey, 
2003) and skin pigmentation (Geria et al., 2009). There are now calls in the literature for 
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the establishment of a forum of negative results and side effects due to the overhelming 
controversy with minocycline efficacy in neuroprotection (Diguet et al., 2004b). 
 
With the emergence of microglia as a target for neuropathic pain treatment (Milligan 
and Watkins, 2009;Inoue and Tsuda, 2009) there is now a rationale for the use of 
minocycline as a potential analgesic treatment for neuropathic pain (Raghavendra et al., 
2003;Ledeboer et al., 2005;Hains and Waxman, 2006;Marchand et al., 2009). 
Preemptive minocycline treatment, 1 hour before PNI in animal models, attenuates the 
development of behavioural hypersensitivity and is essentially linked to microglial 
inhibition (Raghavendra et al., 2003) through inhibition of p38 MAPK, preventing 
activation and proliferation (Tikka et al., 2001;Tikka and Koistinaho, 2001). A similar, 
if not identical, mechanism exists in spinal cord injury, where p38 MAPK expression is 
upregulated just rostrally or caudally to the lesion site, and has been causally linked to 
the occurrence of ‘at-level’ (Crown et al., 2008) and ‘below-level’ neuropathic pain 
(Hains and Waxman, 2006) respectively. Although astroctyes, as well as microglia, 
show upregulation of p38 MAPK after contusive SCI (Crown et al., 2008), minocycline 
is yet to be shown effective at ameliorating astrocyte reactivity (Tikka and Koistinaho, 
2001;Viscomi et al., 2008). As previously mentioned delayed minocycline treatment, 
although effectively reduces microglial reactivity at 5-7 days post PNI, is ineffective at 
ameliorating allodynia and hyperalgesia at this time point, which is attributed to the 
increasing contribution of astrocytes (but not microglia) in the maintenance of 
peripheral neuropathic pain (Raghavendra et al., 2003;Ledeboer et al., 2005). Whereas 
delayed intrathecal minocycline treatment 4 weeks after thoracic SCI, time point of 
established neuropathic behaviour, ameliorates hyperactivity of dorsal horn neurones 
and restored nociceptive thresholds, and microglial cells revert back to quiescent 
morphology (Hains and Waxman, 2006). The beneficial effects of minocycline may 
therefore be related to the level of involvement of microglia compared to astrocytes in 
neuropathic pain maintenance, and minocycline may therefore only be effective as a 
delayed treatment after more central nerve injuries. These therapeutic behavioural 
effects are attributed to the inhibition of IL-1β, TNFα and other cytokine mediators and 
their respective converting enzymes (Ledeboer et al., 2005), as well as endocannabinoid 
reduction (Guasti et al., 2009). Interestingly minocycline treatment in rats does not 
affect the basal threshold levels of nociceptive pain sensitivity (Padi and Kulkarni, 
2008) or post operative pain sensitivity (Ito et al., 2009), or effect lamina I/II neuronal 
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c-Fos induction in uninjured animals after noxious stimulation (Marchand et al., 2009). 
It does, however, reduce microglial activity and the level of neuronal c-Fos induction in 
the hemisected dorsal horn after thermal noxious stimulation to the periphery 
(Marchand et al., 2009). This suggests firstly, that there is an essential role for microglia 
in neuropathic pain generation that is not apparent in nociceptive pain; and secondly, 
but more importantly, advocates that the effectiveness of minocycline’s analgesic 
qualities are dependent on the presence of neurotrauma.  
 
The question relative to this thesis is two fold; firstly, can immediate minocycline 
treatment ameliorate neuropathic pain behaviour and microglial activity after root 
injury, a trauma with both central and peripheral consequences? Secondly, does a 
delayed minocycline administration effectively relieve established avulsion pain? 
 
6.1.3: Therapeutic potential of riluzole for neuronal injury and disease  
 
Riluzole (2-amino-6-trifluoro-methoxy-benzothiazole), or Rilutek™ (Sanofi-Aventis), 
is an anticonvulsant which has been licensed for patients with the fatal neurological 
disease, amyotrophic lateral sclerosis (ALS) for over 10 years. A double-blind, placebo-
controlled, multicentre and international clinical trial was performed across 18 months 
(Lacomblez et al., 1996), and at doses of 100mg/day, riluzole was shown to delay the 
need for tracheostomy surgery, prolonging the life of the patient by 2-3 months (Miller 
et al., 2007). It has a small beneficial effect on bulbar and limb function, but shows no 
improvement on muscle strength. Riluzole has also been implicated as a potential anti-
depressant due to its positive activity on glial reuptake of excitatory amino-acids 
(Valentine and Sanacora, 2009). 
 
The neuroprotective effects of riluzole that have been shown are attributed to 
antagonism of presynaptic calcium dependent glutamate release (Cheramy et al., 1992) 
and enhancement of glutamate re-uptake via the glutmate transporters GLAST (glial), 
GLT1 (glial) and EAAC1 (neuronal) (Sung et al., 2003;Fumagalli et al., 2008). These 
effects pharmacologically are due to inactivation of voltage-sensitive sodium channels 
(Benoit and Escande, 1991), activation of G-protein-dependent signal transduction 
processes, as well as non-competitive NMDA blockade (Doble, 1996), and in this way 
can be described as anti-excitototoxic. Riluzole may also have indirect trophic 
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mechanisms of neuronal support, by increasing neurotrophic factors (BDNF, NGF, and 
GDNF) or cytokine production by non-neuronal cells such as astrocytes and schwann 
cells, improving motor neuronal survival, and dorsal root ganglion neuronal survival, 
neuritogenesis, and sprouting, as observed in adult and neonatal rat cell culture (Peluffo 
et al., 1997;Mizuta et al., 2001;Shortland et al., 2006b). 
 
Riluzole, administered at 4 or 8mg/kg i.p, also reduces lesion size and necrosis in rat 
striatum, in an excitotoxicity model of Huntington’s disease, with a proposed indirect 
mechanism of action of NMDA antagonism (Mary et al., 1995). More specifically to 
root injury, riluzole has been shown to provide acute neuroprotection for avulsed motor 
neurones, as well as promoting enhanced neurite formation and outgrowth in avulsed 
dorsal root ganglion neurones (Shortland et al., 2006b), but has greatest efficacy when 
administered i.p. in conjunction with reimplantation and GDNF i.p. administration, and 
shows improved functional recovery on the BBB scale (Bergerot et al., 2004). When 
retrogradely labelling motor axons in the L4 ventral root after avulsion and 
reimplantation, and corresponding delayed i.p. treatment with riluzole, motor neuronal 
pools were labelled in the spinal cord to the same extent as immediate treatment, even 
after treatment delays of up to 10 days (Nogradi et al., 2007). Muscle wasting of the 
extensor digitorum longus and tibialis anterior was also reduced in delayed riluzole 
administration after avulsion/reimplantation (Nogradi et al., 2007). However at 14 days 
and later, motor neurone survival is not accomplished through riluzole treatment, and is 
related to the irreversible loss of motor neurones around this time point (Nogradi et al., 
2007). This information gives a suitable time window of effective therapeutic 
intervention in the clinic, of <14 days after an avulsion injury to ventral roots.  
 
Riluzole, like minocycline, has an additional therapeutic target; in neuropathic pain 
treatment. When riluzole is administered at 1, 4, 6, or 12mg/kg immediately, twice daily 
for 4 days following CCI in rats, it effectively ameliorates the development of 
mechanical and thermal hypersensitivity (Sung et al., 2003;Coderre et al., 2007). 
Riluzole is different to minocycline, in that it has the ability to affect nociceptive 
thresholds and attenuate anxiety behaviour in naive animals (Coderre et al., 2007;Munro 
et al., 2007), and at high doses such as 23.3-32.2mg/kg shows general anaesthetic 
properties in rats with loss of righting reflex, movement and nociceptive responses 
(Irifune et al., 2007). Nociceptive withdrawal thresholds in naïve and formalin-injected 
  244 
rats were increased with riluzole treatment and this effect was linked to prolonged 
reductions in spinal glutamate and aspartate levels (Coderre et al., 2007) and increased 
glutamate transporter function (Sung et al., 2003).  
 
However, there is some debate as to the effectiveness of riluzole, as when administered 
clinically at 100mg/day and 200mg/day, in a randomized, placebo-controlled study for 
peripheral neuropathic pain and at 100mg/kg in a burn pain trial, and patients did not 
note on a pain intensity visual analogue scale to tactile and thermal stimulation any 
alleviation (Hammer et al., 1999;Galer et al., 2000), but this may have been due to 
collating data from mixed pathologies and small cohert sizes. Like minocycline, side 
effects are apparent clinically at doses of 200mg/kg (recommended dose of riluzole is 
50mg twice daily). Common symptoms include vertigo, diarrhea, nausea, and 
paresthesias around the face, but these are reversible (Siniscalchi, 2004). High 
concentrations of riluzole (100-300µM) in vivo are able to induce cortical neuronal 
casapase-dependent apoptosis (Koh et al., 1999). 
 
6.1.4: Aims 
 
The positive effects of both riluzole and minocycline in pre-clinical animal models 
across a range of neurological disorders and diseases, as well as tolerable side effects, 
have lead to these two drugs entering clinical trials organised in University of Toronto 
Phase I, and Calgary Phase II respectively, for assessment of functional recovery after 
SCI (Hawryluk et al., 2008).  
 
The aim of this final chapter is to ascertain if neuropathic pain after avulsion injury is 
mediated in part by glial and inflammatory mechanisms as well as neuronal loss and 
disinhibition within the spinal cord, and whether these detrimental processes can be 
modulated to prevent the development of, or reverse established avulsion pain. The two 
drugs minocycline and riluzole when administered in the SRA model and analysed 
behaviourally and histologically will provide an opportunity to test ‘proof of principle’; 
that inflammatory responses and neuronal loss in the spinal cord after avulsion lead to 
neuropathic pain.  
 
This shall be accomplished in three ways: 
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• The behavioural assessment of the efficacy of riluzole (i.p. 4mg/kg) and 
minocycline (i.p. 40mg/kg) in an immediate treatment strategy, across a 14 day 
vehicle controlled trial, will ascertain whether the prevention of thermal and 
mechanical hypersensitivity development after L5 SRA is possible. 
 
• The histological effects of riluzole (i.p. 4mg/kg) and minocycline (i.p. 40mg/kg) 
treatment on glial, inflammatory, and neuronal populations compared to a 
vehicle treated group, at 14 days post SRA will be examined and correlated with 
the behaviour at this time point. 
 
• The efficacy of delayed administration of riluzole (i.p. 4mg/kg) and minocycline 
(i.p. 40mg/kg) after establishment of SRA-induced thermal and mechanical 
hypersensitivity will be assessed behaviourally. Drug administration will be 
from 7-13 days post operatively, once a day, and then from 14-21 days, once 
every two days. 
 
If efficacy is proven in this model, it may provide a rationale for the application of these 
drugs in multiple pre-clinical models of neuropathic pain, and perhaps more importantly 
clinically for brachial and lumbosacral plexus avulsion injured patients. Treatment can 
be applied to future patients as a preventative measure, and perhaps more immediately 
needed is treatment for an already pre-established intractable avulsion-pain for current 
sufferers. Both riluzole and minocycline are already approved and licensed for medical 
use, and currently available for clinical testing for neuropathic pain treatment.  
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6.2: Results 
 
6.2.1: Immediate and maintained treatment of L5 SRA-induced hypersensitivity 
across 14 days 
 
6.2.1.1: Vehicle treatment  
 
Vehicle (0.1M HCl) treatment immediately after L5 SRA, and maintained across 14 
days, did not prevent, or reverse at any time point assessed, the development of 
hypersensitivity to tactile or thermal stimulation. Preoperative baseline values for both 
thermal and tactile stimulation were in accordance with values from SRA untreated 
groups (Chapter 4), and again did not differ when compared to ipsilateral and 
contralateral sides. 
 
Mechanical 
 
Significant ipsilateral mechanical hypersensitivity was established against both baseline 
values (21.8g +/- 1.00) and contralateral values (22.0 +/-1.01) by 1 day (15.9g +/-1.98) 
post operatively. This mechanical hypersensitivity was maintained for 14 days where 
final values were recorded at 11.6g (+/-1.41) withdrawal threshold (Fig 6.1A). No 
change was found in contralateral values compared to baseline (Fig 6.1A). 
 
Thermal 
 
Significant ipsilateral thermal hypersensitivity was established against baseline values 
(8.45s +/-0.34) by 5 days (6.79s +/-0.09) and from contralateral values (8.22s +/-0.64) 
by 9 days (5.83s +/-0.75) post operatively. This is maintained up to 14 days where final 
values were recorded at 6.01s (+/-0.32) withdrawal latency (Fig 6.1B). No change was 
found in contralateral values compared to baseline (Fig 6.1B). 
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Figure 6.1: Effects of vehicle treatment on mechanical (A) and thermal (B) thresholds after L5 SRA. 
Administration of vehicle does not prevent the development of ipsilateral behavioural hypersensitivity to 
tactile (A) or thermal (B) stimulation.  Tactile hypersensitivity is established by 1 day compared to 
baseline and contralateral. Thermal hypersensitivity is established by 5 days. Significant differences are 
indicated for ipsi vs contra (*) and against baseline (#). N = 6. 
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6.2.1.2: Riluzole treatment  
 
Riluzole treatment immediately after L5 SRA for 14 days, delayed the development of 
hypersensitivity to mechanical and thermal stimulation, but did not prevent its 
establishment by the end of the treatment period. Preoperative baseline values for both 
thermal (8.75s +/-0.79) and mechanical (21.1 +/- 0.88) stimulation were not 
significantly different to vehicle treated (Fig 6.2B and 6.3B), and again did not differ 
when compared bilaterally (Fig 6.2A and 6.3A). 
 
Mechanical 
 
Significant ipsilateral mechanical hypersensitivity was established against contralateral 
values (21.1g +/-0.92) by 3 days (16.7g +/-2.68). However on days 5, 7, and 9, 
ipsilateral mean withdrawal threshold values were increased such that no significant 
difference to contralateral values was found (Fig 6.2A). Further, on day 7 (17.7g +/-
1.17) and day 9 (20.1g +/-1.53) withdrawal threshold values were significantly higher 
than mean vehicle withdrawal levels (Fig 6.2B). However by day 11 ipsilateral 
withdrawal threshold values (15.6s +/-1.21) returned to vehicle levels representative of 
hypersensitivity, and were significantly lower than contralateral values. Only on the 
final day were ipsilateral values (12.9g +/-2.21) significantly lower than baseline values. 
No change was found in contralateral values compared to baseline (Fig 6.2A). 
 
Thermal 
 
Significant ipsilateral thermal hypersensitivity was established against contralateral 
values (9.53s +/-0.52) only at 5 days (7.44s +/-0.49). However, at all other time points, 
mean ipsilateral withdrawal latencies were not significantly different to contralateral 
values (Fig 6.3A). On days 7-11 riluzole treated thermal withdrawal thresholds were 
significantly higher than compared to vehicle ipsilateral withdrawal latencies (Fig 
6.3B). However, by day 14 riluzole-treated thermal withdrawal threshold values (6.61s 
+/-1.28) returned to vehicle levels. At no time point ipsilateral values (12.9g +/-2.21) 
significantly lower than baseline values. No change was found in contralateral values 
compared to baseline (Fig 6.3A). 
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Figure 6.2: Effects of riluzole on mechanical thresholds after L5 SRA. Riluzole treatment delays the 
development of tactile hypersensitivity against contralateral and baseline values (A) and against vehicle 
levels (B) on days 5, 7, and 9. This effect is not maintained at 11 and 14 days. Significant differences are 
indicated for ipsi vs contra (*), against baseline (#), and against vehicle (x). N = 6 in each group. 
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Figure 6.3: Effects of riluzole on thermal thresholds after L5 SRA. Riluzole treatment prevents the 
development of thermal hypersensitivity against contralateral and baseline values (A) and against vehicle 
levels (B) on all days, except day 5 and 14. Significant differences are indicated for ipsi vs contra (*), 
against baseline (#), and against vehicle (x). N = 6 in each group 
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6.2.1.3: Minocycline treatment  
 
Minocycline treatment that started immediately after L5 SRA for 14 days prevented the 
development of thermal and mechanical hypersensitivity compared to baseline levels 
and vehicle treatment, but on several days contralateral effects were noted. Preoperative 
baseline values for both thermal (9.36s +/-0.27) and mechanical (19.9g +/- 0.71) 
stimulation were not significantly different to vehicle levels (Fig 6.4B and 6.5B), and 
did not differ when compared bilaterally (Fig 6.4A and 6.5A). 
 
Mechanical 
 
No mechanical hypersensitivity was seen compared to baseline values at any time point 
(Fig 6.4A). Minocycline treatment significantly raised ipsilateral mechanical withdrawal 
thresholds compared to vehicle levels from 3 days onwards (Fig 6.4B). However, there 
was development of an intermittent contralateral hyposensitivity, such that ipsilateral 
mechanical withdrawal thresholds were significantly lower than contralateral values 
(24.5g +/-1.17) on day 1 (17.6g +/-2.23), with contralateral values significantly 
increased over baseline. On days 3, 7 and 9, contralateral withdrawal thresholds 
returned to baseline, and were not significantly greater than ipsilateral levels (Fig 6.4A). 
However, contralateral hyposensitivity again developed against baseline on day 5 (10.6s 
+/-1.21), day 11 (25.0g +/-1.83) and day 14 (24.4g +/-0.98), with withdrawal threshold 
values significantly higher than ipsilateral withdrawal levels at 11 and 14 days (Fig 
6.4A). However, across the 14 day time course, contralateral hyposensitivity did not 
increase beyond that noted initially on day 1. 
 
Thermal 
 
No thermal hypersensitivity was established against contralateral or baseline values at 
any time point assessed across 14 days (Fig 6.5A). Minocycline treatment significantly 
maintained ipsilateral thermal withdrawal latency values from day 5-14 compared to 
vehicle treated animals where the threshold began to fall during this time frame (Fig 
6.5B). A contralateral thermal hyposensitivity only developed on day 9 (12.0s +/-0.59), 
and was significantly higher than baseline withdrawal latencies, but was not 
significantly different to ipsilateral values (Fig 6.5A).  
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Figure 6.4: Effects of minocycline on mechanical thresholds after L5 SRA. Minocycline treatment 
prevents the development of tactile hypersensitivity against contralateral and baseline values (A) and against 
vehicle treatment (B) over 14 days. Significant differences are indicated for ipsi vs contra (*), against baseline 
(#), and against vehicle (x). N = 6 in each group. 
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Figure 6.5: Effects of minocycline on thermal thresholds after L5 SRA. Minocycline treatment 
prevents the development of thermal hypersensitivity against contralateral and baseline values (A) and 
against vehicle levels (B) across 14 days. Significant differences are indicated for ipsi vs contra (*), 
against baseline (#), and against vehicle (x). N = 6 in each group. 
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6.2.1.4: Effect of treatment on weight gain after L5 SRA. 
 
Male Wistar rats underwent SRA+vehicle treatment with a pre-surgical baseline weight 
of 234.8g (+/-4.06). Daily weight gain across 14 days was 5.35g/day (+/-0.37) (Fig 6.6). 
Total weight gain across 14 days was 74.8g (+/-5.24).  
 
Age matched male Wistar rats underwent SRA+riluzole treatment with a pre-surgical 
baseline weight of 233.7g (+/-6.06). Daily weight gain across 14 days was 5.61g/day 
(+/-0.37), which was not significantly different to vehicle treatment (Fig 6.6). Total 
weight gain across 14 days was 78.5g (+/-5.18). 
 
Age matched male Wistar rats underwent SRA+minocycline treatment with a pre-
surgical baseline weight of 234.7g (+/-7.42). Daily weight gain across 14 days was 
3.75g/day (+/-0.21), which was significantly lower than vehicle treatment (Fig 6). Total 
weight gain across 14 days was 52.5g (+/-2.93). 
 
Pre-surgical baseline weights were not significantly different between groups. 
 
 
 
 
 
 
Figure 6.6: Mean daily weight gain in adult male Wistar rats after SRA, and different drug 
treatments. Over a period of 14 days vehicle and riluzole treated rats gain a similar amount of weight.  
However, over the same period of assessment with minocycline treatment, SRA injured rats gain 
significantly less weight than SRA-vehicle treated animals. Comparison for treatment vs vehicle (*) is 
indicated. N = 6 in each group. 
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6.2.2: Immunohistological analysis of L4 and L5 spinal cord in riluzole, 
minocycline, and vehicle treated rats 
 
6.2.2.1: Dorsal horn neuronal counts 
 
Fourteen days after SRA-vehicle treatment, similar to SRA-untreated (Chapter 4) 
animals, L5 segmental NeuN loss was seen in the superficial lamina directly underlying 
Lisseaur’s tract and dorsal root entry zone and lateral superficial areas, with small cystic 
cavities within the area of deafferentation (Fig 6.7A). NeuN loss in the adjacent L4 
segment was seen similar to SRA-untreated (Chapter 4), but to a lesser extent than that 
found caudally in L5, but was seen in the superficial lamina underlying Lisseaur’s tract 
(Fig 6.7A). 
 
When quantified spinal cord tissue from 14 day SRA-vehicle treatment, mean dorsal 
horn neuronal counts per section were 351.7 (+/-15.5) for the L5, and 375.7 (+/-10.4) 
for the L4 segments, with counts significantly lower than contralateral values (L5: 387.9 
+/-11.3 and L4: 404.5 +/-9.60) (Fig 6.7B).  
 
Fourteen day SRA treatment with riluzole (4mg/kg) lead to no significant improvement 
in NeuN mean number of cells per section (Fig 7A) in deafferented (L5 = 344 +/-15.7) 
or intact (L4 = 373.5 +/-11.4) dorsal horn against vehicle treated cords (Fig 6.7B). 
 
Fourteen day SRA treatment with minocycline (40mg/kg) lead to no significant 
improvement in mean NeuN number per section in the deafferented L5 segment (355.3 
+/-10.9). However, the mean number of neurones in the L4 dorsal horn (390.8 +/-6.94), 
was not significantly different to the contralateral side. No significant difference was 
found between ipsilateral dorsal horns of vehicle and minocycline treated (Fig 6.7B). 
 
No significant difference was found between contralateral cords of any treatment group 
(Fig 6.7B). 
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Figure 6.7: Photomicrographs of effects of drug treatment on dorsal horn neuronal staining (A) and 
quantification of total dorsal horn neurones per section (B) 14 days after L5 SRA, in L4 and L5 
segments. A: Cavitation and neuronal reduction is noticeable near DREZ and Lisseaur’s tract 2 weeks 
after SRA in vehicle, riluzole and minocycline treated animals. B: NeuN number was similar in the L4 
dorsal horns, ipsilaterally versus contralaterally, but this was not the case in the L5 segment, with 
minocycline treatment. Riluzole had no effect on NeuN counts. Significant differences for ipsi vs contra 
(*) are shown. N = 6 in each group. Scale=100µm 
 
A: 
 
B: 
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6.2.2.2: Ventral horn neuronal counts 
 
Similarly to SRA-untreated animals (chapter 2), a prominent motor neuronal loss was 
found in the ipsilateral ventral horn 14 days after SRA with vehicle treatment, using 
both Toluidine Blue histology and NeuN immunohistochemistry. Again a greater 
percentage reduction using immunohistochemistry, rather than histological dye, was 
visually apparent (Fig 6.8) and quantifiable (Fig 6.9). 
 
Using NeuN immunohistochemistry 14 days after SRA plus vehicle treatment, motor 
neurone loss was seen in L5 (69.3% +/-3.8) and L4 (50.3% +/-4.7) segments compared 
to contralateral sides (Fig 6.9). 
 
When analysing Tol Blue histology for neuronal counts in SRA-vehicle treated rats, a 
marked difference in percentage reduction from NeuN immunohistochemistry was 
noted. Mean reduction was limited to 39.6% (+/-4.5) in L5 and 26.6% (+/-7.4) in L4 
(Fig 6.9). 
 
Treatment with riluzole did not produce significant improvements in the number of 
NeuN or Toluidine Blue stained motor neurones in the ipsilateral cord 14 days after 
SRA (Fig 6.8) in the deafferented (L5 = 68.6% +/-3.4) or intact (L4 = 46.5% +/-1.7) 
ventral horn compared to vehicle treated cords (Fig 6.8). Toluidine Blue histological 
analysis also showed no significant difference between riluzole treated (L5 = 44.5% +/-
6.0 and L4 = 26.6% +/-6.1) and vehicle treated animals (Fig 6.9). 
 
Likewise, treatment with minocycline did not produce significant neuroprotection of 
NeuN or Toluidine Blue stained cells in the ipsilateral cord 14 days after SRA (Fig 6.8) 
in the deafferented L5 (71.1% +/-4.8) or the intact L4 (42.6% +/-10.9) segments 
compared to vehicle treated animals (Fig 6.9). Toluidine Blue histological analysis also 
showed no significant difference between minocycline treated (L5 = 41.7% +/-5.3 and 
L4 = 31.3% +/-6.5) and vehicle percentage motor neurone ratios (Fig 6.9). 
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Figure 6.8: Photomicrographs of effects of drug treatments on motor neurone number 14 days 
after SRA as assessed by NeuN or toluidine blue staining, in L4 and L5 segments. Treatment with 
either riluzole or minocycline does not prevent the loss of motor neurones after SRA, shown with vehicle 
treatment, in either L5 or L4 segments, compared to contralateral numbers. Scale=100µm 
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6.2.2.3: Microglial reactivity in the dorsal and ventral horns 
 
Fourteen days after SRA with vehicle treatment, Iba1 density was significantly 
upregulated in the dorsal horn microglia ipsilateral to the deafferentation, in L5 as well 
as L4 segments, compared to contralateral levels (Fig 6.10). Within the deafferented L5 
ipsilateral segments Iba1 expression could be seen intensely in the DREZ that spreads 
throughout the superficial laminae (Fig 6.10). Iba1 expression increase is confined to 
the grey matter in the L4 cord, but is present in both grey and white matter in L5, 
notably around the DREZ (Fig 6.10). Mean ipsilateral Iba1 density staining reached 
8.85% (+/-0.88) in L4 and 9.39% (+/-0.69) in L5 dorsal horns (Fig 6.11A). No 
significant difference was found between microglial density staininig between the 
deafferented L5 and intact L4 dorsal horns (Fig 6.11A).  
 
Figure 6.9: Quantitative effects of drug treatment on mean number of motor neurones using 
toluidine blue or NeuN labelling 14 days after SRA, in L4 and L5 segments. No significant difference 
is found for either riluzole or minocycline compared to the loss found with vehicle treatment, using either 
Tol Blue or NeuN counts in L4 or L5 ventral horn segments. The loss of motor neurones compared to 
contralateral sides was much less using Tol Blue histology than NeuN immunohistochemistry to perform 
counts. N = 6 per group. 
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Iba1 expression in SRA tissue was also significantly upregulated in the ipsilateral 
ventral horns of both deafferented L5 and intact L4 segments, compared contralateral 
levels (Fig 6.11B). Visually, in the L5 ipsilateral segment as well as the L4 segment, 
Iba1 positive microglia were greatly upregulated around motor neurone pools, 
clustering tightly in the lateral aspect of the ventral horn (Fig 10). Mean ipsilateral Iba1 
ventral density staining reached 8.95% (+/-0.66) in L4 and 9.34% (+/-0.47) in L5, and 
again no significant difference was found between the deafferented L5 and intact L4 
segments (Fig 6.11B). 
 
Treatment with riluzole visibly reduced Iba1 staining in the L5 and L4 ipsilateral dorsal 
horn and L4 ventral horn 14 days after SRA (Fig 6.10). Quantitative analysis showed 
mean dorsal horn Iba1 staining per section was significantly reduced to 5.67% (+/-0.59) 
in L5 and 5.12% (+/-0.55) in L4 cord (Fig 6.11A). In the ventral horn only L4 showed 
significant reduction in mean Iba1 density staining per section (6.43% +/-0.41) (Fig 
6.11B).  
 
Treatment with minocycline reduced microglial staining in all areas of the ipsilateral 
cord, and the pockets of intense staining shown in SRA-vehicle, were absent in this 
tissue (Fig 6.10).  When quantified, mean Iba1 staining per section was significantly 
reduced compared to SRA-vehicle in the intact adjacent L4 (DH=3.86% +/-0.80 and 
VH=4.55% +/-0.93) and deafferented L5 (DH=3.94% +/-0.61 and VH=4.14% +/-0.94) 
spinal cord segments. Values of SRA-minocycline were successfully reduced to sham 
levels in all cases (Fig 6.11). 
 
Mean contralateral Iba1 reduction with minocycline treatment was significant in L4 
ventral horn (1.97% +/-0.21) against SRA-vehicle contralateral values (2.89% +/-0.29) 
(Fig 6.11B). However, no significant contralateral increase in Iba1 expression was 
found after SRA-vehicle, in either deafferented L5 or intact L4 segments, dorsally or 
ventrally (Fig 6.11). 
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Figure 6.10: Photomicrographs of effects of drug treatment on dorsal horn (DH) and ventral horn 
(VH) Iba1 labelling 14 days after L5 SRA in L4 and L5 segments. Increase in Iba1 labeling can be seen 
in the superficial dorsal and lateral ventral horns, in both L5 and L4 ipsilateral segments, compared to 
contralateral. Riluzole reduces Iba1 staining in the dorsal and ventral horns of L4 and the dorsal horn of 
L5, but this is not evident in the ventral horn of L5. Minocycline reduces Iba1 staining in all areas shown. 
Scale=100µm 
 
 
  262 
 
 
 
 
 
Figure 6.11: Quantitative effects of drug treatment on dorsal horn (A) and ventral horn (B) Iba1 
labelling 14 days after L5 SRA in L4 and L5 segments. SRA-vehicle shows significant upregulation of 
Iba1 staining in all areas analysed. Riluzole treatment leads to a significant Iba1 reduction in L5 and L4 
dorsal horns and L4 ventral horn, but not in L5 ventral horn, compared to vehicle. Minocycline treatment 
leads to a significant staining reduction in all areas analysed compared to vehicle (B). Significant 
differences are indicated for, ipsi vs contra (#), and treatment vs vehicle (*). N = 6 per group. 
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6.2.2.4: Astrocyte reactivity in the dorsal and ventral horns 
 
Fourteen days after SRA with vehicle treatment, GFAP density was significantly 
upregulated in the dorsal horn astrocytes ipsilateral to the deafferentation, in L5 as well 
as L4 segments, compared to contralateral levels (Fig 6.12 and 6.13). A network of 
GFAP-positive astrocytes could be seen in the dorsal root entry zone and dorsal column 
of L5, with hypertrophy and increased GFAP expression in the superficial and deep 
dorsal laminae of both L4 and L5 spinal cord (Fig 6.12). Mean ipsilateral GFAP density 
staining per section reached 8.97% (+/-0.80) in L4 and 8.87% (+/-0.81) in L5 dorsal 
horns (Fig 6.13). No significant difference in density staining was found between the L5 
and L4 dorsal horns (Fig 6.13).  
 
GFAP expression in SRA tissue was also significantly upregulated in the ipsilateral 
ventral horns of both L5 and L4 segments, compared contralateral levels (Fig 6.13). In 
the L5 segment, GFAP density staining was upregulated around motor neuronal pools. 
Within the L4 segment, astrocytes had ‘looser’ association with motor neurones, 
surrounding rather than ‘blanketing’ individual cells, but each astrocyte still shows a 
greatly increased GFAP expression (Fig 6.12). Mean ipsilateral GFAP density staining 
per section in the ventral horn reached 7.76% (+/-0.40) in L4 and 7.93% (+/-0.48) in L5, 
and again no significant difference in density was found between the L5 and L4 
segments (Fig 6.13). 
 
Treatment with riluzole showed only a trend toward reduction of GFAP density staining 
in the dorsal and ventral horns after SRA compared to vehicle treated animals (Fig 6.12 
and 6.13). Mean density staining levels per section were 8.40% (+/-0.48) in L5 and 
7.73% (+/-0.41) in L4 (Fig 6.13). Ventral horn GFAP levels were 7.01% (+/-0.46) in L5 
and 7.32% (+/-0.68) in L4 (Fig 6.13).  
 
Treatment with minocycline visibly reduced GFAP staining in all areas of the ipsilateral 
cord (Fig 6.12).  When quantified, mean GFAP staining per section was significantly 
reduced compared to SRA-vehicle in the ventral horns of L4 (6.64% +/-0.25) and L5 
(6.07% +/-0.24) segments (Fig 6.13). However, only a trend in GFAP staining reduction 
was found in the dorsal horns in L4 (7.83% +/-0.30) and L5 (7.23% +/-0.53) segments 
(Fig 6.13).  
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Figure 6.12: Photomicrographs of effects of drug treatment on dorsal horn (DH) and ventral horn 
(VH) GFAP labelling 14 days after L5 SRA, in L4 and L5 segments. GFAP labeling can be seen in 
SRA-vehicle 14 days after SRA, surrounding motor neurones and superficial dorsal horn, Lisseaur’s tract, 
and the dorsal root entry zone, greatly increased from contralateral levels. Riluzole treatment has little 
effect on GFAP staining in the dorsal and ventral horns of L4 and L5. Minocycline treatment reduces 
GFAP staining in the ventral horns of L4 and L5, with no significant effect in the dorsal horns. 
Scale=100µm 
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Figure 6.13: Quantitative effects of drug treatment on dorsal horn (A) and ventral horn (B) GFAP 
staining 14 days after L5 SRA, in L4 and L5 segments. SRA-vehicle shows significant upregulation of 
GFAP staining in all areas. Riluzole treatment leads to a trend in GFAP staining reduction in all areas 
analysed compared to vehicle. Minocycline treatment leads to a trend in GFAP staining reduction in the 
L5 and L4 dorsal horns (A), and a significant staining reduction in the L5 and L4 ventral horns (B). 
Significant differences are indicated for, ipsi vs contra (#) and treatment vs vehicle (*). N = 6 per group. 
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6.2.2.5: Macrophage infiltration in the dorsal horn 
 
Fourteen days after SRA with vehicle treatment, ED-1 expression was found 
exclusively in the ipsilateral dorsal root entry zone and dorsal columns of L5 and L4 
segments respectively (Fig 6.14), with different ED-1 expression patterns between L5 
and L4 segments. Macrophages are seen clustered tightly around the DREZ of L5, and 
were spread more loosely throughout the dorsal columns in the L4 segment (Fig 6.14). 
When quantified this density staining reached 4.34% (+/-0.95) in L5 and 2.06% (+/-
0.41) in L4 (Fig 6.15).  
 
Fourteen days of treatment with riluzole after SRA significantly increased the density of 
ED1 staining in the dorsal columns of L4 (3.72% +/-0.70) and showed a trend in 
increase in L5 (5.12% +/-1.09) (Fig 6.15). 
 
In contrast to riluzole treatment, 14 days of treatment with minocycline after SRA, 
significantly reduced the density of ED1 staining in the dorsal columns of L5 (1.49% 
+/-0.29), and showed a trend toward a reduction in L4 (1.13% +/-0.50) (Fig 6.15). 
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Figure 6.15: Quantitative effects of drug treatment on dorsal horn (A) and ventral horn (B) ED1 
staining 14 days after L5 SRA, in L4 and L5 segments. Riluzole treatment significantly increased the 
staining of ED1 in L4, with a trend in L5. Minocycline treatment significantly reduced ED1 staining in 
L5 with a trend toward reduction in L4. Significant differences are shown for, SRA treatment group vs 
SRA vehicle (*). N = 6 per group. 
 
Figure 6.14: Photomicrographs of effects of drug treatment on dorsal horn ED1 labelling 14 days 
after L5 SRA, in L4 and L5 segments.  ED1 positive labelling can be seen at 14 days after SRA-vehicle 
in both L5 and L4 ipsilateral segments. Similarly to SRA-untreated animals, macrophages were located 
around cystic cavities and dorsal root entry zone in L5, whereas they were dispersed throughout the dorsal 
columns in L4. Riluzole treatment increased the staining of ED1, whereas minocycline treatment reduced 
macrophage recruitment. Scale=50µm 
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6.2.3: Effects of a delayed drug treatment regime on L5 SRA-induced 
hypersensitivity 
 
6.2.3.1: Riluzole delayed treatment 
 
Riluzole treatment (4mg/kg), given daily from 7-13 days, and every other day from 14-
21 days, significantly reverses thermal and tactile hypersensitivity but the effects are 
transient and delayed across a 14 day period, and are not maintained after withdrawal of 
treatment (Fig 6.16). 
 
Mechanical: 
 
Pre-surgical acclimatisation and training produced a mean baseline withdrawal 
threshold of 20.0g (+/-0.78) to mechanical stimulation (Fig 6.16A), similar to previous 
baselines assessed (Section 4.2 and 5.2).  
 
Significant ipsilateral mechanical hypersensitivity was reached against the contralateral 
side by day 3 [15.8g (+/-3.78)], and against both contralateral and baseline values by 
day 7 [11.1g (+/-1.24)] (Fig 6.16A).  
 
Riluzole treatment produced a significant decrease in mechanical hypersensitivity over 
days 15-19 (Fig 6.16A). However, after the withdrawal of treatment on day 21, 
withdrawal thresholds to mechanical stimulation again became hypersensitive [11.2g 
(+/-1.21) on day 21], and remained unchanged thereafter (Fig 6.16A). 
 
Contralateral hyposensitivity to mechanical stimulation, significant from baseline 
values, was noted on day 17 [25.8g (+/-2.22)] only (Fig 6.16A). 
 
Thermal: 
 
Pre-surgical acclimatisation and training produced a mean baseline withdrawal 
threshold of 7.31s (+/-0.34) to thermal stimulation (Fig 6.16B), similar to previous 
baselines assessed (Section 4.2 and 5.2). 
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Significant ipsilateral thermal hypersensitivity was reached against baseline and 
contralateral levels by 3 days post operatively, such that withdrawal thresholds were 
reduced to 5.74s (+/-0.56), and this was maintained thereafter (5.09s +/-0.24) (Fig 
6.16B).  
 
Apart from day 15 (6.45s +/-0.48), riluzole treatment did not produce a significant 
amelioration of thermal hypersensitivity compared to contralateral and baseline values 
(Fig 6.16B). Final withdrawal thresholds were recorded on day 27 as; 5.10s (+/-0.92), 
significantly lower than both baseline and contralateral values. (Fig 6.16B). 
 
Transient contralateral hyposensitivity to thermal stimulation was seen only on days 7 
(8.57s +/-0.33) and 21 (8.86s +/-0.51) (Fig 6.16B). 
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Figure 6.16: Effects of delayed riluzole treatment on established mechanical (A) and thermal (B) 
hypersensitivity after L5 SRA. Delayed riluzole treatment transient reverses mechanical hypersensitivity 
(A). Delayed riluzole treatment has little effect on thermal hypersensitivity, apart from day 15. Significant 
difference is indicated for ipsi vs baseline (#), and ipsi vs contra (X).  N = 6 per group. 
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6.2.3.2: Minocycline delayed treatment 
 
Minocycline treatment (40mg/kg), given daily from 7-13 days, and every other day 
from 14-21 days, significantly reverses an established ipsilateral hypersensitivity to both 
thermal and tactile stimulation. After cessation of treatment this analgesic effect was 
maintained for a further 7 days (21-27 days) (Fig 6.17).  
 
Mechanical: 
 
Pre-surgical acclimatisation and training produced a mean baseline withdrawal 
threshold of 21.6g (+/-0.70), to mechanical stimulation (Fig 6.17A), similar to previous 
baselines assessed (Section 4.2 and 5.2). 
 
Significant ipsilateral mechanical hypersensitivity was reached against contralateral 
levels by day 3 [15.3g (+/-2.22)], and against both contralateral and baseline values by 
day 7 [11.6g (+/-0.66)] (Fig 6.17A). 
  
Minocycline treatment reversed mechanical hypersensitivity by day 9 [17.4g (+/-2.52)] 
(Fig 6.17A) and persisted for the entirety of the treatment period up to day 19 [21.6g 
(+/-2.29)] (Fig 6.17A). Uniquely, after cesation of minocycline treatment after day 19, 
the analgesic effect was maintained up to day 27 [20.5g (+/-2.39)] (Fig 6.17A). 
 
No significant change occurred in withdrawal threshold levels contralaterally for tactile 
stimulation before, during, or after minocycline treatment (Fig 6.17A). 
 
Thermal: 
 
Pre-surgical acclimatisation and training produced a mean thermal withdrawal threshold 
baseline of 7.64s (+/-0.62) (Fig 6.17B), similar to previous baselines assessed (Section 
4.2 and 5.2).  
 
Significant ipsilateral thermal hypersensitivity was reached against baseline and 
contralateral levels by 7 days, such that withdrawal thresholds were reduced to 5.37s 
(+/-0.42) (Fig 6.17B).  
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Minocycline treatment produced a significant amelioration of thermal hypersensitivity 
by day 9 [5.93 (+/-0.52)] compared to contralateral and baseline values, and this is 
maintained up to 15 days (Fig 6.17B). Although thermal hypersensitivity returned on 
days 17 [5.96s (+/-0.39)] and 19 [6.31s (+/-0.37)] compared to the contralateral side, 
these latencies were not significantly lower than baseline (Fig 6.17B). After the 
cessation of treatment, the reversal of thermal hypersensitivity was maintained up to the 
final day [7.44s (+/-0.87) day 27] (Fig 6.17B).  
 
No significant change occurred in withdrawal threshold levels contralaterally for 
thermal stimulation before, during, or after minocycline treatment (Fig 6.17B). 
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Figure 6.17: Effects of delayed minocycline treatment on established mechanical (A) and thermal 
(B) hypersensitivity after L5 SRA. Delayed minocycline treatment permanently reverses established 
tactile hypersensitivity by day 9, and this is maintained across the treatment period (A). Delayed 
minocycline treatment also reverses thermal hypersensitivity by day 9, compared to baseline values. 
After cessation of treatment on day 19, the analgesic effect is still apparent for both modalities. 
Significant difference is indicated for ipsi vs baseline (#), and ipsi vs contra (X).  N = 6 per group. 
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6.3: Discussion 
 
6.3.1: Summary 
 
Immediate and prolonged treatment with riluzole is able to transiently reverse 
hypersensitivity to both mechanical and thermal stimulation. Immediate and prolonged 
treatment with minocycline effectively prevents the development of tactile and thermal 
hypersensitivity across 14 days. 
 
Immediate and prolonged riluzole treatment has no effect on average weight gain across 
14 days compared to vehicle treatment; however, immediate and prolonged minocycline 
treatment has significant detrimental effects on weight compared to vehicle treatment. 
 
Immediate and prolonged riluzole treatment reduces microglial reactivity in the dorsal 
horn, and increases macrophage expression in the adjacent (L4) segment with a trend 
for increase in the injured (L5) segment. Minocycline effectively reduces ipsilateral 
microglial reactivity in the dorsal and ventral horns, and reduces macrophage 
recruitment in injured (L5) and adjacent (L4) segments. Neither riluzole nor 
minocycline treatment shows significant neuroprotective qualities in dorsal or ventral 
horns. 
 
Delayed riluzole treatment, after the establishment of behavioural hypersensitivity, 
produced a transient amelioration of both thermal and mechanical hypersensitivity 
during the treatment period, but this was not maintained after treatment withdrawal. 
 
Delayed minocycline treatment, after the establishment of behavioural hypersensitivity, 
effectively reversed both thermal and mechanical hypersensitivity, with ameliorative 
effects maintained after withdrawal of treatment. 
 
6.3.2: Riluzole 
 
Immediate and maintained treatment with riluzole after L5 SRA injury transiently 
reverses thermal hypersensitivity on days 7-11, and transiently reverses mechanical 
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hypersensitivity on days 7 and 9. This amelioration therefore shows a delay in efficacy, 
which is not maintained in the long term (at 14 days). This amelioration of 
hypersensitivity could be via anaesthetic properties of the drug acting on multiple 
channels and pathways in the nervous system. Indeed riluzole does directly block 
excitatory glutamatergic nerve fibers in CA1 hippocampal cortical slice preparations, 
producing potent depression of population spike amplitude and excitatory postsynaptic 
potential responses (MacIver et al., 1996). However, at clinical relevant doses, used for 
ALS treatment (100mg/kg/day), riluzole was an ineffective anaesthetic for pre-emptive 
treatment of acute burn-induced hypersensitivity, or in normal subjects (Hammer et al., 
1999). Indeed no change in contralateral withdrawal latencies was noted at any time 
point after SRA injury with riluzole treatment, suggesting no anaesthetic behavioural 
properties. The transient efficacy must therefore be through an analgesic action, 
corroborated with previous nerve injury models. Immediate riluzole treatment of CCI-
induced and formalin-induced hypersensitivity at 6 and 12mg/kg/day (Coderre et al., 
2007) and 1-4mg/kg/day (Sung et al., 2003), effectively reduced mechanical and cold 
allodynia on three days analysed post injury, and was causally linked to the reduction in 
glutamate and aspartate in the spinal cord dorsal horn. Intracerebroventricular (ICV) 
administration of riluzole also delays morphine-induced tolerance and thermal 
hyperalgesia in rats by 5 days (Habibi-Asl et al., 2009). This suggests that neuropathic 
pain after avulsion, peripheral nerve, cutaneous damage, and opioid-tolerance can all be 
treated with riluzole; however the maintained effectiveness of riluzole in avulsion injury 
is less apparent. This may be due to more complex trauma to the spinal cord after root 
avulsion, and corresponding gliosis/inflammation within the dorsal horn. Alternatively, 
the dosing regimen in this case is too low to produce maintained efficacy in the SRA 
model compared to PNI (Sung et al., 2003;Coderre et al., 2007). This is clear during the 
second week of administration, where the dose was halved, and this may have lead to 
loss of therapeutic efficacy. The dosing regime was chosen based on positive 
neuroprotective results in avulsion injury (Bergerot et al., 2004), perhaps continuing the 
daily administration of 4mg/kg throughout the second week of L5 SRA treatment could 
yield better analgesic efficacy for riluzole. Further experiments are required to 
determine this. 
 
Analysis of spinal cord tissue from immediate riluzole-treated SRA showed reduced 
microglial reactivity in the injured (L5) and adjacent (L4) dorsal horn, in the adjacent 
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(L4) ventral horn, and a trend for reduction in the injured (L5) ventral horn, but none of 
these values were reduced to sham levels. Riluzole was, however, ineffective in 
reducing astrogliosis, as determined by GFAP staining levels, in all areas analysed, 
showing only a trend in reduction of expression. These effects are difficult to 
substantiate, as very little work has focused on the effects of riluzole on glia. Riluzole 
has been shown to reverse stress-induced amino acid metabolism in glia (Valentine and 
Sanacora, 2009) and reduce stress-induced GFAP mRNA expression in the prefrontal 
cortex (Banasr et al., 2008). However, this work has centred on antidepressant activity 
of riluzole through glutaminergic modulation for mood disorder therapy and not effects 
on neurotrauma. Chronic and high dose (40mg/kg/day for 1 month) riluzole treatment in 
Wobbler mice, a model of motor neurone disease, after establishment of symptoms, 
reduces both GFAP-astrocyte and Cd11b-microglial immunoreactivity in the ventral 
horn, distinct from its anti-glutaminergic effects (Fumagalli et al., 2006). The 
intracellular downstream pathways of glial activation may be influenced by riluzole at 
certain levels. In in vitro experiments riluzole administration has been shown to be a 
direct PKC inhibitor (Noh et al., 2000), and downregulation of PKC leads to a decrease 
in cAMP in microglial cultures, that controls MHC-II expression, differentiation and 
cytokine production (Patrizio et al., 1997). Interestingly, inhibition of PKC-cAMP 
regulation has no effect on astrocyte reactivity in culture, suggesting different 
intracellular signaling pathways of activation of these two glial populations (Patrizio et 
al., 1997). This may explain the significant reversal of microglial reactivity but not 
astroglial activity in SRA injured rats, when treated with riluzole. However, the 
involvement of PKC signalling in these glial cells after injury is again quite different to 
naïve levels in culture. Indeed after PNI the mitogen-activating protein kinase (MAPK) 
pathways, such as ERK, are phosphorylated and activated (Zhuang et al., 2005;Ji et al., 
2009), and are important in the establishment of immediate microglial activation 
(initiation of neuropathic pain) and delayed astrocyte activation (maintainence of 
neuropathic pain) (Raghavendra et al., 2003). However, after L3 and L4 DRR (Cheng et 
al., 2003) and SCI (Hains and Waxman, 2006;Gwak et al., 2009) MAPK and ERK are 
upregulated in microglia, but interestingly not within astrocytes. Very recently riluzole 
has been shown to block MAPK/pERK expression in murine melanocytes (Yip et al., 
2009), and this may be the intracellular mechanism of microglial, but not astroglial 
inhibition, in the case of SRA. The ineffectiveness of riluzole to produce a significant 
reduction in astrogliosis dorsally and ventrally, and microgliosis ventrally may also be 
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dependent upon dosage, similarly to only transient effective analgesia. The dose used in 
this report, 4mg/kg, was based on previous evidence in ventral root avulsion models 
(Nogradi and Vrbova, 2001;Bergerot et al., 2004;Nogradi et al., 2007), however with 
the combination of both dorsal and ventral root avulsion in SRA, the additional trauma 
may have compounded the gliotic effects in the spinal cord, requiring a higher dose of 
riluzole to relieve it.  
 
The actions of riluzole on macrophage recruitment are in direct contrast to its 
ameliorative effects on microglial activation. The mechanisms behind the macrophage 
expression increase in the L4 dorsal column, and the trend toward increase in the L5 
dorsal column after riluzole treatment are unclear. Several possibilities include 
increased extravasation of monocytes, prevention of phagocytosis-induced apoptosis of 
macrophages, or increased microglial-macrophage activity. One mechanism may be 
anti-apoptotic, as riluzole reduces normal lymphocyte apoptosis and HIV-1 induced 
lymphocyte apoptosis in blood plasma (Achour et al., 2009). In these patients the 
cytokines, IL1-β and IL-6, that are notably involved in inflammation and neuropathic 
pain (Milligan and Watkins, 2009), were also reduced. Conversely however, riluzole 
has also been shown to reduce lymphocyte recruitment in the spinal cords of MOG-
induced EAE mice models along with reducing demyelination and axonal damage 
(Gilgun-Sherki et al., 2003). Further confusion arises in clinical studies of ALS patients, 
where continued riluzole treatment actually produces no change in expression levels of 
macrophage/monocyte markers CCR2 and MCP-1 in blood plasma compared to 
untreated ALS patients (Zhang et al., 2006). One reason for the discrepancy may be due 
to the injury model used, and the macrophage increase shown here for SRA-riluzole 
treatment may be trauma dependent. Perhaps a similar immunomodulatory capacity of 
riluzole after avulsion injury may be present for macrophages as in lymphocytes, 
through increasing their number by anti-apoptotic mechanisms. What is unclear is the 
identity of the macrophage lineage that is being increased in the dorsal columns and root 
entry zone. Activated macrophages can fall into 3 categories: classically activated (M1) 
monocytes, alternatively activated (M2) monocytes, and microglial derived. The M1 
macrophage lineage activated by IFN-γ and TNF-α is associated with inflammation, 
phagocytosis, cytokine production, and cell death (Kigerl et al., 2009), processes 
implicated in neuropathic pain. The M2 lineage, activated by IL-4, is associated with 
promoting angiogenesis, matrix remodelling and repair (Kigerl et al., 2009). Many 
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activated microglia develop into macrophages in response to injury (Graeber et al., 
1998), express the ED1 marker, are morphologically identical to monocyte-derived 
macrophages, and as such are indistinguishable at the light microscopic level (Guillemin 
and Brew, 2004). As yet there are no immunohistological markers capable of 
determining macrophage lineage, and without defining what subpopulations of 
macrophages are being upregulated in the dorsal columns, it is impossible to accurate 
predict what effect this has behaviourally. At first glance, these results suggest 
detrimental effects on the management of neuropathic pain in SRA-riluzole animals, as 
macrophages play a key role. Depletion (Liu et al., 2000b;Mert et al., 2009) and genetic 
manipulation (Myers et al., 1996) of the endogenous circulating macrophage population 
have lead to exacerbated diabetic neuropathic pain (Mert et al., 2009) and PNI-induced 
pain (Myers et al., 1996;Liu et al., 2000b;Barclay et al., 2007). However riluzole-
induced upregulation of macrophages is centred solely in the DREZ and dorsal column, 
rather than the dorsal horn grey matter, and is most likely associated with the 
degeneration of ascending primary afferents and subsequent phagocytosis of myelin. 
Therefore, this phenomenon is unlikely to have a direct effect on dorsal horn 
hypersensitivity, but is more likely related to phagocytosis debris clearance and 
remodeling of the dorsal column pathway. 
 
The ineffectiveness of immediate and prolonged riluzole treatment in reproducing the 
neuroprotective effects in motor neurones shown in previous studies of root avulsion 
models (Bergerot et al., 2004), ventral root reimplantation models (Bergerot et al., 
2004;Nogradi et al., 2007), ischemic injury models (Lips et al., 2000), and mouse 
models of MS (Fumagalli et al., 2006) suggests that the trauma of dorsal root injury in 
SRA may compound to further exacerbate the injury, such that riluzole is ineffective at 
preventing cell loss. The combination of the dorsal and ventral root avulsion may 
increase the severity of the trauma from that seen in a single root avulsion, such that a 
greater gliosis and inflammatory reaction occurs in the spinal cord that overwhelms the 
neuroprotective effects of riluzole. Loss of monosynaptic or polysynaptic (via 
interneurones) connection between dorsal afferents and motor neurones may also 
contribute to their fate. DRR has been shown to induce motor neurone plasticity 
(Cuppini et al., 1999), suggesting transneuronal mechanisms in the ventral horn can be 
manipulated through primary afferent degeneration. However, directly initiating cell 
death of motor neurones through transneuronal mechanisms is unlikely, leaving the 
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mechanism unclear. In addition, only one investigation, previously, looked at 
neuroprotection with riluzole without combining re-implantation therapy (Bergerot et 
al., 2004), and a different treatment dosing regimen was used. The dosing regimen was 
a daily i.p. 4mg/kg administration of riluzole from Tockris Cookson Ltd. (UK) for 14 
days. In this thesis riluzole was obtained from Sigma (UK), and was administered at 
half dose during the second week. Therefore not only could the SRA injury be more 
severe trauma than VRA, the dosing regimen is clearly different. Clearly defining motor 
neuronal loss is a crucial point. Tract tracing from ventral roots in the SRA model may 
more accurately locate L5 and L4 motor neuronal pools, to assess motor neuronal loss 
and the potential for neuroprotection. Alternatively, and as previously eluded to 
(Section 4.3.3.3.1), a lesion of the ipsilateral L4 ventral root 12-24 hours prior to 
sacrifice would provide ATF3 identification of this population of motor neurones, 
distinct from L5 motor neurones. 
 
When riluzole treatment is delayed by 7 days post SRA, after hypersensitivity has been 
established, there is a transient amelioration of both thermal and mechanical 
hypersensitivity. This is also seen after a 5 day delayed treatment of riluzole after CCI 
(Sung et al., 2003). However, after SRA, riluzole is ineffective at maintaining efficacy 
after cessation of treatment, which is similar to clinical peripheral neuropathic pain 
studies (Galer et al., 2000) where a 14 day treatment with a 14 day washout resulted in 
no change in pain scores compared to placebo. However, in animal models of CCI, after 
4 days of riluzole treatment and withdrawal, there was still effective alleviation of 
hyperalgesia and allodynia in two independent experiments; up to 6 and 10 days (Sung 
et al., 2003;Coderre et al., 2007). In these CCI models the ameliorative action of 
riluzole on neuropathic pain behaviour was attributed to increased glutamate reuptake, 
and length of effect due to repeated administration every 12 hours, representative of 
half-life in humans (Wokke, 1996); however the plasma half-life of riluzole in the rat is 
approximately 2 hours after i.p. administration (Milane et al., 2009). After repeated 
administration in humans, half-life is greatly increased to 40.3 - 49 hours (Le Liboux et 
al., 1999). It is unclear however, what effect repeated administration has on the half-life 
of riluzole in rats. If therapeutic efficacy is dependent on blood plasma levels, this 
administration regime may be too infrequent in the rat to maintain adequate drug 
concentration. There are clear differences in methodology with previous investigations 
on the action of riluzole on pre-clinical neuropathic pain models (Sung et al., 
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2003;Coderre et al., 2007), and the results presented here. Firstly CCI is a PNI that 
induces inflammatory pain, which results in different hypersensitivity responses than 
noted in neuropathic pain (Jabakhanji et al., 2006). The SRA-riluzole treatment dosage 
was less and more infrequent compared to previous literature (Sung et al., 2003); i.t. 
10µg twice daily; (Coderre et al., 2007); i.p. 6 and 12mg/kg twice daily). In addition 
these CCI models rarely presented data suggesting riluzole treatment could ameliorate 
neuropathic pain behaviour to baseline levels, and contralateral levels were not 
assessed; both a prerequisite for clarification of significant effects in this SRA model. 
These methodological constraints may shadow potential positive effects of riluzole seen 
in previous models of neuropathic pain (Sung et al., 2003;Coderre et al., 2007).  
 
Perhaps higher and more frequent doses in vivo may produce earlier more stable 
ameliorative properties for the treatment of SRA-induced hypersensitivity. However the 
prospective benefits of riluzole treatment for root avulsion patients may not be as robust 
as shown pre-clinically. The ineffectiveness of riluzole in the SRA model suggests that 
excess glutamate and hyperexcitability, are not be the only mechanisms responsible for 
the generation and maintenance of avulsion pain. The contribution of microglial 
activation in neuropathic pain, a central topic of this report, has been implicated 
extensively in both peripheral nerve, ventral root, and spinal cord injury pain 
(Raghavendra et al., 2003;McMahon et al., 2005;Nesic et al., 2005;Hains and Waxman, 
2006;Ohlsson et al., 2006;Hulsebosch et al., 2009;Milligan and Watkins, 2009;Penas et 
al., 2009). Riluzole therefore, with only a limited effect on glia, may not be the most 
suitable candidate for drug trials in avulsion pain clinically. 
 
 
6.3.3: Minocycline 
 
Immediate treatment with minocycline after L5 SRA effectively prevents the 
development of tactile and thermal hypersensitivity. Evidence of minocycline’s 
effectiveness for treatment of neuropathic pain conditions is extensive in the literature. 
Across many different factors such as rat strain, surgical procedure, dosing 
concentration, testing period post administration, mode of administration, and sensory 
testing parameters, immediate or pre-emptive minocycline treatment has been shown to 
successfully reduce, or prevents, the development of trauma-induced hypersensitivity 
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(Raghavendra et al., 2003;Ledeboer et al., 2005;Hains and Waxman, 2006;Lin et al., 
2007;Guasti et al., 2009;Marchand et al., 2009;Mika et al., 2009). The data presented in 
this thesis is the first to show that minocycline treatment prevents the development of 
avulsion-induced hypersensitivity. The positive results of minocyline treatment for 
neuropathic pain relief, across a broad range of injury models, suggest similar 
neuropathic mechanisms may exist between avulsion (presented here), SCI (Hains and 
Waxman, 2006;Marchand et al., 2009) and PNI (Raghavendra et al., 2003;Ledeboer et 
al., 2005;Lin et al., 2007;Guasti et al., 2009;Mika et al., 2009) in the induction of 
neuropathic pain. This is most likely due to the ubiquitous action of microglia in these 
pathologies (Milligan and Watkins, 2009). However, some conflicting evidence comes 
from the significant reduction in weight gain observed over 14 days using prolonged 
minocycline treatment. At first slight, this suggests minocycline is reducing appetite in 
these animals indicative of ongoing pain. However, a variety of reasons could explain 
this result, as minocycline-induced weight loss is also found in a rodent model of 
Parkinson’s disease (Yang et al., 2003). Firstly, the drug could well be showing toxic 
qualities; indeed after sacrifice, discolouration of bone, yellow deposits in the liver and 
peritoneum, liver sclerosis, were noted in some animals, corroborated with previous pre-
clinical (Light et al., 1994;Fagan et al., 2004) and clinical literature (Good and Hussey, 
2003;Losanoff et al., 2007), suggesting poor absorbtion, excessive deposition, and liver 
toxicity. In previous animal studies minocycline, at doses higher than 20mg/kg, results 
in pleurodesis and morbidity in rabbits, such is the potential toxicity of this drug (Light 
et al., 1994). If minocycline hydrochloride (Sigma-Aldrich) is disoolved from the initial 
powder through heating the saline, and administered immediately, these toxic effects are 
not apparent (Teng et al., 2004), and neuroprotective effects are pronounced, suggesting 
poor dissolving may be a contributing factor to increased risk of toxicity and reduced 
efficacy. Using alternative administration methods, such as intravenous or intrathecal 
catheterization can avoid these issues and improve plasma concentrations (Fagan et al., 
2004;Hains and Waxman, 2006). 
 
This thesis is the first evidence to indicate the effectiveness of minocycline treatment in 
microglial reactivity amelioration after avulsion injury. Such is the potency of this 
minocycline treatment, that ipsilateral microglial reactivity to levels similar to 
contralateral, in the ventral and dorsal horns of both the adjacent L4 and avulsed L5 
segments. The correlation of this finding with the prevention of hypersensitivity 
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development across the same time period provides direct evidence to implicate dorsal 
horn microglia reactivity, specifically in the adjacent segment to the injury (L4), in the 
pathology of avulsion-pain, as evoked hypersensitivity is mediated through the ‘spared’ 
L4 root/segment. The action of minocycline on microglia via inhibition of p38-MAPK 
phosphorylation (Tikka et al., 2001;Tikka and Koistinaho, 2001;Hains and Waxman, 
2006), is the likely candidate for pharmacokinetics. A contralateral effect with 
minocycline treatment was noted. Immediate treatment with minocycline has also been 
shown to reduce OX42 expression bilaterally after a unilateral rat spinal cord 
hemisection at T13 (Marchand et al., 2009). In some cases this contralateral effect in 
SRA-minocycline treated tissue is functionally significant, contradictory to literature on 
minocycline treatment of nociceptive pain (Padi and Kulkarni, 2008), but this again may 
be an issue of injury models.  
Minocycline treatment shows a small but significant reduction in astrocyte reactivity in 
the ventral horn. The GFAP reduction may be due to direct inhibition of p38 MAPK 
phosphorylation pathways that have been shown to be activated in astrocytes within and 
around the lesion site after moderate SCI (Crown et al., 2008). Little information exists 
on the mechanisms of astrocyte activation after neuropathy. Minocycline treatment has 
no effect in the dorsal horn astrocyte response; and so there may be multiple activation 
pathways at play after SRA injury. With the successful prevention of hypersensitivity 
development in SRA-minocycline treated animals, it can be suggested that astrocyte 
activity is not a key player in hypersensitivity production and maintenance after root 
avulsion, again similar to SCI models of neuropathic pain (Hains and Waxman, 
2006;Gwak et al., 2009). Certainly there is now a shift in understanding of the role of 
astrocytes in neuropathic pain from original thought (Raghavendra et al., 2003), with 
microglia becoming the main culprits at least after injury to the spinal cord. Recently, it 
has been shown that the astrocyte inhibitor fluorocitrate, when administered i.p. twice 
daily, reduces astrogliosis 7 days after CCI, but does not ameliorate tactile and cold 
hypersensitivity, whereas minocycline does, alongside reducing microgliosis (Mika et 
al., 2009). Sciatic nerve ligation leads to a greater spinal cord microglial response 
including proliferation at 7 days, that is absent in the astrocyte population (Narita et al., 
2006). Notably intrathecal injection of PKC-activated astrocytes into naïve spinal cord 
does not lead to hypersensitivity, whereas PKC-activated microglia injection does 
(Narita et al., 2006). The results from immediate minocycline treatment on the reduction 
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of microglial activity and neuropathic pain, suggests that microglial activity is the 
essential mediator in avulsion pain.  
 
In contrast to riluzole, minocycline treatment effectively reduces macrophage 
recruitment in the dorsal columns significantly in L5 with a trend in L4, and this is in 
accordance with previous literature, using a SCI model (Ritfeld et al., 2010), dorsal 
column crush injury model (McPhail et al., 2004b), cerebral ischemic models 
(Wasserman and Schlichter, 2007) and EAE models (Nikodemova et al., 2007). P38 
MAPK plays a key role in monocyte/macrophage inflammatory responses (Hulsebosch, 
2008). After dorsal root rupture, p38 MAPK is increased in macrophages within 48 
hours in the ipsilateral DREZ and root (Nomura et al., 2005), and both macrophage 
recruitment and activation is dependent upon the extent of traction injury to the root and 
DREZ (Nomura et al., 2005), shown in Section 3.2.3a. Vascular adhesion molecule-1 
(VCAM-1) on endothelia controls the extent of macrophage adhesion to endothelial cell 
membranes and subsequent extravasation into a lesion site, through interaction with α4-
β1 integrin on the surface of leukocytes (Mabon et al., 2000). VCAM-1 surface 
expression is in turn controlled by the cytokines IL-1β and TNFα (Mabon et al., 2000). 
Minocycline could therefore have a ‘two-pronged’ inhibitory action on macrophages; 
through inhibition of infiltration, via suppression of cytokine release from microglia 
(Ledeboer et al., 2005), as well as reduction of activity via p38 MAPK inhibition (Tikka 
et al., 2001;Tikka and Koistinaho, 2001;Hains and Waxman, 2006) leading to the 
reduced ED1 expression shown in the L4 and L5 dorsal columns. The ‘double-edged 
sword’ debate on the consequences of increased macrophage activity, suggests that 
reduction of macrophages in these areas could have either a detrimental effect on 
neuronal tissue regeneration (Thacker et al., 2007;Gensel et al., 2009), or a beneficial 
effect on matrix reformation and prevention of axonal dieback (McPhail et al., 
2004b;McPhail et al., 2004b); as well as, consequently, reducing the propensity for 
neuropathic pain (Myers et al., 1996;Liu et al., 2000b;Barclay et al., 2007), depending 
on the lineages being activated and targeted (Kigerl et al., 2009). It is also unclear 
whether these macrophages are infact distinct from microglial cells. As described 
previously, the function of these ‘white matter’ macrophages is more likely focused on 
phagocytosis and matrix remodelling of the lesion area after SRA, and the decrease in 
ED-1 expression seen with minocycline is unlikely linked to the prevention of 
hypersensitivity development.  
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The neuroprotective qualities of minocycline showed only a trend toward amelioration 
of dorsal horn neuronal loss in L4. If this trend is indeed biologically significant, it 
could be attributable to the neuroprotective quality of minocycline through inhibition of 
mitochondrial cytochrome C release (Teng et al., 2004), and prevention of caspase-3 
activation (Stirling et al., 2004) in neurones, or indirectly via p38 MAPK inhibition in 
microglia (Tikka et al., 2001) preventing inflammation-mediated cell death. As TUNEL 
studies in DRA (Section 3.2.5.4) could not confirm neuronal apopotic cell death, it may 
be the inhibition of microglia/macrophages that tends toward a neuroprotective 
mechanism, and may also substantiate why this neuroprotective quality was not present 
with riluzole that showed limited efficacy on gliosis. Then again, it is not surprising 
significant neuroprotection was absent, such is the controversy over minocycline’s 
ability to prevent neurodegeneration in numerous models of neurotrauma and CNS 
disease (Yang et al., 2003;Diguet et al., 2004a;Stefanova et al., 2004;Tsuji et al., 
2004;Pinzon et al., 2008;Saganova et al., 2008;Viscomi et al., 2008).  
 
Further, the absence of neuroprotective qualities is mirrored in the ventral horn. No 
prevention of motor neurone loss was found, and this is directly contrary to data from 
L6 VRA models (Hoang et al., 2008). However, differences in dosing regimen 
(50mg/kg halved in second week) and injury model, as well as method of motor 
neurone identification and analysis may contribute to this discrepency. The large 
variation in neuronal counts, between methodologies in this report (Section 4.2.3.2b), is 
also found in the literature between different investigators (Koliatsos et al., 
1994;Bergerot et al., 2004;Hoang et al., 2008;Penas et al., 2009), and this variation 
could shadow small  neuroprotective effects of drugs such as minocycline.  
 
It is rather contradictory as to why minocycline shows efficacy in reducing microgliosis 
but not neurodegeneration, although these two processes may be linked. Minocycline 
robustly reduce microglial activation induced by MPTP neurotoxin administration in a 
model of Parkinson’s disease (Yang et al., 2003). Conversely, it exacerbated the loss of 
dopaminergic neurones. The authors speculated that the reduction of microglial activity 
may subsequently lead to reduction in cytokine expression needed for neuronal survival 
(Yang et al., 2003). Activated microglia have the capacity for aiding neuroregeneration 
(Aldskogius, 2001), remyelination and functional recovery (Yaguchi et al., 2008), and 
the loss of the protective aspect of microglial activity through minocycline 
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administration may be the reason why neuroprotection is absent in the SRA model. 
Further, the dependence on correct dose and mode of administration may determine the 
expression of neuroprotective effects from exacerbation of symptoms, such that 
20mg/kg is neuroprotective but 100mg/kg exacerbates symptoms in brain ischemic 
models (Matsukawa et al., 2009). Intraperitoneal administration route may not be the 
best method, due to incomplete and erratic absorbtion of minocycline from the 
peritoneal cavity and deposition in the liver (Fagan et al., 2004). Intravenous 
administration has been shown to produce more reliable plasma and tissue concentration 
levels (Fagan et al., 2004), and correct preparation of the minocycline solution may also 
be an overlooked but essential factor (Teng et al., 2004). Further research to carefully 
assess minocycline pharmacokinetics and phamacodynamics is required both pre-
clinically and, more importantly with caution, clinically for the treatment of neuropathic 
pain. 
 
Minocycline, for the first time, has been shown to be effective at reversing established 
neuropathic hypersensitivity, contrary to previous literature in peripheral nerve injury 
models (Raghavendra et al., 2003;Ledeboer et al., 2005). Moreover, it is the first time 
that minocycline has been shown to maintain efficacy outside the washout period, 
contrary to previous literature (Ledeboer et al., 2005). The biological half life of 
minocycline, when administered orally is on average 18-23 hours in humans (Langevitz 
et al., 2000). In rats this is much shorter, averaging 2.8 hours after intravenous 
administration, and more variable after intraperitoneal administration (Fagan et al., 
2004). This suggests the drug effects will be washed-out before the next testing day 
(day 21). Differences seen here are yet to be correlated with immunohistological 
analysis; but these results suggest, that if microglial activity is indeed responsible for 
avulsion pain, pharmacological inhibition may persist for at least 7 days after drug 
cessation. It is unclear how effective this treatment regimen could be for multiple root 
avulsion, or indeed in the human condition, or whether neuropathic pain is ameliorated 
beyond 7 days. However, these are encouraging results, and provide a potentially new 
therapeutic intervention to further study avulsion injury and neuropathic pain therapy in 
humans.  
 
 
 
  286 
6.3.4: Conclusion 
 
The evidence presented here gives weight to advocate minocycline as a suitable drug 
candidate for preventating and reversing avulsion-pain, as long as side effects are 
minimised. The potential for neuroprotection is currently being assessed in clinical trials 
for SCI (ClinicalTrials.gov Identifier: NCT00559494), traumatic brain injury 
(ClinicalTrials.gov Identifier: NCT01058395), and stroke (ClinicalTrials.gov Identifier: 
NCT00930020). Riluzole was less effective at treating established avulsion-induced 
pain in this model, with only partial anti-glial effects. However, it was effective at 
delaying the onset of thermal hyperalgesia, suggesting some rationale for use. There 
was an inability to confirm neuroprotective effects of either drug; however, this may 
well be an issue of dosing, mode of administration, or different injury models. 
Potentially a combinatorial treatment approach may produce more beneficial effects 
when assessing neuronal sparing, as the drugs have shown synergistic qualities (Milane 
et al., 2009). They have been used recently in ALS treatment (Pontieri et al., 
2005;Gordon et al., 2007), but caution is warranted as the potential for toxicity and 
symptom exacerbation is increased at doses of 400mg/kg of minocycline (Gordon et al., 
2007;Milane et al., 2009). Combinatorial treatment with minocycline and riluzole in 
focal cerebral ischemia, ameliorates both inflammation and excitotoxicity; studies show 
reduced microglial/macrophage reactivity, reduced caspase-3 positivity and decreased 
size of infarction, far beyond the effects of the single treatments alone (Weng and Kriz, 
2007). As ventral root reimplantation strategies are still the most effectively therapy for 
maintaining the motor neurone pool, and promoting functional recovery after brachial 
plexus avulsion (Bergerot et al., 2004;Nogradi et al., 2007;Havton and Carlstedt, 2009); 
a combinatorial reimplantation strategy with minocycline may increase the potential for 
motor neuronal survival and recovery, whilest alleviating or preventing neuropathic 
pain. 
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Chapter 7: General discussion 
 
7.1: Introduction 
 
This thesis has aimed to provide greater insight into the underlying mechanisms that 
contribute to the generation and maintenance of intractable neuropathic pain 
experienced by a large majority of people with spinal root avulsion. A clear, histological 
characterisation of the temporal degenerative events within the avulsed spinal cord is 
lacking in current literature, and in addition, there is no established animal model of 
avulsion injury that mirrors the human condition, that can be used to test drug efficacy 
or to explore the underlying mechanisms. The current in vivo model used for 
histological studies within spinal cord and dorsal root ganglia to mimic avulsion is a 
rhizotomy, and inferences of the clinical condition are based on these findings. 
However, rhizotomy is an artificial surgical lesion and not a ‘traction injury’, so 
therefore does not injure the dorsal horn, as is sometimes the case in avulsion. 
Furthermore, most research has focussed on understanding motor functional deficits 
after avulsion injury (Carlstedt et al., 1986;Koliatsos et al., 1994;Bergerot et al., 
2004;Nogradi et al., 2007;Hoang et al., 2008), rather than neuropathic pain. A model of 
below-level (hind-limb) avulsion-pain induced after brachial plexus avulsion has been 
used to characterise potential pharmacotherapy for avulsion pain (Rodrigues-Filho et al., 
2003), without any clear proof of concept on the model or its clinical relevance. A 
ventral root avulsion model (Bigbee et al., 2007) produces neuropathic pain behaviour 
correlated with primary afferent degeneration, this is however in the absence of direct 
injury to dorsal roots. In the clinic brachial plexus and lumbosacral plexus injuries 
typically present both dorsal and ventral root avulsion injuries.  
 
This thesis has aimed to develop a new model of avulsion pain that mirrors the clinical 
aetiology, and to provide a platform for pharmacological testing.  Establishment of this 
model has enabled the testing of established drugs that have shown clinical efficacy for 
neuropathic pain treatment, and for ameliorating PNI- induced pain in vivo, and to 
assess whether these drugs have any therapeutic efficacy for treatment of avulsion pain. 
Clinically, conventional drugs for neuropathic pain treatment such as anticonvulsants 
and antidepressants have poor efficacy for the treatment of avulsion pain (Parry, 
1980;Berman et al., 1996;Piva et al., 2003). Therefore registered drugs, that are not 
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currently in use for analgesia but have shown potential in vivo for treatment of 
neuropathic pain in spinal cord and peripheral nerve injury models, have also been 
assessed for preventative therapy and treatment of SRA-induced neuropathic pain 
behaviour.  
 
7.2: DRA leads to a progression of gliosis, inflammation, and degeneration within 
the dorsal spinal cord, and is quantitatively more severe than rhizotomy 
 
Loss of inhibitory tone has been implicated as a mechanism of neuropathic pain 
development (Loeser et al., 1968;Ovelmen-Levitt, 1988), and this has been shown to 
occur, in the dorsal horn after PNI and SCI, through neurodegeneration of GABAergic 
interneurones (Ibuki et al., 1997;Moore et al., 2002;Drew et al., 2004;Meisner et al., 
2010) and a microglial controlled shift in anion gradients in neurones via BDNF (Coull 
et al., 2003;Coull et al., 2005;Lu et al., 2007;Lu et al., 2008). Dorsal horn sensitisation 
is also a mechanism by which neuropathic pain can occur, through activation of glia 
(Milligan and Watkins, 2009), and inflammatory cells (Thacker et al., 2007). However, 
a full characterisation of these events in the avulsed dorsal horn has not taken place, and 
neuronal cell death, or loss of GABAergic tone, after PNI is controversial (Polgar et al., 
2003;Polgar et al., 2004;Polgar et al., 2005;Polgar and Todd, 2008). This chapter 
provides quantification of these events within the dorsal horn at early and late time 
points post injury in a model of lumbosacral plexus avulsion (L3-L6 DRA). The model 
produces a gradual loss of immunostaining in primary afferent terminals in the 
superficial dorsal horn, with maximal reduction by 14 days using CGRP and IB4 
antibodies for C-fibre identification, which is similar to DRR and the previous literature 
(Gibson et al., 1984;Traub et al., 1989;Tie-Jun et al., 2001;Muneton-Gomez et al., 
2004). Afferent terminal degeneration coincides with increase in phagocytic cell 
infiltration, neuroinflammation, and neurodegeneration. A two stage trans-synaptic loss 
of dorsal horn neurones occurs firstly within 1 to 2 days, and a second loss from 14 to 
28 days. This loss of the neuronal epitope NeuN could not be linked at these time points 
to apoptotic mechanisms; the only substantial apoptosis involved the neutrophil 
population, after their acute infiltration at 1-2 days. The initial loss of NeuN is likely 
due to the direct trauma of the avulsion, but the reduction in NeuN number at later time 
points is linked closely with a rise in astrogliosis, microgliosis, and macrophage 
recruitment. This suggests that avulsion is not just an acute lesion, but has a chronic 
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progressive stage of secondary cell death, similar to SCI (Totoiu and Keirstead, 
2005;Huang et al., 2007). Encouragingly, this potentially provides an accessible 
therapeutic window for neuroprotective intervention. The continued increase in 
microglial and macrophage activity up to 14-28 days after DRA coincides with 
secondary neuronal loss, and is contradictory to the the decrease in microglial activity in 
PNI at 7 days (Eriksson et al., 1993), and is more reminiscent of SCI gliosis (Hains and 
Waxman, 2006;Gwak and Hulsebosch, 2009). Vascular endothelial staining was 
reduced followed this neuronal loss across 28 days, resembling vascular deterioration in 
SCI (Imperato-Kalmar et al., 1997). However, it is uncertain whether reduction in 
endothelial staining links to loss of vascular integrity and therefore ischemia.   
 
This spatial and temporal assessment gives an insight into possible mechanisms of 
neuropathic pain. Microglia/macrophages and astrocytes heighten dorsal horn neurone 
activity, through expression of TNFα and cytokines (IL6 and IL1-β) (Milligan and 
Watkins, 2009). Microglia and astrocytes have been shown to contribute to SCI-induced 
neuropathic pain maintenance (Hains and Waxman, 2006;Gwak and Hulsebosch, 2009), 
with the latter glial cell contributing to the maintenance of PNI-induced pain (Eriksson 
et al., 1993;Colburn et al., 1997;Raghavendra et al., 2003). 
 
Quantitative analysis of DRA and DRR showed that rhizotomy is a less severe form of 
avulsion injury. This is most likely due to the neuropathological consequences of direct 
trauma to the spinal cord after avulsion injury that does not occur after rhizotomy. This 
is important to distinguish, as 70% of brachial plexus injuries incorporate direct 
avulsion of at least one root from the spinal cord, and brachial plexus avulsion leads to a 
partial Brown-Séquard SCI syndrome (Berman et al., 1996;Carlstedt, 2009). Indeed, 
DRA causes direct injury to the ipsilateral DREZ, dorsal column, and dorsal horn, 
presenting as cavitations and some tissue deformation, with a progressive, ~56%, loss of 
NeuN over 28 days, which does not occur in rhizotomized tissue. Vascular staining, that 
has not been studied in root avulsion models, recovers at 14 days post rhizotomy, in 
comparison with a maintained reduction after avulsion up to 28 days. DRA produces a 
quicker and more pronounced astroglial response than DRR, and is bilateral at 28 days, 
unlike DRR injury. DRA produces a progressive bilateral microglia reaction across 28 
days, greater than DRR at each time point, with DRR showing a decreased microglial 
reactivity after 14 days. This unique finding is important evidence when attempting to 
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determined the conflicting roles of microglia in PNI and SCI pain maintenance 
(Eriksson et al., 1993;Raghavendra et al., 2003;Hains and Waxman, 2006), suggesting 
perhaps that the neuropathology of DRR is similar to PNI, whereas DRA is reminiscent 
of SCI. Bilateral astroglial and microglial responses have been seen before in PNI and 
focal burn injury models (Milligan et al., 2003;Hatashita et al., 2008;Chang et al., 
2010), and is that to be associated with contralateral and ‘extra-territorial’ 
hypersensitivity (Seltzer and Shir, 1991;Tal and Bennett, 1994;Arguis et al., 2008). 
Clinically mirror pain is rare, but is cited in literature concerning causalgia (Seltzer and 
Shir, 1991), atypical facial pain (Woda and Pionchon, 1999) and reflex sympathetic 
dystrophy (Maleki et al., 2000), however it is not reported in the root avulsion literature.  
 
These differences in the severity of the dorsal horn neuropathology may explain why 
rhizotomy pre-clinically does not produce a neuropathic behaviour (Sheen and Chung, 
1993;Yoon et al., 1996;Sukhotinsky et al., 2004), and is clinically used to relieve 
peripheral neuropathic limb pain (White and Sweet, 1969;Loeser, 1972;Gybels and 
Sweet, 1989;Hosobuchi, 1980), whereas clinical avulsion injury almost always results 
in the most severe pain (Parry, 1980;Berman et al., 1998;Piva et al., 2003;Htut et al., 
2006).  
 
7.3: SRA leads to neuropathic pain behaviour 
 
A recent model of brachial plexus avulsion (Rodrigues-Filho et al., 2003) produces a 
bilateral hindlimb hypersensitivity, which has neither a clear mechanistic cause nor is it 
representative of the clinical condition, as pain is not experienced by patients in 
unaffected limbs. Ventral or dorsal root rhizotomy as a model has conflicting evidence 
for neuropathic pain behaviour (Sheen and Chung, 1993;Colburn et al., 
1999;Eschenfelder et al., 2000;Li et al., 2000;Sukhotinsky et al., 2004). Ventral root 
avulsion pain may be due to the influence of degenerating motor axons influencing 
adjacent intact primary afferents within the same peripheral nerve (Bigbee et al., 
2007;Bigbee et al., 2008) akin to that seen in SNL injury models. This thesis has 
developed a reproducible, and clinically relevant avulsion model, as it involves both 
ventral and dorsal root components (Havton and Carlstedt, 2009), for the study of 
evoked neuropathic pain behaviour in the border zone of the avulsed and adjacent intact 
dermatomes. It negates the need for laminectomy, a surgical injury in itself that 
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produces histological (Colburn et al., 1997;Winkelstein and DeLeo, 2002;Bigbee et al., 
2007;Huang et al., 2007), and behavioural effects (Hashizume et al., 2000a;Hashizume 
et al., 2000b).  The neuropathic behaviour induced by SRA is both evoked, through 
stimulation with tactile and thermal probes, and has a spontaneous modality, inferred by 
a reduced weight gain. However a limitation of the model is that it is difficult to 
measure other surrogate methods of spontaneous pain measurements such as autotomy, 
due to the fact the the limb is not fully denervated. The evoked behaviour is not fully 
established until 3-5 days post injury, and is maintained for at least 60 days. The 
locomotor impairment of the ventral root avulsion is minimal. 
 
Phenotypic changes in peptide expression in subpopulations of primary afferents 
(Fukuoka et al., 1998), upregulation in expression of certain receptors, such as TRPV1 
(Hudson et al., 2001;Fukuoka et al., 2002), and activation of satellite glia (Hu and 
McLachlan, 2003;Dublin and Hanani, 2007), all contribute to the generation of PNI 
pain. However, after SRA no obvious change in phenotypic expression occurs in the L4 
DRG cells, through which the evoked behavioural responses must occur. Satellite cells 
show no increase in GFAP expression, notable after activation, and ATF3 expression, a 
ubiquitous marker for neuronal injury (Averill et al., 2002;Shortland et al., 2006a) is 
minimal in the L4 DRG neurones. This suggests neuropathic pain may not be 
attributable to peripheral plasticity within the neurones of L4 DRG, although many 
other peptides and growth factors that are expressed in injured and adjacent DRG 
neurones, after PNI and root injury, such as NPY, NGF, BDNF, NOS, and Galanin 
(Shortland et al., 2006a;Fukuoka et al., 2001;Obata et al., 2004;Zhou et al., 2009) are 
associated with neuropathic pain. These peptides and growth factors have not been 
assessed in this thesis, and would need to be quantified before conclusively saying the 
L4 DRG does not mediate the hypersensitivity seen after SRA to the L5 root. 
 
Degenerative, glial, and inflammatory mechanisms within the spinal cord similar to that 
seen after DRA are also found in the avulsed (L5) segment as a consequence of SRA; 
however not as severe, as the number of roots avulsed determines extent of pathology 
and pain (Berman et al., 1998). Neuronal loss is minimal (8%) in the avulsed dorsal 
horn after SRA compared to DRA (31%) at 14 days. The more substantial ‘secondary’ 
neurodegeneration seen between 14 and 28 days after DRA, has not been assessed in 
SRA. Motor neuronal loss (43-69%) by 14 days is consistent with previous observations 
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(Koliatsos et al., 1994;Hoang et al., 2003;Bergerot et al., 2004;Nogradi et al., 
2007;Penas et al., 2009), but the quanitification varies due to the staining method, with 
immunohistochemistry revealing greater loss than histological dye. This suggests that 
some neurones may well be present at a certain time point post injury, only the epitope 
of interest (in this instance NeuN) is no longer expressed within them, and they cannot 
be viewed through certain methodological staining procedures. Vascular integrity is also 
compromised in the L5 dorsal and ventral horns at 14 days post SRA, bilaterally, but it 
is unclear whether this is a consequence of secondary degenerative phenomena, or 
occlusion of the arterioles and venuoles that supply the spinal cord from the primary 
lesion. Macrophage recruitment is restricted to the dorsal root entry zone and columns at 
14 days post SRA, in stark contrast to the robust and deep infiltration shown in the 
dorsal horn of DRA at the same time point. The most pronounced inflammatory reaction 
within the avulsed L5 dorsal horn is gliosis, microglial especially, an important finding 
given their substantial role in the generation and maintainence of neuropathic pain in 
PNI and SCI (Hains and Waxman, 2006;Hulsebosch, 2008;Gwak and Hulsebosch, 
2009;Hulsebosch et al., 2009;Inoue and Tsuda, 2009;Milligan and Watkins, 2009).  
 
Avulsion of the L5 root leads to similar, but less severe, neurodegenerative phenomena 
within the adjacent L4 segment (47% [NeuN] and 27% [Tol blue] motor neuronal loss, 
and 5% dorsal horn loss). Similar magnitudes of microglial and astrocyte reactivity 
were quantified in the adjacent L4 and avulsed L5 spinal cord. The overlap of L5 and 
L4 afferent collaterals within the L4 segment is well known (Molander and Grant, 
1985;Molander and Grant, 1986;Rivero-Melian and Grant, 1990;Shehab et al., 
2008;Shehab, 2009). The degeneration of L5 terminals within the L4 intact segment is 
the likely mechanism that leads to these histological responses, and therefore leads to 
the hypothesis for the mechanism of this evoked neuropathic pain generation: the 
neuropathic pain behaviour induced by L5 SRA could be generated at and/or processed 
through the adjacent L4 segment. Clinically, 80% of plexus avulsions have a least one 
intact root (Sindou et al., 2005) for signalling between periphery and dorsal horn, and 
this root and the corresponding segment has been shown to mediate neuropathic 
avulsion-pain (Bertelli and Ghizoni, 2008). This thesis therefore provides, for the first 
time, a model that represents these clinical findings, with a hypothesis that substantiates 
the evoked behaviour, and enables the testing of pharmacological agents for treatment 
of this pain. 
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7.4: SRA-induced hypersensitivity can be acutely modulated with the conventional 
analgesics amitriptyline and carbamazepine 
 
Current pharmacological treatments for neuropathic pain, include the antidepressant, 
amitriptyline, and the anticonvulsant, carbamazepine, but these have limited efficacy in 
treating root avulsion pain (Parry, 1980;Berman et al., 1996;Piva et al., 2003). However, 
these drugs have improved efficacy in the long term, when combined with ventral root 
reimplantation surgery (Berman et al., 1998), most likely due to the compounding effect 
of the pain relief that follows motor functional recovery after surgical reimplantation 
(Htut et al., 2006). Amitriptyline and carbamazepine have shown analgesic efficacy in 
PNI rodent models (Chapman et al., 1998;Decosterd et al., 2004;De Vry et al., 2004). 
Effects were short lasting with single bolus administrations of these drugs. This chapter 
has shown that the behavioural hypersensitivity induced by SRA, can be relieved, albeit 
transiently, by administering boluses of amitriptyline and carbamazepine. The positive 
results also validate this model suitable for pre-clinical screening of noval drugs for 
treatment in avulsion pain. 
 
Amitriptyline had no analgesic effect on hypersensitivity at first dose, but 
carbamazapine effectively ameliorated tactile hypersensitivity. A repeated dose leads to 
amelioration of tactile hypersensitivity with both amitriptyline and carbamazepine, 
without relief from thermal hypersensitivity. Increasing efficacy on the third 
administration (double dose) lead to amelioration of both thermal and tactile 
hypersensitivity; however side effects became apparent. The mechanism of action is 
likely related to direct inhibition of voltage gated sodium channels in dorsal horn and 
perhaps supraspinally (Dick et al., 2007;Hur et al., 2008). It is unclear why these drugs 
show more therapeutic efficacy when treating mechanical hypersensitivity compared to 
thermal, as this is converse to established literature on PNI-induced neuropathic pain 
behaviour (De Vry et al., 2004;Bomholt et al., 2005), where mechanical allodynia is 
intractable and thermal hyperalgesia is effectively treated at similar doses.  However, 
this is evidence again for different mechanisms of action between PNI-induced and 
avulsion-induced behavioural hypersensitivity. The ineffectiveness of these drugs to 
maintain efficacy beyond 24 hours, is related to the drugs biological half-life and 
clearance, which is reached in the rodent CNS by approximately 1.6 hours for 
amitriptyline and 3.4 hours for carbamazepine (Coudore et al., 1996;Graumlich et al., 
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2000), and the reversal of sodium channel blockade. The drugs ineffectiveness at 
maintaining efficacy beyond drug washout is in agreement with their mode of action as 
reversible sodium channel blockers, as well as the clinical findings; that these drugs 
have poor long term therapeutic efficacy in avulsion pain (Parry, 1980;Berman et al., 
1996;Piva et al., 2003). Pharmacologically targeting the cause of neuronal 
hyperexcitability, such as the neuroinflammatory cascade, gliosis, and cell death, rather 
than trying to manipulate it directly with sodium channel blockers, may yield a more 
substantial and maintained pain relief in the SRA model.   
 
7.5: Minocycline prevents the establishment of, and can reverse, SRA-induced 
neuropathic pain behaviour through microglial inhibition. Rilzuole was less 
effective for treatment of avulsion pain behaviour  
 
It is now well established that neuropathic pain can be induced and maintained through 
pathologically increased glial activity in the spinal cord (McMahon et al., 2005;Hains 
and Waxman, 2006;Echeverry et al., 2008;Hulsebosch, 2008;Milligan and Watkins, 
2009;Inoue and Tsuda, 2009). This glial reactivity is pronounced after SRA injury 
within the L5 and L4 segments, surrounding deafferented dorsal horn neurones and 
avulsed motor neurones, leading to the hypothesis that avulsion pain could be mediated 
by overactive microglia. This histological finding has lead to the rational in this thesis 
for the application of minocycline to directly target and inhibit microglial activity. In 
contrast, riluzole, an anti-excitotoxic drug, was administered and assessed separately to 
assess therapeutic efficacy of direct inhibition of glutaminergic activity within the spinal 
cord. If these treatments show efficacy in vivo, the immediate benefit for the treatment 
of neuropathic pain is that they are already marketed by pharmaceutical companies for 
treatment of other disorders, and can be applied to clinical trials immediately if 
successful.  
 
Immediate minocycline treatment prevented the development of evoked behaviour. 
However, the treatment displayed some side effects including reduced weight gain and 
contralateral hyposensitivity. The prevention of neuropathic pain behaviour 
corresponded histologically with robust amelioration of microglial/macrophage staining 
in the avulsed and adjacent dermatomes, with partial amelioration of astrocyte 
reactivity. This shows that glial activity, most notably microglial, is important in 
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mediating SRA-induced neuropathic behaviour. Increased microglial reactivity in L5, 
and importantly L4, may lead to central sensitization of dorsal horn neurones, increasing 
their responsiveness to peripheral input from the spared L4 primary afferents. The 
effective prevention by minocycline of the induction of neuropathic pain behaviour in 
rats with L5 SRA may provide rational for this drug to be administered to patients with 
root avulsion. Neuropathic pain symptoms begin to appear 48 hours after avulsion 
injury (Berman et al., 1996) providing a therapeutic window of opportunity for these 
patients. However people who already suffer from excruciating neuropathic avulsion 
pain will have missed this therapeutic window. Encouragingly, delayed minocycline 
treatment can fully reverse established avulsion-induced hypersensitivity to baseline 
levels, at least at 7 days post operatively. Furthermore, the analgesic effects of the drug 
extend well beyond its biological half-life (Fagan et al., 2004) by at least 7 days, 
suggesting long lasting changes to sensory processing. This needs to be assessed at 
much longer time points post operatively, as well as post drug-withdrawal, to see if this 
is a permanent effect. Most importantly, it remains to be seen if these effects are 
causally linked to reversal of microglial activity. If this is indeed the case, this would 
provide conclusive evidence for minocycline as an irreversible potent inhibitor and 
ameliorator of microglial activity. Clinically, this would have implications for the 
treatment of many neuropathic pain conditions that are derived through pathological 
microglial activity, such as PNI (Raghavendra et al., 2003), SCI (Hains and Waxman, 
2006), diabetic neuropathy (Tsuda et al., 2008), focal burn pain (Chang et al., 2010), 
and now root avulsion. Additionally a reevaluation of dosing regimes would be needed 
to see if a single administration would be sufficient to prevent/reverse the behavioural 
effects. 
 
Immediate riluzole treatment delayed the onset of mechanical and thermal 
hypersensitivity. Histologically, it produced partial reduction in glial staining. This 
suggests that the dosing regimen was sub-optimal. An increase in macrophage reactivity 
was present in riluzole treated animals. However the lineage of either neuro-
inflammatory (M1) or neuro-reparatory (M2) orientated macrophages is not presently 
clear to substantiate their role. Riluzole has only limited effects on reversing 
neuropathic pain behaviour; again the most likely reason is a suboptimal dosing regime.  
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Neither drug showed significant neuroprotection of motor or dorsal horn neurones, 
contrary to prior evidence in ventral root avulsion models (Bergerot et al., 2004;Hoang 
et al., 2008). This inconsistancy may be due to the cumulative trauma induced on the 
cord by the dorsal root avulsion. The loss of interneuronal and monosynaptic 
connections between primary afferents and motor neurones is known to induced 
physiological adjustments of the reflex pathways, but does not indicate cell loss 
(Holmberg and Kellerth, 1996;Cuppini et al., 1999). Perhaps the cumulative effect of 
ventral and dorsal gliosis within the ipsilateral cord may overwhelm the effectiveness of 
the treatment and propensity for motor and sensory neuronal survival. These effects are 
yet to be analysed in DRA and VRA models, to corroborate this finding, leaving the 
reasons for this discrepancy in the potential for neuroprotection unclear. 
 
7.6: Summary of thesis findings 
 
This thesis has provided a descriptive and quantitative analysis of the progressive events 
that occur in neuronal, vascular, glial, and inflammatory cell types in the deafferented 
dorsal horn after multiple dorsal root avulsion and rhizotomy. Dorsal root rhizotomy, 
used as the classical model for root avulsion injury, is not representative of such, 
showing less severe consequences compared to dorsal root avulsion, and should be 
replaced with animal models that more closely mimic the clinical condition. Evidence 
here supports the use of an L5 spinal root avulsion as a model of avulsion pain. 
Maintained neuropathic pain behaviour can be elicited from the rat hind-paw, as well as 
behavioural responses suggestive of spontaneous pain. This behaviour is correlated at 
14 days post injury with neuropathological changes within the avulsed L5 segment, but 
also within the adjacent L4 segment, suggesting the hypersensitivity is mediated 
through central changes involving input from the adjacent spared root that innervates 
the hind-paw. This pathological behaviour can be prevented through treatment with 
minocycline, and to a lesser extent riluzole, through inhibition of microglia/macrophage 
reactivity. Importantly, minocycline shows promise when administered as treatment for 
established pain behaviour, as it is able to reverse, and prevent the return of, 
hypersensitivity after drug withdrawal. The evidence put forth in this thesis advocates 
the use of SRA as a suitable model to explore further mechanisms involved in avulsion 
pain, and as a model for the validation of more experimental drugs in the treatment of 
avulsion injury pain. 
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